162
"#$%&’($)& *+’$( ,&(-+’)&( ).&(& /012 0345672 85 92:;5 ;5 ,<-)&"’ (=756=5> ;5 8: ?75 54 ;5 8: >:64@ &=085 ,0=402:85A B@6@47C15 $DD16080975 $6E5=47080975 54 ,@?580//5D564 ,7>=7/8765A $DD16080975 *2@>564@5 54 >0145615 /1387C15D564 /:2 F72: )<.F& 85 %56;25;7 G #0?5D325 HIJK !"#$%& ’L85 ;5> /204@765> =M:/520665>N "#-OKPJ 54 8: =M:765 76?:27:645N ;:6> 8: >796:87>:4706 ;5> )Q’R 54 O ;:6> 85> =588185> P S12T *2U V2@;@27= P:4451W *2@>7;564 ;1 S12T ,2U P@6@;7=45 F:6012T ,725=4512 ;5 4MX>5 ,2U V5;527=: P56?56147 ’://024512 ,2U #1:8: F0065T ’://024512 ,2U S5:6 *M787//5 .52351?:8 &W:D76:4512 ,2U #05885 ,0T56 &W:D76:4512

Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Embed Size (px)

Citation preview

Page 1: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!

!

"#$%&'($)&!*+'$(!,&(-+')&(!

!

).&(&!

/012!0345672!85!92:;5!;5!!

,<-)&"'!

(=756=5>!;5!8:!?75!54!;5!8:!>:64@!

&=085!,0=402:85A!B@6@47C15!$DD16080975!$6E5=47080975!54!

,@?580//5D564!

,7>=7/8765A!$DD16080975!

!

!

*2@>564@5!54!>0145615!/1387C15D564!!

/:2!F72:!)<.F&!

!85!%56;25;7!G!#0?5D325!HIJK!

!

!

!

!"#$%&!'L85!;5>!/204@765>!=M:/520665>N!"#-OKPJ!54!8:!

=M:765!76?:27:645N!;:6>!8:!>796:87>:4706!;5>!)Q'R!54!O!

;:6>!85>!=588185>!P!

!

! ! ! ! ! !

! ! ! ! ! S12T!*2U!V2@;@27=!P:4451W! ! ! ! *2@>7;564!;1!S12T!

,2U!P@6@;7=45!F:6012T! ! ! ,725=4512!;5!4MX>5!!

,2U!V5;527=:!P56?56147! ! ! '://024512!

,2U!#1:8:!F0065T! ! ! ! '://024512!

,2U!S5:6!*M787//5!.52351?:8! ! &W:D76:4512!

,2U!#05885!,0T56! ! ! ! &W:D76:4512!

!

Page 2: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!"#$%&'()*(+($,-

!"#$% &"'$#$%()$%*)++#',%-.&%(#&"#/%&"'%&')0%-1%23+-&')$'$%)/,% #00./#&45% #/%678#&)9%:'*;'+%

,'$% '/1)/&$%0)9),'$% <% =/$&#&.&% >.+#'% ?3)+#$@A% ./,'+% &"'% ,#+'*&#-/% -1% B+% CD/D,#*&'%E)/-.+4F% =&% ()$%

1./,',%G4%)%,-*&-+)9%1'99-($"#8%-1%1-.+%4')+$%8+-H#,',%G4%>.+#'%=/$&#&.&'F%%

E4%$#/*'+'%+'I)+,$%&-%B+%CD/D,#*&'%E)/-.+4%1-+%+'*'#H#/I%0'%#/%"'+%&')0A%1-+%I#H#/I%0'%&"'%

-88-+&./#&4%&-%$&)+&%)%G').&#1.9%&"'$#$A%1-+%"'+%*-/1#,'/*'%)/,%$.88-+&A%)H)#9)G#9#&4%)/,%*-)*"#/IF%=&%#$%

(#&"%"'+%8+'$'/*'%)/,%'/*-.+)I'0'/&%&")&%=%*-.9,%)*"#'H'%04%I-)9$F%=%&")/;%"'+%1-+%9'&&#/I%0'%$")+'%

"'+%$*#'/&#1#*%;/-(9',I'F%6'+%+'0)+;$A%+'J.#+'0'/&$%)/,%I.#,)/*'%"'98',%0'%&-%#08+-H'%04%(-+;F%

K"'%)9()4$%I)H'%0'%&"'%+#I"&%*-/,#&#-/$%1-+%&"'%+')9#L)&#-/%-1%04%&"'$#$F%=%)0%H'+4%I+)&'1.9%&-%"'+%1-+%

&"'%#/&'+/)&#-/)9%*-/1'+'/*'$%)/,%&+#8$%)G+-),%#/%("#*"%=%8)+&#*#8)&',F%CD/D,#*&'%()$%)/%'M)089'%1-+%

0'%(#&"%)99%"'+%8)$$#-/%)/,%'/&".$#)$0% 1-+% +'$')+*"F%K"'% &).I"&%0'% &-%G'9#'H'% #/%04%)G#9#&#'$%)/,%

I#H'%&"'%G'$&%-1%04$'91F%

=%(-.9,%)9$-% 9#;'%&-%&")/;%)99%&"'%0'0G'+$%-1%&"'%N.+4%("-%")H'%)I+'',%&-%N.,I'%04%&"'$#$O%

P','+#*)%C'/H'/.&#A%:.)9)%E--/'4A%Q')/R3"#9#88'%6'+G'.H)9A%P+D,D+#*%C)&&'.M%)/,%:-'99'%B-4'/F%=/%

8)+&#*.9)+A%=%&")/;%P','+#*)%C'/H'/.&#%)/,%:.)9)%E--/'4%&")&%I)H'%0'%&"'%"-/-+%&-%G'%&"'%+'8-+&'+$%

-1%04%&"'$#$F%

=%,''894%&")/;%)99%&"'%0'0G'+$%-1%=:KSTE%U/#&%UVWVX%1-+%&"'%$.88-+&%&"'4%")H'%I#H'/%0'F%

E4% &")/;$% &-% &"'% &')0%-1%B+%Y/)%E)+#)% Z'//-/%B.0D/#9% &")&%G'9-/I$% &-% &"'% =:KSTE%U/#&%

U[X\%#/%>.+#'%=/$&#&.&'F%

=%&")/;%)99%04%*-99')I.'$%1-+%&"'#+%$.88-+&%)/,%I--,%".0-+A%1-+%-.+%1+.#&1.9%,#$*.$$#-/$%)/,%

1-+% &"'%")884% &#0'$% $")+',%,.+#/I% &"'$'% 1-.+% 4')+$F% =/% 8)+&#*.9)+O% K-8"#)A% K#I/'A%E4+#)0A% K)+)/&#$A%

=+#/#A%E#+#)/)A%Y9#*#)A%B'98"4/'A%B)0'94$A%>")/&)9%)/,%P'+/)/,-F%

E)/4%&")/;$%&-%)99%04%1+#'/,$%&")&%")H'%)+-.$',%#/%0'%&"'%8'+$'H'+)/*'%/'*'$$)+4%&-%'/)G9'%

&"'% *-089'&#-/% -1% 04% &"'$#$% #/% 8)+&#*.9)+O% !)/#)A% Z]0)A% Q"'#004A% :--+A% K.L)//'A% >"+#$&'99'A% K)94A%

Q-)/)A% Q),A% S9#'A% >")+G'9A% >"D+#/'A%:)&")9#'A%Y9'MA%T)/#)A%T)1#1A% C+./)A%3)&+#*;A%T-9)/,A%Y40)/A% !-/4%

)/,%Q-'F%

!"#$%(-+;% #$%,',#*)&',%&-%04%,')+%8)+'/&$% ?0-0%)/,%,),@A%04%$#$&'+$%:),#/'A%T)()/'%)/,%

B-/)A%04%/#'*'$%)/,%/'8"'($%K'+'/)A%^-4)A%!-/#A%G)G4% Q-'%)/,%_)+9F%`#&"-.&%4-.A% =%(-.9,%/-&%G'%

"'+'F%

Z'G)/-/%04%*-./&+4A%

3)+#$%04%9-H'a%

b!+.$&%#/%,+')0$A%1-+%#/%&"'0%#$%"#,,'/%&"'%I)&'%&-%'&'+/#&45%?c#G+)/%_")9#9%c#G+)/@%

!

Page 3: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!""

"

!""#$%&!'&()*+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+-"

&)'#(./0'&()+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+12"

'3$+&44/)$+#$*5()*$+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+12"

#$%&'(')*"$(+"'**,(-.-/0"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!2"

345")6%,//.5"7-%"58')65(95"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!2"

345"'(($65"'**,(5"%5):-()5"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!2"

345"$+$:6';5"'**,(5"%5):-()5"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!<"

"+67453(07'$*+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+18"

=')6-%'9$."-;5%;'5&"$(+">5(5%$.'6'5)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!?"

@"95.."A,B)56)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!C"

D(($65EF'G5"@"95..)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!C"

@E!"$(+"H$%/'($."I-(5"@"95..)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!C"

J+$:6';5"@"95..)"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!K"

L-..'9,.$%"@"95..)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!K"

M5/,.$6-%0"@"95..)"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!K"

@"95.."$96';$6'-("111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!N"

A'65)"-7"J(6'/5("5(9-,(65%"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!N"

345"F0*:4"(-+5"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!O"

345"):.55("111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!O"

345"9-(6586"-7"@"95.."%59-/('6'-("11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!P"

M59-/('6'-("-7")-.,B.5"$(6'/5("1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!P"

M59-/('6'-("-7".$%/5"$(6'/5("'(";';-"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!P"

H$9%-:4$/5E*5+'$65+":%5)5(6$6'-("111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!Q"

#RE*5+'$65+":%5)5(6$6'-("111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!Q"

L#R)E*5+'$65+":%5)5(6$6'-("111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"!Q"

345"@E95.."'**,(-.-/'9$.")0($:)5"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<2"

@RM")'/($.'(/"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<!"

J96';5":.$05%)"'("'('6'$6'(/"@RM")'/($.'(/"1111111111111111111111111111111111111111111111111111111111111111111111111111111111"<?"

345"SMH":%-65'()"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<?"

345"#-G?T>%B<"$+$:6-%)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<C"

R#!QTR#<!TR#P!TD5,!?"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<C"

@JLL"$(+"JUMDF"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<K"

R#C2ER#C2F"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<N"

!)'&9$)+5#(0$**&)9+!).+5#$*$)'!'&()+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+:;"

Page 4: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<""

"

H=R"9.$))"DD"$(6'/5(":%5)5(6$6'-("1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<O"

345"R$645:)'("7$*'.0"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"<Q"

J):$%$/'(5"S(+-:5:6'+$)5"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"?!"

345"'(;$%'$(6"94$'(V"$"94$'("-7"9-**$(+"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111"?<"

D(;$%'$(6"94$'(":%-95))'(/"$(+"$(6'/5(":%5)5(6$6'-("111111111111111111111111111111111111111111111111111111111111111"??"

D(;$%'$(6"94$'("$(+"@"95.."+5;5.-:*5(6"11111111111111111111111111111111111111111111111111111111111111111111111111111111111"?K"

D(;$%'$(6"94$'("$(+"'(7.$**$6-%0")'/($.'(/"111111111111111111111111111111111111111111111111111111111111111111111111111111"?O"

D(;$%'$(6"94$'("$(+"+')5$)5)"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"?P"

R.$))'9$."H=R"9.$))"D":%5)5(6$6'-("$(+"9%-))":%5)5(6$6'-("11111111111111111111111111111111111111111111111111111111111111"?P"

H=R"9.$))"D":%5)5(6$6'-("11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"?P"

U5:6'+5"B'(+'(/"6-"H=RED"*-.59,.5)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"C2"

U%-65$)-*5V"'**,(-:%-65$)-*5"$(+"640*-:%-65$)-*5"111111111111111111111111111111111111111111111111111111"C!"

R%-))":%5)5(6$6'-("111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"C<"

DMJU"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"CK"

5!'3(9$)+#$0(9)&'&()+#$0$5'(#*+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+-<"

A59%565+"UMM)"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"CN"

R06-)-.'9"UMM)"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"CO"

MD>EF'G5"45.'9$)5)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"CO"

#JD"$(+"JDH<"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"CQ"

WX#EF'G5"M595:6-%)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"CQ"

3%$()*5*B%$(5"%595:6-%)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"K2"

F596'(5)"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"K2"

3-..EF'G5"%595:6-%)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"K!"

S8:%5))'-("-7"3-..EF'G5"%595:6-%)"'("@".0*:4-9065)"111111111111111111111111111111111111111111111111111111111111111111"K?"

S86%$95..,.$%"3FM)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"KK"

3FM"!V"<"$(+"N"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"KK"

3FMC"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"KK"

3FMKV"3FM!2V"3FM!!"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"KN"

D(6%$95..,.$%"3FM)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"KN"

3FM?"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"KN"

3FMOT3FMP"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"KP"

3FMQ"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"N2"

3FM)")'/($.'(/"$(+"6%$77'9G'(/"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"N?"

3FM)"$(+"645'%"45.:5%)"11111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"NN"

Page 5: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?""

"

H5*B%$(5"B-,(+"%5/,.$6-%)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"NN"

D(6%$95..,.$%"M5/,.$6-%)"111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"NN"

345"YWRQ?@!"9$)5"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"NO"

#$*/6'*+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+;2"

@$9G/%-,(+V"40:-645)')"$(+"$'*)"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"O2"

5=>?+!+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+;1"

D1D(;$%'$(6"94$'("%5/,.$65)"3FMO"6%$77'9G'(/"$(+")'/($.'(/"'(":%'*$%0"@"95..)"111111111111111111111111111111111111"O!"

DD1"J):$%$/'(5"5(+-:5:6'+$)5"%5/,.$65)"HX>"$(6'/5(":%5)5(6$6'-("B0"*-+,.$6'-("-7"9$645:)'("F"

$96';'60"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"O?"

DDD1"D(6%$95..,.$%"3-..EF'G5"%595:6-%)"%59%,'6*5(6"$(+"9.5$;$/5"'("5(+-)-*$."T".0)-)-*$."-%/$(5..5)

"1111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111"PN"

DZ1"D(";'6%-"+'/5)6'-()"&'64":%-65$)5)":%-+,9'(/"H=R"9.$))"DD".'/$(+)"1111111111111111111111111111111111111111111111"PO"

5=>?+"@+0AB?>CDE?CAB+?A+A?FG>+HEDICJ=?CABK+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+LL"

D1"A6-%$/5"5(+-)-*5)"9-(6%-."3FMQ")'/($.'(/"'("+5(+%'6'9"95..)"11111111111111111111111111111111111111111111111111111111"PP"

DD1"J):$%$/'(5"5(+-:5:6'+$)5"')"%5[,'%5+"7-%"3FMO")'/($.'(/"$(+"'(7.,5(I$"'(7596'-("1111111111111111111111"Q2"

DDD1"3FMKV"DFE!\")59%56'-("$(+"$):$%$/'(5"5(+-:5:6'+$)5"$%5"9%'6'9$."7$96-%)"7-%"$.;5-.$%"

*$9%-:4$/5)":4$/-906-)')"]"B$965%'$."G'..'(/"1111111111111111111111111111111111111111111111111111111111111111111111111111111111"Q!"

.&*0/**&()+!).+5$#*5$0'&%$*+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+M:"

"&"6&(9#!537+,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+122"

"

" !

Page 6: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

C""

"

!""#$%&!'&()*+

JSU^"J):$%$/'(5"S(+-:5:6'+$)5"

JD#^"J96';$6'-("D(+,95+"#5$*'($)5"

JUR^"J(6'/5(":%5)5(6'(/"95..)"

JU^"J+$:6-%"U%-65'("

$U_R`"^"J60:'9$.":%-65'("G'($)5"R"I56$"

JAR^"J:-:6-)')E$))-9'$65+"):59GE.'G5":%-65'("9-(6$'('(/"$"9$):$)5"$96';$6'-("$(+"%59%,'6*5(6"+-*$'("

\<E*^"\<E*'9%-/.-B,.'("

@RM^"@"R5.."M595:6-%"

@%5/)^"M5/,.$6-%0"@"95..)"

R![^"!-*:.5*5(6"9-*:-(5(6"!V"[""

R?^"R-*:.5*5(6"9-*:-(5(6"?"

RDD3J^"R.$))"DD"3%$()J96';$6-%""

RDDZ^"R.$))"DD"9-(6$'('(/"Z5)'9.5)"

RJM#^"R$):$)5"M59%,'6*5(6"+-*$'()"

RBF^"R$)'6$)"@EF'(5$/5"F0*:4-*$"

RRZ^"R$.64%'("9-$65+";5)'9.5)"

R#<!^"R-*:.5*5(6"%595:6-%"<"

R#P!^"D(65%75%-(E'(+,95+"6%$()*5*B%$(5":%-65'("!"

RFU^"R-**-(".0*:4-'+":%-/5('6-%"

RFM)^"RE60:5".596'("%595:6-%)"

RWa^"R$.(58'("

RU^"R-%5":$%6'9.5"

RM!^"R-*:.5*5(6"%595:6-%"!"

RM<^"R-*:.5*5(6"%595:6-%"<"

RMU^"R"M5$96';5":%-65'("

Page 7: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

K""

"

RM3^"R$.%56'9,.'("

RAM^"R.$))")&'694"%59-*B'($6'-("

9AHJR^"R5(6%$."AHJR"

R3#F^"RE60:5".596'(E.'G5"+-*$'("

R3F^"R06-6-8'9"3".0*:4-9065)""

RaRF!?^"REaER"*-6'7"945*-G'(5"!?T"@".0*:4-9065"945*-$66%$96$(6"b@FRc"

#JHU)^"#$(/5%EJ))-9'$65+"H-.59,.$%"U$665%()"

#R)^"#5(+%'6'9"95..)""

#READ>W^"#RE):59'7'9"DRJH?E/%$BB'(/"(-(E'(65/%'("

#SWZ^"#5(/,5";'%,)"

#WJ^"#5-80%'B-(,9.5'9"$9'+"

#XR_P^"#5+'9$6-%"-7"906-G'(5)')"P"

#-G?^"J+$:6-%":%-65'("+-&()6%5$*"-7"G'($)5"

#M^"#5$64"M595:6-%"

#M'U)^"#57596';5"%'B-)-*$."U%-+,96"

SJS^"S8:5%'*5(6$."J,6-'**,(5"S(95:4$.-*05.'6')"

S@Z^"S:)65'("@$%%"Z'%,)"

SHRZ^"S(95:4$.-*0-9$%+'6')"Z'%,)"

SM^"S(+-:.$)*'9"M56'9,.,*"

SMJ#^"S(+-:.$)*'9"M56'9,.,*"J))-9'$65+":%-65'("#5/%$+$6'-("

SM>DR^"SME>-./'"'(65%*5+'$65"9-*:$%6*5(6"

SMH^"SI%'(EM$+'8'(EH-5)'("

L#R)^"L-..'9,.$%"+5(+%'6'9"95..)"

LZ^"L%,'6"Z'%,)"

>%B<^">%-&64"7$96-%"M595:6-%"B-,(+":%-65'("<"

=SZ^"='/4"S(+-645.'$.";5(,.5)"

=FJ^"=,*$("F5,9-9065"J(6'/5("

Page 8: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

N""

"

=H>@!^"='/4EH-B'.'60"/%-,:"B-8!"

=):O2^"=5$6")4-9G":%-65'("O2"

=AZ^"=5%:5)"A'*:.58"Z'%,)5)""

=3FZE!^"3E95..".5,G5*'$";'%,)"!"

=I^"=5*-I-'("

DRJH!^"D(6%$95..,.$%"$+45)'-("*-.59,.5"

DRJH!^"D(6%$95..,.$%"J+45)'-("H-.59,.5E!"

DER.':)^"D(6%$*5*B%$(5ER.5$;'(/"U%-65$)5"

D#S^"D(),.'("+5/%$+'(/"5(I0*5"

DLW^"D(65%75%-("

DLWEd^"D(65%75%-(Ed"

DLWJM^"30:5"D"DLW"%595:6-%"

D/^"D**,(-/.-B,.'("

D'^"D(;$%'$(6"94$'("

DFE!M!^"DFE!"M595:6-%"60:5!"

DUAE!^"DLW\":%-*-65%")6'*,.$6-%E!"

DA^"D**,(-.-/'9$."A0($:)5"

D3JH^"D**,(-%595:6-%E60%-)'(5"B$)5+"$96';$6'(/"

FJHUE!^"F0)-)*$."J))-9'$65+"H5*B%$(5"U%-65'("E!"

D5,"!?^"345"656%$):$('("7$*'.0":%-65'("

FLJE!^"F0*:4-9065"7,(96'-(E$))-9'$65+"$(6'/5(E!"

FUA^"F':-:-.0)$94$%'+5"

FMM)^"F5,9'(5E%'94"%5:5$6"

F0(^"30%-)'(5E#$%&'()"G'($)5""

HJR!^"H$9%-:4$/5"%595:6-%"!"

HJF^"H0+PPE$+$:6-%".'G5"

HJU_^"*(&%+'),-.&(/-&'0"#$%&'()"1()-2'"

Page 9: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

O""

"

HJZ)^"H'6-94-(+%'$."$(6';'%$.":%-65'("

H@F^"H$((-)5E@'(+'(/"F596'("

HRHEZ^"H-,)5"906-*5/$.-;'%,)"

H#E<^"H05.-'+"+'775%5(6'$6'-("7$96-%"<"

H#JEK^"H5.$(-*$"+'775%5(6'$6'-(E$))-9'$65+"/5(5"K"

H=R^"H$e-%"4')6-9-*:$6'B'.'60"9-*:.58"

H3XR^"H'9%-3,B,.5)"X%/$('I'(/"R5(65%"

H0+PP^"H05.-'+"+'775%5(6'$6'-(":%'*$%0"%5):-()5":%-65'("PP"

Hf^"H$%/'($."f-(5"

WJR=3^"W,9.5-6'+5"B'(+'(/"$(+"-.'/-*5%'I$6'-("

W_3^"W$6,%$."_'..5%"3"95..)"

UJHU)^"U$64-/5(EJ))-9'$65+"H-.59,.$%"U$665%()"

U@HR^"U5%':45%$."B.--+"*-(-9065)"

UFR^"U5:6'+5".-$+'(/"9-*:.58"

UMM^"U$665%("M59-/('6'-("M595:6-%"

:AHJR^":5%':45%$."AHJR"

U3a?^"U5(6%$8'("?"

U3aC^"U5(6%$8'("C"

MJ>S^"M595:6-%"7-%"$+;$(95+"/.09$6'-("5(+E:%-+,96)"

M#^"M5:%5))-%"#-*$'("

MD>^"M56'(-'9"$9'+"'(+,9'B.5"/5(5"

MFM^"MD>ED"F'G5"M595:6-%"

MF=^"MD>ED"F'G5"=5.'9$)5"

MWJ^"M'B-(,9.5'9"$9'+"

MAZ^"M5):'%$6-%0"A0(906'$."Z'%,)"

AJU^"A5%,*"J*0.-'+"U"9-*:-(5(6"

ARA^"A,B9$:),.$%")'(,)"

Page 10: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

P""

"

A=H^"A-*$6'9"40:5%*,6$6'-("

AHJR)^"A,:%$*-.59,.$%"J96';$6'-("R.,)65%"

AFX^"A59-(+$%0".0*:4-'+"X%/$()"

AXR^"A6-%5"X:5%$65+"R$.9',*"

AFS^"A0)65*'9"F,:,)"S%0645*$6-),)"

AUEJV"AUE#^"A,%7$96$(6":%-65'("J"$(+"#"

AUUF<$^"A'/($.":5:6'+5":5:6'+$)5".'G5"<$"

))MWJ^"A'(/.5")6%$(+5+"MWJ"

A3DH!^"A6%-*$."D(65%$96'-("H-.59,.5"!"

A3DH<^"A6%-*$."D(65%$96'-("H-.59,.5"<"

A0G^"A:.55("60%-)'(5"G'($)5"

3!"@"95..^"3%$()'6'-($."A6$/5"!"@"95.."

3<"@"95..^"3%$()'6'-($."A6$/5"<"@"95.."

3JU^"3%$():-%65%"$))-9'$65+"&'64"$(6'/5(":%-95))'(/"

3@_E!^"3JW_"@'(+'(/"G'($)5"!"

3RM^"3"R5.."M595:6-%"

3#UC?^"3JME#WJ"B'(+'(/":%-65'("C?""

3>W^"3%$()E>-./'"W56&-%G"

3FM)^"3-..EF'G5"M595:6-%)"

3UU"DD^"3%':56'+0."U5:6'+$)5"DD"

3MJDF^"3WLE%5.$65+"$:-:6-)')E'(+,9'(/".'/$(+"

3MJH^"3MDLEM5.$65+"J+$:6-%"H-.59,.5"

3MDL^"3DM"+-*$'(E9-(6$'('(/"$+$:6-%":%-65'("'(+,9'(/"DLW\"

ZJHU?^"Z5)'9.5"J))-9'$65+"H5*B%$(5"U%-65'("?"

ZRJHE!^"Z$)9,.$%"R5.."J+45)'-("H-.59,.5"

ZFJE!^"D(6%$95..,.$%"J+45)'-("H-.59,.5E!"

ZFU^"Z'%,)"F'G5"U$%6'9.5"

Page 11: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Q""

"

gWZ^"g5)6"W'5."Z'%,)"

f@U!^"fE#WJ"B'(+'(/":%-65'("

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

Page 12: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2""

"

&)'#(./0'&()+

'3$+&44/)$+#$*5()*$+

#$%&'(')*"$(+"'**,(-.-/0"

" "J%64,%" A'.;5%)65'(" :-'(65+" -,6" 64$6" 645" #$%&'(')*" 645-%0" ')" $" )56" -7" 7';5" ),B645-%'5)^"

5;-.,6'-("#'$" 2'V" 9-**-("+5)95(6V"/%$+,$.')*V" ):59'$6'-("$(+"($6,%$." )5.596'-(1"=5"$.)-"+5)9%'B5+"

645"#$%&'('$("'(7.,5(95"-("4')"'**,(-.-/'9$."64-,/46)"+,%'(/"'6)"7-%*$6';5"05$%)1"

345")6%,//.5"7-%"58')65(95"

" " 345"#$%&'('$(h)"645-%0"i),%;';$."-7"645"7'665)6j"')"B$)5+"-("645"),%;';$."-7"'(+';'+,$.)"

$*-(/" 645" )$*5" ):59'5V" $" )5.596'-(" 7$;-%'(/" 64-)5" B5)6" 6-" 9-*:5651" D6" &$)" D.0$"H5694'(G-77V" 645"

7$645%"-7"'(($65"$(+"95..,.$%"'**,('60V"&'64"4')":4$/-906'9"645-%0"-7"'**,('60V"&4-"),//5)65+"64$6"

645"9%'6'9$.")6%,//.5"'("+')5$)5"')"B56&55("+'775%5(6"):59'5)"$(+"64,)"'..,)6%$6'(/"645"'*:-%6$(6"%-.5"-7"

645"i-,6)'+5%jk"645"'**,(5"%5):-()5"%5:%5)5(6)"645":%'(9':$."&5$:-(",)5+"B0"645"4-)6"6-"7'/46"645"

:$64-/5('9" -%/$(')*" $96';5.01" " F$65%" -(V" '(" !QPOV" U$,." S4%.'9" +5)9%'B5+" 645" )'+5" 94$'(" 645-%0" -7"

$(6'B-+0"7-%*$6'-("64$6"7'6)"&'64"645"#$%&5('5("645-%0"$(+"&4'94"'*:.'5)"64$6"):59'7'9"%595:6-%)"7-%"

(,6%'5(6)V"6-8'()"$(+")-V"4$+"5;-.;5+"6-":5%*'6"645"95.."6-":5%7-%*"'6)"(-%*$.":40)'-.-/'9$.":%-95))5)1"

J6" 645" 6,%(" -7" !Q64" 95(6,%0V" J*5%'9$h)" .5$+'(/" :$64-.-/')6V"g'..'$*"g5.94" %5;'5&5+"H5694'(G-77h)"

:4$/-906'9" 645-%0" $(+" 645(" S4%.'94h)" )'+5l94$'(" 645-%0" -7" %595:6-%)" $(+" $+;$(95+" $"*-)6" 9,%'-,)"

645-%0" -7" '**,(-.-/'9$." 7,(96'-(" $(+" -7" '**,(-:$64-.-/0V" ),//5)6'(/" 64$6" B$965%'$" *'/46" 4$;5"

5;-.;5+"$("'**,(5"+575()5"*594$(')*"7-%"645'%":%-6596'-("7%-*"645'%";5%65B%$65"-::-(5(6)"b!c1""

J.64-,/4" 645)5" 6&-"*$e-%" +')9-;5%'5)V" -7" 645" $(6'B-+'5)" $(+" -7" 645" :4$/-9065)V"&5%5" $"*$665%" -7"

+5B$65" 7-%" 645" )9'5(6')6)"-7" 64$6"5%$V"(-&$+$0)" '6" ')"&'+5.0"$995:65+" 64$6" 645" '**,(5")0)65*",)5)"

B-64"+575()5"*594$(')*1" 34')" .5$+)" 6-" 645" 7,(+$*5(6$." 9.$))'7'9$6'-("-7" '**,('60" '(6-" 6&-"*$e-%"

B%$(945)^"645"'(($65"$(+"645"$+$:6';5"'**,(5"%5):-()51""

345"'(($65"'**,(5"%5):-()5"

" 345" '(($65" '**,(5" %5):-()5" ')" 645":-65(6"5$%.0" .'(5"-7"+575()5"*594$(')*V"9-*:565(6" 6-"

+56596"$(+"5.'*'($65"5;5%0" '(;$+'(/"*'9%--%/$(')*"B0"+')9%'*'($6'(/"B56&55("645"i'(7596'-,)"(-(E

)5.7j"$(+"645"i(-(E'(7596'-,)")5.7j1"345"%59-/('6'-("-7"*'9%-B'$."(-(E)5.7"')"B$)5+"-("645"+56596'-("-7"

9-()5%;5+"*-.59,.$%" :$665%()" 64$6" $%5" 5))5(6'$." :%-+,96)" -7"*'9%-B'$." :40)'-.-/01" 345)5" '(;$%'$(6"

)6%,96,%5)"$%5"%575%%5+"6-"$)"U$64-/5(EJ))-9'$65+"H-.59,.$%"U$665%()"bUJHU)c"$(+"$%5":%-+,95+"B0"

$.." *'9%--%/$(')*)" b:$64-/5('9" -%" (-6c1" 345" UJHU)" $%5" 9-()'+5%5+" $)" *-.59,.$%" )'/($6,%5)" -7"

'(7596'-(V" $(+" 645'%" %59-/('6'-(" B0" 645" %595:6-%)" -7" 645" '(($65" '**,(5" )0)65*V" 645" U$665%("

Page 13: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!""

"

M59-/('6'-("M595:6-%)"UMM)V".5$+)"6-"645"'(+,96'-("-7"$("'**,(5"%5):-()5"b<c1"345"'(($65")0)65*"')"

,(';5%)$." $(+" 5;-.,6'-($%'.0" $)" $(9'5(6" $)" :.$(6)V" '(;5%65B%$65)" $(+" ;5%65B%$65)V" $(+" :%$96'9$..0" $.."

*,.6'E95..,.$%"-%/$(')*)"9$("*-,(6"$("'(($65"'**,(5"%5):-()51"

345":40)'9$."B$%%'5%)":%5)5(6"$6"645"5(6%0"/$65)"-7"645"B-+0"b)G'(V"*,9-)$"-7"645"$'%&$0V"5:'645.'$"-7"

645" /$)6%-'(65)6'($." 6%$96" $(+" 645" .,(/)c" $%5" 645" '('6'$." 9-*:-(5(6)"*5+'$6'(/" '(($65" '**,('60V" $)"

&5.." $)" 645" 945*'9$." B$%%'5%)" .'G5" $(6'E*'9%-B'$." :5:6'+5)1" @-64" $('*$.)" $(+":.$(6)" :-))5))" :-65(6V"

B%-$+"):596%,*"-7"$(6'E*'9%-B'$.":5:6'+5)V"&4'94"6450",)5"6-"+575(+"7%-*"$"&'+5"%$(/5"-7"*'9%-B5)V"

'(9.,+'(/" B$965%'$V" 7,(/'V" ;'%,)5)" $(+" :%-6-I-$1" J(6'E*'9%-B'$." :5:6'+5)V" :%-+,95+" '(" i+575()';5"

6')),5)j" b5:'645.'$." 6')),5)V" B.--+" 95..)V" .';5%V" )$.';$11cV" 6$%/56" 75$6,%5)" -7" 645" *'9%-B'$." 95..,.$%"

*5*B%$(5"64$6"+')6'(/,')45)"B%-$+"):59'5)"-7"*'9%-B5)"7%-*"*,.6'E95..,.$%":.$(6)"$(+"$('*$.)"b?c1""

D(" 645" )59-(+" .'(5" -7" '(($65" '**,(5" %5):-()5V" .5,9-9065)" 6$G5" -;5%V" B0" *'/%$6'(/" 6-" 645" )'65" -7"

'(7596'-(" $(+" 5.'*'($6'(/" '(;$+'(/" :$64-/5()" $(+" 95..,.$%" +5B%')1" 345" *-)6" %5:%5)5(6$6';5" &4'65"

B.--+" 95..)" $%5^" 5-)'(-:4'.)V" B$)-:4'.)V"*$)6" 95..)" $(+" ($6,%$." G'..5%)" 64$6" '(+,95" +5$64" B0" 95..E95.."

9-(6$96V"$(+":4$/-9065)"'(9.,+'(/"*$9%-:4$/5)V"(5,6%-:4'.)"$(+"+5(+%'6'9"95..)"64$6"$96"B0"5(/,.7'(/"

$(+"+5/%$+'(/" 645":$64-/5(" 7-%" '6)" ),B)5[,5(6" :%5)5(6$6'-(" 6-" 3" 95..)V" $(+" 64,)" 9%5$6'(/" $" B%'+/5"

B56&55("645"'(($65"$(+"$+$:6';5"'**,('601""

X(5" *-%5" 577596';5" 9-*:-(5(6" '(" 645" '(($65" '**,(5" %5):-()5" *$94'(5%0" ')" 645" 9-*:.5*5(6"

)0)65*1" D6" 9-()')6)" -7" $" )56" -7" '($96';5" 9-*:-(5(6)" 64$6" $%5" .'(G5+" $(+" $96';$65+" '(" $" 9$)9$+'(/"

*$((5%1"34')"B'-945*'9$."9$)9$+5"')"$96';$65+";5%0"5$%.0"'("645"%5):-()5"B0"64%55"*$e-%":$64&$0)^"!m"

645"$.65%($6';5":$64&$0"64$6"')"$96';$65+"-("B'-.-/'9$."),%7$95"'("645":.$)*$"$(+"$.."-645%"B-+0"7.,'+)"

bCcV"<m"645"9.$))'9$.":$64&$0"64$6" ')"6%'//5%5+"B0"$("$(6'B-+0"B-,(+"6-"645"6$%/56"$(6'/5("bKc"$(+"?m"

645" .596'(5":$64&$0" 64$6" ')" '('6'$65+"B0" 9$%B-40+%$65)" -("*'9%-B'$." ),%7$95)" bNV" Ock" $(+" 64,)" 645)5"

64%55":$64&$0)"*5+'$65"645"9.5$%$(95"-7"$:-:6-6'9"95..)"$(+"645"%5*-;$."-7":$64-/5()"64$6"5(),%5"

95..,.$%" '(65/%'60" $(+" 6')),5" 4-*5-)6$)')1" W5;5%645.5))V" +0)%5/,.$6'-(" -7" 645" 9-*:.5*5(6" 9$)9$+5"

9-,.+"%5),.6"'("'**,(-E:$64-.-/'5)"$(+"$,6-'**,(5"+')5$)5)"bA0)65*'9"F,:,)"S%0645*$6-),)"bAFScV"

U0-/5('9" '(7596'-()V" H5*B%$(-:%-.'75%$6';5" /.-*5%,.-(5:4%'6')V" 60:5" DD" bHU>W" DDcV" J60:'9$."

4$5*-.06'9",%$5*'9")0(+%-*5"b$=YAcV"=$5*-.0)')"$(+"34%-*B-)')V":$%6'$.".':'+"#0)6%-:40V"n1c1"H$(0"

%5/,.$6-%0"$(+"'(4'B'6-%0":%-65'()"&5%5"+5;5.-:5+"6-"$;-'+"'**,(5"+')-%+5%)"bPc1"

F$)6" B,6" (-6" .5$)6V" 645" '(($65" '**,(5" )0)65*" ')" 5[,'::5+" &'64" '(($65" %595:6-%)" 64$6" &'.." B5"

:%5)5(65+".$65%"-(V"'("+56$'.)1"

Page 14: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!<""

"

345"$+$:6';5"'**,(5"%5):-()5"

" 345"$+$:6';5"'**,(5"%5):-()5)"5*5%/5"75&"+$0)"$765%"'('6'$."'(7596'-("$(+")4-&"7-,%"95(6%$."

94$%$965%')6'9)^" *5*-%0V" ):59'7'9'60V" +';5%)'60V" $(+" )5.7E(-()5.7" +')9%'*'($6'-(1" 345" 7,(+$*5(6$."

:$%6'9':$(6)" *5+'$6'(/" $+$:6';5" '**,(5" %5):-()5" $%5" 645" )*$.." &4'65" B.--+" 95..)" G(-&(" $)"

.0*:4-9065)1" F0*:4-9065)" -%'/'($65" 7%-*" 45*$6-:-'56'9" )65*" 95..)" %5)'+'(/" '(" 645" B-(5"*$%%-&k"

&45%5$)" $" ),B)56" *'/%$65" 6-" 645" 640*,)" 6-" +'775%5(6'$65" '(6-" 3" 95..)V" -645%)" %5*$'(" '(" 645" B-(5"

*$%%-&"6-"9-*:.565" 645'%"+5;5.-:*5(6" '(6-"@"95..)" bQc1"#,%'(/" 645'%"5$%.0"+5;5.-:*5(6$." )6$/5)V"3"

$(+"@".0*:4-9065":%-/5('6-%)"%5$%%$(/5"+'775%5(6")56)"-7":%-6-60:'9"D**,(-/.-B,.'("bD/c";$%'$B.5"bZcV"

+';5%)'60" b+c" $(+" e-'('(/" boc" /5(5" )5/*5(6)" 6-" /5(5%$65" 645" $(6'/5(" B'(+'(/" %5/'-()" -7" 645'%" 3" 95.."

%595:6-%" b3RM)c"$(+"@"95.." %595:6-%" b@RM)c1"345"+'775%5(6"Zb#co"9-*B'($6'-()"$%5"+';5%)'7'5+" 7,%645%"

64%-,/4" 645" 5(I0*$6'9" $++'6'-(" -7" (-(5(9-+5+" (,9.5-6'+5)" '(" 645" e-'(6)" 9%5$65+" Zb#co" )5/*5(6"

$))5*B.0" b!2E!<c1"345" %$(+-*"($6,%5"-7" 64')"+';5%)'7'9$6'-(":%-95))" %5),.6)" '(" 645"/5(5%$6'-("-7"$("

'**5()5" %5:5%6-'%5" -7" $(6'/5(" %595:6-%)" b*-%5" 64$(" K8!2!?c" %5(+5%'(/" 645" $+$:6';5" '**,(5"

%5):-()5"9$:$B.5"-7"+5$.'(/"&'64"$"B'/";$%'560"-7":$64-/5()"&'64"/%5$6"):59'7'9'60"$(+".-(/5;'601"@"$(+"

3".0*:4-9065)"&'64"%595:6-%)"%59-/('I'(/")5.7"$(6'/5()"$%5"+5.565+"'("645'%"640*'9"$(+"B-(5E*$%%-&"

B'%64":.$95)"B0"(5/$6';5")5.596'-(1"345")5.5965+".-(/E.';5+"*$6,%5"3"$(+"@"95..)"9'%9,.$65"64%-,/4-,6"

645" B-+0" $(+" $%5" -765(" .-9$.'I5+" '(" )59-(+$%0" .0*:4-'+" -%/$()" ),94" $)" 645" .0*:4" (-+5)" $(+" 645"

):.55(" &4'94" $%5" ):59'$.'I5+" )'65)" 7-%" .0*:4-9065" $96';$6'-(" b!?cV" $(+" &45%5" 6450" *$0" 5(/$/5"

'(;$+'(/" :$64-/5()1" 3" 95..)" $%5" %5):-()'B.5" 7-%" 95..E*5+'$65+" '**,('60" B0" %59-/('I'(/" :5:6'+5)"

/5(5%$65+" 7%-*" $(6'/5()" 64$6" 4$;5" B55(" :$%6'$..0" +'/5)65+" B0" $(6'/5(" :%5)5(6'(/" 95..)V" :%'*$%'.0"

+5(+%'6'9"95..)V":4$/-906'9"95..)V"$(+"@".0*:4-9065)1"345)5":5:6'+5)"$%5":%5)5(65+"-("645"95.."),%7$95V"

&'64'("*-.59,.5)"5(9-+5+"B0"645"*$e-%"4')6-9-*:$6'B'.'60"bH=Rc"9.$))" D"$(+"DD1"3"95..)"$%5"9.$))'7'5+"

'(6-"R#Cp"45.:5%"$(+"R#P

p"906-6-8'9"3"95..)"$99-%+'(/"6-"645'%"58:%5))'-("-7"),%7$95"9-"%595:6-%)1" D("

$++'6'-(V" ($6,%$..0" -99,%%'(/" %5/,.$6-%0" 3" 95..)" bR#<Kp"R#C

pcV" &4'94" 58:%5))" 9-()6'6,6';5.0" 645"

6%$()9%':6'-(" 7$96-%" L-8:?V" 58')6" $(+" :.$0" $" 9%'6'9$." %-.5" '("*$'(6$'('(/" '**,(5" )5.7" 6-.5%$(95" $(+"

4-*5-)6$)')"B0"),::%5))'(/"$B5%%$(6"-%"5895))';5"'**,(5"%5):-()5)"64$6"$%5"4$%*7,."6-"645"4-)61"@"

F0*:4-9065)V" -(" 645" -645%" 4$(+V" *5+'$65" 4,*-%$." '**,('60" $(+" %59-/('I5" 58:-)5+" 5:'6-:5)" -7"

($6';5"$(+"'(6$96"$(6'/5()V"'(9.,+'(/"),%7$95":%-65'("$(+"9$%B-40+%$65"*-'56'5)"-7"'(;$)';5"*'9%-B5)V"

%5),.6'(/" '(" 645"+'775%5(6'$6'-("$(+"$96';$6'-("-7"@"95..)V"$":%-95))" 6-"B5"+5)9%'B5+"$(+"+')9,))5+" '("

+56$'.)"B5.-&1"

Page 15: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!?""

"

"+67453(07'$*+

=')6-%'9$."-;5%;'5&"$(+">5(5%$.'6'5)"

" J")'*:.5"+57'('6'-("-7"@".0*:4-9065)"')"$":-:,.$6'-("-7"95..)"64$6"58:%5))"9.-($..0"+';5%)5"95.."

),%7$95"D**,(-/.-B,.'("%595:6-%)"%59-/('I'(/"):59'7'9"$(6'/5('9"5:'6-:5)1"345'%"-%'/'("9$("B5"6%$95+"

6-" 645" 5;-.,6'-(" -7" $+$:6';5" '**,('60" '(" ;5%65B%$65)"*-%5" 64$(" K22"*'..'-(" 05$%)" $/-" b!<c1" @" 95.."

+5;5.-:*5(6"-99,%)"'("+'775%5(6")6$/5)"64$6"B5/'("'(":%'*$%0".0*:4-'+"6')),5"b581"=,*$("756$." .';5%"

$(+"756$.T$+,.6"B-(5"*$%%-&cV"&'64"),B)5[,5(6"7,(96'-($."*$6,%$6'-("'(")59-(+$%0".0*:4-'+"6')),5"

b.0*:4"(-+5)"$(+"):.55(c"b3(+4$'"5c1"345"7,(96'-($."5(+:-'(6" ')"645"/5(5%$6'-("-7":.$)*$"95..)"64$6"

:%-+,95"$(6'B-+'5)"6-"(5,6%$.'I5":$64-/5()"b!Cc1"

"

L'/,%5"!^"@"95.."+5;5.-:*5(6V"-0-#&'0"6$%7"8'9(')"'&"-:;"<==>"

345"+')9-;5%0"-7"@"95..)"+'+"(-6"-%'/'($65"'("645"'+5(6'7'9$6'-("-7"$"95..V"B,6"%$645%"'("645"'+5(6'7'9$6'-("

-7"$":%-65'("bD/V"$(6'B-+0c1"D+5(6'7'9$6'-("-7")5%,*"/$**$/.-B,.'("$)"645")-,%95"-7"$(6'B-+'5)"&$)"$"

.$,(94'(/":-'(6"7-%"645"5;5(6,$."+')9-;5%0"-7"$(6'B-+0":%-+,9'(/"95..)"b!Kc1"J6"645"6'*5V"6&-"+'775%5(6"

645-%'5)" -7" $(6'B-+0" 7-%*$6'-(" &5%5" 9-*:56'(/^" i645" ($6,%$." )5.596'-(j" 645-%0" $+-:65+" B0" W'5.)"

o5%(5" $(+" 645" i9.-($." )5.596'-(" 645-%0j" -7" A'%" H$97$%.$(5" @,%(56V" B-64" &'((5%)" -7" W-B5." U%'I5" '("

U40)'-.-/0"$(+"*5+'9'(51"A4-%6.0"$765%V"i9.-($.")5.596'-(j"645-%0"&$)":%-;5+"&'64"$"7'%)6"58:5%'*5(6$."

5;'+5(95")6,+0'(/")'(/.5"95..)"b!Nc1"L5&"05$%)"$765%V">1"S+5.*$("$(+"M1"U-%65%"+5)9%'B5+"645"945*'9$."

)6%,96,%5"-7"645"$(6'B-+0"*-.59,.5V"$(+"7-%"64$6V"6450")4$%5+"645"&'("-7"645"W-B5."U%'I5"'("!QO<"b!OV"

!Pc1""

Page 16: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!C""

"

"345" 94$%$965%'I$6'-(" -7" @" 95..)" -99,%%5+" '(" 645"*'+E" !QN2h)V" $(+" 5$%.0" !QO2h)V" ,)'(/" 58:5%'*5(6$."

$('*$." *-+5.)V" 9.'('9$." 5;$.,$6'-(" -7" :$6'5(6)" &'64" '**,(5" +57'9'5(90" +')5$)5)V" $(+" 645" ($)95(6"

6594(-.-/0"-7"95.."),%7$95"*-.59,.5"94$%$965%'I$6'-(^"H$8"R--:5%"$(+"M-B5%6">--+":,6"'("5;'+5(95"

645" 7,(96'-($." +';')'-("B56&55(" 645" 95..)" '(" 645" 94'9G5("B,%)$"-7"3-9$(.(42" 64$6" $%5" %5):-()'B.5" 7-%"

$(6'B-+0" :%-+,96'-(" $(+" 95..)" 64$6" %5[,'%5+" $(" '(6$96" 640*,)" 7-%" *$('75)6$6'-(" -7" +5.$05+E60:5"

40:5%)5()'6';'60" b!QV" <2c1" F$65%"-(V" '("*$**$.'$("*,%'(5"*-+5.)V" 95..)" +5%';5+" 7%-*"B-(5"*$%%-&"

&5%5"94$%$965%'I5+"$)"645"),B)56"64$6"*5+'$65)"$(6'B-+0"%5):-()5)"b<!V"<<c1"345".'(G"B56&55("@"95..)"

$(+" 645'%" :%-+,96'-(" 7-%" $(6'B-+'5)"&$)" 645(" %5;5$.5+" $765%" 645" ,)5" -7" ),%7$95" D/" 58:%5))'-(" $)" $"

*$%G5%"6-"94$%$965%'I5"(-%*$."$(+".5,G5*'9"@"95..)"b<?c1"

@"95.."A,B)56)"

" @$)5+" -(" :45(-60:'9$.V" 7,(96'-($." $(+" 6-:-/%$:4'9$." 94$%$965%')6'9)" $)" &5.." $)" 645'%" @RM"

%5:5%6-'%5V"($q;5"*$6,%5"@"95..":-:,.$6'-()"4$;5"B55("+57'(5+"$)"5'645%"'(($65E.'G5"95..)"-%"$+$:6';5"

95..)1"

D(($65EF'G5"@"95..)"

?,5"-)0"*-$+()-:"@%)'"?".'::2"

" " " @E!"95..)"b"D/H4'/4""

D/#.-&"

"HJR!p"@<<2

.-&"R#<?

E"c"$%5"5(%'945+"'("645":.5,%$."$(+"

:5%'6-(5$."9$;'6'5)" b<Cc"B,6"9$("$.)-"B5" 7-,(+" '(" 645"):.55(1"Y(.'G5" 645"9-(;5(6'-($."@E<"95..)V" 64$6"

+5;5.-:" 7%-*" 9-**-(" B-(5"*$%%-&" :%59,%)-%)" $(+" $%5" .-9$65+" '(" 645" B-(5"*$%%-&V" ):.55(" $(+"

.0*:4"(-+5)V"@E!"95..)"$%5" 64-,/46" 6-"$%')5"5$%.0" '("-(6-/5(0" 7%-*"+5+'9$65+":%-/5('6-%)" 7-,(+" '("

645"/%5$65)6"$B,(+$(95"'("756$."B-(5"*$%%-&"b<Kc1"R#K"58:%5))'-("7,%645%"),B+';'+5)"*-,)5"@E!"95..)"

'(6-"@E!$"R#Kp95..)"$(+"@E!B"R#K

r95..)1"M595(6"&-%G"4$)"+57'(5+"$"@"95.."),B)56"'("4,*$(":5%':45%$."

B.--+"&'64"7,(96'-($."%5):-()5)")'*'.$%"6-"64-)5"-7"*-,)5"@E!"95..)"b<Nc1"

H$%/'($."I-(5"@"95..)" bHfc" bD/H4'/4" "

D/#.-&"

R#<!"4'/4"

R#<?"l" "R#!+"

4'/4"c" %5)'+5" "B56&55("645"*$%/'($."

)'(,)"$(+"645"%5+":,.:""-7"645"):.55("V"$",('[,5".0*:4-'+"$%5$".-9$65+"$6"645"'(65%7$95"B56&55("645"

9'%9,.$6'-(" $(+" 645" '**,(5" )0)65*V" $(+" 64,)" Hf" @" 95..)" $%5" .-9$65+" $6" 645" 7'%)6" .'(5" -7" +575()5"

$/$'()6"B.--+EB-%(5":$%6'9,.$65":$64-/5()1"3450"$%5"4565%-/5(-,)V"$(+"$%5"9-*:-)5+"-7"$"*'86,%5"

-7" ($q;5" $(+"*5*-%0"@" 95..)1" J765%" $(" $(6'/5(" B'(+'(/V"Hf"@" 95..)" %$:'+.0" +5;5.-:" '(6-" )4-%6E.';5+"

:.$)*$"95..)"b<OV"<Pc1"

@E!" $(+"Hf" @" 95..)" $%5" 9-()'+5%5+" 6-" B5" '(($65" .'G5" '**,(5" @" 95..)k" 6450" /5(5%$65" %$:'+" B,6" .-&"

$77'('60" $(6'B-+0" %5):-()5)" 64$6" $%5" '(+5:5(+5(6" -7" 3" 95.." 45.:1" 3450" *$'(.0" 58:%5))" /5%*.'(5E

5(9-+5+"$(6'/5("%595:6-%)"64$6"4$;5".'*'65+"+';5%)'60"$(+"$%5"5(%'945+"7-%"):59'7'6'5)"64$6"%59-/('I5"

Page 17: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!K""

"

*'9%-B'$."$(+")5.7"$(6'/5()1"H-%5-;5%" 645)5" 6&-"),B)56)"$%5" 645":%'*$%0":%-+,95%)"-7"($6,%$." D/H"

$(6'B-+'5)"$(+"64,)"9%,9'$."'("645"5$%.0":4$)5"-7"3E'(+5:5(+5(6"'**,(5"%5):-()5)"b<OV"<Qc1"

"J+$:6';5"@"95..)"

3%::(.4:-$"?".'::2"

" " " L-..'9,.$%"@"95..)"bD/H.-&""

D/#4'/4"

R#<!*5+""

R#<?p""R#!+"

.-&"c"$%5"645"*$'(":.$05%)"

+,%'(/"3"95..E+5:5(+5(6"'**,(5"%5):-()5)"$(+"B5.-(/"6-"645"$+$:6';5"$%*"-7"645"'**,(5")0)65*1"

3450":-:,.$65" 645" 7-..'9.5)"-7" 645" ):.55("$(+" .0*:4"(-+5)V" /5(5%$65"$" 9.-($..0" %5$%%$(/5+"$(6'/5("

):59'7'9" @" 95.." %595:6-%" b@RMc" $(+" 7-%*"*5*-%0" %5):-()5)" 64$6" $%5" +5:5(+5(6" -(" 3" 95.." 45.:1" 345"

4$..*$%G" -7" 3E95.." +5:5(+$(6" '**,(5" %5):-()5" ')" 645" '(+,96'-(" -7" /5%*'($." 95(65%)V" .0*:4-'+"

)6%,96,%5)" 64$6" $%')5" '(" 7-..'9.5)" $(+" $%5" ):59'$.'I5+" '(" 7$9'.'6$6'(/" 645" +5;5.-:*5(6" -7" 4'/4" $77'('60V"

.-(/".';5+":.$)*$"$(+"*5*-%0"@"95..)"&4'94"9-(75%".-(/".$)6'(/":%-6596'-("7%-*")59-(+$%0"94$..5(/5"

&'64"$(6'/5(1"

M5/,.$6-%0"@"95..)"

345"40:-645)')"64$6"),::%5))-%"-%"%5/,.$6-%0"@"b@%5/)c"95..)"-%945)6%$65"645"'**,(5"

)0)65*"&$)"-%'/'($..0":%-:-)5+"'("645"!QO2)"$(+"64$6"645"),::%5))';5"7,(96'-("-7"@"95..)"&$)"*$'(.0"

%5)6%'965+" 6-" 645'%" $B'.'60" 6-" :%-+,95" s'(4'B'6-%0h" $(6'B-+'5)" b?2c1" g4'.5" )6,+0'(/" 645" :,6$6';5"

:$64-/5('9"%-.5"-7"@"95..)"'("9-.'6')"+')5$)5V"@$("$(+"H'I-/,)4'"&5%5"645"7'%)6"6-"'(6%-+,95"645"65%*"-7"

i%5/,.$6-%0"@" 95..)j" b?!c1" "M5/,.$6-%0"@"95..)"$%5":%-:-)5+" 6-"B5"$%')5+" 7%-*"$"9-**-(":%-/5('6-%"

($*5+" 3%$()'6'-($." )6$/5" <" b3<c" @" 95..)" 64$6" 9-.-('I5" 645" 7-..'9.51" 3<" @" 95..)" $%5" 645" %5),.6" -7" 645"

+'775%5(6'$6'-("-7"645"3%$()'6'-($."!"b3!c"@"95..)":-:,.$6'-(V"$"(5&.0"7-%*5+"'**$6,%5"@"95..)":%5)5(6"

'("645"B-(5"*$%%-&V"$(+"4$)",(+5%/-(5"(5/$6';5")5.596'-("6-"%5*-;5")6%-(/.0")5.7E%5$96';5"95..)"b?<c1"

345"),%;';$."-7"3<"@"%5[,'%5)")'/($.)"7%-*"645"@RMV"$)"&5.."$)")'/($.)"7%-*"$"%595:6-%"64$6"B'(+)"645"

3WL" 7$*'.0" *5*B5%" @E95.." $96';$6'(/" 7$96-%" b@JLLk" $.)-" G(-&(" $)" @FtAc" b??c1" D6" 4$)" .-(/" B55("

%59-/('I5+"64$6"B-64"*-,)5"$(+"4,*$("@"95..)"9$(":%-+,95"DFE!2V"$("$(6'E'(7.$**$6-%0"906-G'(5"b?CV"

?Kc"$)"&5.."$)"645"6%$()7-%*'(/"/%-&64"7$96-%E\"b3>LE\c"b?Nc1"34')"9$:$9'60"6-"/5(5%$65"4'/4".5;5.)"-7"

DFE!2"4$+"+57'(5+":-:,.$6'-()"-7"@"95..)"&'64" %5/,.$6-%0" 7,(96'-()V"&4'94"45.:" 6-"),::%5))" '**,(5"

%5):-()5)"$(+"*$'(6$'(")5.7E6-.5%$(951"D("*'95V"$(+"B$)5+"-("645'%"7,(96'-(V"6&-"+')6'(96"%5/,.$6-%0"

:-:,.$6'-()"4$;5"B55("'+5(6'7'5+^"645"@%5/"@"95..)"R#!Qp"R#<!

4'/4R#<?

4'/4R#!+

4'/4"$(+"645"@!2"@"95..)"

R#!+4'/4"

R#Kp" b?OE?Qc1"A-9:'"5" .')6)"+'775%5(6"*$%G5%)"58:%5))5+"-("4,*$("$(+"*-,)5" %5/,.$6-%0"@"

95..)1"M595(6.0V")6%-*$."'(65%$96'-("*-.59,.5)"bA3DHcV"&4'94"9-()')6"-7"A3DH!"$(+"'6)"4-*-.-/V"A3DH<V"

64$6" )5%;5"$)"SM"9$.9',*")5()-%)"$(+"$%5"5))5(6'$." 7-%"AXR" '(7.,8"$765%"@RM")6'*,.$6'-(V"$%5" " 7-,(+"

9%'6'9$."7-%"%5/,.$6-%0"@"95.."7,(96'-("64%-,/4"DF!2":%-+,96'-("bC2c1""

Page 18: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!N""

"

345" '*:-%6$(95" -7" DFE!2" :%-+,9'(/" @" 95..)" 4$)" B55(" +5*-()6%$65+" '(" $" %$(/5" -7"*-,)5"*-+5.)" -7"

$,6-'**,(5" +')5$)5)" '(9.,+'(/" )0)65*'9" .,:,)" 5%0645*$6-),)" AFS" bC!cV" 58:5%'*5(6$." $,6-'**,(5"

5(95:4$.-*05.'6')"bSJSc"bC<cV"9-..$/5("'(+,95+"$%64%'6')"b!?cV"$(+"'(7.$**$6-%0"B-&5."+')5$)5"bC?cV"'("

'(7596'-(" *-+5.)" &'64" 8'(2B7-)(-" 7-C%$" bCCcV" ?$4+(-" D-B-)+(" bCKcE" F;&G#B(74$(47" bCNc" -)0"

H':(.%9-.&'$"#G:%$("bCOcE"$)"&5.."$)"'("6%$():.$(6$6'-("*-+5.)"$(+"'("9$(95%"b!Cc;"

"

"

3$B.5"!^"H$%G5%)"7-%"4,*$("$(+"*-,)5"@%5/)V"-0-#&'0"6$%7"!:-40(-"*-4$("-)0"I))':'')"?%27-E"

<2!<1"

@"95.."$96';$6'-("

A'65)"-7"J(6'/5("5(9-,(65%"

" " J)" 95..)" -7" '**,(5" )0)65*" 9$(" %5):-(+" 6-" 4,/5" %$(/5" -7" :-65(6'$." :$64-/5('9"

94$..5(/5)" 64%-,/4-,6" 645" &4-.5" B-+0V" 645)5" %5):-()5)" *,)6" B5" 6'/46.0" 9--%+'($65+" 6-" 9-(75%"

577596';5":%-6596'-(1"X&'(/"6-"645"/%5$6"$(6'/5('9"+';5%)'60V"645"5;5(6"-7"$(6'/5("5(9-,(65%"&'64"$("

$(6'/5(E):59'7'9" .0*:4-9065"64$6"9$("*-,(6"$"%$:'+"$(+"577596';5"%5):-()5")4-,.+"-99,%" '("+57'(5+"

)'65)V"),94"$)"645".0*:4"(-+5)"$(+"):.55("bA59-(+$%0"F0*:4-'+"X%/$()"AFX)c1"345)5")'65)":-))5))"$"

4'/4.0" -%/$('I5+" *'9%-$%94'6596,%5" 64$6" ')" (595))$%0" 7-%" 645" 9-*:$%6*5(6$.'I$6'-(" -7" (,*5%-,)"

Page 19: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!O""

"

95..,.$%" '(65%$96'-()" $(+" 64,)" :%-;'+'(/" $(" -:6'*$." 5(;'%-(*5(6" 7-%" 645" '('6'$6'-(" -7" '**,(5"

%5):-()5)"b!?c1"L,%645%*-%5V" .0*:4-9065)"64$6"+'+"(-6"),9955+"6-"%59-/('I5"$(0"J(6'/5("&'64'("<C"

4-,%)"%59'%9,.$65"B56&55("645"B-+0"$(+"645"AFX)"6-"'(9%5$)5"645":%-B$B'.'60"-7"5(9-,(65%'(/"9-/($65"

$(6'/5()1"

AB'"8G7#B")%0'"

" " " 345" .0*:4" (-+5" ')" -%/$('I5+" '(6-" 64%55" +')9%565" (-(" %'/'+" %5/'-()^" 645"

*5+,..$V" 645" :$%$9-%658" b645" 3" 95.." I-(5c" $(+" 645" 7-..'9.5)" b645" @" 95.." I-(5c1" #'%596.0" B5(5$64" 645"

),B9$:),.$%")'(,)V"645%5"')"*$9%-:4$/5"5(%'945+"I-(5"64$6"),%%-,(+)"645"7-..'9.5)"J3(+4$'"<K;"L-..'9.5)"

9-(6$'("645" .$%/5)6":-:,.$6'-("-7" D/H.-&" "

D/#4'/4"

R#<!*5+" "

R#<?p" "R#!+"

.-&"@"95..)" '("645"B-+0k"6450h%5"

$.)-"%'94"'("%$+'$6'-("%5)')6$(6"7-..'9,.$%"+5(+%'6'9"95..)"bL#R)c"64$6"58:%5))"4'/4".5;5.)"-7"645"$+45)'-("

*-.59,.5)" ),94" $)" ;$)9,.$%" 95..E$+45)'-("*-.59,.5" bZRJH!c" $(+" '(6%$95..,.$%" $+45)'-("*-.59,.5" !"

bDRJH!c" $)" &5.." $)" 9-*:.5*5(6" $(+" L9" %595:6-%)" bCPEK!c1" L-..-&'(/" 58:-),%5" 6-" $(6'/5()V" @" 95..)"

:%-.'75%$65"%$:'+.0"&'64'("645"L#R)"(56&-%G"6-"7-%*"/5%*'($."95(65%)V")'65)"-7"$77'('60"*$6,%$6'-("$(+"

-7"645"/5(5%$6'-("-7".-(/".';5+":.$)*$"95..)1"345"3"95.."I-(5"9-(6$'()"4'/4"5(+-645.'$.";5(,.5)"b=SZc"

64$6"$%5"):59'$.'I5+"9$:'..$%'5)"64$6"),::.0"645".0*:4"(-+5"&'64"$(+"+%$'("'6"-7".0*:4-9065)"7%-*"$(+"

6-"645":5%':45%0k"'6"9-(6$'()"$)"&5.."(,*5%-,)"$(6'/5(E:%5)5(6'(/"95..)"$(+"$"(56&-%G"-7"9-..$/5(-,)"

9-(+,'6" 7'B5%)" 64$6" $..-&" 645" :$))$/5" -7" .-&E*-.59,.$%E*$))" 9-*:-(5(6)" -7" .0*:4$6'9" 7.,'+"&4'94"

9-(6$'()";$%'-,)"945*-G'(5)"$(+"$(6'/5()"9-..5965+"7%-*"645"B-+0"bK<c1"345"*5+,..$"9-(6$'()"@"$(+"

3"95..)V"$)"&5.."$)"*$9%-:4$/5)"$(+"#R)1"

AB'"2#:'')"

" " " 345"):.55("9-(6$'()"$"&4'65":,.:"$(+"$"%5+":,.:V")5:$%$65+"B0"645"*$%/'($."

I-(51"345"):.5('9"&4'65":,.:"9-(6$'()"@"95.."7-..'9.5)"$(+"3"95.."I-(5)"$(+"$")'*'.$%"9-(+,'6")0)65*"$)"$"

.0*:4"(-+51"345"%5+":,.:" ')"%'94.0"),::.'5+"&'64"B.--+"$(+"9-(6$'()":.$)*$"95..)V" .0*:4-9065)"$(+"

$(6'/5(" :%5)5(6'(/" 95..)1" 345"*$%/'($." I-(5" 9-(6$'()" +5(+%'6'9" 95..)" $(+"*$9%-:4$/5)" $)"&5.." $)" $"

:-:,.$6'-(" -7" (-(E9'%9,.$6'(/" @" 95..)" :$%6'9':$6'(/" '(" 5$%.0" '(($65" '**,(5" %5):-()5)" bK?V" KCc1" 345"

):.55("')"):59'$.'I5+"'("*-,(6'(/"'**,(5"%5):-()5)"6-"B.--+"B-%("$(6'/5()V"7-%")-V"'6"')"(-6"),::.'5+"

&'64"$775%5(6".0*:4$6'9"7.,'+"bKKc1"

Page 20: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!P""

"

"

L'/,%5"<^"A59-(+$%0".0*:4-'+"-%/$()V"-0-#&'0"6$%7"?-&(2&-"'&"-:;E"<==L"

345"9-(6586"-7"@"95.."%59-/('6'-("

" " 3%$+'6'-($..0V" @" 95.." %5):-()5)" 4$;5" B55(" )6,+'5+" ()" /(&$%" 6-" )-.,B.5" $(6'/5()1" D("

%595(6" 05$%)V" 645" +5;5.-:*5(6" -7" *,.6':4-6-(" *'9%-)9-:0" bHUHc" 4$)" 5($B.5+" 645" +'%596" $(+"

+0($*'9" ;'),$.'I$6'-(" -7" '**,(5" 95..)" &'64'(" )59-(+$%0" .0*:4-'+" 6')),5" bKNV" KOc1" Y)'(/" 64')"

$::%-$94V"(,*5%-,)"/%-,(+EB%5$G'(/")6,+'5)"4$;5"%5;5$.5+"64$6"@"95..)"5(9-,(65%"$(6'/5("()"/(/%";'$"

+'775%5(6"*594$(')*)"$99-%+'(/"6-"645":%-:5%6'5)"-7"645"$(6'/5("'6)5.7"J3(+4$'"MK"bKPc;""

N'.%+)(&(%)"%6"2%:49:'"-)&(+')"

" " " A-.,B.5" $(6'/5()" &'64" $" *-.59,.$%" *$))" .5))" 64$(" O2" G#$" ),94" $)" .-&E

*-.59,.$%" *$))" 6-8'()" +'77,)5" '(6-" 645" 7-..'9.5" $9%-))" 645" ),B9$:),.$%" )'(,)" bARAc" 7-..-&'(/" 5(6%0"

64%-,/4" 645" $775%5(6" .0*:4" ;5))5.V" 64,)" @" 95..)" '(" 9.-)5" :%-8'*'60" -7" ARA" 9$(" $9[,'%5" $(+" :%5)5(6"

9-/($65"$(6'/5("6-"R#Cp"3"95.."7-%"*$8'*$."$96';$6'-("bKQc1"J"9-(+,'6"(56&-%G"9-*:-)5+"-7"B,(+.5)"

-7"9-..$/5("7'B5%)"')"%5[,'%5+"7-%"6%$():-%6'(/"645")-.,B.5"$(6'/5("7%-*"645"ARA"'(6-"645"7-..'9.5"bN2c"$)"

&5.." $)" 645" 6%$():-%6"-7" 945*-G'(5)" ),94"$)"RaRF!?" 6-"$66%$96"@" 95..)" bN!c1" " 34')" %$:'+"+'77,)'-("-7"

$(6'/5("')"'(+5:5(+5(6"-7"#R)"$(+"+-"(-6"%5[,'%5"*'/%$6'-("-7"@"95..)"7%-*"645'%"7-..'9,.$%".-9$6'-(1"

N'.%+)(&(%)"%6":-$+'"-)&(+')"()"/(/%"

" " " H-)6"$(6'/5()"5(9-,(65%5+"+,%'(/"'**,(5"%5):-()5)"4$;5"$"*-.59,.$%"*$))"

9-()'+5%$B.0" /%5$65%" 64$(" O2" G#$V" ),94" $)" :$%6'9,.$65" $(6'/5()V" ;'%$." :$%6'9.5)" $(+" '**,(5"

9-*:.585)1"34-)5"$(6'/5()"$%5":%-;'+5+"-("645"),%7$95"-7"JUR)"6-"B5":%5)5(65+"$(+"%59-/('I5+"B0"@"

95..)^""ARA"*$9%-:4$/5)"6-"7-..'9,.$%"@"95..)V"'**'/%$(6"+5(+%'6'9"95..)"6-"645":$%$9-%658$."@"95..)"$(+"

7-..'9,.$%" +5(+%'6'9" 95..)" 6-" /5%*'($." 95(65%" @" 95..)1" 34')" %59-/('6'-(" .5$+)" 6-" 645" 7-%*$6'-(" -7"

'**,(-.-/'9$.")0($:)5"bDAc"64$6"%5)5*B.5)"645"-(5"-%'/'($..0"+5)9%'B5+"'("3"95..)"bN<V"N?c1""

Page 21: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!Q""

"

*-.$%#B-+',7'0(-&'0"#$'2')&-&(%)"

" " " " " L-..-&'(/" 5(6%0" 6-" 645" .0*:4" (-+5V" .$%/5" $(6'/5()" $%5"

9-(95(6%$65+"$6"645"ARA"$(+"$%5"9$:6,%5+"B0"R#!NQp"*$9%-:4$/5)V"$"),B60:5"-7"*$9%-:4$/5)"&'64"

:--%" :4$/-906-)')" $96';'60" &4'94" $..-&)" 645" :%5)5(6$6'-(" -7" '(6$96" $(6'/5()" 6-" @" 95..)" bNCc1" 34')"

:%5)5(6$6'-(" -99,%)" 64%-,/4" $" ;$%'560" -7" 95.." ),%7$95" %595:6-%)V" '(9.,+'(/" $+45)'-(" *-.59,.5E!"

bHJR!^"$"%595:6-%"7-%"9-*:.5*5(6"9-*:-(5(6"?"R?c"7-%"9-*:.5*5(65+E9-$65+"$(6'/5(V"L9dMDD@"7-%"

'**,(5" 9-*:.585)V" $(+" 645" 9E60:5" .596'(" #RE):59'7'9" DRJHE?" /%$BB'(/" (-('(65/%'(" b#READ>Wc" 7-%"

9$%B-40+%$65E9-(6$'('(/" $(6'/5(" bN!c1" 345)5"*$9%-:4$/5)"*'/46" 7$;-%" 645" %565(6'-("-7" $(6'/5("-("

645'%" ),%7$95" 64%-,/4" 645'%" 58:%5))'-(" -7" ),.:4$65+" /.09-:%-65'()V" ),94" $)" R#!NQV" $(+" 645" .$9G" -7"

58:%5))'-(" -7" 645" *$((-)5" %595:6-%V" &4'94" ')" ,),$..0" $))-9'$65+" &'64" :4$/-906-)')" -7" -:)-('I5+"

$(6'/5("bNKc1"345"$99,*,.$65+"$(6'/5("')"),B)5[,5(6.0":%5)5(65+"'("'6)"'(6$96"7-%*"B0"*$9%-:4$/5)"

7-%"%59-/('6'-("B0"(5'/4B-%'(/" 7-..'9,.$%"@"95..)1"J)"$"%5),.6V"@"95..)"$9[,'%5"):59'7'9"$(6'/5("64%-,/4"

645'%"@RM"$(+"*'/%$65"6-"645"@E3"B-,(+$%0"6-"%59%,'6"R#Cp"3"95..)"7-%"*$8'*$."$96';$6'-(1"

O!,7'0(-&'0"#$'2')&-&(%)"

" " " " " @" 95..)" $%%';'(/" $6" 645" .0*:4" (-+5" 64%-,/4" 645" =SZ" '(" 645"

:$%$9-%658"$%5"$B.5"6-"%59-/('I5"'(6$96",(:%-95))5+"($6';5"$(6'/5()"-("645"),%7$95"-7"#R)"bNNc1"345"

#R)V"9-()'+5%5+"$)"645"*-)6"577'9'5(6":%-75))'-($."$(6'/5(":%5)5(6'(/"95..)V",)5"+'775%5(6"*594$(')*)"

6-" G55:" )6$B.5" $(6'/5()" +'):.$05+" -(" 645'%" 95.." ),%7$951" D(+55+V" " '**,(5" 9-*:.585)" '(65%($.'I5+"

64%-,/4" 645" L9dMDD@" $%5" 6$%/565+" 6-" (-(" +5/%$+$6';5" '(6%$95..,.$%" 9-*:$%6*5(6)" bNOc" $(+" 645" #RE

AD>W"*5+'$65+"$(6'/5(""'(65%($.'I$6'-("$..-&)"645"$99,*,.$6'-("-7"J/"'("(5,6%$."5(+-)-*5)"'("#R)V"

),//5)6'(/" 64$6" #R)" 9$(" '(65%($.'I5" $(+" 645(" %5909.5" '(6$96" $(6'/5(" 6-" 645'%" ),%7$951" 34')" #RE"

*5+'$65+":%5)5(6$6'-("-7"J/"6-"@"95..)"%5),.6)"5'645%"'("645"$96';$6'-("-7"@"95..)"$(+"645'%"/5(5%$6'-("

-7" 586%$7-..'9,.$%" :.$)*$" 95..)" 64$6" *-,(6" 5$%.0" $(6'B-+0" %5):-()5)k" 5'645%" '(" 645" *'/%$6'-(" -7"

$96';$65+" @" 95..)" 6-" 7-..'9.5)" &45%5" 6450" *5+'$65" 3E+5:5(+5(6" %5):-()5)" $(+" /5%*'($.E95(65%"

7-%*$6'-("bNPc1"

D("645"):.55(V"$")'*'.$%"#RE*5+'$65+"$96';$6'-("-7"*$%/'($."I-(5"@"95..)"-99,%)V" .5$+'(/"6-"645"%$:'+"

/5(5%$6'-("-7":.$)*$"95..)"64$6":%-+,95"D/H"bNQc1"

3O!2,7'0(-&'0"#$'2')&-&(%)"

" " " " " D6" 4$)" .-(/" B55(" 5)6$B.')45+" 64$6" L-..'9,.$%" #R)" $99,*,.$65"

$(+"%56$'("$(6'/5("'("645"7-%*"-7"$(6'B-+0"9-*:.585)"$765%"645"'('6'$."&$;5"-7"$(6'/5(":%5)5(6"'("645"

.0*:4"7.,'+"4$)":$))5+"bCQV"O2V"O!c1"345"'**,(5"9-*:.585)"$%5"%56$'(5+"-("645"95.."),%7$95"B0"6&-"

*594$(')*)^"!m"645"7'%)6"*594$(')*"+5:5(+)"-("645"9-*:.5*5(6")0)65*k"L#R)"58:%5))"9-*:.5*5(6"

%595:6-%)" RM!" $(+" RM<" &4'94" B'(+" 6-" +'775%5(6" 7%$/*5(6)" -7" R?" bO<EOCck" $(+" <m" 645" )59-(+"

Page 22: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<2""

"

*594$(')*"'(;-.;5)"L9"%595:6-%)"58:%5))5+"B0"L#R)"'("/5%*'($."95(65%)"$(+"64$6"%59-/('I5"'**,(5"

9-*:.585)" 9-(6$'('(/" D/>" bOKc1" 34')" *-+5" -7" $(6'/5(" :%5)5(6$6'-(" 6-" @" 95..)" ')" 9%'6'9$." 7-%" $77'('60"

*$6,%$6'-("'("645"/5%*'($."95(65%"$(+"7-%"645"/5(5%$6'-("-7"586%5*5.0"4'/4"$77'('60"$(6'B-+'5)"bONc1"

3AN+OAGK+=B?CPGB+P=CB+=JJGKK+?A+Q.0KR"M595(6")6,+'5)"4$;5")4-&("64$6"(-("):59'7'9"@"95..)"9$("9$%%0"

J/" 7%-*"ARA"*$9%-:4$/5)" 6-"L#R)k" 64')" 6%$():-%6" ')"*5+'$65+"B0"9-*:.5*5(6" %595:6-%)"58:%5))5+"

-(" 645" ),%7$95"-7" 645"@"95..)" bO<V"OOc1"J" )'*'.$%"*594$(')*" ')":%-:-)5+" 6-"58:.$'(" 645" 6%$():-%6"-7"

'**,(5"9-*:.585)"B0"):.5('9"*$%/'($."I-(5"@"95..)"6-"L#R)"bOPc1"

"

L'/,%5"?^"J(6'/5(":%5)5(6$6'-("6-"9-/($65"@"95..)"'("645".0*:4(-+5"()"/(/%E"-0-#&'0"6$%7"P;H-$Q%%0"

-)0"3;"?-&(2&-E"<=5="

AB'"?,.'::"(774)%:%+(.-:"2G)-#2'""

" " " U$,."$(+"A5+5%"&5%5"645"7'%)6"6-"'(6%-+,95"645"65%*"'**,(-.-/'9$.")0($:)5"DA"

6-" +5)9%'B5" 645" ),%7$95" -7" '(65%$96'-(" B56&55(" @" $(+" 3" 95..)" " '(" $($.-/0" 6-" 645" )59%56'-(" -7"

(5,%-6%$()*'665%)" B56&55(" 645" )0($:)5" -7" 6&-" (5,%-()" bOQc1" D(" 645" .$65" !QQ2h)V" 645" .$(+*$%G"

75$6,%5)" -7" 645" $96,$." DA" &$)" 5.,9'+$65+" $(+" &4'94" 9-()')6)" -(" 645" )5/%5/$6'-(" -7" %595:6-%)" '(6-"

+57'(5+" ),:%$*-.59,.$%" $96';$6'-(" 9.,)65%)" bAHJR)c" bN<V" P2c1" A'(95" 645(V" 64')" )6%,96,%5" 4$)" B55("

-B)5%;5+" '("45.:5%"$(+"906-6-8'9"3" 95..)V" $)"&5.." $)"@"95..)V" %5),.6'(/" '("+57'('(/" 645" DA"$)"$"/5(5%$."

*-.59,.$%")6%,96,%5"7-%"$(6'/5("%59-/('6'-("bP!EP?c1"

Page 23: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<!""

"

g45(" B'(+'(/" *5*B%$(5" $(6'/5()V" @" 95..)" 7-%*" $" 4'/4.0" -%/$('I5+" 9-(6$96" $%5$V" 645" DAV" 64$6" ')"

9-*:-)5+" -7" 95(6%$." $//%5/$65" -7" 645" $(6'/5(E5(/$/5+" @RM)V" 9$..5+" 645" 95(6%$." AHJR" b9AHJRc1"

A,%%-,(+'(/" 645" 9AHJR" ')" $" %'(/" -7" $+45)'-("*-.59,.5)" 9$..5+" 645" :5%':45%$." AHJR" b:AHJRc" 64$6"

'(9.,+5)" 645" FLJE!T" DRJHE!":$'%1" FLJE!" iF0*:4-9065" 7,(96'-(E$))-9'$65+"$(6'/5(E!j"B5.-(/)" 6-" 645"

'(65/%'(" 7$*'.0" -7" 95.." $+45)'-("*-.59,.5)" $(+" ')" 58:%5))5+" -(" $.." .5,G-9065)V" '(9.,+'(/" @" 95..)1" D6)"

*$'(" .'/$(+" ')" DRJH!" bD(6%$95..,.$%"J+45)'-("H-.59,.5E!c" 64$6" ')" 58:%5))5+"-("$"&'+5" %$(/5"-7" 95.."

.'(5$/5)" b.5,G-9065)V" L#R)V"#R)" $(+" 5(+-645.',*c" bPCc1" FLJE!" B'(+'(/" 6-" DRJHE!" ')" '(;-.;5+" '(" 645"

.-9$.'I$6'-("-7"@"95..)"6-"645"Hf"$(+"645'%"6%$()'6"'(6-"&4'65":,.:"9-%+)"bPKcV"'("645":40)'9$."'(65%$96'-("

-7"@"95..)"&'64"#R)"$(+"L#R)"bPNV"POcV"'(":%5;5(6'(/"$:-:6-)')"-7"/5%*'($."95(65%"@"95..)"bPPcV"$(+"'("

645":%-95))"-7"$(6'/5("%59-/('6'-(1"FLJE!T"DRJHE!"')"(-6"645"-(.0"'(65/%'(":$'%"64$6"9-,.+":$%6'9':$65"

'("%59-/('I'(/"$(6'/5(V";5%0".$65"$(6'/5(EJ"bZFJECc"4$)"$.)-"B55("'*:.'9$65+"'(":%-*-6'(/"645":40)'9$."

'(65%$96'-("-7"@"95..)"$(+"L#R)"64%-,/4"B'(+'(/"6-"'6)".'/$(+"Z$)9,.$%"R5.."J+45)'-("H-.59,.5"bZRJHE

!c"58:%5))5+"-("L#R)"bPQc1"#,%'(/"645"DA"7-%*$6'-(V"@"95..)"$%5"(-6"-(.0"$96';$65+"6-")'/($.V"B,6"$.)-"6-"

586%$96"$(+"'(65%($.'I5"645"J/1"J";5%0"%595(6"$(+"5.5/$(6")6,+0"7%-*"645"/%-,:"-7"JH"F5((-(")4-&5+"

64$6" ,:-(" @RM" 5(/$/5*5(6" &'64" $(" '**-B'.'I5+" J/V" 645" H'9%-6,B,.5" X%/$('I'(/" R5(65%" bH3XRc"

6-/5645%"&'64"FJHU!p".0)-)-*5)":-.$%'I5"6-&$%+"645"J/T@RM"'(65%7$95V"$":%-95))"64$6"%5.'5)"-("645"

)*$.." >3U$)5" R+9C<" $(+" '6)" +-&()6%5$*" 577596-%" $U_R`1" U-.$%'I5+" .0)-)-*5)" $%5" .-9$..0" )59%565+"

$..-&'(/" 645" %5.5$)5" -7" .0)-)-*$." :%-65$)5)" $(+" 645" $9'+'7'9$6'-(" -7" 645" DAV" &4'94" :%-*-65)" J/"

586%$96'-("7%-*"645"),%7$95"-7"JUR)"bQ2c1"

@RM")'/($.'(/"

" " @" 95.." $96';$6'-(" ')" '('6'$65+" '(" %5):-()5" 6-" ):59'7'9" $(6'/5(" B'(+'(/" 6-" 645" @" 95.."

%595:6-%1" 345" @RM" ')" $" *,.6':%-65'(" )6%,96,%5" 64$6" 9-()')6)" -7" $(" $(6'/5(" B'(+'(/" ),B,('6V" 645"

*5*B%$(5" '**,(-/.-B,.'("*D/V" $(+" $" )'/($.'(/" ),B,('6V" $" +'),.7'+5E.'(G5+"4565%-+'*5%"-7" 645" D/u"

$(+"D/\":%-65'()V"64$6"$%5"(-(E9-;$.5(6.0"$))-9'$65+"bQ!c1"g'64'("645'%"906-:.$)*'9"6$'.)V" D/u"$(+"D/\"

9-(6$'(" $" )'(/.5" '**,(-%595:6-%E60%-)'(5"B$)5+" $96';$6'(/"*-6'7" bD3JHc" 64$6" ')" :4-):4-%0.$65+"B0"

645"A%9E7$*'.0"G'($)5)"),94"$)"F0(V".5$+'(/"6-"645"$96';$6'-("-7"A0G"G'($)51"34')"$96';$6'-("'('6'$65)"645"

$))5*B.0"-7"645")'/($.-)-*5"64$6"')"9-*:-)5+"-7"$";$%'560"-7"'(6%$95..,.$%")'/($.'(/"*-.59,.5)V"),94"

$)"Z$;"V"@%,6-(h)"60%-)'(5"G'($)5"b@6GcV":4-):4-'(-)'6'+5"?EG'($)5"bUD?_cV":4-):4-.':$)5"REd<"bUFRd<cV"

$)"&5.."$)"$+$:6-%":%-65'()V"),94"$)"@"95..".'(G5%"b@.(Gc"J3(+4$'"RK"bQ<EQOc1"

J(" '(65%5)6'(/")6,+0" %5;5$.)" 645":-))'B'.'60"-7"A0G" '(65%$96'-("&'64" 645"@RM" '(+5:5(+5(6.0"-7"F0(" '("

#%-)-:4'.$" A<" A94(5'+5%" 95..)^" A0G" B'(+)" $(+" :4-):4-%0.$65)" 6&-" D3JH" 60%-)'(5)" %5),.6'(/" '(" 645"

)6$B'.'I$6'-(" -7" 645" @RM" '(" $(" -:5(" $(+" $96';5" 9-(7-%*$6'-(1" 34')" $..-&)" 645" :4-):4-%0.$6'-(" -7"

(5'/4B-%'(/" D3JH" )5[,5(95)V" 7,%645%" A0G" %59%,'6*5(6" $(+" 645" %$:'+" $*:.'7'9$6'-(" -7" 645" @RM"

)'/($.'(/"bQPc1"

Page 24: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<<""

"

345"$96';'60"-7")'/($.'(/"*-.59,.5)"6%'//5%)"$";$%'560"-7"95..,.$%":%-95))5)V"'(9.,+'(/"%5/,.$6'-("-7"/5(5"

58:%5))'-(V"9$.9',*"*-B'.'I$6'-("bQOV"QQcV"'(+,96'-("-7"HJU_"$(+"JG6"_'($)5":$64&$0)"b!22cV"(,9.5$%"

6%$().-9$6'-("-7" 6%$()9%':6'-($..0"$96';5"WLEv@"+'*5%)" b!2!cV" %5-%/$('I$6'-("-7" 645"906-)G5.56-("$(+"

@RM"*5+'$65+"'(65%($.'I$6'-("-7"$(6'/5("9-*:.585)"&'64'("):59'7'9"5(+-)-*$."9-*:$%6*5(6)V"&45%5"

645"J/"')"),B)5[,5(6.0":%-95))5+"$(+":%5)5(65+"-("*$e-%"4')6-9-*:$6'B'.'60"9-*:.58"DD"bH=RDDc"6-"3"

95..)"b!2<V"!2?c1""

@RM" )'/($.'(/" '('6'$65)" $6" 645" :.$)*$"*5*B%$(5"&'64" 645" %59%,'6*5(6" $(+" :4-):4-%0.$6'-(" -7" 645"

5$%.0" :%-8'*$." G'($)5)" F0(" $(+" A0GV" $(+" 9-(6'(,5)" 6-" )'/($." $)" '6" 6%$77'9)" '(6%$95..,.$%.0" &45%5"

+-&()6%5$*"G'($)5)"'('6'$..0"9M$7"$(+"),B)5[,5(6.0"645"HJU_)"SM_V":?P"$(+"o(G"$%5":4-):4-%0.$65+1"

345" +')%,:6'-(" -7" @RM" 5(+-906-)')" %5),.6)" '(" 645" %59%,'6*5(6" -7" B-64" :%-8'*$." $(+" +-&()6%5$*"

G'($)5)" 6-" 645" :.$)*$"*5*B%$(5" &45%5" 645'%" $96';$6'-(" ')" +0)%5/,.$65+1" @RM" '(65%($.'I$6'-(" 64,)"

)5%;5)" 6-" '(+,95" :%-:5%" G'($)5" :4-):4-%0.$6'-(" 5))5(6'$." 6-" $96';$65" 6$%/56" /5(5" 58:%5))'-(" $(+"

%5/,.$65"645"-,69-*5"-7"645"@RM")'/($."b!2Cc1"

"

L'/,%5"C^"@"95.."$(6'/5("%595:6-%")'/($."6%$()+,96'-("9$)9$+5V"-0-#&'0"6$%7"S*;"O-:"D%$&%"'&"-:;E"<==R"

"

D("%5)6'(/"@"95..)V"645"@RM"58')6)"'("$"*-(-*5%'9"'($96';5"7-%*k"B'(+'(/"-7"*-(-;$.5(6")-.,B.5"$(6'/5("

+-5)" (-6" 94$(/5" 645" 9-(7-%*$6'-(" -7" 645" @RM" $(+" +-5)" (-6" $..-&" '6)" )'/($.'(/1" D6h)" -(.0" ,:-("

$96';$6'-("&'64" $("J/"B-,(+"*5*B%$(5" 64$6" 645"+')6%'B,6'-("-7" 645" %595:6-%" ')" $.65%5+^" 345"@RMh)"

596-+-*$'()" 9.,)65%" '(6-" $(" $96';5" 9-(7-%*$6'-(" 58:-)'(/" $(" -.'/-*5%'I$6'-(" '(65%7$95" '(" 645"

*5*B%$(5":%-8'*$."%5/'-("-7"645"*5*B%$(5"'**,(-/.-B,.'(1"J))5*B.0"-7"645"@RM"-.'/-*5%".5$+)"

6-" :5%6,%B$6'-()" -7" 645" .-9$." .':'+" 5(;'%-(*5(6V" -:5('(/" -7" 645" 906-:.$)*'9" +-*$'()" $(+" 645"

'('6'$6'-("-7")'/($.'(/"J3(+4$'"TK"b!2Kc1"

Page 25: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<?""

"

"

L'/,%5"K"^"D..,)6%$6'-("-7"645"w"9-(7-%*$6'-(E'(+,95+"-.'/-*5%'I$6'-(j"*-+5."7-%"@RM")'/($.'(/V"

-0-#&'0"6$%7"A%:-$"-)0"D('$.'E"<=5="

I.&(/'"#:-G'$2"()"()(&(-&()+"?!N"2(+)-:()+"

" " " M59-/('6'-(" -7" J/" B-,(+" *5*B%$(5" ')" $99-*:$('5+" &'64" $" 6&-" :4$)5"

95..,.$%"%5):-()5"94$%$965%'I5+"B0"%$:'+"):%5$+'(/"-7"645"@"95.."-;5%"645"$(6'/5(EB5$%'(/"*5*B%$(5V"

7-..-&5+"B0"$").-&5%"9-(6%$96'-(":4$)5" b!2Nc1"#,%'(/"645"):%5$+'(/":4$)5V"*'9%-9.,)65%)"-7"!2E!22"

@RMEJ/" 9-*:.585)" 7-%*" 64%-,/4-,6" 645" 9-(6$96" )'65V" &4'94" $%5" 645(" $//%5/$65+" +,%'(/" 95.."

9-(6%$96'-(1"345)5"*'9%-9.,)65%)"$%5")'/($.'(/"$96';5"$)"6450"6%'//5%"$77'('60E+5:5(+5(6"):%5$+'(/"-7"

645"@"95.."),%7$95"-;5%"645"JUR"),%7$95V"'(9%5$)'(/"645"95..E95.."9-(6$96"$%5$"$(+"%5),.6'(/"'("'('6'$6'(/"

645"'(6%$95..,.$%")'/($.'(/"$(+"645"%5-%/$('I$6'-("-7"645"$96'("906-)G5.56-(1"D*:-%6$(6.0V"645"(,*B5%"

-7"*'9%-9.,)65%)" 7-%*5+"+,%'(/" 645" ):%5$+'(/" %5):-()5"+565%*'(5)" 645"$*-,(6"-7"J/"/$645%5+" 7-%"

),B)5[,5(6" '(65%($.'I$6'-(" 7-%" :%-95))'(/" $(+" :%5)5(6$6'-(" 6-" 3" 95..)1" " H$(0" $96';5" 577596-%)" $%5"

'(;-.;5+"'("645"-%/$('I$6'-("-7"645"*'9%-9.,)65%)"$(+"9-(6%-."645"5$%.0"5;5(6)"'("@RM"$96';$6'-(^"

AB'"UN*"#$%&'()2"

" " " " " 345" SI%'(EM$+'8'(EH-5)'(" bSMHc" :%-65'()" $%5" $" 7$*'.0" -7"

4'/4.0" 9-()5%;5+" :%-65'()" 64$6" :%-;'+5" $" %5/,.$65+" .'(G$/5" B56&55(" '(65/%$." :.$)*$" *5*B%$(5"

:%-65'()"$(+"645"$96'("906-)G5.56-(1"U4-):4-%0.$6'-("-7"$"9-()5%;5+"64%5-('(5"'("645"906-:.$)*'9"6$'."

'(+,95)"$"9-(7-%*$6'-($."-:5('(/"-7"645":%-65'("6-"58:-)5"$"LSMH"+-*$'("'("645"W"65%*'(,)"$(+"$("

$96'(/EB'(+'(/"+-*$'(" '(" 645"R" 65%*'(,)" b!2Oc1" 34,)" 645)5":%-65'()" 9-,.+":%-;'+5"$"*594$(')*" 6-"

%$:'+.0"$.65%" 645" '(65%$96'-("B56&55(" 645":.$)*$"*5*B%$(5"$(+" 645",(+5%.0'(/"$96'(" 906-)G5.56-("

,:-(" $(6'/5(" %595:6-%" )6'*,.$6'-(" $(+" 9-,.+" B5" '*:-%6$(6" '(" %5/,.$6'(/" $(6'/5(" %595:6-%"

*'9%-9.,)65%)" 7-%*$6'-(1" D(+55+" SI%'(" $(+" $96'(" (56&-%G)" %5/,.$65" 645" )65$+0" )6$65" +'77,)'-("

+0($*'9)" -7" 645" @RM" b!2Pc" $(+" 9-(6%-." @RM" *'9%-9.,)65%" -%/$('I$6'-(^" ,:-(" @RM" 5(/$/5*5(6V" $"

.-9$.'I5+" +5:4-):4-%0.$6'-(" -7" SMH" :%-65'()" -99,%)" %5),.6'(/" '(" 645" +'))-9'$6'-(" -7" 645" :.$)*$"

*5*B%$(5"7%-*"645"$96'("906-)G5.56-(".5$+'(/"6-"645".-))"-7"645"@RM"+'77,)'-("B$%%'5%)"b!2Pc"$(+"645"

Page 26: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<C""

"

'(9%5$)5" '(" 645" +'77,)'-(" -7" ,(5(/$/5+" @RM)" " 6-" 7-%*" $" (5&" *'9%-9.,)65%V" 645" B$)'9" ,('6" -7"

.0*:4-9065")'/($.'(/"b!2Qc1"

AB'"O%1MVW$9<"-0-#&%$2"

" " " " " J(-645%" 9%'6'9$." 577596-%" 7-%" $(" -:6'*$." @RM" *'9%-9.,)65%"

)'/($.'(/"$(+"$(6'/5("/$645%'(/" ')" 645"#-G?T>%B<"-.'/-*5%)1"#-G?" b$+$:6-%":%-65'("+-&()6%5$*"-7"

G'($)5"?c" ')":5%*$(5(6.0" .-9$.'I5+"$6" 645":.$)*$"*5*B%$(5V" '6":%-;'+5)"$"+-9G'(/" )'65" 7-%" 645"A=<"

+-*$'("-7"645"/%-&64"7$96-%"%595:6-%EB-,(+":%-65'("<"b>%B<cV"-(95":4-):4-%0.$65+"$(+"$96';$65+"B0"

F0(",:-("@RM"5(/$/5*5(61"#-G?T>%B<"9-*:.58"6-/5645%"&'64"645",B'[,'6'(" .'/$)5"RB."$%5" .-9$.')5+"

&'64'(" $(6'/5(" 9-(6$'('(/"@RM"*'9%-9.,)65%)" $(+" $%5" '(;-.;5+" '(" 645" %59%,'6*5(6" -7" +0(5'(" 6-" @RM"

*'9%-9.,)65%)"$..-&'(/" 645'%" ),B)5[,5(6"*-;5*5(6"-("*'9%-6,B,.5)" 6-"/$645%"$(6'/5(" %5[,'%5+" 7-%"

),B)5[,5(6" $9[,')'6'-(" $(+" :%5)5(6$6'-(" 6-" 3" 95..)1" 3-" (-65V" 64')" 9-*:.58" +-5)" (-6" '(7.,5(95" @RM"

*'9%-9.,)65%"7-%*$6'-("(-%"):%5$+'(/"b!!2c"1"H-%5-;5%V"645"#-G?T>%B<"9-*:.58"6%$().-9$6'-("6-"@RM"

*'9%-)'/($.-)-*5" ')" %595(6.0" )4-&(" 6-" B5" '(;-.;5+" '(" 645" +-&(%5/,.$6'-(" -7" A0G" $96';'60V" &4'94"

%5),.6)" '("645"%5/,.$6'-("-7"@RM"$96';$6'-("$(+"645"$+e,)6*5(6"-7"645"@RM"'(+,95+E95..,.$%"%5):-()5"

6-"$"/';5("+5;5.-:*5(6$."@"95..")6$/5"b!!!c1"

!O5LV!O<5V!O>5VX'45M"

" " " " " R#!Q" ')"$("5))5(6'$."9-E%595:6-%"-("645"),%7$95"-7" 645"@"95.."

*5*B%$(5"$(+"*-)6"&'+5.0"G(-&("$)"$"9-*:-(5(6"-7"$"9-*:.58"9-(6$'('(/"9-*:.5*5(6"%595:6-%"<"

bR#<!cV" 645" 656%$):$('(" 7$*'.0" :%-65'(" bR#P!c" $(+" '(65%75%-(E'(+,95+" 6%$()*5*B%$(5" :%-65'(" !"

bD5,!?c" b!!<c1"345"906-:.$)*'9"+-*$'()"-7"R#!Q"9-(6$'("$"(,*B5%"-7"B'(+'(/" )'65)" 7-%" '(6%$95..,.$%"

)'/($.'(/" $(+" $+$:6-%" *-.59,.5)" '(9.,+'(/" UFRd<" $(+" Z$;" b!!?cV" R#!Q" 9$(" 645%57-%5" *5+'$65" 645"

%59%,'6*5(6" -7" )'/($.'(/" *-.59,.5)" 6-" @RM" *'9%-9.,)65%)" $(+" 64,)" $..-&" 645" )6$B'.'I$6'-(" $(+"

$*:.'7'9$6'-("-7")'/($.'(/"&'64'("'(+';'+,$."@RM"*'9%-9.,)65%)V"64,)"7$9'.'6$6'(/"@"95.."$96';$6'-("b!!Cc1"

34')"*594$(')*"')"$.)-"-B)5%;5+"&45("9-*:.5*5(6"6$//5+"$(6'/5("5(/$/5)"645"@RM"6-/5645%"&'64"

645"R#!QTR#<!TR#P!TD5,"!?"9-*:.58"b!!Kc1"

345" 7$96" 64$6" 645" +')%,:6'-(" -7" 645" $96'(" 906-)G5.56-(" '(" %5)6'(/" @" 95..)" ')" ),77'9'5(6" 6-" 6%'//5%"

'(6%$95..,.$%" )'/($.'(/" 64%-,/4" @RM" '(" $B)5(95" -7" J/" b!2PcV" +57'(5)" $" G50" %-.5" 7-%" 645" 906-)G5.56-("

(56&-%G"'("%595:6-%"$96';$6'-("B,6"+-5)"(-6")4-&"645"%5[,'%5*5(6"-7"645"@RM"'6)5.7"'("645")'/($.'(/1"

D(+55+V" $(+" ,:-(" )6'*,.$6'-(V" 645" 906-)G5.56-(" ')" %5-%/$('I5+" '(" $" &$0" 64$6" 645" @RM" 9.,)65%)" $%5"

%5.5$)5+" $(+" 9-(;5%/5" 6-" '(65%$96" &'64" 645" R#!Q" %595:6-%)" 45.+" '(" :.$95" $(+" '**-B'.'I5+" B0" 645"

R#P!E656%$):$('("(56&-%G"b!!Nc1"

Page 27: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<K""

"

@JLL"$(+"JUMDF"

" " 345"6,*-%"(59%-)')"7$96-%"b3WLc"7$*'.0"*5*B5%)V"@"95.."$96';$6'(/"7$96-%"b@JLLc"$(+"

JUMDF" b$" U%-.'75%$6'-(E'(+,9'(/" .'/$(+c" $%5" 9%,9'$." ),%;';$." 7$96-%)" 7-%" :5%':45%$." @" 95..)1" @JLL" $(+"

JUMDF" $%5" 4-*-6%'*5%'9" 60:5" DD" 6%$()*5*B%$(5" :%-65'()1" J" *5*B%$(5" B-,(+" 7-%*" -7" JUMDFV" 645"

3gSEUMDFV" $.)-" 58')6)V" B,6" 75&" ')" G(-&(" $B-,6" '6)" :40)'-.-/'9$." 7,(96'-(1" @-64" *5*B5%)" $%5"

:%-65-.06'9$..0":%-95))5+"$6"7,%'("9-()5(),)")5[,5(95)"6-"/5(5%$65")-.,B.5"906-G'(5)1"

@JLL" $(+" JUMDF" $%5" *$'(.0" :%-+,95+" B0" '(($65" '**,(5" 95..)" ),94" $)" (5,6%-:4'.)V" *$9%-:4$/5)V"

*-(-9065)V" +5(+%'6'9" 95..)V" 7-..'9,.$%" +5(+%'6'9" 95..)V" 3" 95..)V" $96';$65+" @" 95..)" $(+" @" 95.." 94%-('9"

.0*:4-906'9" .5,G5*'$" 95..)" b!!OE!!Qc1" 3450" $%5" $.)-" 58:%5))5+" B0" (-(" 45*$6-:-'56'9" 95..)" .'G5"

-)65-9.$)6)V" 7'B%-B.$)6)V" 5:'645.'$." 95..)V" B%5$)6" $+':-9065)" $(+" 9$%9'(-*$" 95..)1" 345'%" 58:%5))'-(" ')"

'(9%5$)5+" ,:-(" 60:5" D" DLWV" DFE!2V" /%$(,.-9065" 9-.-(0E)6'*,.$6'(/" 7$96-%" b>ERALc" $(+" 3FMC" $(+" Q"

)6'*,.$6'-("b!<2V"!<!c1"@JLL"$(+"JUMDF"B-64"B'(+"645"7-..-&'(/"%595:6-%)^"@RHJ"b@"95.."*$6,%$6'-("

$(6'/5(c" $(+" 3JRD" b3%$()*5*B%$(5" $96';$6-%" $(+" 9$.9',*" *-+,.$6-%" $(+" 909.-:4'.'(" .'/$(+"

'(65%$96-%ck" @JLL" $.)-" B'(+)" 645" @JLL" %595:6-%" b@JLLMc" $(+" JUMDF" 9$(" $.)-" '(65%$96" &'64" 645"

:-.0)$994$%'+5" )'+5"94$'()"-7"45:$%$(" ),.:4$65":%-65-/.09$()" b=AU>)c" J3(+4$'"5LK1"@JLL"$(+"JUMDF"

%595:6-%)"$%5"*$'(.0"58:%5))5+"B0"@"95..)k"A6'..V"@JLLM"9$("B5"$.)-"58:%5))5+"B0"%5/,.$6-%0"3"95..)"$(+"

3JRD"B0"*-(-9065)"$(+"#R)1"F'/$(+E%595:6-%"$))-9'$6'-(" '(+,95)" 645"$96';$6'-("-7"3MJL"*-.59,.5)V"

UD?_" $(+" @6G" G'($)5)" .5$+'(/" 6-"WLEv@" 6%$().-9$6'-(" %5[,'%5+" 7-%" @" 95.." ),%;';$.k" '6" $.)-" :5%*'6)" $("

5(4$(95*5(6"-7" 645"58:%5))'-("-7"$(6'E$:-:6-6'9":%-65'()V"$(" '(65/%'(E*5+'$65+" %5.-9$.'I$6'-("-7"@"

95..)" 6-" 645"*$%/'($." I-(5" $(+" $" 3" 95..E'(+5:5(+5(6" $(6'B-+0" 9.$))" )&'694'(/" b!<<c1" @JLL" 9$(" $.)-"

:%-*-65" /.09-.0)')V" :%-65'(" )0(645)')" $(+" 95.." /%-&64" 64%-,/4" 645" $96';$6'-(" '(":$%6" -7" 645":%-65'("

G'($)5"*$**$.'$(" 6$%/56" -7" %$:$*09'(" b*3XMc" b!<?V" !<Cc1" A6,+'5)" -7" +57'9'5(6" *-,)5" )6%$'()" 7-%"

5'645%" @JLLV" JUMDF" -%" 645'%" %595:6-%)" %5;5$." 64$6" @JLL" $(+" @JLLM" 9-(6%-." 645" +5;5.-:*5(6" $(+"

),%;';$." -7" @<" $(+" *$%/'($." I-(5" @" 95..)k" &45%5$)" JUMDF" ')" '(;-.;5+" '(" 645" %5/,.$6'-(" -7" R#C2E

'(+5:5(+5(6"9.$))")&'694'(/"$(+"'(":.$)*$"95.."),%;';$.k"3JRD"45.:)"'(($65"@"95..)"6-"'('6'$65"4,*-%$."

'**,(5" %5):-()5)" ,:-(" %5:56'6';5" .'/$(+" %59-/('6'-(" $(+" @RHJ" 9-(6%'B,65)" 6-" :.$)*$" 95..)"

*$'(65($(951" D(65%5)6'(/.0V"*5*-%0" @" 95..)" +-" (-6" %5.0" -(" @JLL" $(+" JUMDF" )0)65*" b??V" !<Kc1" D6" ')"

&-%64"*5(6'-('(/"64$6"@JLLM"$(+"@RM")'/($.'(/":$64&$0)"9-*:.5*5(6"5$94"-645%"$(+")0(5%/'I5"7-%"

:%-*-6'(/" :5%':45%$." @" 95.." *$'(65($(95" $(+" :%-;'+5" )'/($.)" (595))$%0" 7-%" @" 95.." 4-*5-)6$)')1"

H-%5-;5%V"3-..".'G5"%595:6-%)")'/($.'(/",:%5/,.$65)"3JRD"58:%5))'-(":$%6'9,.$%.0"-("@!"$(+"Hf"@"95..)"

):59'$.'I5+"'("7$)6"D/"%5):-()5)1"3FM)"$.)-"9--:5%$65"&'64"3JRD"B0"9-(;5%/'(/"WLEv@")'/($.'(/"9%,9'$."

7-%"JD#"b$96';$6'-(E'(+,95+"906-)'(5"+5$*'($)5c"$(+"/5%*.'(5"D/"/5(5"6%$()9%':6'-("5))5(6'$."7-%"9.$))"

)&'694"%59-*B'($6'-("b!<Nc1""

Page 28: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<N""

"

@5)'+5)" 645'%" 9%'6'9$." %-.5" '(" '(+,9'(/" @" 95.." 4-*5-)6$)')" $(+" 6-.5%$(95V" @JLL" $(+" 3JRD" $%5" $.)-"

'(;-.;5+"'("$,6-'**,('60"$(+"4,*$("+')5$)5)"),94"$)".,:,)"5%0645*$6-),)V"Ae-/%5(h)")0(+%-*5"$(+"

%45,*$6-'+"$%64%'6')1"D6"')"&5.."5)6$B.')45+"64$6"'(".0*:4-'+"9$(95%)V"645".5;5.)"-7"@JLL"$(+"JUMDF"$%5"

'(9%5$)5+" b!<Oc1"@JLL" .5;5.)"$%5"$.)-" '(9%5$)5+"+,%'(/" '(7.$**$6'-(V"$..5%/0"$(+";'%$." '(7596'-(1"L-%"

)-V" +'775%5(6" '(4'B'6-%)" '(" 645" 9.'('9" $%5" -(" 645'%" &$0" 6-" B5" +5;5.-:5+" 6-" .'*'6" @" 95..E):59'7'9"

$B(-%*$.'6'5)1"

"

"

L'/,%5"!Q^"@JLL"$(+"JUMDF"$(+"645'%"%595:6-%)V"-0-#&'0"6$%7"N(.1'$&"'&"-:;E"<=55"

R#C2ER#C2F"

" " 345" R#C2ER#C2F" .'/$6'-(" ')" 9%,9'$." 7-%" 3" 95.." +5:5(+5(6" $(6'B-+0" %5):-()5)" $(+"

,(+5%.'5)" /5(56'9" +57596)" 64$6" $%5" $))-9'$65+" &'64" D/H" )0(+%-*51" R#C2" 9-(6%'B,65)" 6-" :%'*$%0"

7,(96'-()" ),94" $)" @" 95.." ),%;';$." $(+" :%-.'75%$6'-(k" '6" $.)-" 5(4$(95)" 3" 95.." 9-..$B-%$6'-(V" /5%*'($."

95(65%" 7-%*$6'-("$(+" 64,)"5($B.5)" 9.$))" )&'694" %59-*B'($6'-(" bRAMc" 7%-*" D/H" 6-" D/>V" D/J"$(+" D/S1"

Y:-("@RM"5(/$/5*5(6V"R#Cp"3"95..)"6%$()'5(6.0",:%5/,.$65"R#C2F"58:%5))'-("6-"5(/$/5"R#C2"-("@"

95..)V":%-*-6'(/"@"95.."$(6'/5(":%5)5(6$6'-("9$:$9'6'5)"64%-,/4",:%5/,.$6'-("-7"H=R"9.$))"DD"*5*B5%)"

$(+"-7"645"@EO"7$*'.0"-7"9-)6'*,.$6-%0"*-.59,.5)"b!<Pc1"34,)V"'("645"$B)5(95"-7"R#C2V"/5%*'($."95(65%"

7-%*$6'-(" ')" $B-.')45+"$(+"$(6'B-+0" %5):-()5)"$%5" .'*'65+" 6-" .-&"$77'('60" D/H":%-+,95+" '(" $" 3" 95.."

'(+5:5(+5(6"*$((5%"b!<QV"!?2c1"R#C2")'/($.'(/"-99,%)"64%-,/4"645"%59%,'6*5(6"-7"3MJL!V"<V"?"K"$(+"

N"*-.59,.5)V":%-*-6'(/"645"$96';$6'-("-7"B-64"9$(-('9$."$(+"(-("9$(-('9$."WLEv@":$64&$0)" J3(+4$'"

<=K;"3MJL<"$(+"3MJL?"B'(+"6-"645")$*5"%5/'-("-7"R#C2"$(+"$96"'(+5:5(+5(6.0"'("*5+'$6'(/"D/"9.$))"

)&'694'(/"+%';5("B0"R#C2"b!?!cV"&45%5$)"3MJLN"B'(+)"6-"$"+')6'(96"%5/'-(k"R#C2"')")4-&("6-"$))-9'$65"

'(+'%596.0"&'64"3MJL!"$(+"K"*-.59,.5)1""

Page 29: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<O""

"

R#C2"58:%5))'-("B0"*-,)5"$(+"4,*$("@"95..)"')",:%5/,.$65+",:-("3FMQ"$96';$6'-(V"$(+")-"')"645"9$)5"

7-%" 3JRD" %595:6-%1" 34')" 5(4$(95+" 58:%5))'-(" -7" B-64" R#C2" $(+" 3JRD" ,:-(" 3FMQ" 5(/$/5*5(6"

9-(6%'B,65)"6-"645")0(5%/0"B56&55("645"64%55"%595:6-%)"'("+%';'(/"$("-:6'*$."@"95.."$96';$6'-("b!?<cV"

'(9.,+'(/"@"95..":%-.'75%$6'-(V"RAMV":.$)*$"95.."+'775%5(6'$6'-("$(+"D/!"$(+"D/S")59%56'-(1"R#C2".'/$6'-("

(-6"-(.0"9-(6%'B,65)"6-"D/S")59%56'-("B,6"$.)-"6-",:%5/,.$6'-("-7"'6)"%595:6-%"bR#<?c"58:%5))'-("-("645"

@"95..)V"&4'94"'(;-.;5)"R#C2"'("*$(0"$..5%/'9"'(7.$**$6'-("+')5$)5)1"D("64')"9-(6586V"-(5"%5/,.$6-%"-7"

R#C2" )'/($.'(/" 4$)" B55(" '+5(6'7'5+" &4'94" ')" R#CNV" $" %595:6-%" 7-%" 645" :%-+,96" -7" $96';$65+"

9-*:.5*5(6"RCB^"A-*5"*'9%-B'$."$(6'/5()"B'(+"B-64"RCE@'(+'(/"U%-65'("b$"R#C2".'/$(+c"$(+"R#CNV"

B%'+/'(/" R#C2" 6-" R#CN^" 64')" 9-E.'/$6'-(" '(4'B'6)" R#C2E*5+'$65+" ,:%5/,.$6'-(" -7" ),%7$95" R#<?V" $(+"

'(+,96'-("-7"D/S"9.$))E)&'694'(/"$)"&5.."$)"WLEv@"$96';$6'-(1"

"

L'/,%5"<2^"H-+5."+5:'96'(/"645"9$(-('9$."$(+"(-(E9$(-('9$."(,9.5$%"7$96-%"lv@":$64&$0V"-0-#&'0"

6$%7"N(.1'$&"'&"-:;E"<=55"

!)'&9$)+5#(0$**&)9+!).+5#$*$)'!'&()+

H=R"9.$))"DD"$(6'/5(":%5)5(6$6'-("

" R5.."*5+'$65+"$(+"4,*-%$."%5):-()5)"6-"58-/5(-,)"$(6'/5()"+5:5(+"-("645"7-%*$6'-("$(+"

),%7$95" +'):.$0" -7" $(6'/5(E+5%';5+" :5:6'+5" H=R" 9.$))" DD" 9-*:.585)1" D(" 9-(6%$)6" 6-" H=R" 9.$))" D"

*-.59,.5)" 64$6" $%5" 58:%5))5+" -(" 5;5%0" (,9.5$65+" 95.." -7" 645" B-+0V" 645" 58:%5))'-(" -7"H=R" 9.$))" DD"

*-.59,.5)"')".$%/5.0"%5)6%'965+"6-"340*'9"S:'645.'$."R5..)"b3SRc"$(+"6-"95..)"-7"645"'**,(5")0)65*"64$6"

$%5"):59'$.'I5+"'(":%-95))'(/"$(+":%5)5(6'(/"645"J/"'(9.,+'(/"#R)V"@"95..)"$(+"*$9%-:4$/5)1"=-&5;5%V"

'("$("'(7.$**$6-%0")'6,$6'-("-%",:-("DLWEd")6'*,.$6'-(V"H=R"9.$))"DD"*-.59,.5)"$%5"7-,(+"58:%5))5+"

-(" (-(EJUR)" ),%7$95" .'G5" 5(+-645.'$." 95..)V" 5:'645.'$." 95..)" $(+" G5%$6'(-9065)V" $)6%-9065)" $(+"

7'B%-B.$)6)" b!??E!?Kc1" 345"*$)65%" %5/,.$6-%" -7"H=R" 9.$))" DD" 58:%5))'-(" ')"&5.." +57'(5+" $)" 645"H=R"

9.$))" DD" 3%$()$96';$6-%" bRDD3JcV" 4-&5;5%V" " ;$%'-,)" )59-(+$%0" )6'*,.'V" '(9.,+'(/" 6%$()7-%*'(/" /%-&64"

7$96-%"b3>LE\cV"DLWE\V"6,*-%E(59%-)')"7$96-%V"DFE!V"DFE!2V"'(7596'-("&'64";$%'-,)":$64-/5()"$(+"95%6$'("

Page 30: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<P""

"

+%,/)V")55*"6-"*-+,.$65"645"58:%5))'-("-7"9.$))"DD"*-.59,.5)" '(" '**,(5"-%"(-(E'**,(5"95..)"b!?NV"

!?Oc1" 3%$+'6'-($..0V" H=R" 9.$))" DD" *-.59,.5)" :%5)5(6" $(6'/5('9" :5:6'+5)" +5%';5+" 7%-*" 58-/5(-,)"

:%-65'()"6-"R#Cp"3"95..)1"M595(6")6,+'5)"4$;5"'(65%5)6'(/.0"%5;5$.5+"645":-))'B'.'60"-7"645":%5)5(6$6'-("

-7"5(+-/5(-,)"J/"b906-:.$)*'9"$(+"(,9.5$%c"-("H=R"9.$))"DD"*-.59,.5)"(-6$B.0";'%$.V"6,*-%"$(+")5.7"

J/)1"34')"$.65%($6';5":$64&$0"')"*5+'$65+"B0"$,6-:4$/0"&45("5(+-/5(-,)"$(6'/5()"$%5")5[,5)65%5+"

'(6-" +-,B.5"*5*B%$(5" )6%,96,%5)" G(-&(" $)" $,6-:4$/-)-*5)" 64$6" 9-(6'(,-,).0" 7,)5" &'64"*$6,%5"

5(+-)-*5)V"64,)"$..-&'(/"J/"6-"$))-9'$65"&'64"H=R"9.$))"DD"*-.59,.5)"b!?Pcb3(+4$'"YK;""

"

L'/,%5"N^"3&-"*$e-%"H=R"9.$))"DD":%5)5(6$6'-(":$64&$0)"-7"58-/5(-,)"b!c"$(+"5(+-/5(-,)"$(6'/5()"

b<cV"-0-#&'0"6$%7"?4.1Q-:&'$"-)0"I:9'$&E"<==L"

Y:-(" '**,('I$6'-(V"J/"):59'7'9"@" .0*:4-9065)"$%5"645"7'%)6" .0*:4-'+"-%/$("95..)" 6-"$9[,'%5"J/"$(+"

58:%5))" 645" 9-%%5):-(+'(/" ),%7$95"H=RE:5:6'+5" 9-*:.585)V" 4'/4.'/46'(/" 645" 9$:$9'60" -7" @" 95..)" 6-"

577'9'5(6.0":%-95))"$(+":%5)5(6"@RME'(65%($.'I5+"J/"-(6-"H=R"9.$))" DD"*-.59,.5)" ()" /(/%" b!?QV"!C2c1"

J(6'/5(" 9$:6,%5+" 64%-,/4" 645" @RM" ,(+5%/-5)" $995.5%$65+" 6%$():-%6" 6-" 5(+-)-*5)" $(+" 5(4$(95+"

:%5)5(6$6'-("577'9'5(90"$)" 9-*:$%5+"&'64"J/" 6$G5(",:"B0" 7.,'+":4$)5"5(+-906-)')" b!C!V"!C<c1"H=R"

9.$))" DD"*-.59,.5)"$))5*B.5")4-%6.0"$765%")0(645)')" '(" 645"SM"&'64"$" 60:5" DD" 6%$()*5*B%$(5":%-65'(V"

645"'(;$%'$(6"94$'("bD'cV"&4'94":%5;5(6)"645'%":%5*$6,%5"$))-9'$6'-("&'64"5(+-/5(-,)":5:6'+5)"b!C?c1"

D("$++'6'-("D'"9-(6$'()"'("'6)"906-:.$)*'9"6$'."645"6$%/56'(/")'/($.)"64$6"+5.';5%"H=R"9.$))"DD"*-.59,.5)"

'(6-" 5(+-906'9" 9-*:$%6*5(6)" 7-%" 645*" 6-" B5" .-$+5+" &'64" $(6'/5('9" :5:6'+5)" %5),.6'(/" 7%-*" 645"

+5/%$+$6'-(" -7" '(65%($.'I5+" J/" B0" 5(+-906'9" :%-65$)5)" $(+" 9$645:)'()" b!CCE!CNc1" g'64'(" 645" .$65"

5(+-906'9" 9-*:$%6*5(6V" 645" )$*5" 5(+-906'9" :%-65$)5)" 64$6" :%-65-.0)5" $(6'/5('9" :%-65'()V"

:%-/%5))';5.0" :%-95))" D'" 6-" 7%55"H=R" DD" *-.59,.5)" 7-%" $(6'/5(" .-$+'(/V" $" %5$96'-(" 9$6$.0)5+" B0" 645"

Page 31: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

<Q""

"

94$:5%-(5" =<E#HV" $" :%-95))" 6-" B5" +5)9%'B5+" '(" +56$'.)" .$65%" -(1" 345%57-%5V" ),995))7,." J/"

:%5)5(6$6'-("%5.'5)"-("'6)"577'9'5(6"+5.';5%0"$(+"6$%/56'(/"'(6-"):59'$.'I5+"9-*:$%6*5(6)"577'9'5(6"7-%"

J/" :%-95))'(/1" 34')" '(;-.;5)" $" 9%'6'9$." %-.5" 7-%" 645" @RM" '(" +'%596'(/" 645" J/" 6%$77'9" 6-&$%+" " 9.$))" DDE

9-(6$'('(/"5(+-906'9";5)'9.5)" bRDDZ)cV"$":45(-*5(-("64$6" %5[,'%5)",B'[,'60.$6'-("-7" 645"@RM"B0" 645"

A0GEB'(+'(/" S?" YB'[,'6'(" F'/$)5" 9ERBD" bR$)'6$)" @E.'(5$/5" .0*:4-*$c" b!COV" !CPc1" D(" $++'6'-(V" 64')"

:%-95))" ')" $99-*:$('5+"&'64" ),B)6$(6'$."*-+'7'9$6'-()" '(" 645" 5(+-906'9" :$64&$0" -7" @" 95..k" '(+55+V"

@RM"5(/$/5*5(6"6%'//5%)"$96'(EB$)5+"*-6-%"H0-)'("DD"$96';$6'-("$(+"$))-9'$6'-("&'64"H=R"9.$))"DDED'"

9-*:.585)" $..-&'(/" 645*" 6-" B5" 6%$():-%65+" 6-&$%+" '(9-*'(/" @RM" $))-9'$65+" J/" b!CQc1" 345"

$))-9'$6'-(" B56&55("H=RE9.$))" DDED'" 9-*:.585)" $(+"*0-)'(" DD" -99,%)" /(-" 645" D'" 906-)-.'9" 6$'." $(+" ')"

*5+'$65+" B0" @RME6%'//5%5+" +-&(" %5/,.$6'-(" -7" 9$645:)'(" A" $96';'60" b'(;-.;5+" '(" 645" 7'($." )65:" '(" D'"

:%-95))'(/cV"&4'94":5%*'6)"6%$()'5(6"$99,*,.$6'-("-7"H=RDDED'"9-*:.585)1"J6"$" .$65%"6'*5",:-("@RM"

)6'*,.$6'-(V"H0-)'(" DD"+'))-9'$65)"7%-*"H=RDDED'"9-*:.585)"$)"%5),.6"-7" D'"906-)-.'9"6$'.":%-65-.0)')" '("

645" .0)-)-*5)" &4'94" :5%*'6)" 645" %5.5$)5" -7" H=RDD" *-.59,.5)" 6-" B'(+" $(6'/5('9" :5:6'+5)" 7-%" $"

),B)5[,5(6" :%5)5(6$6'-(" 6-" 3" 95..)" b!K2c1" L,%645%*-%5V" H0)-)'(" DD$" 4$)" B55(" %595(6.0" )4-&(" 6-"

*5+'$65V" ,:-(" %59-/('6'-(" -7" *5*B%$(5" B-,(+" J/V" +0($*'9" 9-(6%$96'-()" %5):-()'B.5" -7" 645"

'(;$/'($6'-(" -7" :%5)5(6'(/" *5*B%$(5)" $(+" 645" 586%$96'-(" -7" 645" $(6'/5(1" 345)5" 9-(6%$96'-()"

/5(5%$65" 7-%95)" 64$6" $%5" $B.5" 6-" B%5$G" *-)6" '(+';'+,$." @RME$(6'/5(" B-(+)" $(+" :%-*-65" 645"

'(65%($.'I$6'-("-7"-(.0"*,.6';$.5(6"@RM"*'9%-9.,)65%)"&'64"4'/4"$77'('60"b!K!c1"

345"R$645:)'("7$*'.0"

" " 345"*$'("+5/%$+$6';5"9-*:$%6*5(6"'("5,G$%0-6'9"95..)"$%5"645".0)-)-*5)k"4-&5;5%"'("

)-*5" 95.." 60:5)V" 5):59'$..0" 95..)" +5%';5+" 7%-*"45*$6-:-56'9" .'(5$/5V" :-))5))" ):59'$.'I5+" .0)-)-*$."

9-*:$%6*5(6"($*5+"i.0)-)-*$.E%5.$65+"-%/$(5..5)j"-%"i)59%56-%0"-%/$(5..5)j"&4'94V"'("%5):-()5"6-"

5865%($.")6'*,.$6'-(V"9$(")59%565"645'%"9-(65(6)"'(6-"645"586%$95..,.$%"5(;'%-(*5(6"$(+"64,)",(+5%/-"

%5/,.$65+" )59%56'-(" b!K<V" !K?c1" R-(;5(6'-($." .0)-)-*5)" $(+" )59%56-%0" .0)-)-*5)" )4$%5" 645" )$*5"

:%-:5%6'5)" $)" 6450" :-))5))" '(65%($." $9'+'9" :=" $(+" 9-()'+5%$B.5" (,*B5%" -7" :%-65$)5)" *$'(.0"

9$645:)'()1" 345" ($*5" 9$645:)'(" ')" +5%';5+" 7%-*" 645" /%55G" G$645:)5'(" b6-" +'/5)6c" $(+" &$)" 7'%)6"

:%-:-)5+" 6-" +5)9%'B5" :%-65$)5)" 64$6" $%5" $96';5" '(" $" ).'/46.0" $9'+'9" 5(;'%-(*5(61" @5)'+5)" 645'%"

)'/('7'9$(6"%-.5"'("H=R"9.$))"DD"$(6'/5(":%5)5(6$6'-(V"9$645:)'()"$%5"+5)9%'B5+"6-"B5"'(;-.;5+"'("-645%"

'**,(5":%-95))5)V":40)'-.-/'9$."$)"&5.."$)":$64-.-/'9$.V"),94"$)"95.."+5$64"%5/,.$6'-(V"H=R"9.$))" DD"

9-*:.58" *$6,%$6'-(V" 3-..E.'G5" %595:6-%" )'/($.'(/V" B-(5" %5*-+5.'(/V" G5%$6'(-9065" +'775%5(6'$6'-(V"

6,*-%":%-/%5))'-("$(+"*56$)6$)')V"%45,*$6-'+"$%64%'6')"$(+"-)65-$%64%'6')V"$645%-)9.5%-)')V"+'$B565)V"

$6-:'9"+5%*$6'6')"$(+"*$(0"-645%)"b!KCV"!KKc"bA-9:'<K;"

345"9$645:)'("7$*'.0"9$("B5"9.$))'7'5+"'("64%55"+'775%5(6"/%-,:)^"$):$%6'9":%-65$)5)"b9$645:)'("#"$(+"

ScV")5%'(5":%-65$)5)"b9$645:)'()"J"$(+">c"$(+"90)65'(5":%-65$)5)"b9$645:)'()"@VRVLV=V_VFVXVAVZVa"$(+"

Page 32: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?2""

"

gck" 6450" " 9-(6$'(" '(" 645'%" $96';5" 9$6$.06'9" )'65" 5'645%" $(" $):$%6'9" $9'+V" -%" $" )5%'(5" $*'(-" $9'+" -%" $"

90)65'(5" 64'-.V" %5):596';5.01" 345"B'//5%" ),B/%-,:"-7" 645" 9$645:)'(" 7$*'.0" ')" 645" 90)65'(5":%-65$)5)k"

6450" B5.-(/" 6-" 645" :$:$'(E.'G5" 7$*'.0" +,5" 6-" 645" )'*'.$%'60" -7" )6%,96,%5)" 6-" 64$6" -7" :$:$'(1" J("

$++'6'-($."90)65'(5":%-65$)5"64$6"')"*-%5"9.-)5.0"%5.$65+"6-"645"9$):$)5)V" ')"7-,(+"'(".0)-)-*5)"$(+"

'6)" ($*5+" $):$%$/'(0." 5(+-:5:6'+$)5" bJSUc" -%" .5/,*$'(1" J)"*$(0" -645%" :%-65$)5)V" 9$645:)'()" $%5"

)0(645)'I5+" $)" '($96';5" I0*-/5()V" 9-(6$'('(/" $" :%-E+-*$'(" $6" 645'%"WE65%*'(,)"&4'94" $..-&)" 645'%"

:%-:5%" 7-.+'(/" $(+" )6$B'.'60" $(+" :%5;5(6)" 645'%" :%5*$6,%5" $96';$6'-(" B57-%5" 6450" %5$94" 645" 5(+-E

.0)-)-*$." 9-*:$%6*5(6)1" 345" /5(5%$6'-(" -7" 9$6$.06'9$..0" $96';5" 5(I0*5"-99,%)" ,:-(" :%-95))'(/" -7"

645" '($96';5" I0*-/5("&'64'(" .0)-)-*5)V" $" %5$96'-(" 64$6" ')" )4$:5+" B0" -645%" $96';5" :%-65$)5)" -%" B0"

$,6-9$6$.06'9"*594$(')*"*5+'$65+"B0" 645" .-&":="-%" B0" 645" :%5)5(95" -7" /.09-)$*'(-/.09$()" b!KNE

!KPc1"

R$645:)'(" 7$*'.0" #')6%'B,6'-(""" L,(96'-(" D(;-.;5*5(6"'("

+')5$)5"

0=?FGHKCB+"+ R0)65'(5"

S(+-:5:6'+$)5":=xN"

S8-:5:6'+$)5":=yK"

YB'[,'6-,)" S$%.0"(5,6%-:4'.V"3"$(+"@"95.."

$:-:6-)')"

3FM)")'/($..'(/"$(+"3WLE$.:4$"

:%-+,96'-("

A5.596-%)"7-%":5:6'+5EH=R"DD"

9-*:.585)"

D(7.$**$)-*5"$96';$6'-("

F0)-)-*$.E*5+'$65+"$:-:6-)')""

SRH":%-65-.0)')V"*56$)6$)')"

D(7.$**$6-%0""

+')-%+5%)J.I45'*5%h)"

+')5$)5"

R$(95%"

0=?FGHKCB+0+ R0)65'(5"

J*'(-"+':5:6'+0."

58-:5:6'+$)5"

YB'[,'6-,)" J96';$6'-("-7"/%$(I0*5)"J"$(+"@"

A5%'(5":%-65$)5"$96';$6'-("

$))-9'$65+"&'64"W_V"R3FV"*$)6"95.."

$(+""(5,6%-:4'."7,(96'-("

D(7.$**$6-%0"+')-%+5%)"

0=?FGHKCB+.+ J):$%6'9"

S(+-:5:6'+$)5"

YB'[,'6-,)" S$%.0"(5,6%-:4'.V"3"$(+"@"95.."

$:-:6-)')"

A5.596-%)"7-%":5:6'+5EH=R"DD"

9-*:.585)"

SRH"+5/%$+$6'-("

F0)-)-*$.E*5+'$65+"$:-:6-)')"

D(7.$**$6-%0"+')-%+5%)V"

9$(95%"

M45,*$6-'+"$%64%'6')V"

J.I45'*5%h)"+')5$)5"

0=?FGHKCB+$+ J):$%6'9"

S(+-:5:6'+$)5"

D**,(5"95..)" A5.596-%)"7-%":5:6'+5EH=RDD"

9-*:.585)"

J6-:'9"+5%*$6'6')V"

+5%*$6'6')"

0=?FGHKCB+Q+ R0)65'(5"

S(+-:5:6'+$)5"

YB'[,'6-,)" A5.596-%)"7-%":5:6'+5EH=RDD"

9-*:.585)"

R$(95%"

0=?FGHKCB+9+ A5%'(5"

S(+-:%-65$)5"

W5,6%-:4'."

.0)-)-*5)"

=,*$("@"95..)"

b58-/5(-,)")-,%95c"

DFEPV"DFE!B56$"$(+"3WLE$.:4$"

$96';$6'-("

DFEN"+')$96';$6'-("

#5)6%,96'-("-7"645"$,6-$(6'/5("H@U"

b'("@"95..)c"

D(7.$**$6-%0"+')-%+5%)"

0=?FGHKCB+3+ R0)65'(5"

J*'(-:5:6'+$)5"$(+"

S(+-:5:6'+$)5"

YB'[,'6-,)" SRH"+5/%$+$6'-(" R$(95%"

0=?FGHKCB+S+ R0)65'(5"

S(+-:5:6'+$)5"

#R)V")0(-;'$."95..)" 3FM)")'/($..'(/"

SRH"+5/%$+$6'-("$(+"B-(5"

%5*-+5.'(/"

M45,*$6-'+"$%64%'6')"

0=?FGHKCB+6+ R0)65'(5"

S(+-:5:6'+$)5"

YB'[,'6-,)" 3FM)")'/($..'(/"

A5.596-%)"7-%":5:6'+5EH=R"DD"

9-*:.585)T"D'"+5/%$+$6'-("

W_3"$(+"R#C"3"95..)":%-+,96'-(V"

(5,%-($."95.."+5$64"$(+"-)65-9.$)6'9"

B-(5"+5/%$+$6'-("

340*'9":$64-.-/0"

J645%-)9.5%-)')"

M45,*$6-'+"$%64%'6')"

R$(95%"

+ " " SRH"+5/%$+$6'-(" "

0=?FGHKCB+*+ R0)65'(5"

S(+-:5:6'+$)5"

JUR" 3FM)")'/($..'(/"

A5.596-%)"7-%":5:6'+5EH=R"DD"

9-*:.585)T"D'"+5/%$+$6'-("

W_3"95..)":%-+,96'-(V"SRH"

J%64%'6')V"$645%-)9.5%-)')"

@%-(94'$."$)64*$V"RXU#"

U)-%'$)')V"9$(95%"

Page 33: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?!""

"

+5/%$+$6'-("

Z5)'9,.$%"9%-))E:%5)5(6$6'-("

:$64&$0"

0=?FGHKCB+%+TABIU+

H>GKGB?+CB+

FEV=BW+

R0)65'(5"

S(+-:5:6'+$)5"

YB'[,'6-,)" A5.596-%)"7-%":5:6'+5EH=R"DD"

9-*:.585)V"

W_3"$(+"R#C"3"95..)":%-+,96'-("

340*'9":$64-.-/0V"9$(95%"

0=?FGHKCB+X+ R0)65'(5"

YG(-&("

W_"$(+"R#Pp"

906-6-8'9"3"95..)"

A5.596-%)"7-%":5:6'+5EH=R"DD"

9-*:.585)"

J,6-'**,(5"$6%-:4'9"

/$)6%'6')"

0=?FGHKCB+Y+ R0)65'(5"

R$%B-80"*-(-E"$(+"

+'E58-:5:6'+$)5"

YB'[,'6-,)" 3"95.."$96';$6'-("

3"95.."*'/%$6'-("$(+"'(;$)'-("

H$9%-:4$/5"$+45)'-("$(+"#R"

*$6,%$6'-("

R$(95%"

3$B.5<^"S(+-)-*$."9$645:)'()"$(+"645'%"'(;-.;5*5(6"'("'**,(5"%5):-()5)E".%79()'0"6$%7"!%)42"'&"

-:;E"<=5=Z"!%:9'$&"'&"-:;E"<==LK"

J):$%$/'(5"S(+-:5:6'+$)5""

" " J):$%$/'(5"5(+-:5:6'+$)5" bJSUc" ')" $" 90)65'(5":%-65$)5" 64$6"&$)" 7'%)6.0"+5)9%'B5+" '("

!QQO"$)" 645"*$**$.'$("4-*-.-/,5"-7" .5/,*$'(":%5)5(6"-(.0" '(":.$(6)"$(+":$%$)'65)1" D6"B5.-(/)"6-"

645"7$*'.0"R!?"$(+"')"/%-,:5+"6-/5645%"&'64"(-(E:$:$'(":%-65$)5)".'G5")5:$%$)5)V"9$):$)5)"$(+")-*5"

B$965%'$.":%-65$)5)"'("9.$("R#"b!KQV"!N2c1"JSUV",(.'G5"-645%".0)-)-*$."90)65'(":%-65$)5)V"')"'()5()'6';5"

6-" 9-**-(E90)65'(5" '(4'B'6-%)" .'G5" .5,:5:6'(" $(+" SNCV" $(+" ')" ):59'$.'I5+" '(" 9.5$;'(/" 645" 9$%B-80."

65%*'($." )'65)" -7" $):$%$/'(5" %5)'+,5)1" 345" $96';$6'-(" -7" JSU" ')" )6%'96.0" :=E+5:5(+5(6" $(+"

$,6-9$6$.06'9k",:-("'6)")0(645)')"'("645"SM"$)"$("'($96';5"KN_#$"I0*-/5(V"'6"')"6$%/565+"6-"645"5(+-E

.0)-)-*$."9-*:$%6*5(6)"&45%5"'6",(+5%/-5)"$"7'%)6"$,6-9$6$.06'9"9.5$;$/5"$6"645"J)(?<?"%5),.6'(/"-("

645"/5(5%$6'-("-7"$"CO"G#$" '(65%*5+'$65" 7-%*V"64$6" ')"),B)5[,5(6.0"$,6-9.5$;5+"$6" 645"J)(<K"/';'(/"

%')5"6-"645"CN"G#$"$96';5"7-%*1"L'($..0"645"R"65%*'($."-7"645"CN"G#$"7-%*"')"6%'**5+"B0"$(",(G(-&("

:%-65$)5"/5(5%$6'(/"645"7'($."*$6,%5"7-%*"-7"?N"G#$"JSU"b!N!V"!N<c1"#5):'65"'6)"$,6-9$6$.06'9"$96';'60V"

JSU" ')" $.)-" %5[,'%5+" 7-%" 645" :%-95))'(/" -7" 645" :%-E7-%*)" -7" -645%" 5(+-)-*$." :%-65$)5)" ),94" $)"

9$645:)'()" @V" F" $(+" =" 6-" /5(5%$65" $" 7'($." *$6,%5" 7-%*k" 4-&5;5%" '*:$'%*5(6" -7" 9$645:)'(" F"

*$6,%$6'-("+,5"6-"JSU"+57'9'5(90"+-5)"(-6"$77596"9$645:)'("F"*5+'$65+EW_3"$(+"3"95.."+5;5.-:*5(6"

b!N?V"!NCcV"&45%5$)"-,%"/%-,:":%-;'+5"9-(6%$+'96-%0"+$6$"4'/4.'/46'(/"645"5(4$(95*5(6"-7"9$645:)'("

F"$96';'60" "$(+" '6)"*5+'$65+EW_3"95.."$96';$6'-(" '("JSU"+57'9'5(6"95..)" bM5),.6":$%6" DDc" 1"JSU"4$)"B55("

+5)9%'B5+"6-"B5"$("577596';5":.$05%"'("H=R"9.$))"DD"$(6'/5(":%5)5(6$6'-(V"'(+'%596.0"$(+"+'%596.01"D("@"

95..)" 6%$()7-%*5+" &'64" S:)65'(E@$%%" ;'%,)" bS@ZcV" JSU" ')" +5*-()6%$65+" 6-" B5" $B.5" 6-" '('6'$65" 645"

:%-95))'(/"-7" '(;$%'$(6" 94$'("B0" 6$%/56'(/"+'775%5(6"$):$%$/'(5" %5)'+,5)" '(" 645" .,*'($."+-*$'("-7" D'"

/';'(/"%')5"6-"645":!2"$(+":<<"'(65%*5+'$65)"'("*,%'(5"$(+"4,*$("D'V"%5):596';5.0k"&4'94"')"9%'6'9$."7-%"

H=R"9.$))" DD"*-.59,.5)"*$6,%$6'-("$(+"3"95.."$96';$6'-(" b!N!c1"J"+'%596" '(;-.;5*5(6"-7"JSU" '("H=R"

9.$))" DD" :%5)5(6$6'-(" ')" -B)5%;5+" B0" 645"g$66)" /%-,:"&4-" )4-&5+" 64$6" JSU" ')" %5):-()'B.5" 7-%" 645"

:%-95))'(/"-7"645"*'9%-B'$."656$(,)"6-8'9"$(6'/5("()"/(&$%"$(+"()"/(/%"b!NKcV"$(+"$(-645%"%595(6")6,+0"

'*:.'9$65)"$)"&5.."JSU"'("645"+'%596"9.5$;$/5"-7"645"3JME#WJ"B'(+'(/":%-65'("C?"b3#UC?c"&4'94" ')"$"

(,9.5$%":%-65'("'(;-.;5+"'("MWJ"):.'9'(/"$(+"$"*$e-%":%-65'("9-*:-(5(6"-7"645"7%-6-6-*:-%$.".-B$%"

Page 34: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?<""

"

+5/5(5%$6'-(" $(+" $*0-6%-:4'9" .$65%$." )9.5%-)')" b!NNc1" JSU" ')" $.)-" '(;-.;5+" '(" 645" +5)6%,96';5"

:%-95))'(/" -7" 645" '**,(5E+-*'($(6" 5:'6-:5" -7" *05.'(" B$)'9" :%-65'(" bH@UcV" $(" $,6-$(6'/5("

9$(+'+$65"'("645"'(7.$**$6-%0"+5*05.'($6'-("+')5$)5"*,.6':.5")9.5%-)')"$(+"9$("'(+,95"645"*,.6':.5"

)9.5%-)')E.'G5" +')5$)5" 58:5%'*5(6$." $,6-'**,(5" 5(95:4$.-*05.'6')" bSJScV" 64,)" 4'/4.'/46'(/" 645"

'*:-%6$(95"-7"JSU"'("*$'(6$'('(/"$(+"'(+,9'(/"6-.5%$(95"'("645"640*,)"b!NOc1"D(65%5)6'(/.0V"JSU"$(+"

9$645:)'()"$%5"B55(".$65.0"+5)9%'B5+"6-"B5"'*:.'9$65+"'("3-..".'G5"%595:6-%":%-95))'(/"$(+")'/($.'(/V"$"

:%-95))"+5)9%'B5+"*-%5"9.-)5.0".$65%"-(1"

345"'(;$%'$(6"94$'(V"$"94$'("-7"9-**$(+"

" " 345"'(;$%'$(6"94$'("D'V"$.)-"G(-&("$)"R#OC"&45("58:%5))5+"-("645"95.."),%7$95V"')"$("

5;-.,6'-($%'.0" 9-()5%;5+" 60:5" DD" 6%$()*5*B%$(5" :%-65'(" '+5(6'7'5+" 7'%)6" B0" $))-9'$6'-(" 6-" H=RDD"

*-.59,.5)1" 3-" )6,+0" 645" D'" 7,(96'-(V" 645"*-,)5"*-+5." &$)" 94-)5(" 7-%" 645" 4,/5" 4-*-.-/0" )4$%5+"

B56&55("645"4,*$("/5(5"b94%-*-)-*5"KV"Q"58-()c"$(+"645"*,%'(5"9-,(65%:$%6"b94%-*-)-*5"!PV"P"

58-()c" $)" 6450" B-64" )6$%6" &'64" $(" 58-(" 5(9-+'(/" 645" Kh" ,(6%$().$65+" %5/'-(" $(+" 645" WE65%*'($."

906-:.$)*'9"6$'.1"3&-"*$'("6%$()9%':6)";$%'$(6)"58')6"'("4,*$("$(+"*'95V"-(5".-(/"7-%*"b:C!c"$(+"-(5"

)4-%65%" 7-%*" b4,*$(":??"$(+"*-,)5":?!c" 64$6":%5+-*'($65)" '("B-64" ):59'5)1" 3&-"*-%5" ')-7-%*)"

4$;5" B55(" '+5(6'7'5+" '(" 4,*$(" $(+" $%5" $%')'(/" 7%-*" $(" $.65%($6';5" 6%$().$6'-(" )6$%6" )'65" CP" B:"

,:)6%5$*"-7"645"6&-"*$'("7-%*)V"5(9-+'(/"645"%5/'-("%5):-()'B.5"-7"D'"%565(6'-("'("645"SM"b:C?"$(+"

:?Kc1"345"7-,%";$%'$(6)"-7"645"'(;$%'$(6"94$'("'("4,*$()"$%5":C?V":C!V":?K"$(+":??"$(+"'("*'95":C!"

$(+":?!k"6450"$.."'(9.,+5"$"6%$()*5*B%$(5"+-*$'(V"$"RFDU"+-*$'("bR.$))"DDE$))-9'$65+"'(;$%'$(6"94$'("

:5:6'+5c" $(+" $" 6%'*5%'I$6'-(" +-*$'(" 64$6" $..-&)" 645" '(65%$96'-(" &'64" 64%55" H=R" DD" 4565%-+'*5%)"

bu^\ck" :C?" $(+" :C!" 9-(6$'(" $)" &5.." $" 640%-/.-B,.'(E.'G5" +-*$'(" b!NPE!O2c1" D(;$%'$(6" 94$'(" ')"

)0(645)'I5+" '("645"SM"&45%5" '6"$))-9'$65)"&'64" '6)"*-.59,.$%"94$:5%-(5"9$.(58'("64$6"9-(6%'B,65)"6-"

'6)"9-%%596"7-.+'(/"$(+":%5;5(6)"'6)"5/%5))"7%-*"645"SM1"34')"$))-9'$6'-("%5[,'%5)"645"/.09-)0.$6'-("-7"

6&-"G50"$):$%$/'(5" %5)'+,5)" b!O!E!O?c1" " 345"9-()5%;5+" D'" 7-,(+"9-$))5*B.5+"&'64" 9.$))" DD" ),B,('6)"

:%5;5(6)" '%%5;5%)'B.5"*')7-.+'(/"-7" 645"),B,('6)V":%-6596)" 645"($)95(6"5*:60"/%--;5V"$(+":%-*-65)"

%5.5$)5" 7%-*" 645" %5)'+5(6" 94$:5%-(5)" ),94" $)" >MUQCT@'U" $(+" SM:O<T9$.(58'(" %5):-()'B.5" 7-%" 645"

5(+-:.$)*'9" %56'9,.,*" [,$.'60" 9-(6%-." b!OCE!ONc1" D6" ')" '*:-%6$(6" 6-" :-'(6" -,6" 64$6" +57'9'5(90" '(" D'"

+')%,:6)"645"9-%%596"7-.+'(/"$(+"$))5*B.0"-7"9.$))"DD"),B,('6)"'("DEJB"4$:.-60:5V"&45%5$)"645"+"$(+"G"

4$:.-60:5"*,6$(6)"577'9'5(6.0":%-+,95"9.$))"DD"+'*5%)"b!OOc1"

345" '*:-%6$(95" -7" D'" ')" %5;5$.5+" '(" *$(0" :%-95))5)" -7" 645" '**,(5" )0)65*V" '(9.,+'(/" $(6'/5("

:%5)5(6$6'-(V"@"95.."+'775%5(6'$6'-("$(+"'(7.$**$6-%0")'/($.'(/1"

Page 35: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

??""

"

X)/-$(-)&".B-()"#$%.'22()+"-)0"-)&(+')"#$'2')&-&(%)"

" " " J765%" )0(645)')V" '(;$%'$(6" 94$'(" $))-9'$65)" &'64" u" $(+" \" 4565%-+'*5%)" -7"

H=RDD"*-.59,.5)"6-"7-%*"(-($*5%'9"9-*:.58"bu^\^D'c?"J3(+4$'"[KV"&4'94"645("58'6)"645"SM"b!OPc1""

"

"

L'/,%5O^"M5:%5)5(6$6';5"A945*$"-7"$("D'"6%'*5%"b.576c"$(+"$"9.$))"DDlD'"94$'("9-*:.58V"-0-#&'0"6$%7"

D;!$'22Q'::E"5LLY"

3-"(-65V" 64%55":$'%)"-7" 9.$))'9$."H=RDD"/5(5)"=FJ" b=,*$("F5,G-9065"J(6'/5(c"#MV"#UV"#z"$(+" 6&-"

(-(" 9.$))'9$." =FJE#H" $(+" =FJE#X" 58')6" '(" 4,*$()V" &45%5$)" 645"*,%'(5" $($.-/)" 7-%" 645" 9.$))'9$."

H=RDD"/5(5)"$%5"DEJ"$(+"DES"$(+"=E<HV"=E<X"7-%"645"(-("9.$))'9$.1"X(95"7-%*5+"'("645"SMV"645"bu^\^D'c?"

')" 6%$():-%65+"6-" 645"6%$()E>-./'"&45%5" '6"+';5%6)" 7%-*"645")59%56-%0":$64&$0"6-" e-'(" 645"5(+-906'9"

)0)65*"$(+" %5$94" 645" 5(+-.0)-)*$." 9-*:$%6*5(6)1"W5&.0" )0(645)'I5+" bu^\^D'c?" 9-*:.585)" $%5" $.)-"

7-,(+"-(" 645"95.." ),%7$95" 7-..-&5+"B0"$" %$:'+" '(65%($.'I$6'-(" 6-" 645"5(+-)-*$.":$64&$0" b!OQc1"345"

577'9'5(6"6$%/56'(/"-7"645"H=RDDED'"9-*:.585)"6-"645"5(+-906'9":$64&$0"-99,%)"+,5"6-"645"+'.5,9'(5E

B$)5+"6$%/56'(/"*-6'7)"b645"*5*B%$(5E+')6$.")'/($.^"F5,9'(5ED)-.5,9'(5"'(":-)'6'-()"O"$(+"PV"$(+"645"

*5*B%$(5E:%-8'*$." +')6$(95^" U%-.'(5EF5,9'(5" '(" :-)'6'-()" " !K" $(+" !Oc" 7-,(+" '(" 645" W" 65%*'($."

906-:.$)*'9"6$'."-7"D'"b!P2V"!P!cV"$.64-,/4"$"%-.5"-7"645"906-:.$)*'9"6$'.)"-7"645"u"$(+"\"94$'()"$%5"$.)-"

+5*-()6%$65+" 6-" B5" '(;-.;5+" '(" 645" 6%$77'9G'(/" -7" 645" 9-*:.58" 6-" 645" 5(+-)-*5)" b!P<E!PCc1" 345"

+'.5,9'(5EB$)5+"6$%/56'(/"*-6'7)"$%5"-7":$%6'9,.$%"'(65%5)6k"6450"'(65%$96"&'64"B-64"JU!"$(+"JU<V"6&-"

$+$:6-%" 9-*:.585)" $(+" 9-*:-(5(6)" -7" 645" 5(+-906'9" $(+" 58-906'9" )-%6'(/" *$94'(5%0" 64$6" $%5"

'(;-.;5+" '(" 645" 7-%*$6'-(" -7" 9.$64%'(" 9-$65+" ;5)'9.5)" $..-&'(/" 645" +5.';5%0" -7" (5&.0" )0(645)'I5+"

:%-65'()"bH=RDDED'"9-*:.585)c"7%-*"645"3%$()E>-./'"(56&-%G"b3>Wc"6-"645'%"7'($."+5)6'($6'-()V"*$'(.0"

5(+-)-*5)"$(+".0)-)-*5)1"JU!"9-*:.585)"$%5"$))-9'$65+"&'64"645"6%$():-%6"-7"645"H=RDDED'"9-*:.58"

'(" 9.$64%'(E9-$65+" ;5)'9.5)" bRRZ)c" 7%-*" 3>W" 6-" 645" 5(+-)-*5)V" &45%5$)" JU<" :5%*'6)" '6)" '(+'%596"

)-%6'(/" 6-" 645" :.$)*$" *5*B%$(5" $(+" '6)" ),B)5[,5(6" 5(+-906-)')" '(" 5(+-906'9" RRZ)" 6-&$%+)" 645"

5(+-)-*5)" b!P2V" !PKc1" J" %5%-,6'(/" -7" H=RDDED'" 9-*:.58" 6-" $" +'%596" )-%6'(/" 6-" .$65"

5(+-)-*$.T.0)-)-*$." )6%,96,%5)" ')" $.)-" :-))'B.5" &45(" ),B)6'6,6'(/" 64%55" $*'(-$9'+)" '**5+'$65.0"

,:)6%5$*"-7"645".5,9'(5")'/($."7$;-%'(/"JU?"B'(+'(/"$(+"$"),B)5[,5(6"589.,)';5"+'%596"6%$77'9"6-".$65"

5(+-)-*5)"b!PNc1"

Page 36: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?C""

"

D("645"5(+-906'9"9-*:$%6*5(6)V"D'"94$'("')":%-95))5+"'("$")65:&')5"*$((5%":%-955+'(/"'("$"RE65%*'($."

6-"WE65%*'($." +'%596'-(V" 6-" /5(5%$65" $" )*$.." 7%$/*5(6V" RFDU" 7-%" 9.$))" DDE$))-9'$65+" D'" 94$'(" :5:6'+5V"

B-,(+"6-"645"%5.5$)5+"u\"+'*5%"$(+"$"6%,(9$65+"6%$()*5*B%$(5"D'"J3(+4$'>K;""

"

L'/,%5"P^"D(;$%'$(6"94$'(":%-95))'(/E"-0-#&'0"6$%7"O;*-&@-"'&"-:;E"<==M"

345" 9.5$;$/5" -7" 4,*$(" D'E:??" ')" '('6'$65+" B0" JSUV" $(" $):$%$/'(5" 5(+-:5:6'+$)5" 64$6" 6$%/56)" 645"

$):$%$/'(5" %5)'+,5)" J)(!KK" $(+" J)(!?<" -(" 645" -,6)'+5" -7" 645" 6%'*5%'I5+" RE65%*'($." +-*$'(V" 6-"

/5(5%$65" 645" 645" D'E:<<" 7%$/*5(61" =-&5;5%V" D'" :%-95))'(/" 9$(" $.)-" B5" '('6'$65+" B0" :%-65$)5)" -645%"

64$("JSU"b!N!c1"345"D'E:<<"')"7,%645%":%-95))5+"6-"/5(5%$65"645"'(65%*5+'$65"D'E:!21"345"D'E:!2"'6)5.7"')"

$.)-" 9.5$;5+" .5$;'(/" -(.0" 645" RFDU" 7%$/*5(6" '(" 645" :5:6'+5" l" B'(+'(/" /%--;5" -7" H=RDD" $(+" 645"

6%,(96$65+" 6%$()*5*B%$(5" D'1" 345" :%-95))'(/" -7" D'E:!2" ')" 9$6$.0)5+" B0" 9$645:)'(" A" '(" @" 95..)" $(+"

+5(+%'6'9"95..)"b!POcV"9$645:)'("F"'("*,%'(5"640*'9"9-%658"5:'645.'$."95..)""b!PPcV"9$645:)'("Z"$(+"A"'("

645"4,*$("640*,)"b!PQV"!Q2c"$(+"B0"9$645:)'("L"'("*,%'(5"*$9%-:4$/5)".$9G'(/"9$645:)'()"A"$(+"F"

b!Q!c1"345"RFDU"7%$/*5(6"')"+'))-9'$65+"7%-*"645"/%--;5"B0"645"$96'-("-7"645"(-("9-(;5(6'-($."9.$))"DD"

#H"*-.59,.5V" '(" 5894$(/5" &'64" :-65(6'$..0" $(6'/5('9" :5:6'+5)" &'64" 4'/45%" $77'('60" 7-%" 645"H=R" DD"

B'(+'(/" /%--;5" b!Q<E!QCc1" #H" $.)-" B'(+)" 5*:60" 9.$))" DD" $(+" 7,(96'-()" $)" $" :5:6'+5" 5+'6-%V" &4'94"

:5%*'6)"645"'(9%5$)5"-7"645"-;5%$.."$77'('6'5)"-7":5:6'+5T9.$))"DD"9-*:.585)"b!Q?V"!QKE!QPc1""

Page 37: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?K""

"

X)/-$(-)&".B-()"-)0"?".'::"0'/':%#7')&"

" " " Y(6'." %595(6.0V" D(;$%'$(6" 94$'(" &$)" 64-,/46" 6-" 7,(96'-(" *$'(.0" $)" $(" H=R"

9.$))" DD" 94$:5%-(5k" 4-&5;5%V" %595(6" )6,+'5)" 4$;5" )4-&(" 64$6" B5)'+5)" '6)" $96';'6'5)" '(" $(6'/5("

:%5)5(6$6'-(V"D'"4$)"$("$++'6'-($."7,(96'-("'("@"95.."*$6,%$6'-(1"D("*'95".$9G'(/"D'V"645"+5;5.-:*5(6"-7"

@" 95..)" 7%-*" '**$6,%5" 6-"*$6,%5" )6$/5" ')" '*:$'%5+k" 645"@" 95..)" $%5" $%%5)65+" $6" $(" '**$6,%5" )6$/5"

94$%$965%'I5+"B0".-&"58:%5))'-("-7"B-64"D/#"$(+"R#<?"$(+":--%"%5):-()5"6-"3E'(+5:5(+5(6"$(6'/5()"

J3(+4$'LK"b!QQE<2<c1"

"

L'/,%5"Q^"H,.6'E)65:"+5;5.-:*5(6"-7"@"95..)"'("645"B-(5"*$%%-&"$(+"):.55(^"#'775%5(6'$6'-("-7"@"95..)"

')"$%%5)65+"$6"645"3!"6%$()'6'-($.")6$/5"'("$B)5(95"-7"D'V"-0-#&'0"6$%7"O;*-&@-"'&"-:;E"<==M"

345"%5*$'('(/"6%,(9$65+"D'"bW"65%*'($."7%$/*5(6^"$$"!EP<c"')"645")'/($.'(/"*-.59,.5"64$6"')"%5):-()'B.5"

-7"@"95..)"*$6,%$6'-("$(+"')"+'%596.0"'(;-.;5+"'(":%-*-6'(/"@"95.."+'775%5(6'$6'-("'("=E<B"4$:.-60:5"$(+"

(-6" 645" =E<G"4$:.-60:5V" B0" '(+,9'(/" $" ):59'7'9" /5(5" 58:%5))'-(" :%-/%$*" 64$6" '(9.,+5)" 645" :NK"

9-*:-(5(6"-7"WLEv@"$(+" '6)" 9-$96';$6-%"3JLDD"!2KV"$" ),B,('6"-7" 645"B$)$." 6%$()9%':6'-("3LDD#" 64$6" ')"

4'/4.0"58:%5))5+"'("@"95..)"b<2?E<2Nc1"345"9.5$;$/5"-7"645"W"65%*'($."7%$/*5(6"-7"D'"')"%595(6.0")4-&("

6-" B5" *5+'$65+" B0" 645" AUUF<$" bA'/($." U5:6'+5" U5:6'+$)5" F'G5V" <$cV" $(" '(6%$*5*B%$(5E9.5$;'(/"

:%-65$)5" bDERD'U)cV" $6" $1$" C<V" /5(5%$6'(/" 645" D'" 906-)-.'9" +-*$'(" 64$6" '(+,95)" WLEv@" $96';'60" 5'645%"

+'%596.0"-%"B0"$96';$6'(/"$(-645%":%-65'("-%":$64&$0"64$6"9$("'(+,95"WLEv@"$96';$6'-(V"645"7%$/*5(6"')"

645("+5/%$+5+"B0"645":%-65$)-*5E,B'[,'6'(":$64&$0"J3(+4$'"5=K"b<2OV"<2Pc1"

Page 38: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?N""

"

"

"

L'/,%5"!2^"!,"J")65:&')5":%-95))'(/"-7"'(;$%'$(6"94$'(V"&'64"$"7'($.":%-65-.0)')"-7"645"W"65%"7%$/*5(6"

B0"AUU.<$":%-65$)5V"-0-#&'0"6$%7"S;F.B)'##')B'(7"'&"-:;E"<=5M;"",+H-+5."7-%"$96';$6'-("-7")'/($."

6%$()+,96'-("64%-,/4"645"'(;$%'$(6"94$'(V"-0-#&'0"6$%7"O;*-&@-"'&"-:;E"<==M"

AUUF<$"')"$"*5*B5%"-7"645"AUUE.'G5"bAUUFc"'(6%$*5*B%$(5"9.5$;'(/"$):$%60.":%-65$)5".-9$.'I5+"'("645"

5(+-)-*5T.0)-)-*5" b<2QcV" $(+" ')" 577'9'5(6" '(" 645" 9.5$;$/5" -7" )'(/.5" :$))V" 60:5" DD" 6%$()*5*B%$(5"

:%-65'()"),94"$)"@%'6')4":%59,%)-%":%-65'("<"b@MD<c"b<!2cV"*5*B%$(5"LJA".'/$(+"b<!!cV"*5*B%$(5"3WL"

b<!<c"$(+")-" 7$%" 645"906-)-.'9" 6$'."-7" '(;$%'$(6"94$'(1" "#5):'65" '6)" %-.5" '(" '(+,9'(/"@"95.."*$6,%$6'-(V"

AUUF<$" ')" $.)-" '(;-.;5+" '(" '(+,9'(/" D/H" $(+" D/#" 58:%5))'-(" -(" 645" 95.." ),%7$95V" $)" &5.." $)" 645"

58:%5))'-("-7"@JLL"%595:6-%"64,)"*5+'$6'(/"@"95.."),%;';$.1"345"&-9:'"M"+5)9%'B5)"645"577596"-7"AUU.<$"

+57'9'5(90"-("645"@"95..)"),B)56)"b<!?c1"

"

Page 39: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?O""

"

"

3$B.5"?^"@"95.."),B)56)"'("AUUF<$"g3"$(+"_X"*'95V"-0-#&'0"6$%7"?'$+7-))"'&"-:;E"<=5M"

X)/-$(-)&".B-()"-)0"()6:-77-&%$G"2(+)-:()+"

" " " 345" *$9%-:4$/5" *'/%$6'-(" '(4'B'6-%0" 7$96-%" bHDLcV" $(" 5('/*$6'9" 906-G'(5"

58:%5))5+" B0" *$9%-:4$/5)V" ')" 645" .'/$(+" -7" 645" 95.." ),%7$95" D(;$%'$(6" 94$'(" bR#OCc1" HDL" 4$)" :%-E

'(7.$**$6-%0" :%-:5%6'5)k" '6" '(9%5$)5)" 645" :4$/-906'9" $96'-(" -7"*$9%-:4$/5)" $(+" 645'%" )59%56'-(" -7"

:%-E'(7.$**$6-%0" 906-G'(5)" ),94" $)" 3WL" $(+" DFEP" b<!CV" <!Kc" 1" HDL" ')" %59-/('I5+" B0" 645" %595:6-%"

9-*:.58"R#OCT"R#CC"&4'94"'*:.'5)"645"$96';$6'-("-7"J_3V"A0G"$(+"WLEv@")'/($.'(/":$64&$0)"%5),.6'(/"

'("@"95.."$96';$6'-(V":%-.'75%$6'-("$(+"),%;';$."b<2CV"<!NV"<!Oc1"HDL"')"$.)-":%-:-)5+"6-")'/($.";'$"R#OC"

B0"B'(+'(/"6-"645"945*-G'(5"%595:6-%"RaRM<"&4'94"4$)"B55("+5)9%'B5+"6-"$))-9'$65"&'64"R#OC"$6"645"

95.."),%7$95"-7"*-(-9065)"b<!PV"<!Qc1"

D(;$%'$(6" 94$'(" ')" $.)-" '(;-.;5+" '(" -645%" '**,(5" :%-95))5)" ),94" $)" 640*'9" )5.596'-(" &45%5" D'"

+57'9'5(90"$.65%)"645":%-:-%6'-("-7"R#Cp"3"95..)"'("645"640*,)"$(+"645'%"58:$()'-("'("645":5%':45%$."

.0*:4-'+"-%/$()V"%5),.6'(/"'("$665(,$65+"%5):-()5)"6-"),:5%"$(6'/5()V":5:6'+5"$(+":%-65'("$(6'/5()"

b<<2c"k" D'" ')"$)"&5.." '*:.'9$65+"'("645"%5/,.$6'-("-7"+5(+%'6'9"95..)"*'/%$6'-("$(+"*-6'.'60"7%-*")'65"-7"

'(7.$**$6'-("6-" .0*:4"(-+5)V"&45%5"D'E+57'9'5(6"95..)"*-;5"'("$"7$)6"$(+",('7-%*"*$((5%V"&45%5$)"

Page 40: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?P""

"

g3"95..)"$.65%($65"B56&55("4'/4"$(+".-&"*-6'.'60V"$":%-95))"64$6"')"+5:5(+5(6"-("$96'(EB$)5+"*-6-%"

H0-)'("DD"b<<!c1"

X)/-$(-)&".B-()"-)0"0(2'-2'2"

" " " J.64-,/4"(-")'(/.5E(,9.5-6'+5":-.0*-%:4')*)"bAWU)c" '(" '(;$%'$(6"94$'("/5(5"

4$;5" B55(" %5:-%65+V" )5;5%$." *-.59,.5)" &'64" &4'94" D'" '(65%$96)" ),94" $)" H=RDD" *-.59,.5)V" R#CC"

%595:6-%"$(+"HDL" b<<<E<<Cc":-))5))"$..5.5)"$(+"AWU)" 64$6"$%5"$))-9'$65+"&'64" '(7.$**$6-%0"B-&5."

+')5$)5V" 9.'('9$." -,69-*5" '(" )5:)')V" 95.'$9" +')5$)5V" 9$(95%" $(+" 94%-('9" '(7.$**$6-%0" +')5$)5)"

b<<Kcb!Q2cb<<<E<<Cc1"

345" 58:%5))'-(" -7" R#OC" ')" 7-,(+" '(9%5$)5+" '(" *$(0" 95.." 60:5)" +,%'(/" +')5$)5)^" '(" 645" U@HR)" -7"

:$6'5(6)"&'64"$645%-)9.5%-)')"9-*:$%'(/"6-"45$.640"9-(6%-.)"b<<NcV"'("645"@"95..)"-7"AFS"$775965+"*'95"

b<<OcV" '("645"*'9%-/.'$"$(+"(5,%-()"-7"J.I45'*5%h)":$6'5(6)" b<<PV"<<Qc1"R#OC" ')"$.)-"58:%5))5+"-("$"

;$%'560"-7"*$.'/($(6"95..)V"')"-B)5%;5+"'("{Q2|"-7"@E95.."*$.'/($(9'5)V"$(+"4$)"$.)-"B55("+5)9%'B5+"'("

(-(E45*$6-.-/'9" 9$(95%)V" '(9.,+'(/" /$)6%-'(65)6'($.V" %5($.V" (-(E)*$.." 95.." .,(/" $(+V" %595(6.0V" '("

/.'-B.$)6-*$"95.." .'(5)1"34,)V"R#OC"58:%5))'-("'("*$(0"-7"645)5"9$(95%)"4$)"B55("),//5)65+"6-"B5"$"

:%-/(-)6'9"7$96-%"&'64"4'/45%"%5.$6';5"58:%5))'-("-7"R#OC"B54$;'(/"$)"$"*$%G5%"-7"6,*-%":%-/%5))'-("

-%" :--%" 9.'('9$." -,6E" 9-*5" b<?2c1" X(" 645" -645%" 4$(+V" '(;$%'$(6" 94$'(" 58:%5))'-(" 9-,.+" $.)-" B5"

+-&(%5/,.$65+"'(")-*5"'(7596'-()"),94"$)"Z$99'('$";'%,)"'(7596'-("&45%5"$"+%$*$6'9"%5+,96'-("-7"645"

9.$))"DD"94$:5%-(5"4$)"B55("+5)9%'B5+"+,%'(/"645".$)6")6$/5"-7"'(7596'-("b<?!c1""

R.$))'9$."H=R"9.$))"D":%5)5(6$6'-("$(+"9%-))":%5)5(6$6'-("

" 345" H=R" 9.$))" D" $(6'/5(" :%5)5(6$6'-(" :$64&$0" 5($B.5)" 645" '**,(5" )0)65*" 6-" +56596"

:5:6'+5)"-7"*-+'7'5+" )5.7" :%-65'()"-%" 7-%5'/(":%-65'()"+5%';5+" 7%-*" 6%$()7-%*5+"$(+" '(75965+" 95..)"

%5):596';5.0V"$(+"645'%"),B)5[,5(6":%5)5(6$6'-("6-"R#Pp"906-6-8'9"3" .0*:4-9065)1"=-&5;5%V"$(6'/5("

):59'7'9"($q;5"R#Pp"3"95..)"$%5",($B.5" 6-"+'%596.0"5.'*'($65" 6%$()7-%*5+"-%" '(75965+"95..)k" 6450"(55+"

7'%)6"6-"B5"$96';$65+"B0":%-75))'-($."$(6'/5(":%5)5(6'(/"95..)"bJUR)cV"6-"B59-*5"577596-%)1"g45("645"

JUR)"$%5"(-6"+'%596.0" '(75965+V" 6450"$9[,'%5" 645"58-/5(-,)"$(6'/5(" 7%-*" 645" '(7596'-,)" $/5(6"B0" $"

*594$(')*"9$..5+"9%-))E:%5)5(6$6'-(1"

H=R"9.$))"D":%5)5(6$6'-("

" " J765%"5(9-,(65%"$(+"%59-/('6'-("B0"645'%"3"95.."%595:6-%"-7"):59'7'9"$(6'/5('9":5:6'+5)"

B-,(+"-("645"/%--;5"-7"H=R"9.$))"D"*-.59,.5)"$(+"+5%';5+"7%-*"5(+-/5(-,)"$(6'/5()"b;'%$."$(6'/5()"

7%-*"+'%596.0";'%,)E'(75965+"95..)V"'(6%$95..,.$%"B$965%'$V"$(+":%-+,96)"-7"6,*-%"6%$()7-%*$6'-(c""V"R#Pp"

3" 95..)" $%5" $96';$65+" $(+" '('6'$65" '**,(5" %5):-()51" 345" 9.$))'9$." %-,65" $765%" $(6'/5(" $9[,')'6'-("

9-()')6)"-7" 645" 7-..-&'(/")65:)^" 645"$(6'/5(" ')" 6$//5+"&'64",B'[,'6'($6'-(" 7-%"+'/5)6'-("*5+'$65+"B0"

Page 41: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

?Q""

"

645" :%-65$)-*5" -%" '**,(-:%-65$)-*5" 9-*:.58V" '(" 645" 906-)-.1" 345" %5),.6'(/" :5:6'+5)" $%5"

6%$():-%65+"B0"645"6%$():-%65%"$))-9'$65+"&'64"$(6'/5(":%-95))'(/"b3JUcV"$"4565%-+'*5%"-7"3JU!"$(+"

3JU<"),B,('6)V"'(6-"645"5(+-:.$)*'9"%56'9,.,*V"&45%5"6450"$%5".-$+5+"-(6-"(5&.0")0(645)'I5+"H=R"

9.$))" D"*-.59,.5)V"&'64" 645"45.:"-7"SME%5)'+5(6":%-65'()"9-()6'6,6'(/"$.6-/5645%" 645":5:6'+5" .-$+'(/"

9-*:.58"bUFRc1"H=R"9.$))"D":5:6'+5"9-*:.585)"$%5"645("6%$():-%65+"64%-,/4"645">-./'"$::$%$6,)";'$"

645")59%56-%0":$64&$0"6-"645"95.."),%7$95"7-%":%5)5(6$6'-("6-"R06-6-8'9"3"F0*:4-9065)"bR3F)c"b<?<c1"""

R.$))'9$."H=R"9.$))"D"*-.59,.5)"$%5"5(9-+5+"B0"64%55"/5(5)"'("*'95V"+5:5(+'(/"-("645")6%$'(V"9$..5+"

=<E#V"E_"$(+"lF"&'64'("645"=<"9-*:.58V"&45%5$)"4,*$("H=R"9.$))"D"*-.59,.5)"$%5"5(9-+5+"B0"64%55"

/5(5)"&'64'(" 645"=FJ")0)65*V"9$..5+"=FJEJV" E@"$(+" ER1" D(" "*'95"$(+"4,*$(V" 645%5"$%5"-645%" 9.$))" D"

/5(5)" :%5)5(6" '(" 645"H=R" $(+" $%5" G(-&(" $)" 9.$))" DB" /5(5)" b<??c1"H=RED" /5(5)" 584'B'6" 5(-%*-,)"

$..5.'9":-.0*-%:4')*"$(+"$*'(-"$9'+")5[,5(95";$%'$6'-(" ')"45$;'.0"9-(95(6%$65+" '("645":$%6"-7"5$94"

)6%,96,%5"64$6"'(65%$96)"&'64":5:6'+5)V"$..-&'(/"+'775%5(6"$..5.5)"6-"B'(+"$"+'775%5(6"%$(/5"-7":5:6'+5)1"

345"/%--;5"&45%5":5:6'+5"B'(+)"')"7-%*5+"B0"6&-"$(6'E:$%$..5."uE45.'95)"-;5%.$0'(/"$("5'/46")6%$(+E\"

)45561" 345"*5*B%$(5":%-8'*$." %5/'-(" 9-()')6)"-7" 6&-"9-()5%;5+"+-*$'()" 64$6"$%5"4-*-.-/-,)" 6-"

'**,(-/.-B,.'(" 9-()6$(6" %5/'-(" +-*$'()V" -(5" :%-;'+5+" B0" 645" 45$;0" 94$'(" bCCECO_#$c" $(+" 645"

-645%"')"$")5:$%$65":%-65'(V"\<E*'9%-/.-B,.'("b\<E*V"!<_#$cV"$")-.,B.5":%-+,96"-7"$"(-("H=R".'(G5+"

/5(5"b3(+4$'"55c1"345"u!"$(+"u<"+-*$'()"7-%*"645"/%--;5E.'G5")6%,96,%5":%-;'+'(/"645"4$%B-%'(/")'65"

7-%".'/$(+"B'(+'(/"&45%5$)"645"u?"+-*$'("4-.+)"645"u!E"u<":.$67-%*"$(+"645"\<E*"$(+"64,)")5%;5)"$)"$"

B'(+'(/")'65"7-%"645"R#P"*-.59,.5"b<?CV"<?Kc1"

"

L'/,%5"!!^"A6%,96,%5"-7"645"H=RED"*-.59,.5^"=FJEJ<"9-*:.585+"&'64"%5)'+,5)"KPENN"-7"645"'(7.,5(I$"

*$6%'8":%-65'("b%5+cV"-0-#&'0"6$%7"S;?:47"'&"-:E"<=5M"

Page 42: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

C2""

"

D'#&(0'"9()0()+"&%"*H!,X"7%:'.4:'2"

" " " 345" '('6'$." 7-.+'(/" 5;5(6)" '(;-.;5" 645" 6%$()*5*B%$(5" 9$.%56'9,.'(" 4-*-.-/"

645"9$.(58'("bRWac"64$6"$..-&)"645"),B)5[,5(6"$))5*B.0"-7"H=RED"45$;0"94$'("&'64"\<E*'9%-/.-B,.'(1"

345"5*:60"4565%-+'*5%V"64$6"')",()6$B.5V"')"645("%59%,'65+"B0"9$.%56'9,.'("bRM3c"6-"645":5:6'+5".-$+'(/"

9-*:.58"bUFRc1"345")6$B'.'I$6'-("-7"H=R"9.$))"D"*-.59,.5"$(+"645"*$'(6$'("-7"645"B'(+'(/"/%--;5"'("$"

9-(7-%*$6'-("64$6"7$;-%)"4'/4"$77'('60":5:6'+5".-$+'(/"V"$%5"*5+'$65+"B0"+'%596"'(65%$96'-()"B56&55("

H=R"45$;0"94$'("$(+"6$:$)'("$(+"645'%"),B)5[,5(6"9--%+'($6'-("&'64"RM3"$(+"SMUOK"'("645"UFR1"X("

645"-645%"4$(+V"H=RD"*-.59,.5)"&'64".-&"$77'('60":5:6'+5)"$%5"),Be5965+"6-"645"Y@>3E!"bY#UE/.,9-)5"

/.09-:%-65'(" 6%$()75%$)5E!c" $96'-(" %5),.6'(/" '(" 645" %5:.$95*5(6" -7" 645" /.,9-)5" -(.0" &45(" 645"

/.09-:%-65'(" '(" 645"B'(+'(/"/%--;5" ')":$%6'$..0",(7-.+5+" b<?NE<?PcV" 64,)"$..-&'(/" 645" %55(6%0"-7" 645"

H=RD"'(6-"645"UFR"$(+"5894$(/5"7-%"4'/4"$77'('60":5:6'+5)"b3(+4$'"5<c1"U5:6'+5)"6%$().-9$65+"'(6-"645"

SM"B0" 645" 6%$():-%65%"$))-9'$65+"&'64"$(6'/5(":%-95))'(/" b3JUc"-%'/'($65":%'*$%'.0"-7"5'645%" )5.7"-%"

7-%5'/("5(+-/5(-,)":%-65'()"b<?QV"<C2cV"-%"7%-*"+57596';5"%'B-)-*$.":%-+,96)"9$..5+"#M'U)"64$6"$%')5"

7%-*" $" :%5*$6,%5" 65%*'($65+" 6%$().$6'-(V" +57596';5" 6%$()9%':6'-(" -%" 7%-*" $(" '*:5%7596" 7-.+'(/" -7"

:-.0:5:6'+5)" b<C!c1" 34-)5"#MDU)" $%5" B5.'5;5+" 6-" B5" 9-*:$%6*5(6$.'I5+" '(" ):59'$." )6%,96,%5)" 9$..5+"

i'**,(-%'B-)-*5)j" b<C<cV" &4'94" :5%*'6)" 6-" $;-'+" 9-*:56'6'-(" 7-%" 9.$))" D" :%5)5(6$6'-(" B56&55("

:5:6'+5)" /5(5%$65+" 7%-*" 645" #MDU)" $(+" 906-)-.'9" :5:6'+5)" /5(5%$65+" 7%-*" -645%" :%-95))5)" b<C?c1"

*MWJ)"9$%%0'(/"":%5*$6,%5")6-:"9-+-()"9$("$.)-":%-+,95":5:6'+5)"6-"B5":%5)5(65+"-("H=R"9.$))"D"

*-.59,.5)"B0"$"(-("9$(-('9$."*MWJ"6%$().$6'-(":%-95))"b<CCc1"J.64-,/4"'6"')"&'+5.0"$995:65+"64$6"645"

:%-65$)-*5" ')" 645"*$'("+5/%$+$6';5" )-,%95" 7-%"H=R" 9.$))" D" :%5)5(65+":5:6'+5)V" )6'.." '(" %$%5" 9$)5)V"

)-*5"906-)-.'9":%-65$)5)"),94"$)"6%':56'+0.":5:6'+$)5" DD" b3UU" DDcV" 645" '(),.'("+5/%$+'(/"5(I0*5"bD#Sc"

$(+" -645%)" b.5,9'(5" $*'(-:5:6'+$)5V" B.5-*09'(" 40+%-.$)5V" :0%-*09'(E)5()'6';5" $*'(-:5:6'+$)5V"

9$):$)5)"K"$(+"!2c"9$(":%-;'+5"H=D"9.$))" D" .'/$(+)"$(+"),B)6'6,65" 645":%-65$)-*5"b<CKc1"=-&5;5%V"

645" 5(I0*5"*5+'$6'(/" i:%-65$)-*5E'(+5:5(+5(6" i:%-+,96'-(" -7"H=R" 9.$))" D" .'/$(+)V" 3UU" DD" 4$)" $"

9-(6%-;5%)'$."%-.5k"3UU"DD"')"$B.5"6-"6%'*".-(/"$(6'/5('9":%59,%)-%)"B,6"9$((-6")6'*,.$65"R3F"%5):-()5)"

6-")5;5%$."$(6'/5()" ()"/(/%" b<CNV"<COc1"H$(0"-7"645":5:6'+5)"64$6"$%5"+5.';5%5+" '("645"SM"$%5" .-(/5%"

64$("645"PE!2"%5)'+,5)":%575%%5+"B0"H=R"9.$))"D"*-.59,.5)"$(+"(55+"6-"B5"6%'**5+"B0"):59'$.'I5+"SM"

$*'(-:5:6'+$)5)V" SM" $*'(-:5:6'+$)5" $))-9'$65+" &'64" $(6'/5(" :%-95))'(/" " bSMJJUc" '(" *'95V" $(+"

SMJU!"$(+"<"'("4,*$(V"$..-&'(/"645"/5(5%$6'-("-7":5:6'+5)"-7"$::%-:%'$65".5(/64"7-%"H=RED"B'(+'(/"

b<CPE<K!c1"

Page 43: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

C!""

"

"

L'/,%5"!<^"H=R"B'-)0(645)')"$(+":5:6'+5"7-.+'(/V"'("645"5(+-:.$)*'9"%56'9,.,*V"-0-#&'0"6$%7"S;?:47"

'&"-:;E"<=5M"

L'($..0V"4'/4"$77'('60":5:6'+5)"B'(+"H=R"9.$))"D"*-.59,.5)"6-"7-%*"H=REDE:5:6'+5"9-*:.585)"64$6"$%5"

7,%645%"%5.5$)5+"$(+"6%$():-%65+"6-"645"95.."),%7$95"7-%"R#Pp"%59-/('6'-(1"

D$%&'-2%7'E"(774)%#$%&'-2%7'"-)0"&BG7%#$%&'-2%7'"

" " " 345" :%-65$)-*5" ')" $" )5.7E9-*:$%6*5(6$.'I5+V" 5(5%/0" +5:5(+5(6" :%-65$)5"

7-,(+"'("5,G$%0-65)V"$%945$"$(+"$96'(-B$965%'$"b/%$*":-)'6';5"B$965%'$c"b<K<c1"D6"')"'(;-.;5+"'(":%-65'("

[,$.'60" 9-(6%-."B0"+5/%$+'(/"*')7-.+5+V"+$*$/5+"$(+" '($99,%$65.0" )0(645)'I5+":%-65'()" b<K?V"<KCc1"

U%-65$)-*5"')"$.)-"'(;-.;5+"'("%5/,.$6'(/"95.."+';')'-(V"#WJ"%5:$'%"B0"+5)6%-0'(/"%5/,.$6-%0":%-65'()"

'(" $" ):59'7'9" 6'*5" $(+" .-9$6'-(" +5:5(+5(6" *$((5%" b<KKV" <KNc1" 345" :%-65$)-*5" +5/%$+5)" -765("

:%-65'()"6-"/5(5%$65")*$..":5:6'+5)V"4-&5;5%"'6"9$("$.)-"9.5$;5":%59,%)-%)"6-"0'5.+"B'-.-/'9$..0"$96';5"

:%-65'()"b<KOV"<KPc1"345":%-65$)-*5"')"):59'$.'I5+" '("645"%59-/('6'-("-7":%-65'()"64$6"-765("9-(6$'("

$*'(-" $9'+" )5[,5(95)" 64$6" $96" $)" ):59'7'9" +5/%$+$6'-(" )'/($.)k" 645)5" )'/($.)" $%5" %59-/('I5+" B0" 645"

,B'[,'6'(0.$6'-(" )0)65*" 64$6" $..-&)" 645" 9-;$.5(6" .'/$6'-(" -7" :-.0,B'[,'6'(" 94$'()" 6-" 645" ),B)6%$65"

:%-65'(" 64$6" ')" 6$%/565+" $(+" B-,(+" 6-" :%-65$)-*5" 7-%" +5/%$+$6'-(1" 345" 9-()6'6,6';5" :%-65$)-*5"

9-()')6)" -7" $" <2A" 9$6$.06'9" 9-%5" :$%6'9.5" bRUc" 64$6" 4$%B-%)" 645" :%-65-.06'9" $96';5" )'65)1" 345" RU" ')"

Page 44: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

C<""

"

9-*:-)5+"-7")5;5("+'775%5(6"uE),B,('6)"bu!E"uOc"$(+")5;5("+'775%5(6"\E),B,('6)"b\!E"\<c"$))5*B.5+"

'(" +05+" )0**56%0V" &'64" \!" 9$6$.0)'(/" 5(+-:5:6'+$)5" >.,ERE.'G5" $96';'60V" \<" 9$6$.0)'(/" 6%0:6'9"

:5:6'+$)5"$96';'60"$(+"\K" 9$6$.0)'(/" 940*-6%0:6'9":5:6'+$)5"$96';'601"RU"$))-9'$65)"&'64"!QA" 9$:" 6-"

7-%*" $" <NA" :%-65$)-*51" 345" !QA" 9$:" ')" )5:$%$65+" '(6-" B$)5" $(+" .'+" 9-*:.585)V" &'64" 645" .'+"

%59-/('I'(/" $(+"+5,B'[,'6'.$6'(/" ),B)6%$65)"&4'.5" 645"B$)5" )6%,96,%5" 9-(6$'()" )'8" +'775%5(6"J3U$)5)"

),B,('6)" bM:6!EM:6Nc" 64$6"$%5",)5+"6-" 7,5." 7-.+5+":%-65'()" " 7-%" 645'%"),B)5[,5(6"+5/%$+$6'-(" '(" 645"

<2A"RU"J3(+4$'"5MK"b<KQV"<N2c1"

"

"

L'/,%5"!?^"A6%,96,%5"-7"$"9-()6'6,6';5":%-65$)-*5V"-0-#&'0"6$%7"*-4#(),34$:%QE"<=5<"

Y:-(" '(65%75%-(Ed" bDLWEdc")6'*,.$6'-(V" 645"9-()6'6,6';5";5%)'-()"-7" 645"9$6$.06'9"),B,('6)"\!V"\<"$(+"

\K" $%5" %5:.$95+" B0" (5&" ;$%'$(6)" -7" \E),B,('6)" 9$..5+" \'!V" \'<V" $(+" \'Kk" :%-65$)-*5)" 64$6" 9-(6$'("

645*" $%5" 9$..5+" i'**,(-:%-65$)-*5)j" b<N!c1" D**,(-:%-65$)-*5)" :-))5))" +'775%5(6" 9$6$.06'9"

):59'7'9'6'5)"64$(")6$(+$%+":%-65$)-*5)"$(+"6450"$%5"*-%5"577'9'5(6"'("/5(5%$6'(/"5:'6-:5)"7-%"R#Pp"3"

95.."%5):-()5"$765%"'(7596'-("$.64-,/4"+57'9'5(90"'("+'775%5(6"'**,(-:%-65$)-*5"),B,('6)"9$("+%';5"

;$%'$B.5" %5):-()5)" $)" )4-&(" B0" ()" /(/%" 58:5%'*5(6)" '(" '(75965+" *'95" b<N<c1" X(5" *-%5" 60:5" -7"

:%-65$)-*5" 4$)" B55(" +5)9%'B5+V" 645" 640*-:%-65$)-*5V" 64$6" ')" 589.,)';5.0" 58:%5))5+" '(" 9-%6'9$."

640*'9" 5:'645.'$." 95..)" $(+" 64$6" B5$%)" $" \K6" 9$6$.06'9" ),B,('6" '()65$+" -7" 645" )6$(+$%+" \K1"

340*-:%-65$)-*5"')"'(;-.;5+"'("3"95..":-)'6';5")5.596'-("'("645"640*,)"$(+")4$:5)"645":%5)5(6$6'-("

-7" )5.7" :5:6'+5)" 64,)" :%-;'+'(/" 645" '()6$..*5(6" -7" $(" '**,(-9-*:565(6" $(+" )5.7" :%-6596';5"

%5:5%6-'%5"-7"R#Pp"3"95..)"b<N?c1""

R%-))":%5)5(6$6'-("

" " 345":%-95))"-7":%5)5(6$6'-("-7"58-/5(-,)":5:6'+5)"-("H=R"9.$))"D"*-.59,.5)"G(-&("

$)"9%-))E:%5)5(6$6'-("-%"9%-))E:%'*'(/"&$)"7'%)6.0"+5)9%'B5+"B0"@5;$("'("!QON"b<NCcV"4'/4.'/46'(/"645"

(55+"-7" 906-6-8'9" 3" 95..)" 6-" B5" i:%'*5+j"B0"JURAV"*$'(.0" 645"#R)V" 6-" 585%6" 645'%" 7,(96'-(1" Z$%'-,)"

60:5)" -7" $(6'/5(" :%5)5(6'(/" 95..)" $%5" $B.5" 6-" 9%-))E:%5)5(6" $(6'/5()" ()" /(&$%" '(9.,+'(/" @" 95..)V"

Page 45: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

C?""

"

*$9%-:4$/5)"$(+":.$)*$906-'+"+5(+%'6'9"95..)E"B,6"*-)6")6,+'5)"4$;5"'*:.'9$65+"+5(+%'6'9"95..)"$)"645"

*$'(" $(+" *-)6" 577'9'5(6" 9%-))E:%5)5(6'(/" JUR)" ()" /(/%" b<NKc;" R%-))" :%5)5(6$6'-(" ')" *5+'$65+" B0"

'(65%($.'I$6'-("-7"58-/5(-,)"$(6'/5(";'$"%595:6-%E*5+'$65+"5(+-906-)')V":4$/-906-)')V"-%":'(-906-)')"

$(+" 645'%" ),B)5[,5(6" :%-95))'(/" $(+" .-$+'(/" -(" H=R" 9.$))" D" *-.59,.5)1" 3&-" *$'(" '(6%$95..,.$%"

:$64&$0)" -7" 9%-))E:%5)5(6$6'-(" 4$;5" B55(" +5)9%'B5+" '(" #R)^" 645" 906-)-.'9" :%-65$)-*5" +5:5(+5(6"

$(+"645";$9,-.$%"b$.)-"($*5+"5(+-)-*$.c":%-65$)-*5"'(+5:5(+5(6":$64&$0)"J3(+4$'"5RK;""

"

L'/,%5"!C^"345"9%-))":%5)5(6$6'-(":$64&$0)"'("+5(+%'6'9"95..)V"0'$(/'0"6$%7"S%66$'"'&"-:;E"<=5<"

345"*$'("+'775%5(95"B56&55("645"906-)-.'9"$(+"645";$9,-.$%":$64&$0"')"645")'65"-7"$(6'/5(":%-95))'(/"

$(+"645"*-.59,.$%":.$05%)"'(;-.;5+1"D("645"906-)-.'9":$64&$0V"645"'(65%($.'I5+"$(6'/5("')"58:-%65+"6-"

645"906-)-."&45%5"'6"')":%-95))5+"B0"645":%-65$)-*5"*$94'(5%01"345"58:-%6"7%-*"645"5(+-)-*5)"6-"

645"906-)-."-99,%)"$99-%+'(/"6-"645")'I5"$(+"645"):59'7'9'60"-7" 645"J/"&'64-,6"6%$()75%"-7"$(0"5(+-E

.0)-)-*$."*$%G5%)"b<NNc"$(+")55*)"6-"B5"*5+'$65+"B0"645"SMJ#"bS(+-:.$)*'9"M56'9,.,*""J))-9'$65+"

:%-65'("#5/%$+$6'-(c")0)65*" '(9.,+'(/"A59N!V":QO"$(+"645"45$6")4-9G":%-65'("=):Q2":%-65'()" b<NOV"

<NPcV" $" :$64&$0" 64$6" ')" G(-&(" 6-" 6$%/56" 645" *')7-.+5+" :%-65'(" '(" 645" SM" 6-" 645" :%-65$)-*5" 7-%"

+5/%$+$6'-(1" 345" :%-95))5+" $(6'/5(" ')" 645(" 6%$():-%65+" 6-" 645" SM" B0" 645" 3JU" 6%$():-%65%" 6-" B5"

.-$+5+" -(" (5&.0" )0(645)'I5+"H=RD"*-.59,.5)1" 345" .-$+'(/" -7" 645" $(6'/5(" -("H=RD"*-.59,.5)" 9$("

$.)-" -99,%" '(" :4$/-)-*5)" $(+" 5(+-)-*5)"&45%5" SM" $))-9'$65+" :%-65'()" ),94" $)" 3JU" 6%$():-%65%V"

A59N!V" 9$.(58'(V" 9$.%56'9,.'(" $(+" H=R" D" .-$+'(/" 9-*:.58V" $%5" %59%,'65+" b<NQc1" 34')" %59%,'6*5(6" ')"

*5+'$65+"B0"A59<<BV"$"AWJMS"64$6"')".-9$.'I5+"'("SME>-./'"'(65%*5+'$65"9-*:$%6*5(6"SM>DRV"$(+"64$6"

'(65%$96)"&'64")0(6$8'("C"'("645":4$/-)-*5)"b<O2c1"U-.0:5:6'+5)"/5(5%$65+"7%-*"645":%-65$)-*5"$%5"

Page 46: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

CC""

"

7,%645%" 6%'**5+" &'64" $*'(-" 65%*'($." :5:6'+$)5)" .'G5" SMJU!" b<O!c" $(+" 5(+-)-*$." DMJU" b<O<c" b$("

589.,)';5" 5(+-)-*$." D(),.'(EM5):-()';5" J*'(-U5:6'+$)5c" 7-%" ),B)5[,5(6" .-$+'(/" $(+" 9%-))"

:%5)5(6$6'-(1"X("645"-645%"4$(+V"645"5(+-)-*$.":$64&$0"')":%-65$)-*5"'(+5:5(+5(6"$(+"/5(5%$..0"

$.)-"3JU"'(+5:5(+5(6"6-V"'6"%5.'5)"-("5(+-)-*$.":%-65$)5)"7-%"$(6'/5(":%-95))'(/"(-6$B.0"9$645:)'("A"

b<O?ck" 4-&5;5%" 645" /%-,:" -7" U1" Z$(" S(+5%6" &$)" $B.5" 6-" )4-&" 645" 58')65(95" -7" $" 906-)-.'9" 9%-))E

:%5)5(6$6'-(" :$64&$0" 64$6" ')" :%-65$)-*5" +5:5(+5(6" B,6" 3JU" '(+5:5(+5(6V" 4'/4.'/46'(/" 645"

:-))'B'.'60"-7"645"'(;-.;5*5(6"-7"$"(5&":5:6'+5"6%$():-%65%V"056"6-"B5"'+5(6'7'5+"b<OCc1"345")-,%95"-7"

H=R" 9.$))" D"*-.59,.5)" '(;-.;5+" '(" 645" 9%-))" :%5)5(6$6'-(" :%-95))" ')" )6'.." $"*$665%" -7" +5B$651"H=R"

9.$))"D"*-.59,.5)"-("645"95.."),%7$95"9-(6$'("'("645'%"906-)-.'9"6$'."$"9-()5%;$6';5"60%-)'(5"%5)'+,5"64$6"

*5+'$65)" 645'%" '(65%($.'I$6'-("$(+" 645'%" %5909.'(/" 6-" 645"5(+-)-*5)V"$(+" ')" )4-&("6-"B5"9%,9'$." 7-%"

9%-))" :%5)5(6$6'-(" b<OKc1"X(" 645" -645%" 4$(+V" $(" '(65%5)6'(/" (5&" )6,+0" %5;5$.)" 645" '(;-.;5*5(6" -7"

D(;$%'$(6" 94$'(" '(" +'%596'(/" 645" (5&.0" )0(645)'I5+" 9.$))" D" *-.59,.5)" 7%-*" SM" 6-" 5(+-.0)-)-*$."

9-*:$%6*5(6)" 7-%" .-$+'(/" &'64" 58-/5(-,)" $(6'/5()V" '(" +5(+%'6'9" 95..)" $(+" 64,)" :%'*'(/" 9.$))ED"

*5+'$65+" R3F" %5):-()5)" b<ONc1" L,%645%*-%5" MJ@?@" $(+" MJ@?RV" 6&-" >3U$)5)" %5):-()'B.5" -7"

%5/,.$6'(/" 645" )59%56'-(" '(" )-*5" 95.." 60:5)V" &5%5" $)" &5.." +5)9%'B5+" 6-" B5" '(;-.;5+" '("H=R" 9.$))" D"

*-.59,.5)"6%$77'9V"64,)"$77596'(/"9%-))":%5)5(6$6'-("-7"S)945%'94'$"R-.'E$))-9'$65+"$(6'/5("'("+5(+%'6'9"

95..)"b<OOc1""

#5):'65" 645" 9-(6%-;5%)'$." +5B$65" $B-,6" 645" $B'.'60" -7" @" .0*:4-9065)" 6-" 9%-))E:%5)5(6" 58-/5(-,)"

$(6'/5()V"645"+56$'.5+"*594$(')*)"-7"@"95.."*5+'$65+"9%-))":%5)5(6$6'-("')"(-6"+55:.0")6,+'5+"'("645"

.'65%$6,%51"345"/%-,:"-7"o1"_$::"&$)"645"7'%)6"6-")4-&V"'("!QQNV"645"$B'.'60"-7"@"95..)"6-"9%-))E:%5)5(6"

58-/5(-,)"$(6'/5()"-(.0"&45("6450"$%5"'(65%($.'I5+";'$"645'%"@RMV"B0",)'(/"$("4$:65("9$%%'5%")0)65*"

b<OPc1"L,%645%" )6,+'5)"9-(7'%*5+" 645"$B'.'60"-7"@"95.." 6-" '(+,95"$(+"5(4$(95"R#Pp" 9%-))

":%'*'(/V"B0"

4'/4.'/46'(/" 645" (55+" -7" 9-,:.'(/" 645" J/" b*-)6" )6,+'5+" 645" -;$.B,*'(" -%" =5(" S//" F0)-I0*5c" 6-"

$+e,;$(6)".'G5"R:>E#WJ"b$"3-..".'G5"%595:6-%"Q".'/$(+V"6-"B5"58:.-%5+"'("+56$'.)"B5.-&c"b<OQV"<P2c"-%"6-"

H09-B$965%',*" 6,B5%9,.-)')" =5$6" )4-9G" :%-65'(" O2" V" &45%5" 5(4$(95+" :%-95))'(/" $(+" 9%-))"

:%5)5(6$6'-("$%5"*5+'$65+"B0"R#Q!"$(+"$%5":%-65$)-*5E'(+5:5(+5(6"b<P!cV"-%"B0"'(9-%:-%$6'(/"645"

J/"'("'**,(5E)6'*,.$6'(/"9-*:.585)"b<P<c1"R#C2".'/$6'-(":.$0)"$.)-"$"%-.5"'("$96';$6'(/"@"95..)".-$+5+"

&'64" $(" H=R" 9.$))EDEB'(+'(/" 6,*-%" :5:6'+5" $(+" 5($B.5)" 645*" 6-" '('6'$65" $" :%-6596';5" '**,(5"

%5):-()5"$/$'()6"$"6,*-%"94$..5(/5"()"/(/%";'$"$"9-*B'($6'-("-7"+'%596"$96';$6'-("-7"R#Pp"3"95..)"$(+"

9%-))E:%'*'(/" 6-" %5)'+5(6"JUR" b<P?c1"H-%5-;5%V" @" 95..)" $%5" '(;-.;5+" '(" :%-*-6'(/" +'$B565)" '("WX#"

*'95V"B0"9%-))E:%5)5(6'(/" ').56"$,6-$(6'/5(" 6-" )5.7" %5$96';5"R#Pp"3"95..)" %5),.6'(/" '(" 645'%"58:$()'-("

$(+" 645" $9[,')'6'-(" -7" $" 906-6-8'9" :45(-60:5" :%-*-6'(/" 645" G'..'(/" -7" \" 95..)" b<PCc1" D(" 645" 9$)5" -7"

2-:7%)'::-"'(7596'-(V"$(6'/5(E):59'7'9"@".0*:4-9065)"$%5"(-6"-(.0"9%'6'9$."7-%"$(6'B-+0":%-+,96'-("B,6"

$.)-" '(" 9%-))" :%'*'(/" $" F-:7%)'::-,):59'7'9" 906-6-8'9" 3" 95.." %5):-()5" &'64" 645" 45.:" -7" R#Cp"3" 95..)"

Page 47: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

CK""

"

b<PKc1"X("645"-645%"4$(+V"645"/%-,:"-7"@$94*$((")4-&5+"64$6"$.64-,/4"7-..'9,.$%"$(+"*$%/'($."I-(5"

@" 95..)" 577'9'5(6.0" 9$:6,%5" $(+" :%-95))" 58-/5(-,)" Z'%,)" F'G5" :$%6'9.5)" bZFUc" 7-%" ),B)5[,5(6"

:%5)5(6$6'-(" -(" H=R" 9.$))" DDV" 6450" 7$'.5+" 6-" :%-95))" 58-/5(-,)" ZFU)" 7-%" :%5)5(6$6'-(" -(" H=R" D"

*-.59,.5)" ()"/(&$%"$(+" ()"/(/%"J<>YK;"J(-645%")6,+0")4-&)"$(-645%"7$'.,%5"7-%"645"@"95..)"'("645"B-(5"

*$%%-&" b64$6" 4-)6)" *5*-%0" .0*:4-9065)" $(+" ),::-%6)" )59-(+$%0" '**,(5" %5):-()5)c" 6-" 9%-))"

:%5)5(6" B.--+" B-%(" $(6'/5()" 6-" ($q;5" R#Pp"3" 95..)" b<POc1" 34,)V" 645" ($6,%5" -7" 645" $(6'/5(V" 645"

.-9$.'I$6'-("-7" 645"@"95.." $(+" 645"$++'6'-($." )'/($.)" 64$6" 6450" %595';5"$%5"9%'6'9$." 7-%" 645"$B'.'60"-7"@"

.0*:4-9065)"6-"9%-))":%'*5"906-6-8'9"3"95..)1""

XNID""

" " " D(),.'(5E%5/,.$65+" $*'(-:5:6'+$)5" DMJU" B5.-(/)" 6-" 645" -806-9'($)5"

),B7$*'.0"-7"H!"$*'(-:5:6'+$)5)"64$6"9-(6$'("I'(9EB'(+'(/"$(+">JHSW"*-6'7)"64$6"$%5"5))5(6'$."7-%"

645'%" 5(I0*$6'9" $96';'60" b<PPc1" U%'-%" 6-" '6)" 94$%$965%'I$6'-(" $)" $(" $*'(-:5:6'+$)5" %5[,'%5+" 7-%"

6%'**'(/"-7"5:'6-:5":%59,%)-%)"589.,)';5.0"'("H=R"9.$))"D"$(6'/5(E9%-))":%5)5(6$6'-(V"DMJU"4$)"B55("

+5)9%'B5+" 6-" 9.5$;5" )5;5%$." 4-%*-(5)V" ;$)-$96';5" :5:6'+5)" $(+" (5,%-:5:6'+5)" ),94" $)" -806-9'(V"

)-*$6-)6$6'(" $(+" *$(0" -645%)" 5):59'$..0" 645" (5,%-:5:6'+5)" 64$6" $%5" '(;-.;5+" '(" .5$%('(/" $(+"

*5*-%01"345"58:%5))'-("-7"DMJU"')"+')6%'B,65+"'("$";5%0".$%/5"$%%$0"-7"6')),5)"),94"$)"645"45$%6V"645"

):.55(V"645"B%$'(V"645".,(/"$(+"$+':-)5"6')),5)"$(+"$6"$".-&5%"5865(6"'("645"G'+(50"$(+"645"*,)9.5)V"'6"

')"$)"&5.."58:%5))5+"'("'**,(5"95..)"),94"$)"+5(+%'6'9"95..)V"@"95..)"$(+"3"95..)"b<O<c1"DMJU"%5)'+5)"'("

5(+-)-*$." ;5)'9.5)" ($*5+" >AZ" 7-%" >.,6C" A6-%$/5" Z5)'9.5)" '(" $+':-9065)" $(+" *,)9.5)" -%" *-)6"

9-**-(.0" ($*5+" i95.." ):59'7'9" )6-%$/5" 5(+-)-*5j"&4-)5" +0($*'9)" $%5" %5/,.$65+" B0" 95..E):59'7'9"

)6'*,.'1"Y:-("95.."):59'7'9")6'*,.$6'-(V"DMJU";5)'9.5)"6%$().-9$65"+'%596.0"6-"645":.$)*$"*5*B%$(5V"$"

:%-95))"*5+'$65+"B0"645"WE65%*'($."906-)-.'9"6$'."-7"645":%-65'(1"345"%-.5"-7"DMJU"'("+'$B565)"')"&5.."

+-9,*5(65+" $(+" &$)" )6,+'5+" 7-%" *-%5" 64$(" 6&-" +59$+5)" '(" $+':-9065)^" D(" %5):-()5" 6-" '(),.'("

)6'*,.$6'-(V" 645" 9$)9$+5" -7" UD?_EU#_!EJG6" :%-65'(" G'($)5)V" +-&()6%5$*" -7" '(),.'(" %595:6-%V" ')"

$96';$65+V"%5),.6'(/"'("645":4-):4-%0.$6'-("-7"645"M$B>JU"J)!N2"B0"JG6<V" .5$+'(/"6-"'6)"+'))-9'$6'-("

7%-*" 645" )6-%$/5" 5(+-)-*5)" 64$6" 9-(6$'(" DMJU" $(+" 645" /.,9-)5" 6%$():-%65%" >FY3CV" $(+" 64,)"

$96';$6'(/"M$BCV"!2"$(+"!K"%5):-()'B.5"-7"5(+-)-*5"6%$().-9$6'-("6-"645":.$)*$"*5*B%$(51"D(),.'("

+5:5(+5(6"6%$().-9$6'-("-7"5(+-)-*5)"%5),.6)" '(" 645" '(9%5$)5"-7"95.." ),%7$95">.,6C"58:%5))'-("64,)"

$..-&'(/" 645" 6%$():-%6" -7" 9'%9,.$6'(/" /.,9-)5" $(+" 645'%" 577'9'5(6" $B)-%:6'-(1" 345" +57'9'5(90" '(" DMJU"

+')6,%B)" 645" .-9$.'I$6'-(" -7" >FY3C" '(" (-(" )6'*,.$65+" $+':-9065)V" &45%5" 95.." ),%7$95" >FY3C" ')"

'(9%5$)5+"B0"$"7-.+"-7"64%55"$(+"'(6%$95..,.$%">FY3C"7-,(+"%5%-,65+"6-"6%$()75%%'("%595:6-%":-)'6';5"

5(+-)-*5)"b<PQc1"

345" 6%$77'9G'(/" -7" DMJU" '(" '**,(5" 95..)" ')" .5))" &5.." +-9,*5(65+1" M595(6" )6,+'5)" 4$;5" )4-&(" 645"

'(6%$95..,.$%".-9$.'I$6'-("-7"DMJU"'("645"5(+-)-*5)".-9$.'I'(/"6-/5645%"&'64"M$B!CV")0(6$8'("N"$(+"645"

Page 48: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

CN""

"

*$((-)5" %595:6-%"$(+" 6-"$" .5))5%"5865(6"&'64"H=R"9.$))" D"*-.59,.5)" $(+"S$%.0" S(+-)-*$."*$%G5%"

SSJ!1"34')".-9$.'I$6'-("')"-B)5%;5+"'(")5;5%$."60:5)"-7"+5(+%'6'9"95..)V"4,*$("*-(-9065)E+5%';5+"#RV"

*,%'(5"B-%("*$%%-&"+5%';5+"#R"$(+"):.5('9"#R)" b9-(;5(6'-($."R#Pp"$(+"R#PE"+5(+%'6'9" 95..)V" $(+"

:.$)*$906-'+"+5(+%'6'9" 95..)c1"345" %5/,.$6'-("-7" DMJU"5(+-)-*5)" 6%$77'9" '("#R)" ')"(-6"056" '+5(6'7'5+V"

)6'.."%595(6"5;'+5(95")4-&)"645"%59%,'6*5(6"-7"DMJU"5(+-)-*5)"6-"5$%.0":4$/-)-*5)"64,)"5(4$(9'(/"

645'%"9%-))":%5)5(6$6'-("9$:$9'60"b<O<V"<Q2c1"

F$)6"B,6"(-6".5$)6V"DMJU"5(+-)-*5)"$%5"+5)9%'B5+"6-"+57'(5"$")6-%$/5"9-*:$%6*5(6"%5[,'%5+"7-%"6-.."

.'G5" %595:6-%"Q" )'/($.'(/" '("+5(+%'6'9" 95..)k" 645"*594$(')*)" '(;-.;5+"&'.."B5":%5)5(65+" '(" 645" %5),.6"

:$%61"

5!'3(9$)+#$0(9)&'&()+#$0$5'(#*+

U$665%("M59-/('6'-("M595:6-%)" bUMM)c"$%5"9-**-(.0"G(-&("$)")5()-%":%-65'()"9%,9'$." 7-%" 645"5$%.0"

+56596'-("-7"*'9%-B'$."-%"4-)6E+5%';5+")6%5))" )'/($.)"B0" '(($65" '**,(5"95..)1" D(65%5)6'(/.0V" )-*5"-7"

645)5"UMM)"$%5"58:%5))5+"$(+"7,(96'-($."$)"&5.." '("95..)"-7"645"$+$:6';5" '**,(5")0)65*".'G5"@"95..)"

$(+"3"95..)V"5(%'94'(/"645*"&'64"'(($65")5()'(/"$B'.'6'5)1"UMM)"$%5"/5%*.'(5E5(9-+5+V"(-("9.-($."$(+"

'(+5:5(+5(6" -7" '**,(-.-/'9$." *5*-%0" %595:6-%)" $(+" 6450" %59-/('I5" U$64-/5(EJ))-9'$65+"

H-.59,.$%" U$665%()" 64$6" 4$;5" 9%'6'9$." 7,(96'-()" '(" 645" .'75" -7" 645" :$64-/5()1" UMM)" $%5" '(;-.;5+" '("

+'775%5(6" $):596)" -7" '**,(5" +575()5" '(9.,+'(/" -:)-('I$6'-(V" $96';$6'-(" -7" 9-*:.5*5(6" $(+"

9-$/,.$6'-("9$)9$+5)V":4$/-906-)')V"$96';$6'-("-7":%-E'(7.$**$6-%0")'/($.'(/":$64&$0)"$(+"'(+,96'-("

-7" $:-:6-)')1" UMM)" 9$(" B5" B%-$+.0" 9$65/-%'I5+" '(6-" 64%55" 9.$))5)^" )59%565+V" 906-)-.'9" $(+"

6%$()*5*B%$(5"%595:6-%)1"

A59%565+"UMM)"

" 345"4,*-%$."$%*"-7"'(($65"'**,(5"%5):-()5"')"/-;5%(5+"B0"U$665%("M59-/('6'-("H-.59,.5)"

bUMH)c"64$6"$%5")59%565+"'("645"B.--+)6%5$*"$(+"6')),5"7.,'+)"'("645"5$%.0":4$)5"-7"*'9%-B'$."'(;$)'-(1"

345"UMH)"'(9.,+5":5(6%$8'()V"9-..596'()V"$(+"7'9-.'()"$(+"$%5",),$..0"9-*:$%5+"&'64"645"$(6'B-+'5)"-7"

645"$+$:6';5"'**,('601"A59%565+"UMH)",)5"+'775%5(6"*594$(')*)"-7"7,(96'-(^"6450"B'(+"6-"*'9%-B'$."

95.." ),%7$95)" $(+" 9--:5%$65"&'64" 95..,.$%" %595:6-%)" 6-" 5(4$(95" 645'%" 7,(96'-(k" 6450" $96';$65" 9.$))'9"

$(+".596'(":$64&$0)"-7"645"9-*:.5*5(6")0)65*"$(+"6450"-:)-('I5":$64-/5()"6-"%5(+5%"645*"%5$+0"

7-%":4$/-906-)')"B0"*$9%-:4$/5)"$(+"(5,6%-:4'.)1"

345":5(6%$8'("7$*'.0"')"94$%$965%'I5+"B0"$"909.'9"*,.6'*5%'9")6%,96,%5"&'64"$"<22"$*'(-"$9'+":5(6%$8'("

+-*$'("'("645"RE65%*'($."$(+"$("P"$*'(-"$9'+"9-()5%;5+")5[,5(95"b=8R8AT3g8Ac"($*5+":5(6%$8'("

)'/($6,%5"b<Q!c1"U5(6%$8'("7$*'.0"9-(6$'()"*$'(.0"645"R"M5$96';5":%-65'("bRMUcV"645"A5%,*"$*0.-'+"U"

Page 49: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

CO""

"

9-*:-(5(6"bRJUcV":5(6%$8'("?"bU3a?c"$(+"645"(5&.0"'(+5(6'7'5+":5(6%$8'("C"bU3aCc1""A4-%6":5(6%$8'()"

bRMUV" RJUc" $%5" :%-+,95+" B0" 45:$6-9065)" &45%5$)" .-(/" :5(6%$8'()" bU3a?" $(+" Cc" $%5" )59%565+" B0"

*-(-9065)V" *$9%-:4$/5)V" 5(+-645.'$." $(+" 5:'645.'$." 95..)V" +5(+%'6'9" 95..)" $(+" 7'B%-B.$)6)V" ,:-("

*'9%-B'$." '(6%,)'-(" -%" 6')),5" +$*$/51" 345" .'/$(+)" -7" :5(6%$8'()" $%5" -7" $" B'/" ;$%'560" '(9.,+'(/"

9-*:.5*5(6" 9-*:-(5(6)V" *'9%--%/$(')*)" bB$965%'$V" ;'%,)5)V" 7,(/'V" $(+" :$%$)'65)cV" $:-:6-6'9" 95..)"

$(+"*$(0"*-%51"

R-..596'()" $%5" $" 7$*'.0" -7" *,.6'*5%'9" $(+" *,.6'7,(96'-($." UMH)" &'64" 9$%B-40+%$65" %59-/('6'-("

+-*$'()" 64$6" $))-9'$65"&'64" 9-..$/5(-,)" )6%,96,%5)" b<Q<c1" 345" B5)6" 94$%$965%'I5+"*5*B5%)" -7" 645"

9-..596'("7$*'.0"$%5"645"*$((-)5EB'(+'(/".596'("bH@FcV"645"),%7$96$(6":%-65'("AUEJ"$(+"AUE#"$(+"645"

9-*:.5*5(6"9-*:-(5(6"R!["64$6" ')":%-+,95+"B0" 6')),5"*$9%-:4$/5)V"+5(+%'6'9"95..)"$(+"5:'645.'$."

95..)" .-9$.'I5+" '(" 645" 586%$95..,.$%" *$6%'81" L'9-.'()" $%5" )6%,96,%$..0" $(+" 7,(96'-($..0" %5.$65+" 6-"

9-..596'()V" 6450" %59-/('I5" 9$%B-40+%$65EB$)5+" UJHU)" -(" *'9%--%/$(')*)" &4'94" *5+'$65)" 645"

$96';$6'-("-7"645".596'("9-*:.5*5(6":$64&$0"b<Q?c1"34,)V":4$/-9065)")5%;5"$)"$")-,%95"-7"UMH)"64$6"

$%5" )0(645)'I5+" $(+" %5.5$)5+" $6" )'65)" -7" '(($65" '**,(5" %5$96'-()V" *,94" .'G5" @" 95..)" :%-+,9'(/"

$(6'B-+'5)1"

R06-)-.'9"UMM)"" " "

" 345" 906-)-.'9" %595:6-%)" '(9.,+5" 645" MWJE)5()'(/" %56'(-'9" $9'+E'(+,9'B.5" /5(5" D" bMD>EDc" .'G5"

%595:6-%)"-%"45.'9$)5)" bMFM)"-%"MF=)cV" 645"#WJ")5()'(/"#WJ"+5:5(+5(6"$96';$6-%"-7" DML)" b#JDc"$(+"

$B)5(6" '(" *5.$(-*$" <" bJDH<c" %595:6-%)V" $(+" 7'($..0" 645" (,9.5-6'+5EB'(+'(/" +-*$'(" bWX#c" $(+"

.5,9'(5"%'94"%5:5$6E9-(6$'('(/"%595:6-%)"bWFM)c1"

MD>EF'G5"45.'9$)5)"

" " MD>ED" $(+" *5.$(-*$" +'775%5(6'$6'-(E$))-9'$65+" /5(5" K" bH#JEKcV" *5*B5%)" -7" MD>E

F'G5E=5.'9$)5" 7$*'.0V" $%5" ):59'$.'I5+" '(" %59-/('I'(/" MWJ" ;'%,)5)" +565965+" '(" 645" 906-:.$)*" '(" $.."

'(75965+" 95..)V" 5895:6" 645" ):59'$.'I5+" :.$)*$906-'+" +5(+%'6'9" 95..)V" $(+" $96';$65" $(" $(6';'%$." '(($65"

'**,(5" %5):-()5" 60:'7'5+" B0" 645" :%-+,96'-(" -7" 60:5" D" DLW)" $(+" '(7.$**$6-%0" 906-G'(5)1" MD>ED" $(+"

H#JEK")4$%5"645")$*5")6%,96,%5V"6450"9-(6$'("'("645'%"WE65%*'($."6&-"9$):$)5"%59%,'6*5(6"+-*$'()"

bRJM#)cV"&4'94"'(65%$96"&'64"-645%"RJM#"9-(6$'('(/":%-65'()"$(+"$%5"%5[,'%5+"6-"6%'//5%"+-&()6%5$*"

)'/($.'(/V" 645"*'++.5":$%6"9-(6$'()"$"#S8#T="45.'9$)5"+-*$'("&'64"$("J3U"B'(+'(/"*-6'7"$(+"645"R"

65%*'($." 9-(6$'()" $" %5:%5))-%" +-*$'(" bM#c" &'64" %5/,.$6-%0" 7,(96'-(" b<QCcV" 4-&5;5%" '6" ')" (-6" 9.5$%"

&45645%"645"R"65%*'($."-7"H#JEK"7,(96'-()"$)"$("M#1"MD>ED"')"5))5(6'$."7-%"645"%59-/('6'-(""-7"$")5%'5)"

-7" )'(/.5" )6%$(+5+" MWJ" ;'%,)5)" '(9.,+'(/" '(7.,5(I$" J" $(+" @" ;'%,)5)V" =5:$6'6')" R" ;'%,)V" o$:$(5)5"

5(95:4$.'6')";'%,)V"&45%5$)"H#JEK"%59-/('I5"-645%"MWJ";'%,)5)"*$'(.0"+-,B.5")6%$(+5+"MWJ"),94"$)"

H5(/-"Z'%,)V"5(95:4$.-*0-9$%+'6')";'%,)"$(+"345'.5%h)";'%,)1"MD>ED"')"$.)-"$B.5"6-"+56596"906-:.$)*'9"

Page 50: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

CP""

"

+)#WJV" $" %59-/('6'-(" 64$6" ')" *5+'$65+" B0" 645" MWJ" :-.0*5%$)5" DDD" bMWJ" U-." DDDc" 64$6" ,)5)" 645" 645"

+)#WJ"$)"$" 65*:.$65" 6-" )0(645)'I5"$"KhE6%':4-):4$65"MWJ"),'6$B.5" 7-%"MD>ED" %59-/('6'-(" b<QKV"<QNc1"

H-%5-;5%" MD>ED" +')6'(/,')45)" B56&55(" ;'%$." $(+" 4-)6" MWJ" B$)5+" -(" 645" %59-/('6'-(" -7" $" KhE

6%':4-):4$65"*-+'7'9$6'-(" :%5)5(6" '(" ;'%$." MWJ" B,6" $B)5(6" '(" (-%*$." 9$::5+" -%" :%-95))5+" 95..,.$%"

MWJ)k" :)5,+-,%'+'(5" *-+'7'9$6'-()" 7-,(+" 7%5[,5(6.0" -(" 95..,.$%" MWJ)" $%5" $.)-" :.$0" $" %-.5" '("

:%5;5(6'(/"MD>ED"$(+"H#JEK"$96';$6'-("b<QOc1"J++'6'-($..0V"MD>ED"9$("%59-/('I5")4-%6"+)MWJV"&45%5$)"

.-(/"+)MWJ"$%5":%575%$B.0"+565965+"B0"H#JEKk"7'($..0"645"+)MWJ"$($.-/"U-.0"D^R"')"-(.0"+565965+"B0"

H#JEK1"34,)V"MD>ED" .'G5"%595:6-%)"7$*'.0"')"4'/4.0":-65(6"'("+56596'(/"$"&'+5"%$(/5"-7";'%,)5)"&'64"$"

(-(E%5+,(+$(6"9-*:56'6'-(1""

Y:-(" $96';$6'-(V" MD>ED" .'G5" %595:6-%)" '(65%$96" &'64" $" 9-**-(" $+$:6-%" *-.59,.5" 7-,(+" '("

*'6-94-(+%'$" $(+" ($*5+" *'6-94-(+%'$" $(6';'%$." )'/($.'(/" :%-65'(" bHJZ)cV" $.)-" G(-&(" $)" DLWE\"

:%-*-65%" )6'*,.$6-%E!" bDUAE!c1" 3MJL?" ')" %5[,'%5+" 7-%" $96';$6'-("-7" DUAED" )'/($.'(/":$64&$0)V" $(+" 7-%"

_N?E60:5" :-.0,B'[,'6'($6'-(" %5/,.$65+" B0" #Y@J1" 3JW_TWJU!TADW3@J#" 9-*:.58" $(+" ),B)5[,5(6.0"

3@_!TD__ED"9-*:.58"$%5"%59%,'65+"B0"3MJL?V"*5+'$65"DMLE?"$(+"DMLEO":4-):4-%0.$6'-("$(+"'(+,95"645"

58:%5))'-(" -7" 60:5" D" DLW" /5(5)1" DUAED" $.)-" $96';$65)" WLEv@" ;'$" LJ##" $(+" 9$):$)5" PT9$):$)5" !2E

+5:5(+5(6":$64&$0"J3(+4$'"5TK"b<QPc1""

J"64'%+"MD>ED" .'G5"%595:6-%"$.)-"58')6)"($*5+"F>U<V" '6" .$9G)"645"RJM#)"+-*$'("$(+"'6" ')"),//5)65+"6-"

)5%;5"$)"$"(5/$6';5"%5/,.$6-%"-7"MWJ";'%,)E'(+,95+"%5):-()5)1"

"

"

"

L'/,%5"!K^"M59-/('6'-("-7"MWJ";'%,)5)"B0"MD>ED".'G5"%595:6-%)V"-0-#&'0"6$%7"A-1'4.B("'&"-:;E"<==>"

Page 51: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

CQ""

"

#JD"$(+"JDH<"

" " #JDV"$.)-"9$..5+"fE#WJ"B'(+'(/":%-65'("bf@U!cV"')"$"906-)-.'9"#WJ")5()-%"$(+"$96';$6-%"

-7" '(($65" '**,('60" B0" '(+,9'(/" :%-E'(7.$**$6-%0" 906-G'(5)" $(+" 60:5" D" DLW" )59%56'-(1" #JD" &$)"

+')9-;5%5+" $)" $" 9$(+'+$65" 906-)-.'9" #WJ" %595:6-%" 7%-*" $" 9#WJ"*'9%-$%%$0" $($.0)')" 9$%%'5+" -,6" 6-"

)9%55("7-%"DLWE'(+,9'B.5"/5(5)"64$6"9-(6$'("#WJ"B'(+'(/"+-*$'()"b<QQc1"#JD"4$)"(-")6%'96":%575%5(95"

7-%" 645" )5[,5(95" -%" 645" 9-(7'/,%$6'-(" -7" #WJ1" M595(6.0V" #JD" &$)" +5)9%'B5+" 6-" B5" '(;-.;5+" '(" 645"

+56596'-("-7"=DZED"+)#WJ")0(645)'I5+"'("645"906-:.$)*",:-("'6)"%5;5%)5"6%$()9%':6'-("b?22c1"

JDH<"')"$"+-,B.5")6%$(+5+"#WJ"%595:6-%"64$6"9-()')6)"-7"$"R"65%*'($."=DW<22"+-*$'("64$6"B'(+)"6-"

#WJ" $(+" $(" W" 65%*'($." :0%'(" +-*$'(" 64$6" $))-9'$65)" &'64" 645" $+$:6-%" *-.59,.5" JAR" bJ:-:6-)')E

$))-9'$65+" ):59GE.'G5" :%-65'(" 9-(6$'('(/" $" 9$):$)5" $96';$6'-(" $(+" %59%,'6*5(6" +-*$'(c1" Y:-("

$96';$6'-("&'64"B$965%'$."-%";'%$."+)#WJ"),94"$)"Z$99'('$";'%,)V"JDH<"7-%*)V"6-/5645%"&'64" '6)" .'/$(+"

$(+" JARV" $(" '(7.$**$)-*5" 64$6" .5$+)" 6-" 645" $96';$6'-(" -7" 9$):$)5E!" 64$6" 9-(6%-.)" 645" 9$6$.06'9"

9.5$;$/5"-7"645":%-E7-%*)"-7"DFE!\"$(+"DFE!P"'(7.$**$6-%0"906-G'(5)"b?2!c1"

WX#EF'G5"M595:6-%)"

" " 345"WX#E.'G5"%595:6-%)"$%5"$"7$*'.0"-7"*-.59,.5)"64$6")5()5"$"&'+5"%$(/5"-7"B$965%'$"

$(+" )6%5))" )'/($.)k" 6450" $%5" 58:%5))5+" '(" *$(0" '**,(5" 95..)" $(+" $.)-" (-(" '**,(5" 95..)" .'G5"

:%-75))'-($." JUR)" $(+" 5:'645.'$." 95..)1" " 345" WFM)" 7$*'.0" 9-,(6)" <?" *5*B5%)" '(" 4,*$(" $(+"

$::%-8'*$65.0"?C"'("*'95"$(+"'6"')"9-()6'6,65+"B0"64%55"+-*$'()^"345"R"65%*'($."+-*$'("64$6"9-()')6"

-7")5;5%$."F5,9'(5EM'94"M5:5$6"bFMM)c"+-*$'()"64$6"$%5"'(;-.;5+"'("*'9%-B'$."UJHU)"%59-/('6'-(V"645"

'(65%*5+'$65" +-*$'(" 64$6" 9-()')6)" -7" (,9.5-6'+5" B'(+'(/" $(+" -.'/-*5%'I$6'-(" bWJR=3c" +-*$'()"

%5[,'%5+"7-%"J3UE+5:5(+5(6"-.'/-*5%'I$6'-("-7"645")5()-%)"$(+"64,)"645"7-%*$6'-("-7"$96';5"%595:6-%"

9-*:.585)" '(;-.;5+" '(" +-&()6%5$*" )'/($.'(/V" $(+" $"W" 65%*'($." 577596-%" +-*$'(" 64$6" 9.$))'7'5)" 645"

WFM)"'("+'775%5(6"),B7$*'.'5)^"645"+5$64"577596-%"+-*$'("b#S#cV"645":0%'("+-*$'(EbUt#c"'("645"WJFU"

),B7$*'.0V"645"9$):$)5"%59%,'6*5(6"+-*$'(E"bRJM#c" '("645"WX#"),B7$*'.0V"645"B$9,.-;'%,)" '(4'B'6-%"

%5:5$6)E"b@DM)c"'("645"WJDU"),B7$*'.0"$(+"645"$9'+'9"+-*$'(E9-(6$'('(/"WFM)1""

345"B5)6"94$%$965%'I5+"*5*B5%)"-7"645"WX#"7$*'.0"$%5"WX#!"$(+"WX#<1"3450"B-64")5()5"+'775%5(6"

),B,('6)"-7"B$965%'$.":5:6'+-/.09$()"'(9.,+'(/"dE'SE#JU"):59'7'9"7-%"/%$*E(5/$6';5"B$965%'$V"$(+"H#UV"

$" 9-*:-(5(6" -7" $.." 60:5)" -7" B$965%'$." :5:6'+-/.09$()1" Y:-(" .'/$(+" )6'*,.$6'-(V" WX#!" $(+" WX#<"

)'/($.";'$"WLEv@"$(+"HJU_":$64&$0)"%5),.6'(/"'("645"'(+,96'-("-7"'(7.$**$6-%0"/5(5)"b?2<c1"WJFU!"

$(+"WJFU?V"*5*B5%)"-7"645"WJFU"),B7$*'.0V"%59-/('I5"+$(/5%")'/($.)"%5.5$)5+"7%-*"'(e,%5+"-%"+0'(/"

95..)V" .5$+'(/" 6-" 645" $96';$6'-(" -7" 645" *,.6':%-65'(E9-*:.58V" 645" '(7.$**$)-*5V" &4'94" $..-&)" 645"

9.5$;$/5"-7"645"'($96';5"7-%*"-7"9$):$)5)"b645":%-9$):$)5)c"$(+"645"/5(5%$6'-("-7"645"$96';5"*$6,%5"

7-%*"-7"645":%-65$)5)V"&4'94"'("6,%(":%-*-65"645":%-65-.0)')"-7"645"I0*-/5("7-%*"-7"'(7.$**$6-%0"

Page 52: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

K2""

"

906-G'(5)" b:%-EDF!V" :%-EDFP" $(+" :%-EDF??c" '(6-" 645'%" $96';5" 7-%*)1" WJDU)" 7$*'.0" +56596)" '(6%$95..,.$%"

7.$/5..'(" '(" $" 3-.." F'G5" M595:6-%" KE'(+5:5(+5(6" *$((5%" $(+" 6%'//5%)" $)" &5.." 645" 7-%*$6'-(" -7"

'(7.$**$)-*5)"b?2?c1""

S8:%5))'-("-7"WFM)"4$)"B55("+565965+"'(";$%'-,)"95.."60:5)V"'(9.,+'(/"*$9%-:4$/5)V"#R)V"*-(-9065)V"

5:'645.'$."$(+"5(+-645.'$."95..)V"$)6%-9065)V"$(+"-)65-B.$)6)1"X(5"%595(6")6,+0":%-;'+5+"5;'+5(95"-7"

WX#!" $(+" WX#<" 58:%5))'-(" B0" 6%$()7-%*5+" @" 95..)" -B6$'(5+" 7%-*" 94%-('9" .0*:4-906'9" .5,G5*'$"

:$6'5(6)" b?2Cc1" F$65%" -(V" 645" /%-,:" -7" R$%+5.." )9%55(5+" 645" 58:%5))'-(" -7" )-*5" WFM)" '(" :%'*$%0"

4,*$("@" .0*:4-9065)"$(+")4-&5+"64$6":5%':45%$."@"95..)"58:%5))" 7,(96'-($."WX#!V"WX#<V"WJFU!V"

WJFU?"$(+"WJDUV"&45%5$)" 6-()'..$%" @" 95..)" 58:%5))"WX#!V"WJFU!"$(+"WJDU"&'64"-(.0"WX#!" 64$6" ')"

7,(96'-($.1"J96';$6'-("-7"@"95..)"64%-,/4"WFM)"+5:5(+)"-("@RM"5(/$/5*5(6"B,6" ')" '(+5:5(+5(6"-7"3"

95.."45.:1"H-%5-;5%V"WFM)"$%5"$B.5"6-"5(4$(95"3-..EF'G5"%595:6-%"'(+,95+"@"95.."$96';$6'-("b?2Kc1"

3%$()*5*B%$(5"%595:6-%)"

F596'(5)"

" " 345" RE60:5" .596'(" ),:5%7$*'.0" 9-()6'6,65)" $" 7$*'.0" -7" :%-65'()" 64$6" 9-(6$'(" -(5" -%"

*-%5" RE60:5" .596'(E.'G5" +-*$'(" bR3F#c" $(+" 4$;5" B55(" +';'+5+" '(6-" !C" /%-,:)" B$)5+" -(" 645"

-%/$('I$6'-("-7"645'%"R3F#)k"6450"$%5"'(;-.;5+"'("645"+56596'-("-7"*'9%-B'$.E+5%';5+"),/$%)V"/.,9$()V"

$(+"4'/4"*$((-)5"$(+" 7,9-)5" )6%,96,%5)1"RE60:5" .596'(" %595:6-%)" bRFM)c" $%5" 7,(96'-($..0"+';5%)5"$)"

6450"$%5"'*:.'9$65+"'("+'%596":$64-/5("%59-/('6'-("$(+"645"'('6'$6'-("-7"'(($65"$(+"$+$:6';5"%5):-()5V"

$)"&5.."$)"-645%":%-95))5)"'(9.,+'(/"95.."$+45)'-(V"9-*:.5*5(6"$96';$6'-(V"5(+-906-)')V":$4/-906-)')V"

:.$65.56"$96';$6'-("$(+"6')),5"%5*-+5.'(/"b?2Nc1"345"B5)6"94$%$965%'I5+"$(+")6,+'5+"*5*B5%"-7"RFM)"

')"#596'(E!"64$6"&$)"-%'/'($..0" 64-,/46" 6-"B5"58:%5))5+"589.,)';5.0"-("+5(+%'6'9"95..)" 7%-*"&4'94" '6)"

($*5" ')" +5%';5+" b+5(+%'6'9E95..E$))-9'$65+" RE60:5" .596'(" !cV" B,6" %595(6.0" '6" &$)" $.)-" )4-&(" 6-" B5"

58:%5))5+" B0"*$(0" -645%" 95.." 60:5)" '(9.,+'(/"*$9%-:4$/5)V"*-(-9065)V" (5,6%-:4'.)V" $" ),B)56" -7" 3"

95..)V"4,*$("B,6"(-6"*-,)5"@"95..)"$(+"5-)'(-:4'.)1"#596'(ED"%59-/('I5)"/.,9$()"7-,(+"*$'(.0"'("645"

95.."&$..)"-7"7,(/'V"B,6"$.)-"'("B$965%'$"$(+":.$(6)1"#596'(ED"$.)-"%59-/('I5)"I0*-)$("9-*:-)5+"*$'(.0"

-7" \E/.,9$(" $(+" 7-,(+" '(" 645" 95.." &$.." -7" A$994$%-*095)" R5%5;')'$1" Y:-(" .'/$(+" B'(+'(/V" #596'(E!"

B59-*5)"60%-)'(5":4-):4-%0.$65+"B0"A%9"G'($)5)":%-;'+'(/"$"+-9G'(/")'65"7-%"A0G"G'($)5"&4'94"'("6,%("

'('6'$65)" $(" '(6%$95..,.$%" )'/($.'(/" 9$)9$+5" 64$6" .5$+)" 6-" 645" :%-+,96'-(" -7" ;$%'-,)" 906-G'(5)" $(+"

945*-G'(5)" '(9.,+'(/"RaRE945*-G'(5" .'/$(+"<"$(+" DFE!2V"$(+"9$("$.)-" '(+,95" 645" %5):'%$6-%0"B,%)6"

$(+".'/$(+",:6$G5"64%-,/4":4$/-906-)')1"#596'(E!"9--:5%$65)"$)"&5.."&'64"6-..EF'G5"%595:6-%"<"$(+"N"

64%-,/4"H0+PP"b*05.-'+"+'775%5(6'$6'-(":%'*$%0E%5):-()5"/5(5"PPc"$(+"WLEv@"b(,9.5$%"7$96-%E"v@c"6-"

/5(5%$65"6,*-%"(59%-)')"7$96-%"b3WLcV"DFE!<"$(+"DFE<"b?2Oc1"

Page 53: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

K!""

"

3-..EF'G5"%595:6-%)"

" " 345" +')9-;5%0" -7" 3-..EF'G5" %595:6-%)" b3FM)c" $(+" 645'%" 9%'6'9$." '*:-%6$(95" '(" '**,(5"

%5):-()5)"&5%5"%59-/('I5+"&'64"645"$&$%+'(/"-7"645"<2!!"W-B5."U%'I5"'("U40)'-.-/0"-%"*5+'9'(5"B0"

o,.5)"=-77*$((V"@%,95"@5,6.5%"$(+"M$.:4"A65'(*$("b&4-"+')9-;5%5+"645"+5(+%'6'9"95..cV"645":'-(55%)"

'(" 645" 7'5.+" -7" '(($65" '**,('601" 3FM)" %59-/('I5" :$64-/5(E$))-9'$65+" *-.59,.$%" :$665%()" bUJHU)c"

7%-*" *'9%--%/$(')*)" -%" +$(/5%E$))-9'$65+" *-.59,.$%" :$665%()" b#JHU)c" 7%-*" +$*$/5+" 6')),51"

R4$%.5)"o$(5&$0"&$)"645"7'%)6"6-":%5+'96V"'("!QPQV"645"58')65(95"-7"'(($65"'**,(5"%595:6-%)"64$6".'(G"

'(($65"$(+"$+$:6';5" '**,(5"%5):-()5)" b?2Pc1"345" 7'%)6"*-.59,.5" 64$6"4$)"B55("+5)9%'B5+" '('6'$6'(/"

645" %-$+" 6-" 645" +')9-;5%0" -7" 3FM)"&$)" 645" DFE!" M595:6-%" 60:5!" bDFE!M!c" 64$6" :-))5))5)" $" 906-)-.'9"

+-*$'(" 4-*-.-/-,)" 6-" 645" 3-.." +-*$'(" 7-,(+" '("O$%2%#B(:-"7':-)%+-2&'$" $(+" '*:.'9$65+" $6" 64$6"

6'*5"'("5)6$B.')4'(/"645"+-%)-;5(6%$.":-.$%'60"-7"645"7.0"b?2QcV"645("$765%"6-.."$(+"DFE!M!"&5%5")4-&("

6-" )4$%5" 9-**-(" $*'(-" $9'+)" 64$6"&5%5" 9%,9'$." 7-%" WLEv@" )'/($.'(/" b?!2c1" 34')" 9-()5%;5+" +-*$'("

($*5+" i645" 6-..EDFE!E%5)')65(95" b3DMc" +-*$'(j" &$)" $.)-" +5)9%'B5+" '(" $" :.$(6" :%-65'(" 64$6" 9-(75%)"

%5)')6$(95" 6-" 6-B$99-" *-)$'9" ;'%,)V" '(+'9$6'(/" '6)" '(;-.;5*5(6" '(" 4-)6" +575()5" '(" B-64" :.$(6)" $(+"

$('*$.)1" 34')" .5+" =-77*$(h)" .$B" 6-" :-)6,.$65" 645" 40:-645)')" -7" 3-.." '(;-.;5*5(6" (-6" -(.0" '("

+5;5.-:*5(6$." :%-95))5)" B,6" $.)-" '(" '**,(5" /5(5" 58:%5))'-(1" D(+55+V" 645" +57'('6';5" :%--7" &$)"

:%-;'+5+"B0"@1"F5*$'6%5V"$"*5*B5%"-7"=-77*$(h)".$B-%$6-%0V")4-&'(/"64$6",:-("*'9%-B'$."'(7596'-(V"

645"58:%5))'-("-7"#%-)-*09'(V"$("$(6'7,(/$.":5:6'+5V"&$)",:%5/,.$65+"7-..-&'(/"645"$96';$6'-("-7"645"

3-..":$64&$0"b?!!c1"F$65%"-(V" '("!QQOV"M,).$("H5+I4'6-;"$(+"o$(5&$0"&5%5"$B.5"6-"9.-(5"$(+")6,+0"

645" 7'%)6"*$**$.'$(" 6-..E4-*-.-/,5" 645" 3FMC" '(" 4,*$(" b?!<c1" J" .-))" -7" 7,(96'-("*,6$6'-(" -7" 645"

*-,)5" 4-*-.-/,5" -7" 3FMC" &$)" ),B)5[,5(6.0" +')9-;5%5+" '(" *-,)5" )6%$'()" 64$6" &5%5" ,($B.5" 6-"

:%-*-65" '(($65" '**,(5" %5):-()5)" $/$'()6" B$965%'$." FUA" b?!?c1" @0" !QQPV" 7';5" *$**$.'$(" 3-.."

4-*-.-/,5)"&5%5"+5)9%'B5+"b?!Cc1"#,%'(/"645".$)6"7'7655("05$%)V"$"4,/5"(,*B5%"-7")6,+'5)"4$)"B55("

9$%%'5+"-,6"6-"%5;5$."645")6%,96,%5V"645")'/($.'(/":$64&$0"$(+"645"'**,(5"%5):-()5"+%';5("B0"3FM)1"

@57-%5"645"+')9-;5%0"-7"3-..EF'G5"%595:6-%)V"645"'(($65"'**,('60"&$)"9-()'+5%5+"B0"'**,(-.-/')6)"$)"

$(",()-:4')6'9$65+":$%6"-7"645"'**,(5")0)65*1"345"94$%$965%'I$6'-("-7"3FM)":%-;'+5+"(5&"*-.59,.$%"

'()'/46)" $(+":5%*'665+" 645"+')9-;5%0" -7" -645%" 7$*'.'5)" -7" '(($65" '**,(5" %595:6-%)" $.)-" 9%'6'9$." 7-%"

:$665%(" %59-/('6'-(1"J6":%5)5(6V" 3FM)" 9-,(6" 7-%" 65("*5*B5%)" '("4,*$()V" $(+"*-%5" 64$(" 6&5.;5" '("

*'95k" 3FM!E3FMQ" $%5" 9-()5%;5+" B56&55(" 4,*$()" $(+" *'95" &'64" 3FM!2" (-(" 7,(96'-($." '(" *'95"

B59$,)5" -7" $" %56%-;'%,)" '()5%6'-(V" $(+" 3FM!!V" !<" $(+" !?" $%5" .-)6" '(" 645" 4,*$(" /5(-*5)1" 345"

/5(5%$6'-("-7"*'95"+57'9'5(6" 7-%" '(+';'+,$."3FM)"&$)" 645"&$0" 6-" '+5(6'70"*-)6"-7" 6-..EF'G5" %595:6-%)"

.'/$(+)1"3FM)"$%5"60:5"D"6%$()*5*B%$(5":%-65'()"b645"W"65%*'($."')"-,6)'+5"-7"645"*5*B%$(5c"$(+"$%5"

9-*:-)5+"-7"64%55"+'775%5(6"+-*$'()^"$("W"65%*'($."596-+-*$'("64$6"*5+'$65)".'/$(+"%59-/('6'-(V"$"

Page 54: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

K<""

"

6%$()*5*B%$(5"+-*$'("$(+"$"R"65%*'($."'(6%$95..,.$%")'/($.'(/"+-*$'("64$6"')"4-*-.-/-,)"6-"64$6"-7"

DF!EM!"$(+"')"%5[,'%5+"7-%"+-&()6%5$*")'/($.'(/"J3(+4$'5YK"JM5TK;"

"

"

L'/,%5"!N^")6%,96,%$.")'*'.$%'6'5)"B56&55("3FM"$(+"DFE!M!"%595:6-%)V"-0-#&'0"6$%7"8'7-(&$'E"<==R"

"

345"W"65%*'($."596-+-*$'("($*5+"FMM"bF5,9'(5"M'94"M5:5$6c"+-*$'("9-(6$'()"!QE<K"6$(+5*"9-:'5)"

-7"FMM"*-6'7)"$(+"5$94"FMM"*-6'7"9-*:%')5)"<2E?2"$*'(-"$9'+)"'(".5(/64"9-(6$'('(/"645"i8F88F8F88j"

*-6'71"345"9%0)6$.")6%,96,%5)"-7"FMM"+-*$'("%5;5$.)"645"58')65(95"-7"$"\E)6%$(+"$(+"$("uE45.'8".'(G5+"

B0"$".--:")6%,96,%5"64$6"')"),Be5965+"6-":%-65-.0)')"'("645"9$)5"-7"3FM?V"OV"P"$(+"Q1"345"3DM"b3-..T"DF!EM"

!c"E"+-*$'("'("645"R"65%*'($.":$%6"')"9%,9'$."7-%"645"%59%,'6*5(6"$(+"B'(+'(/"-7"3DME+-*$'("9-(6$'('(/"

$+$:6-%"*-.59,.5)" .5$+'(/"6-"645"$96';$6'-("-7"+-&()6%5$*")'/($.'(/":$64&$0)"$(+"645"),B)5[,5(6"

:%-+,96'-(" -7" :%-E'(7.$**$6-%0" 906-G'(5)" $(+" 60:5" D" DLW1" 345" 3DM" +-*$'(" 9-(6$'()" $)" &5.." $("

-.'/-*5%'I$6'-(" )'65" $..-&'(/" 645"+'*5%'I$6'-("B56&55(" 645"+'775%5(6" ),B,('6)V" /';'(/" 64$6" 3FM)" $%5"

&'+5.0"B5.'5;5+"6-"7,(96'-("$)"+'*5%'9":%-65'()V"5'645%"$)"4-*-+'*5%)"-%"4565%-+'*5%)"b3FM!T3FM<"-%"

3FM<T3FMNc1" 3-..EF'G5" %595:6-%)" $%5" 58:%5))5+" '(" *-)6" '**,(5" 95..)" ),94" $)" +5(+%'6'9" 95..)V"

*$9%-:4$/5)V" W_" 95..)V" *$)6" 95..)" $(+" (5,6%-:4'.)V" '(" @" $(+" 3" .0*:4-9065)V" '(" 5(+-645.'$." $(+"

5:'645.'$." 95..)V" :$(9%5$6'9" 95..)V" )G'(" G5%$6'(-9065)V" 7'B%-B.$)6)" $(+" 9$(95%" 95..)" b?!NV" ?!Oc1"

R-()5[,5(6.0" 645" '*:-%6$(95" -7" 3FM)" ')" %5;5$.5+" '(" )5;5%$." '**,(-.-/'9$." '(($65" $(+" $+$:6';5"

:%-95))5)V"$(/'-/5(5)')V"6')),5"4-*5-)6$)')V"'(7.$**$6-%0"+')5$)5)"$(+"9$(95%1""

3-..EF'G5" %595:6-%)" $%5" +';'+5+" '(6-" 6&-" /%-,:)" +5:5(+'(/" -(" 645'%" ),B95..,.$%" .-9$.'I$6'-(^" 645"

:.$)*$"*5*B%$(5"3FM)"64$6" '(9.,+5"3FM"!V"<V"CV"KV"NV"!2V"!!V"!<"7-,(+"-("645"95.."),%7$95V"$(+"645"

'(6%$95..,.$%"3FM)"'(9.,+'(/"3FM"?V"OV"P"$(+"Q"$(+"645"(5&.0"+5)9%'B5+"3FM!?"64$6"$%5"7-,(+"$))-9'$65+"

&'64"YWRQ?@!1"YWRQ?@!"')"$"94$:5%-(5"*-.59,.5"5))5(6'$."7-%"645"6%$().-9$6'-("-7"645"'(6%$95..,.$%"

3FM)"7%-*"645"5(+-:.$)*'9"%56'9,.,*"6-"645"5(+-)-*5)"7%-*"&45%5"6450")'/($."b?!Pc1"3FM)")5%;5"$)"

Page 55: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

K?""

"

UMM)"6-"%59-/('I5"$"&'+5"%$(/5"-7"UJHU)V"'(9.,+'(/".':'+)V".':-:%-65'()V":%-65'()V"/.09$()"$(+"(,9.5'9"

$9'+)1"A-9:'" R" ),**$%'I5)" 645" +'775%5(6" 3FM)V" 645" $+$:6-%"*-.59,.5)" (55+5+" 7-%" 645'%" )'/($.'(/" $)"

&5.."$)"645")6'*,.$6'(/".'/$(+)1"

"

"

"

3$B.5"C^"3FM)"$(+"UJHU)V"-0-#&'0"6$%7"\-Q-("'&"-:;E"<==L"

"

U]#$'22(%)"%6"A%::,8(1'"$'.'#&%$2"()"?":G7#B%.G&'2"

" " " A5;5%$." )6,+'5)" 4$;5" 58$*'(5+" 645" ):59'7'9" 58:%5))'-(" -7" '(+';'+,$." 3FM"

*5*B5%)" '(" +'775%5(6" @E95.." ),B)56)" '(" B-64"*-,)5" $(+" 4,*$(" 6')),5)k" 645)5" )6,+'5)"&5%5"*$'(.0"

$))5))5+"B0" %5$." 6'*5"URMV"$(+"4'/4.'/46" 645"9-(6%'B,6'-("-7" 645)5"3FM)" 6-"B-64"3E+5:5(+5(6"$(+" E

'(+5:5(+5(6" '**,(5" %5):-()5)1" J.64-,/4" @" 95.." +5;5.-:*5(6" $(+" ),%;';$." B-64" $::5$%"

:45(-60:'9$..0" ,(:5%6,%B5+" '(" 645" $B)5(95" -7" 3FM)" )'/($.)V" :$6'5(6)" &'64" $" +57'9'5(90" '(" $" 3FM"

)'/($.'(/"*-.59,.5"l"5'645%"*05.-'+"+'775%5(6'$6'-(":%'*$%0E%5):-()5":%-65'("PP"bH0+PPc"-%"DFE!EM"!"

$))-9'$65+" G'($)5" C" bDMJ_CcV" :-))5))" $(" $.65%5+" @RM" %5:5%6-'%5" &'64" $(" '(9%5$)5+" :%-:-%6'-(" -7"

$,6-%5$96';5"@"95..)"+,5"*-)6":%-B$B.0"6-"$.65%$6'-()"'("@"95..")5.596'-(":%-95))5)"b?!Qc1"#'775%5(6"@"

95.." ),B)56)" 584'B'6" ;$%'$6'-()" '(" 3FM" 58:%5))'-(" :$665%()" $(+" )'/($.'(/" /(-" 3FM)" 9$("*-+'70" @" 95.."

%5):-()5)" ),94" $)" $(6'B-+0" :%-+,96'-(V" $(6'/5(" :%5)5(6$6'-(" $(+" 906-G'(5" )59%56'-(1" 345%57-%5V"

'(+';'+,$." 3FM" 58:%5))'-(" :%-7'.5)" :5%*'6" ;$%'-,)" 577596-%" @" 95.." :-:,.$6'-()" 6-" 5.,9'+$65" ):59'7'9"

%5):-()5)"7-..-&'(/"3FM"5(/$/5*5(6"b?<2c1"A-9:'"T"-)0"Y"%5),*5"645".5;5."-7"58:%5))'-("-7"+'775%5(6"

3FM)"'("B-64"*-,)5"$(+"4,*$("),B)56)"%5):596';5.01"

"

Page 56: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

KC""

"

"""""""""""""""""""""""""""""""""""""H-,)5"@!"""""""""""""""""""H-,)5"Hf"""""""""""""""""""""""""""""H-,)5"L-..'9,.$%"

!"#$%! "! ""! """"!

!"#$&$ pp" ppp" pp"

!"#$'$ p" pp" p"

!"#$($ pp" ppp" ppp"

!"#$)$ p" p" p"

!"#$*$ p" p" p"

!"#$+$ pppp" pppp" pppp"

!"#$,$ p" p" p"

!"#$-$ pppp" ppp" pppp"

"

3$B.5"K^"3FM)"58:%5))'-(":$665%()"'("*-,)5"'(($65EF'G5"@"95..)"b@!"$(+"H$%/'($."I-(5"@"95..)c"$(+"

$+$:6';5"7-..'9,.$%"@"95..)"bp^"&5$G"pp^"$;5%$/5"ppp^")6%-(/"pppp^";5%0"4'/4.0"58:%5))5+1"

$ ./012$ 324567$ 890:;<2=$324567$

!"#$%$ bpc" bpc" bpc"

!"#$&$ bpc" bpc" bpc"

!"#$'$ bpc" bpc" bpc"

!"#$($ bpc" bpc" bpc"

!"#$)$ bpc" bpc" bpc"

!"#$*$ p" ppp" ppp"

!"#$+$ p" ppp" ppp"

!"#$,$ bpc" bpc" bpc"

!"#$-$ p" ppp" ppp"

!"#$%>$ p" ppp" ppp"

"

3$B.5"N^"R-*:$%')-("-7"3FM)"58:%5))'-("'("($q;5V"*5*-%0"$(+")&'6945+"*5*-%0"4,*$("@"95..)V"&'64"

bpc"*5$('(/"$B)5(6"-%"B$%5.0"+565965+V"p^"&5$G"$(+"ppp^")6%-(/"

"

J)"'(+'9$65+"'("&-9:'"YV"4,*$("@"95..)"58:%5))")5;5%$."3FM)"64$6")4-&"+'775%5(6":$665%()"'("($q;5"$(+"

*5*-%0"95..)1"=,*$("@"95..)"58:%5))";5%0" .-&" .5;5.)"-7"3FM!V"<"$(+"CV" 64,)" 6450" 7$'." 6-" %5):-(+"6-"

645'%"):59'7'9".'/$(+)1"3FMNV"OV"Q"$(+"!2"$%5"58:%5))5+"$6".-&".5;5.)"'("($q;5"@"95..)"$(+"$6"4'/4".5;5.)"

'("*5*-%0"95..)V"%$')'(/"645":-))'B'.'60"64$6"3FM"58:%5))'-("*$0"B5"+'775%5(6'$..0"%5/,.$65+"'("4,*$("

($q;5"$(+"*5*-%0"@"95..)1"D(+55+V"645"/%-,:"-7"F$(I$;5944'$")4-&5+"64$6"@RM"5(/$/5*5(6"%$:'+.0"

,:E%5/,.$65)" 645"58:%5))'-("-7" 3FMQ"$(+"!2" '("($q;5"4,*$("@" 95..)V" )-" 64$6"-(.0"($q;5"@" 95..)" 64$6"

4$;5" 9$:6,%5+" *'9%-B'$." $(6'/5()" &'.." B5" $96';$65+" '(" $" 3E'(+5:5(+5(6" %5):-()5V" &45%5$)" 645"

9-()6'6,6';5"4'/4"58:%5))'-("-7"645)5"3FM)"'("*5*-%0"@"95..)":%-;'+5)"$"*594$(')*"6-"9-(6'(,-,).0"

/5(5%$65"$(6'B-+'5)"-7"$.."*5*-%0"):59'7'9'6'5)V"64,)"),)6$'('(/"$")5%-.-/'9$."*5*-%0"b?<!c1"

Page 57: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

KK""

"

U]&$-.'::4:-$"A8N2"

A8N"5E"<"-)0"Y"

" " " " " 3-..EF'G5" %595:6-%" <" %59-/('I5)" .':-:%-65'()" ),94" $)"

*09-:.$)*$V" /%$*" (5/$6';5" B$965%'$" $(+" ):'%-94565)V" :5:6'+-/.09$()" $(+" .':-65'94-'9" $9'+" 7%-*"

/%$*E:-)'6';5" B$965%'$V" .':-$%$B'(-*$(($(" 7%-*" *09-B$965%'$V" I0*-)$(" 7%-*" 7,(/'V" :-%'()" 7%-*"

P'(22'$(-V":45(-.")-.,B.5"*-+,.'("7%-*"F&-#BG:%.%..42"U#(0'$7(0(2"$(+"45*$//.,6'('(":%-65'("7%-*"

*5$).5)" ;'%,)1" X(5" $):596" -7" 3FM<" .'/$(+" %59-/('6'-(" '(;-.;5)" 9--:5%$6'-(" &'64" -645%" 3FM" 7$*'.0"

*5*B5%)V" '(" :$%6'9,.$%" 3FMN" $(+" 3FM!V" &4'94" 9-(75%" +')9%'*'($6'-(" $*-(/" +'775%5(6" *'9%-B'$."

9-*:-(5(6)1" A:59'7'9$..0V" 3FM<E3FM!" 4565%-+'*5%" %59-/('I5)" 6%'$90.$65+" .':-:5:6'+5)" 7%-*" >%$*E

(5/$6';5" B$965%'$" $(+" *09-:.$)*$" &45%5$)" 645" 3FM<E3FMN" 4565%-+'*5%" %59-/('I5)" +'$90.$65+"

.':-:56'+5)" 7%-*" >%$*E:-)'6';5" B$965%'$" $(+" *09-:.$)*$1" H-%5-;5%V" 3FM<" 4$)" 645" $B'.'60" 6-" $96"

6-/5645%"&'64"-645%"9-%595:6-%)"-("645"95.."),%7$95"),94"$)"R#?N"b?<<c"$(+"#596'(ED"b?<?c"64$6"$))')6"

UJHU"%59-/('6'-(1"S(/$/5*5(6"-7"3FM<"'(+,95)"*$'(.0"645":%-+,96'-("-7"'(7.$**$6-%0"906-G'(5)"B0"

*$9%-:4$/5)V" +5(+%'6'9" 95..)" $(+" @" 95..)k" '6" 9$(" $.)-" 6%'//5%" 60:5ED" '(65%75%-(" B0" '(7.$**$6-%0"

*-(-9065)"'(75965+"&'64"Z$99'('$";'%,)"b?<Cc1"

A8NR"

" " " " " 3FMCV"645"7-,(+'(/"*5*B5%"-7"3FM)V"%59-/('I5)"645"B$965%'$."

.':-:-.0)$994$%'+5"bFUAcV"$"9-*:-(5(6"-7"645"-,65%"*5*B%$(5"-7"/%$*E(5/$6';5"B$965%'$"64$6"9$,)5)"

$")5:6'9")4-9G"b?<Kc1"3FMC"7-%*)"&'64"645"*05.-'+"+'775%5(6'$6'-("7$96-%"bH#E<c"$"9-*:.58"$6"645"95.."

),%7$95" )5%;'(/" $)" 645"*$'(" FUAEB'(+'(/" 9-*:-(5(61" J++'6'-($." :%-65'()" ),94" $)" F@U" bFUAEB'(+'(/"

:%-65'(cV"$" )-.,B.5":.$)*$":%-65'(" 64$6"B'(+)"FUAV"$(+"R#!C" b$"/.09-)0.":4-):4$6'+0.'(-)'6-.E.'(G5+V"

.5,9'(5E%'94"%5:5$6E9-(6$'('(/":%-65'("64$6"B'(+)"F@Uc"$%5"$.)-"'(;-.;5+"'("FUA"B'(+'(/1"F@U"%59-/('I5)"

$(+" B'(+)" FUA" 6-" 7-%*" 645" FUAEF@U" 9-*:.58V" &4'94" ')" +5.';5%5+" ;'$" R#!CV" 6-" 3FMCEH#<" 9-*:.58"

'('6'$6'(/" )'/($." 6%$()+,96'-(" B0" %59%,'6'(/" '(6%$95..,.$%" $+$:6-%" *-.59,.5)1" M5):-()5)" 6-" 3FMC" $%5"

$.)-" *-+,.$65+" B0" 3FMC" 4-*-.-/V" 645" MU!2K1" MU!2K" ')" $" 60:5" D" 6%$()*5*B%$(5" :%-65'(" &'64"

)6%,96,%$." )'*'.$%'6'5)" 6-" 3FM)V" 9-(6$'('(/" $(" 586%$95..,.$%" .5,9'(5" %'94E%5:5$6" +-*$'(1" MU!2K" &$)"

7'%)6.0"+5)9%'B5+"'("*-,)5"@"95..)V"$(+"'6)"58:%5))'-("')"%5/,.$65+"B0"H#E!"$(+"')"$))-9'$65+"&'64"@"95.."

$96';$6'-(1"Y:-("FUA")6'*,.$6'-(V"MU!2K"$))-9'$65)"&'64"3FMC"$(+"6%'//5%)")6%-(/"@"95..":%-.'75%$6'-("

$(+"4,*-%$."'**,(5"%5):-()5)"b?<Nc1"J("4-*-.-/,5"-7"MU!2K"&$)"$.)-"'+5(6'7'5+"'("4,*$("@"95..)"

b?<Oc1"W-6$B.0V"*,%'(5"+5(+%'6'9"95..)"$(+"*$9%-:4$/5)"$.)-"58:%5))"MU!2K"&4'94V" '("9-(6%$)6"6-"'6)"

)6'*,.$6-%0"577596" '("@"95..)V"(5/$6';5.0"%5/,.$65)"3FMC"%5):-()5)" b?<Pc1"3FMC" ')"$.)-" '(;-.;5+" '(" 645"

%59-/('6'-(" -7" :.$(6E+5%';5+" 906-)6$6'9" +%,/" :$9.'6$85.V" %5):'%$6-%0" )0(906'$." ;'%,)" 7,)'-(" :%-65'()V"

*-,)5"*$**$%0"6,*-%";'%,)"5(;5.-:5":%-65'()"$(+"F&$'#&%.%..42"D)'47%)(-'":(5,*-.0)'("b?<Kc1"

Page 58: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

KN""

"

A8NTE"A8N5=E"A8N55"

"" " " " " 3FMK" )5()5)" 645" 7.$/5..'(" :%-65'(" 9-*:-(5(6" -7" B$965%'$."

7.$/5..$1" D6" :.$0)" $" 9%'6'9$." %-.5" '(" $(6'EB$965%'$." '(7596'-()" $/$'()6" A$.*-(5..$" 60:4'*,%',*" -)0"

D2'40%7%)-2" -'$4+()%2-" b?<QV" ??2c1" 3FMK" ')" 4'/4.0" 58:%5))5+" -(" R#!!9" p"R#!!B

p".$*'($" :%-:%'$"

+5(+%'6'9"95..)":%5)5(6" '("645")*$.." '(65)6'(5V"&4'94"$%5"$B.5"6-":%-*-65"645"+'775%5(6'$6'-("-7" DFE!O"

:%-+,9'(/"45.:5%"3"95..)"b3="!O"95..)c"$(+"3"45.:5%"60:5"D"b3="!cV"$(+"'(+,95"($q;5"@"95.."+'775%5(6'$6'-("

'(6-" D/JE:%-+,9'(/" 95..)V" '(" %5):-()5" 6-" 7.$/5..'(" b??!c1"@.$++5%"$(+"G'+(50"4$;5"4'/4"58:%5))'-("-7"

*-,)5" 3FM!!V" $" %5.$6';5" -7" 3FMK1" 3FM!!" +57'9'5(6" *'95" $%5" ),)95:6'B.5" 6-" '(7596'-(" &'64"

,%-:$64-/5('9" B$965%'$." 9-*:-(5(6" .'G5" U2.B'$(.B(-" !%:(V" $(+" A%]%#:-27-" W%)0((^2" :%-7'.'(/E.'G5"

*-.59,.51" 3FM!2" ')" 589.,)';5.0" 58:%5))5+" B0" 4,*$(" @" 95..)" $(+" :.$)*$906-'+" +5(+%'6'9" 95..)" b??<c1"

3FM!2" ')" $" 4'/4.0" WE/.09-)0.$65+" :%-65'(" 64$6" 9$(" $))-9'$65" &'64" 3FM<" -%" 3FM!V" -%" 9-()6'6,65)" $("

4-*-+'*5%1" D6)"$/-(')6)"$%5"(-6"056"G(-&("+,5"6-"645"$B)5(95"-7"$" 7,(96'-($."4-*-.-/,5" '("*'95V"

B,6" )6'.." 645" )6,+0"-7" 94'*5%'9" %595:6-%)" '("&4'94" 645" '(6%$95..,.$%":$%6"-7"3FM!2"&$)" %5:.$95+"&'64"

64$6" -7" 3FM!" %5;5$.5+" 64$6" 3FM!2"*'/46" B5" $B.5" 6-" )5()5" 6%'$90.$65+" .':-:5:6'+5)" $(+" $" ;$%'560" -7"

-645%" *'9%-B'$.E+5%';5+" $/-(')6)" )4$%5+" B0" 3FM!" b???c1" D(65%5)6'(/.0V" 3FM!2" ')" 7-,(+" 58:%5))5+" $6"

/%5$65%" .5;5.)" '(" (-(" )&'6945+"*5*-%0" @" 95..)" 9-*:$%'(/" 6-" )&'6945+" @" 95..)" :%-:-)'(/" $" %-.5" 7-%"

3FM!2"'("645"+5;5.-:*5(6"-%T$(+"*$'(65($(95"-7"D/Hp""D/#

p"R#<O

p"@"95..)"'("4,*$()"b??Cc1""

X)&$-.'::4:-$"A8N2"

A8NM"

" " " " " 3-..EF'G5" %595:6-%" ?" %59-/('I5)" +-,B.5" )6%$(+5+" MWJ"

:%-+,95+"+,%'(/"645"9-,%)5"-7"%5:.'9$6'-("-7")'(/.5")6%$(+5+"MWJ"b))MWJc";'%,)5)"),94"$)"g5)6"W'5."

Z'%,)" bgWZcV" S(95:4$.-*0-9$%+'6')" Z'%,)" bSHRZc" $(+" M5):'%$6-%0" A0(906'$." Z'%,)" bMAZc1" D6" $.)-"

%59-/('I5)" /5(-*'9" MWJ" :,%'7'5+" 7%-*" +)MWJ" ;'%,)5)" ),94" $)" %5-;'%,)5)" $(+" ')" $B.5" 6-" +56596"

:-.0'(-)'('9E:-.0906'+0.'9" $9'+" bU-.0" DRcV" $" )0(6456'9" $($.-/,5" -7" +)MWJ" b??KV" ??NcV" $(+" 645" )*$.."

'(65%75%'(/"MWJ"'("$")5[,5(95"'(+5:5(+5(6"*$((5%".5$+'(/"6-V"%$645%"64$("$"),::%5))'-("-7"645"/5(5"

58:%5))'-(V"B,6"6-"$("'(4'B'6'-("-7"$(/'-/5(5)')"'("$"94-%-'+$."(5-;$)9,.$%')$6'-("*-,)5"*-+5."b??Oc1"

Y:-(".'/$(+"%59-/('6'-(V"3FM?"$96';$6'-("6%'//5%)"$(6'E;'%$."'**,(5"%5):-()5)"$(+"645":%-+,96'-("-7"

60:5" D" '(65%75%-(" $(+" :%-E'(7.$**$6-%0" 906-G'(5)1" 3FM?" +57'9'5(90" $.65%)" 645" '**,(5" %5):-()5"

$/$'()6" *,%'(5" 906-*5/$.-;'%,)" bHRHZc" '(" $" *-,)5" *-+5." $(+" $/$'()6" 645" 45%:5)" )'*:.58" ;'%,)"

b=AZcED" '(7596'-(" '(" 4,*$()" b??PV" ??Qc1" =-&5;5%V" '(" 645" 9$)5" -7" D(7.,5(I$" J" ;'%,)" $(+" 645" gWZ"

'(7596'-(V" 3FM?" *5+'$65)" :$64-/5(5)')" %$645%" 64$(" :%-6596'-(" b??NV" ?C2c1" 3-..E.'G5" %595:6-%" ?" ')"

58:%5))5+"B0"9-(;5(6'-($."+5(+%'6'9"95..)V"*$9%-:4$/5)V"W_"95..)"$(+"*-,)5"*$%/'($."I-(5"@"95..)k"'6"

')"+565965+"$.)-"'("(-(E'**,(5"95..)"),94"$)"7'B%-B.$)6)"$(+"5:'645.'$."95..)1"3FM?":.$0)"$("'*:-%6$(6"

%-.5" '(" 6%'//5%'(/" 9%-))E:%5)5(6$6'-(" -7" ;'%,)" '(75965+" 95..)" B0" R#P$p"95..)" &4'94" :-))5))" 4'/4"

Page 59: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

KO""

"

:4$/-906'9"$96';'60"$(+"-;5%58:%5))"3FM?k"64')":5%*'6)"645"9%-))E:%'*'(/"-7"R3F)"$/$'()6";'%,)5)"64$6"

+-"(-6"(-%*$..0"'(7596"+5(+%'6'9"95..)"b?C!c1"

3FM?"%5)'+5)" '(" 645"SMV"$(+" '6" ')",:-(")6'*,.$6'-("&'64" '6)"$::%-:%'$65" .'/$(+"64$6" '6" 6%$().-9$65)" 6-"

5(+-)-*$."9-*:$%6*5(6)" 7%-*"&45%5" '6" )'/($.)V" 64')" 6%$().-9$6'-(" ')"*5+'$65+"B0"YWRQ?@!V"$("SM"

%5)'+5(6" *-.59,.51" 3FM?" 9$(" $.)-" B5" 7-,(+" -(" 645" 95.." ),%7$95" $)" '6" ')" )4-&(" B0" 645" &-%G" -7"

H1H$6),*-6-" $(+" 9-..5$/,5)" b?C<c1" J" ;5%0" '(65%5)6'(/" 7'(+'(/" )4-&)" 645" '*:.'9$6'-(" -7" @%,6-(h)"

30%-)'(5"G'($)5" b@6Gc" '("+'%596"3FM?":4-):4-%0.$6'-(" '("*$9%-:4$/5)V" .5$+'(/"6-"645" '('6'$6'-("-7" '6)"

)'/($.'(/"$(+"645"$96';$6'-("-7"*,.6':.5")'/($.'(/":$64&$0)"64$6"9,.*'($65"'("645"$96';$6'-("-7"WLEv@V"

JUE!"$(+"DMLE?V"64%55"6%$()9%':6'-("7$96-%)"9%'6'9$."7-%"645":%-+,96'-("-7"906-G'(5)"$(+"'(65%75%-()1"X("

645" -645%" 4$(+V" +')%,:6'-(" -7" 3FM?" )'/($.'(/" ')" -B)5%;5+" ,:-(" '(7596'-(" &'64" 45:$6'6')" R" ;'%,)V"

S(65%-;'%,)" O!" ?R" -%" 45:$6'6')" J" ;'%,)" 64$6" 58:%5))" $(" WA?TCJ" )5%'(5" :%-65$)5V" :'9-%($;'%,)" R"

:%-65$)5"$(+"?R#":%-65$)5E:-.0*5%$)5":%59,%)-%"%5):596';5.0V"%5):-()'B.5"-7"3MDL"9.5$;$/5"&4'94"')"

645" $+$:6-%" *-.59,.5" 64$6" .'(G)" 3FM?" 6-" G'($)5)" %5):-()'B.5" -7" $96';$6'(/" DMLE?" $)" &5.." $)" WLEv@V"

&4'94" .'*'6)" 3FM?E*5+'$65+" $(6';'%$." %5):-()5)" b?C?E?CKc1" X(5" *-%5" )6,+0" 64$6" 4'/4.'/46)" 645"

%5/,.$6'-("-7"3FM?")'/($.'(/"&$)"+-(5"B0"645"#$.6-("/%-,:"&45%5"6450")4-&"$"+5/%$+$6'-("-7"645"3-.."

.'G5" %595:6-%"?"&'64'(" 645"5(+-)-*5)"B0"90)65'(5":%-65$)5)")59%565+",:-(" '(7596'-("&'64"45.*'(64"

:$64-/5()"L$)9'-.$"45:$6'9$"bL45RF!c"$(+")94')6-)-*$"*$()-('"bA*R@!cV"&4'94".5$+)"6-"$"B.-9G$/5"

-7" 3MDLE+5:5(+5(6" )'/($.'(/" :$64&$0" $(+" :%-;'+5)" $" (-;5." *594$(')*" $+-:65+" B0" =5.*'(64"

:$%$)'65)"6-"*-+,.$65"645"'(($65"%5):-()5)"-7"645'%"4-)6)"$(+"),::%5))"34!"%5):-()5)"b?CNc1"

@$%6-(h)"/%-,:"&$)"645"7'%)6"6-"+5)9%'B5"$":%-65-.0)')"-7"3FM?"'("MJg"95..)"%5),.6'(/"'("645"/5(5%$6'-("

-7" $(" WE65%*'($." $(+" RE65%*'($." 7%$/*5(6)" $(+" 64$6" 64')" :%-95))'(/" ')" (55+5+" 7-%" $(" -:6'*$."

%5):-()5" 6-" '6)" .'/$(+" :-.0" D^RV" /';'(/" 64$6" 645" R" 65%*'($." :%-+,96" 9-(6$'()" %5)'+,5)" '*:.'9$65+" '("

+'%596" '(65%$96'-(" B56&55(" 645" 6&-" 3FM?"*-.59,.5)"&'64'(" 645" +'*5%" $(+" " $%5" %5[,'%5+" 7-%" .'/$(+"

B'(+'(/" b?COV" ?CPc1" F$65%" -(V" 645" /%-,:" -7" U1" @5($%-94" '+5(6'7'5+" 9$645:)'()" @" $(+" =" $)" 645"*$'("

:.$05%)"'("3FM?":%-95))'(/"$(+"*$6,%$6'-("'("4,*$("5:'645.'$."95..)"b?CQcV"&45%5$)"-,%"/%-,:")4-&5+"

645" +,$." '(;-.;5*5(6" -7" 9$645:)'()" A" $(+" F" '(" /5(5%$6'(/" 645" 7,(96'-($." 9.5$;5+" 7-%*" -7" 3FM?"

%5[,'%5+"7-%"'6)"),B)5[,5(6")'/($.'(/"'("+5(+%'6'9"95..)"b,(:,B.')45+"+$6$c1"R-(6%$+'96-%0"%5),.6)"&5%5"

$.)-"%5:-%65+"9-(95%('(/"645"(595))'60"-7"3FM?"9.5$;$/5"7-%"5'645%")'/($.'(/"-%"7-%".'/$(+"%59-/('6'-(1"

D(+55+V" R45(/" _$-" /%-,:" %5:-%65+" 64$6" 3FM?" :%-65-.06'9" :%-95))'(/" ')" YWRQ?@!E*5+'$65+" $(+" ')"

%5[,'%5+" 7-%" '6)" )6$B'.'60V" 5(+-)-*$." .-9$.'I$6'-(" $(+" .'/$(+" %59-/('6'-(" B,6" (-6" (595))$%'.0" 7-%" '6)"

)'/($.'(/"5):59'$..0"'("4,*$("95.." .'(5)"b?K2c1"L'($..0V"$";5%0"%595(6")6,+0"+%';5("B0"F5B59[,5"/%-,:V"

)4-&)"64$6"645"9.5$;$/5"-99,%)"$6"645"FMM!<"64$6".'5)"B56&55("645"6&-"+)MWJ"B'(+'(/")'65)"%5[,'%5+"

7-%"3FM?"+'*5%'I$6'-("$(+")'/($.'(/k"-("645"-645%"4$(+V"64')"9.5$;$/5"+-5)"(-6"+'))-9'$65"645"RE"$(+"

WE65%*'($."7%$/*5(6)"B,6"'6"/5(5%$65)"$")6$B.5"i9.5$;5+T$))-9'$65+j"3FM?"%595:6-%"'("645"5(+-)-*5)"

Page 60: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

KP""

"

&4'94" 7$;-%)" 645"40:-645)')"-7" %5[,'%5*5(6" 7-%"3FM?"9.5$;$/5" 7-%" 7,.7'..'(/" '6)" 7,(96'-(" %$645%" 64$("

)5:$%$6'(/"645"6&-"7%$/*5(6)"6-"/5(5%$65"$"7,(96'-($."%595:6-%"b?K!c1"J.."645)5"7'(+'(/)"+5*-()6%$65"

64$6" 3FM?" )'/($.'(/" ')" ,(+5%" $" 9-*:.58" (56&-%G" -7" %5/,.$6'-(" 64$6" '(9.,+5)" :%-65'(" 6%$77'9G'(/" $(+"

9$645:)'("$96';'601"

A8N[VA8N>"

" " " " " 3-..EF'G5" %595:6-%" O" %59-/('I5)" /,$(-)'(5" %'94" $(+" ,%'+'(5"

%'94" )'(/.5" )6%$(+5+" MWJ" +5%';5+" 7%-*"=DZ" -%" D(7.,5(I$" ;'%,)V" )0(6456'9" :-.0,%'+'(5" ))MWJV" 95%6$'("

)'MWJ" $(+" *'9%-MWJ)1" 3FMO" 9$(" $.)-" +56596" '*'+$I-[,'(-.'(5" +5%';$6';5)" ),94" $)" '*'[,'*-+" $(+"

%5)'[,'*-+" bMEPCPc" $(+" /,$('(5" $($.-/,5)" ),94" $)" .-8'%'B'(5" &'94" 4$;5" $(6'E;'%$." $(+" $(6'E6,*-%"

:%-:5%6'5)1" 3FMO" ')" 58:%5))5+" B0"*$(0" '**,(5" 95..)" '(9.,+'(/"*-(-9065)"*05.-'+" +5(+%'6'9" 95..)V"

*$9%-:4$/5)V" W_" 95..)V" 3" 95..)V" @" 95..)" $(+" 5):59'$..0" B0" :.$)*$906-'+" +5(+%'6'9" 95..)" b:#R)c1" D("

4,*$()V"3FMO"')"$.*-)6"589.,)';5.0"58:%5))5+"B0"@"95..)"$(+":#R)"64$6"$%5",('[,5"'("645'%"9$:$9'60"6-"

%$:'+.0")59%565";$)6"$*-,(6)"-7"60:5"D"DLW)"'("%5):-()5"6-";'%$."'(7596'-("b?!Oc1"=,*$(":#R)"$%5"$B.5"

6-"+56596" 4,*$("3E95.." .5,G5*'$" ;'%,)" !" b=3FZE!c" $(+"+5(/,5" ;'%,)" b#SWZcV" $" )'(/.5E)6%$(+5+"MWJ"

64$6" B5.-(/)" 6-" /5(,)" L.$;';'%,)V" /(-" 3FMOV" %5),.6'(/" '(" %5.-9$.'I$6'-(" -7" 3WLE%5.$65+" $:-:6-)')E

'(+,9'(/".'/$(+"b3MJDF^"&4'94"'(+,95)"+5$64"-7"95..)"64$6"58:%5))"'6)"+5$64"%595:6-%)"b#MccV"6-"645"95.."

),%7$95"$(+"645":%-+,96'-("-7"DLWEu"&4'94"$..-&)"645"+59%5$)5"-7"645")5;5%'60"-7"645"+')5$)5)"b?K<V"

?K?c1" DLWEu" %5.5$)5+" B0" :#R)" ')" )4-&(" 6-" B5" '(;-.;5+" '(" 645" %5/,.$6'-(" -7" 4,*$(" ($q;5" @" 95..)"

%5):-()5)" 6-" 3FMO" B0" )5.596';5.0" ,:%5/,.$6'(/" 3FMO" 58:%5))'-(" '(" @" 95..)V" $(+" :%-*-6'(/" 645'%"

:-.09.-($." 58:$()'-(" $(+" +'775%5(6'$6'-(" 6-&$%+)" D/E:%-+,9'(/" :.$)*$" 95..)" b?KCc1"X(5"*-%5" )6,+0"

9-(7'%*5+"64')"-B)5%;$6'-("'("*,%'(5"@"95..)"B0")4-&'(/"64$6"+57'9'5(90"-7"60:5"D"DLW"%595:6-%"bDLWJMc"

4$)"$"+%$*$6'9"$(+")5.596';5"'*:$96"-("645"$B'.'60"-7"@"95..)"6-"7,..0"%5):-(+"6-"3FMO"5(/$/5*5(6"$(+"

%5),.6'(/"'("645".-))"-7"577596-%"7,(96'-()"),94"$)"906-G'(5":%-+,96'-("$(+"$(6'/5(":%5)5(6$6'-("64$6"

9-(6%'B,65V" '(" )-*5" 9$)5)V" 6-" B-64" 645" '('6'$6'-(" $(+" %59,%%5(95" -7" )0)65*'9" $,6-'**,(5"+')5$)5)"

b?KKc1" J(-645%" :.$05%" &$)" +')9-;5%5+" '(;-.;5+" '("*-+,.$6'(/" 3FMO" 58:%5))'-(" '(" @" 95..)V" 6-/5645%"

&'64"60:5"D"DLWV"ZDAJ1"ZDAJ"$.)-"G(-&("$)"DUAE!V"HJZAV"-%"R$%+'7V"')"$"*'6-94-(+%'$."6%$()*5*B%$(5"

:%-65'("5))5(6'$."7-%"MFM)"*5+'$65+"%5):-()5)"6-"906-)-.'9"MWJ"$(+"')"%5[,'%5+"7-%"3FMO"58:%5))'-("$)"

&5.."$)"R#<?"58:%5))'-("'("@"95..)"b?KNc1"=-&5;5%V"ZDAJ"+57'9'5(6"@"95..)"4$;5"(-%*$."60:5"D"DLW".5;5.)V"

),//5)6'(/"64$6"60:5"D"DLW")'/($.'(/"')"(-6"),77'9'5(6"7-%"@"95.."58:%5))'-("-7"3FMO"B,6"$")59-(+"'(6%'()'9"

)'/($."7%-*"ZDAJ"64%-,/4"MD>EDTH#JV"5'645%"B0"6-('9"-%"(-("*'9%-B'$."MWJ".'/$(+)V"')"$.)-"%5[,'%5+"7-%"

3FMO"58:%5))'-(":-))'B.0"B0"ZDAJ"*5+'$65+"$96';$6'-("-7"WLEv@1"J.." 645)5" 7'(+'(/)"$%5" '(65%5)6'(/" '("

645" 9-(6586" -7" 645" 9%'6'9$." %-.5" -7" 3FMO" 58:%5))'-(" '(" .,:,)E.'G5" $,6-'**,(5" +')5$)5" &45%5" -;5%"

58:%5))'-("-7"3FMO"')"-B)5%;5+"+,5"6-"$"+,:.'9$6'-("-7"645"3FMO"/5(5"%5),.6'(/"'("645"+5;5.-:*5(6"-7"

.,:,)"(5:4%'6')"$(+":%-+,96'-("-7"$,6-$(6'B-+'5)"$/$'()6"MWJE$))-9'$65+"(,9.5$%"$(6'/5("b?KOc1"345"

Page 61: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

KQ""

"

/%-,:"-7"@-..$(+"$.)-" '(;5)6'/$65+"645" .'(G"B56&55("3FMO"58:%5))'-("$(+")0)65*'9" .,:,)"+')5$)5"B0"

/5(5%$6'(/"$"6%$()/5('9"3FMO"*-,)5"*-+5."&'64" '(9%5$)5+"3FMO"$96';'60"$(+")4-&5+"64$6"5895))';5"

3FMO":%-*-65)"):-(6$(5-,)"/5%*'($."95(65%"$(+":.$)*$B.$)6"@"95.."+5;5.-:*5(6"$(+"645"/5(5%$6'-("

-7"$,6-$(6'B-+'5)"'("$"3"95.."+5:5(+5(6"*$((5%"b?KPc1"S(4$(95*5(6"-7"3FMO"58:%5))'-("9$("$.)-"B5"

*5+'$65+" /(-" DFE<PV" $" 60:5" DDD" DLW" %5.5$)5+" B0" W_" 95..)" ,:-(" 9-(6$96E*5+'$65+" '(65%$96'-()"&'64" @"

95..)k" 64')" '(9%5$)5+" 58:%5))'-(" $..-&)" @" .0*:4-9065)" 6-" %$:'+.0" %5):-(+" 6-" 3FMO" .'/$(+" $(+" *$0"

9-(6%'B,65"6-"645"%59-/('6'-("()"/(/%"6-"-645%"3FMO".'/$(+)V"),94"$)"$,6-$(6'/5()"b?KQc1"

3-..E.'G5"%595:6-%"O"5(/$/5*5(6"'("@"95..)"$.)-":%-;'+5)":%-6596';5"'**,(5"%5):-()5)k"D(+55+V"3FMO"

+57'9'5(6"*'95"7$'."6-"+5;5.-:"$":-65(6")5%,*"$(6'B-+0"%5):-()5"$765%"'(7596'-("&'64"$"%56%-;'%$.";'%,)V"

645" L%,'6" Z'%,)" bLZcV" $(+" 64')" 9-%%5.$65)" &'64" $" )'/('7'9$(6" %5+,96'-(" '(" 645" 7-%*$6'-(" -7" /5%*'($."

95(65%" @" 95..)" 64$6" %5/,.$65" $(6'B-+'5)" +5;5.-:*5(6" $/$'()6" ;'%$." '(7596'-(1" X645%" )6,+'5)" +-(5" B0"

+'775%5(6" /%-,:)" 9-(7'%*5+" $)" &5.." 64$6" @" 95..E'(6%'()'9" 3FMO" $96';$6'-(" 9-(6%-.)" /5%*'($." 95(65%"

%5):-()5)" 6-" ;'%,)5)"&'64" MWJ" /5(-*5)" b?N2E?N?c" B0" %5/,.$6'(/" 5'645%" 645" 58:%5))'-(" -7" $" )56" -7"

6%$()9%':6'-(" 7$96-%)" -%" /5(5)" 64$6" :%-*-65" 645" '('6'$6'-(" -7" /5%*'($." 95(65%" %5$96'-()" $(+"

'**,(-/.-B,.'(" 9.$))" )&'694'(/V" ),94" $)" J96';$6'-(" D(+,95+" #5$*'($)5" bJD#c" -%" B0" %5/,.$6'(/" 645"

58:%5))'-(" -7" 906-G'(5)" 64$6"*5+'$65" $,6-9%'(5" 577596)" -(" @" 95..)1" J" %5:5$65+" )6'*,.$6'-(" 64%-,/4"

3FMO" '(" B-64" 4,*$(" $(+" *-,)5" @" 95..)" '(+,95)" $" )6$65" -7" 40:-%5):-()';5(5))" 94$%$965%'I5+" B0"

%5+,95+"@"95..":%-.'75%$6'-(V"906-G'(5":%-+,96'-("$(+"D/H")59%56'-(1"345"40:-%5):-()';5(5))"6-"3FMO"

%5)6'*,.$6'-("')")4-&("6-"B5"$))-9'$65+"&'64"%5+,95+"WLEv@"$(+"HJU"G'($)5"$96';$6'-("$(+"+57596';5"

9Eo,(":4-):4-%0.$6'-(k"4-&5;5%V"3FMO"6-.5%$(95"')":%5;5(65+"B0"5(/$/'(/"645"@"95.."%595:6-%"-%"645"

60:5"D"DLW"%595:6-%"b?NCc1"3FMO")0(5%/'I5)"&'64"-645%"%595:6-%)"$(+"577596-%)"6-"/5(5%$65"$("-:6'*$."

@" 95.." $96';$6'-(" +,%'(/" 4,*-%$." '**,(5" %5):-()5)1" D(+55+V" 645" 9-E5(/$/5*5(6" -7" @RM" $(+" 3FMO"

%5),.6)" '("645"+59%5$)5"-7"645"64%5)4-.+"7-%"@"95.."$96';$6'-(V"$..-&'(/"%5):-()';5(5))"6-".-&"$77'('60"

3FMO".'/$(+)V"'("B-64"$,6-E%5$96';5"$(+"(-("$,6-E%5$96';5"@"95..)"b?NKV"?NNc1"3FMO"$.)-")0(5%/'I5)"&'64"

R#C2" %595:6-%" %5),.6'(/" '(" 645" +'775%5(6'$6'-(" -7" @" 95..)" '(6-" :.$)*$" 95..)" $(+" $(6'B-+0" :%-+,96'-("

b?NOc"$(+"'("5(4$(9'(/"645":%-+,96'-("-7"906-G'(5)"64%-,/4"'(9%5$)5+"9Eo,("_'($)5")'/($.'(/"$(+"JUE!"

$96';'60"b?NPc1""

F'G5" 3-..EF'G5" %595:6-%" ?" $(+" ,:-(" )6'*,.$6'-(V" 3FMO" 6%$77'9)" 7%-*" SM" 6-" 5(+-.0)-)-*5)" '(" $("

YWRQ?@!"+5:5(+5(6"*$((5%V"&45%5"'6"')"),Be5965+"6-":%-65-.0)')"%5),.6'(/"'("645"/5(5%$6'-("-7"$"RE

65%*'($." 3FMO" 7%$/*5(6"-7" N2_#$" 64$6" ')" 7,..0" 9-*:565(6" 7-%"$("-:6'*$." )'/($.'(/" '("*$9%-:4$/5)V"

+5(+%'6'9"95..)"$(+"5:'645.'$."95..)1"X,%"/%-,:")4-&5+"64$6"3FMO"9.5$;$/5"')"*5+'$65+"B0"J):$%$/'(5"

S(+-:5:6'+$)5"bJSUc"'("B-64"+5(+%'6'9"$(+"5:'645.'$."95..)k"$(+"64')"9.5$;$/5"-99,%)"B56&55("645"6&-"

.5,9'(5E%'94"%5/'-()"bFMM!CE!Kc"b+5)9%'B5+"6-"B5"$"),)95:6'B.5"6$%/56"7-%"JSU"9.5$;$/5"'("3FMQc"&4'94"

9-(6$'(" $(" $):$%$/'(5" %5)'+,5" $6" :-)'6'-(" COPV" $" :,6$6';5" 9.5$;$/5" )'65" 7-%" JSU1" H-%5-;5%V" JSUE

Page 62: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

N2""

"

+57'9'5(6" *'95" &5%5" ,($B.5" 6-" *-,(6" )6%-(/" $(6';'%$." '**,(5" %5):-()5)" &45(" 94$..5(/5+" &'64"

D(7.,5(I$";'%,)"%59-/('I5+"B0"3FMOV"4'/4.'/46'(/"645"9%'6'9$."%-.5"-7"JSU"'("3FMO":%-95))'(/V")'/($.'(/"

$(+"),B)5[,5(6" '(+,96'-("-7" '(7.$**$6'-("$(+"R#Pp"3"95.."$96';$6'-(" b?COV"?NQc1"=-&5;5%V"$(-645%"

'(65%5)6'(/" $(+" %595(6" )6,+0" )4-&)V" B0" 645" ,)5" -7" (5&.0" 5)6$B.')45+" *-(-9.-($." $(6'EW" 65%*'($."

3FMOV"64$6"9.5$;5+"WE65%*'($."3FMO"%5*$'()"'("645"5(+-.0)-)-*5)V",:-(".'/$(+"%59-/('6'-(V"B0"B5'(/"

9-;$.5(6.0" .'(G5+"&'64" $" +'),.7'+5EB-(+" 6-" 645" RE65%*'($." 7%$/*5(6k" 645" 90)65'(5)" %5[,'%5+" 7-%" 645"

'(6%$*-.59,.$%" +'),.7'+5" B-(+" $%5" R0)QP" '(" 3FMOW" $(+" R0)COK" '(" 3FMOR" $(+" $%5" '(+'):5()$B.5" 7-%"

:%-65-.06'9"9.5$;$/5"$(+"MWJ")5()'(/V"B,6"(-6"7-%"3FMO"6%$77'9"7%-*"645"SM"6-"645"5(+-)-*5)"b?O2c1"

X("645"-645%"4$(+V"'("@".0*:4-9065)V"(-")6,+'5)"&5%5"%5:-%65+"9-(95%('(/"645"%5[,'%5*5(6"-7"3FMO"

9.5$;$/5"7-%"$("-:6'*$.")'/($.'(/"(5'645%"645":%-65$)5)"'(;-.;5+"'("645":%-65-.0)')":%-95))1"

3FMP"')":40(-/5(56'9$..0"$(+")6%,96,%$..0"%5.$65+"6-"3FMOV"6450"$%5"B-64".-9$65+"'("9.-)5":%-8'*'60"-("

a:<<" 94%-*-)-*5" $(+" %59-/('I5" )'(/.5" )6%$(+5+" MWJ" ;'%,)5)" +5%';5+" 7%-*" =DZV" ZAZV" D(7.,5(I$" J"

;'%,)V"$(+")0(6456'9"'*'+$I-[,'(-.'(5"9-*:-,(+)".'G5"%5)'[,'*-+"bMPCPc"b?O!c1"3FMP"')"58:%5))5+"'("

;$%'-,)" 6')),5)V" '(" *-(-9065)" $(+" *$9%-:4$/5)V" $)" &5.." $)" '(" *05.-'+" +5(+%'6'9" 95..)" $(+" ')"

,:%5/,.$65+",:-("B$965%'$." '(7596'-(1"Y(6'."%595(6.0V"3FMP"&$)"-(5"-7"645".5))")6,+'5+"3FM)"$(+"&$)"

%5:-%65+" 6-" B5" (-(" 7,(96'-($." '("*'95V" /';'(/" 64$6" 3FMP" +57'9'5(6"*'95"&5%5" $B.5" 6-" %5):-(+" 6-" $"

(-%*$." 5865(6" 6-" *$(0" ))MWJ" ;'%,)5)1" H-%5-;5%V" *,%'(5" B,6" (-6" 4,*$(" 3FMP" ')" )4-&(" 6-" B5"

,(%5):-()';5" 6-" '*'+$I-[,'(-.'(5)" bMPCPc" '(" 645" $B)5(95" -7" :-.03E-.'/-+5-80(,9.5-6'+5)" b:-.03E

X#Wc" *-)6" :%-B$B.0" +,5" 6-" $" .$9G" -7" $" 7';5" $*'(-" $9'+" *-6'7" '(" 645" ,(+57'(5+" %5/'-(" -7" 3FMP"

596-+-*$'(V" ),//5)6'(/" 64$6" 64')" %5/'-(" ')" %5[,'%5+" 7-%" ):59'5)" .'/$(+" %59-/('6'-("+'*5%'I$6'-("$(+"

'(6%$95..,.$%".-9$.'I$6'-("-7"645"%595:6-%"b?O<c1"=-&5;5%V"$"%595(6"%5:-%6":%-;'+5+"5;'+5(95"64$6"3FMP"

9$("B5"$96';$65+"B0":#R)",:-("Z$99'('$";'%,)"'(7596'-(V"$("JT3"%'94"#WJ";'%,)"b?O?ck"H-%5-;5%V"3FMP"

'*:-%6$(95"&$)" ,(+5%.'(5+" '(" 645" (5%;-,)" )0)65*" B0" (5/$6';5.0" %5/,.$6'(/" 645" (5,%'65" -,6/%-&64"

$(+"'(+,9'(/"(5,%-($."$:-:6-)')"b?OCc1"3FMP"')"$.)-")4-&("6-"B5"'(;-.;5+"'(":%5;5(6'(/"):-(6$(5-,)"

$,6-'**,('60"'("*'95"B0"9-(6%-..'(/"3FMO"58:%5))'-("b?OKc1"

A8NL"

" " " " " 3FMQ" %59-/('I5" ,(*5640.$65+" <hE+5-80%'B-906'+'(5E

:4-):4$65E/,$(-)'(5" bR:>c" #WJ" *-6'7)" 64$6" $%5" 7%5[,5(6.0" :%5)5(6" '(" B$965%'$" B,6" $%5" %$%5" '("

;5%65B%$65)1"R:>"-.'/-(,9.5-6'+5)"&5%5"%595(6.0"+5*-()6%$65+"6-"B5"$.)-"%59-/('I5+"B0"*,.6'E.596'("

%595:6-%"#SRE<2K"b?ONc1"@5)'+5)"B$965%'$."#WJ"%59-/('6'-(V"3FMQ"+56596)"#WJ";'%,)5)"),94"$)"*-,)5"

906-*5/$.-;'%,)"HRHEZV"=5%:5)")'*:.58";'%,)5)"!"$(+"<"b=AZE!"$(+"=AZE<c"b?OOE?OQc"$(+"/5(-*'9"

)'/($6,%5)" 7%-*":%-6-I-$" .'G5"A$G#-)%2%7'"!$4@(" JM>=Kk" '("$++'6'-("6-"#WJV"=5*-I-'(" b=Ic"+5%';5+"

7%-*" D:-27%0(47" 3-:.(#-$47" $(+"*$.$%'$" :$%$)'65" D:-27%0(47" G%':((" $%5" $B.5" 6-" 6$%/56" 3FMQ" $(+"

$96';$65"645":%-+,96'-("-7"'(7.$**$6-%0"906-G'(5)"$(+"945*-G'(5)"b?P!c1"J)"$.%5$+0"'*:.'5+"B57-%5V"

Page 63: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

N!""

"

R:>"-.'/-+5-80(,9.5-6'+5)"$96';$65"3FMQ"B,6")6'.."6%'//5%"+'775%5(6")'/($.'(/":$64&$0)"B$)5+"-("645'%"

B'-.-/'9$.":%-:5%6'5)V"9.$))'70'(/"645*"'("64%55"9$65/-%'5)^"30:5"J"X#W)"$%5"+5)9%'B5+"6-"B5":-65(6"'("

'(+,9'(/" 60:5" D" DLW)"$(+"4$;5" .-&"$B'.'60" '(" '(+,9'(/"@" 95.." $96';$6'-("$(+" DFE!<":%-+,96'-(V" 60:5"@"

X#W)"+%';5"@"95.."$96';$6'-("$(+"DFE!<")59%56'-("$(+"60:5"R"X#W)"4$;5"75$6,%5)"-7"B-64"9.$))5)"J"$(+"

@V" $(+" 64,)" '(+,95"B-64" 60:5" D" DLW" $(+":%-E'(7.$**$6-%0" 906-G'(5)" )59%56'-(1" 30:5"J" $(+"@"X#W)"

:-))5))")6%,96,%$."+'775%5(95)"64$6"$..-&"64')"):$6'$."+';5%/5(95"'("3FMQ")'/($.'(/"7$651"D(+55+V"R:>J"

4$;5"$":$.'(+%-*'9")6%,96,%5"9-()')6'(/"-7"$":4-):4-+'5)65%"B$9GB-(5"$6"645"95(65%"-7"645")5[,5(95"

$(+":-.0E>"*-6'7)"&'64"$":4-):4-%-64'-$65"B$9GB-(5"$6"5$94"5(+V"&4'94",(+5%"95%6$'(":40)'-.-/'9$."

9-(+'6'-()V"9$(" 7-%*"*,.6'*5%)"/(-" )5.7"$))5*B.0"B5.'5;5+"9%,9'$." 7-%"4'/4" '(65%75%-("u" '(+,96'-(" '("

:#R)" b?P<ck" &45%5$)" 9.$))" @" R:>" X#W)" 4$;5" $" .'(5$%" )6%,96,%5" 9-()')6'(/" 5(6'%5.0" -7" $"

:4-):4-%-64'-$65"B$9GB-(5"$(+"64,)".$9G"645":-65(6'$."6-"7-%*"),94"4'/4"*,.6'*5%)V"7$;-%'(/"645'%"

%$:'+"6$%/56'(/"6-"645"5(+-.0)-)-*5)"7%-*"&45%5"6450"6%'//5%":%-'(7.$**$6-%0"906-G'(5")59%56'-(1"

D(65%5)6'(/.0V" 60:5" D" DLW" :%-+,96'-(" 4$)" B55("-B)5%;5+"&45(" 9.$))" @" R:>"X#W)"&5%5" .-$+5+"-(6-"

:-.0)60%5(5"($(-:$%6'9.5)V"),//5)6'(/"64$6"($(-:$%6'9.5)":.$0"$"%-.5"'("B-64"R:>"X#W"+5.';5%0"$(+"'("

9-(6%-..'(/"'6)"$96';'60"$(+"645"-,69-*5"-7"645"'**,(5"%5):-()5"b?P?c1"J++'6'-($..0V"-(5"*-%5"7$96-%"

64$6" ')" '*:.'9$65+" '(" 645"%5/,.$6'-("-7"3FMQE*5+'$65+")'/($."B'7,%9$6'-(" ')"$" 60%-)'(5EB$)5+"*-6'7"$6"

645" 906-:.$)*'9" 6$'." -7" 3FMQ"&4'94" :%-*-65)" :%-E'(7.$**$6-%0" 906-G'(5" )59%56'-(" -;5%" 60:5" D" DLW"

'(+,96'-(" ,:-(" R:>E#WJ" )6'*,.$6'-(1" 3FMQ" /$'()" $995))" 6-" 645)5" #WJ)" B0" 6%$77'9G'(/" 7%-*" 645" SM"

64%-,/4"645">-./'V"'("$("YWRQ?@E!"+5:5(+5(6"*$((5%1"M595(6"+$6$"'*:.'9$65"645"$+$:6-%":%-65'("?"

bJU?c" '("645"%5/,.$6'-("-7"3FMQ"6%$77'9" 7%-*"645"5(+-)-*5)"6-"645" .0)-)-*5)"&45%5" DLW":%-+,96'-("

-99,%)k"B,6"&45645%"JU?"')")5.596';5.0"'*:.'9$65+"7-%"DLW"-%"')"$.)-"%5[,'%5+"7-%"3WL":%-+,96'-("')")6'.."

9-(6%-;5%)'$."b?PCV"?PKc1"

D(" 4,*$(" ($q;5" @" .0*:4-9065)V" 645" *$'(" %5/,.$6-%" -7" 3FMQ" 58:%5))'-(" ')" 645" @RM" /';5(" 64$6"

:%-.'75%$6'-(" $(+" +'775%5(6'$6'-(" 6-" '**,(-/.-B,.'(E)59%56'(/" 95..)" '(" %5):-()5" 6-" R:>" -(.0" -99,%"

&45(")'*,.6$(5-,).0"6%'//5%5+"64%-,/4"645"@RM"b?<!c1"D("64')":%-95))V"):.55("60%-)'(5"G'($)5"b)0GcV"$"

G50"%5/,.$6-%"'("7,%645%":%-:$/$6'-("-7"645"@RM")'/($.'(/":$64&$0V"$(+"#XR_PV"-%'/'($..0"'(;-.;5+"'("

95.." *'/%$6'-(V" *-%:4-.-/0V" $+45)'-(" $(+" /%-&64V" $%5" +5)9%'B5+" 6-" B5" 9%,9'$." 7-%" 3FMQEH0+PP"

)'/($.'(/":$64&$0" '("@" 95..)k" D(65%5)6'(/.0V",:-("3FMQ" .'/$6'-(V"#XR_P" 64$6"$))-9'$65)" 9-()6'6,6';5.0"

&'64" 645" $+$:6-%"*-.59,.5"H0+PPV" B59-*5)" 60%-)'(5" :4-):4-%0.$65+" B0" :0G<V" 645(" B'(+)" 645" A%9"

7$*'.0"G'($)5"F0(V"$(+"64,)"$..-&)"645".'(G$/5"B56&55("3FMQ"$(+"A%9EG'($)5"A0GE6%$()9%':6'-("7$96-%"

A3J3?" 9$)9$+5" 5))5(6'$." 7-%" 3FMQ" +%';5(" @" 95.." :%-.'75%$6'-(" $(+" +'775%5(6'$6'-(" b?PNc1" J(" ,:E

%5/,.$6'-("-7"3FMQ"58:%5))'-("')"$.)-"-B)5%;5+",:-("5)6%-/5(")6'*,.$6'-("G(-&("6-"B5"'(;-.;5+"'("645"

/5(+5%"B'$)"'("AFS"+')5$)5V"%5),.6'(/"'(",:"%5/,.$6'-("-7"3FMQE*5+'$65+"@"95.."%5):-()5)"b?POc1""

Page 64: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

N<""

"

"345"+5.';5%0"-7"#WJE9-(6$'('(/"'**,(5"9-*:.585)"6-"645"5(+-)-*5)"&45%5"3FMQ"%5)'+5"'("@"95..)"')"

*5+'$65+" B0" +'775%5(6" :.$05%)1" L'%)6V" @" R5.." M595:6-%" 5(/$/5*5(6" ')" )4-&(" 6-" *-B'.'I5" 3FMQE

9-(6$'('(/" 5(+-)-*5)" &'64'(" $,6-:4$/-)-*5)" &4'94" ),B)5[,5(6.0" 7,)5" &'64" '(65%($.'I5+" @RME

$(6'/5("9-(6$'('(/";5)'9.5)V"'("&4'94"645%5"')")6$B.5")$*:.'(/"-7"$(6'/5("$(+":%5),*$B.0"$96';$6'-("-7"

3FMQ" '7" ,(*5640.$65+" #WJ" ')" :%5)5(6" '(" 645" $(6'/5(" 9$%/-" -7" 645" @RMV" %5),.6'(/" '(" $" )0(5%/')*"

B56&55("B-64"%595:6-%)"3FMQ"$(+"@RM"$(+"$("-:6'*$."@"95..":%-.'75%$6'-("$(+"$(6'/5("):59'7'9":.$)*$"

95.."7-%*$6'-("b?PPE?Q2c1"J(-645%"$96';5":.$05%"'("*5+'$6'(/"#WJ"+5.';5%0"6-"3FMQ"')"645"4'/4E*-B'.'60"

/%-,:"B-8!"=H>@!V"$"4'/4.0"$B,(+$(6"94%-*$6'("B'(+'(/":%-65'(".-9$65+"*$'(.0"'("645"95.."(,9.5,)"

&4'94"B'(+)"6-"645"*'(-%"/%--;5"-7"#WJV"$(+"')")4-&("6-"B5"%5.5$)5+"B0"#R)",:-("R:>")6'*,.$6'-("

-%" ,:-(" 6')),5" '(e,%01" =H@>!" B'(+)" 6-" #WJE9-(6$'('(/" '**,(5" 9-*:.585)" $(+" :5%*'6" 645"

$))-9'$6'-("-7"MJ>SV"$("'**,(-/.-B,.'("i),:5%7$*'.0j"*5*B5%V"&'64"3FMQ"%5),.6'(/"'("$,6-%5$96';5"

@"95.."$96';$6'-("$(+"645"9-(6%'B,6'-("6-"'**,(5"+0)%5/,.$6'-("+')-%+5%)"),94"$)"AFS"b?Q!c1"=H>@!"

9$(" $.)-" :%-*-65" @" 95.." %5):-()5)" 6-" 5(+-/5(-,)" 3FMQ" .'/$(+)" 64%-,/4" $" MJ>S" '(+5:5(+5(6"

*594$(')*"b?Q<c1"345"9.,)65%"-7"+'775%5(6'$6'-("R#!CV"$"*5*B%$(5"$))-9'$65+":%-65'(V" ')"+5)9%'B5+"

$)" &5.." 6-" 7,(96'-(" $)" $" +5.';5%0" %595:6-%" -7" ;$%'-,)" .'/$(+)" 6-" 3FM?V" CV" O" $(+" QV" '(9.,+'(/" FUAV"

.':-65'94-'9"$9'+V"95%$*'+5V"+)MWJV"))MWJ"$(+"#WJ"b?Q?c1"D("645"9-**-("$,6-'**,(5")G'("+')5$)5V"

:)-%'$)')V")59%565+"$(6'*'9%-B'$.":5:6'+5"FF?O"')"'*:.'9$65+"'("#WJ"+5.';5%0"6-"'6)"6-..".'G5"%595:6-%"Q"V"

B0" B'(+'(/" )5.7" #WJ" 6-" 7-%*" 9-(+5()5+" )6%,96,%5)" :-65(6" 7-%" 3FMQE6%'//5%5+" '(65%75%-(" 60:5" D"

:%-+,96'-("'(":#R)"b?QCc1""

J6"645")65$+0")6$65V"3FMQ"58')6)"'("645"'($96';5"7-%*"-7"4-*-E+'*5%)1"Y:-("%59-/('6'-("-7"'6)".'/$(+V"

3FMQ" ,(+5%/-5)" $" 9-()'+5%$B.5" 9-(7-%*$6'-($." 94$(/5" 64$6" B%'(/)" 645" 906-:.$)*'9" 3DM" +-*$'()" '("

9.-)5":%-8'*'60"%5),.6'(/"'("645"B'(+'(/"-7"H0+PP"&'64"645"3DM"+-*$'()"$(+"645"'('6'$6'-("-7")'/($.'(/"

b?QKc1" D(65%5)6'(/.0V" -:6'*$." 3FMQER:>E#WJ" '(65%$96'-(" ()" /(&$%" )55*)" 6-" %5[,'%5" $(" $9'+'9"

5(;'%-(*5(6" ),//5)6'(/" $" 9%'6'9$." %-.5" 7-%" $9'+'9" 5(+-.0)-)-*5)" '(" 3FMQ" $96';$6'-(" b?QNc1" D(+55+V"

.0)-*-6%-:'9"$/5(6)"),94"$)"9-(9$($*09'("@"-%"94.-%-[,'(5V"64$6"B.-9G"$9'+'7'9$6'-("-7" '(6%$95..,.$%"

9-*:$%6*5(6)V" +')%,:6" 3FMQ" )'/($.'(/" '(" *$9%-:4$/5)" $(+" +5(+%'6'9" 95..)V" 4'/4.'/46'(/" $" %-.5" -7"

5(+-.0)-)-*$.":%-65$)5)"'("3FMQ"$96';$6'-("$(+")'/($.'(/1"D(65%5)6'(/.0V"645"/%-,:)"-7">H"@$%6-("$(+"

=" U.-5/4" +5)9%'B5+" $" 9.5$;$/5" -7" 7,.." .5(/64" 3FMQ" '(6-" $(" WE65%*'($." 7%$/*5(6" B5.'5;5+" 6-" B5"

'*:.'9$65+" '(" #WJ" )5()'(/" b?QOc" $(+" $" 7,(96'-($." RE65%*'($." 7%$/*5(6" 64$6" %59%,'6)" 645" $+$:6-%"

*-.59,.5"H0+PP" $(+" ')" ),77'9'5(6" 7-%" )'/($.'(/" b?QPV" ?QQc1"H$(0" 9$645:)'()" b*$'(.0" F" $(+" Ac"&5%5"

)4-&("6-"B5"'(;-.;5+"'("3FMQ"9.5$;$/5"'("*$9%-:4$/5"95..".'(5)"bC22ck"&45%5$)V"'(":%'*$%0"+5(+%'6'9"

95..)V"9$645:)'("_"$(+"J):$%$/'(5"S(+-:5:6'+$)5"&5%5")4-&("9%'6'9$."7-%"64')":%-95))'(/"bC2!V"C2<c1"J"

%595(6" &-%G" +-(5" '(" :%'*$%0" JUR)" -7" 6%$()/5('9" 3FMQE>LU" *'95V" )4-&)" 64$6" 645" G'(56'9)" -7" 3FMQ"

:%-95))'(/" +'775%" B56&55("*$9%-:4$/5)" $(+" @" 95..)k" 3FMQ" :%-65-.0)')" -99,%)" $6" $" 7$)65%" %$65" '(" @"

Page 65: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

N?""

"

.0*:4-9065)" 9-()')6'(/" &'64" '6)" 589.,)';5" .-9$.'I$6'-(" '(" 5(+-.0)-)-*5)" $6" 645" )65$+0" )6$65k"

*-%5-;5%V" 3FMQ" 9.5$;$/5" '(" @" 95..)" )55*)" 6-" B5"*5+'$65+" B0" 9$645:)'(" F" $(+" 9-%%5.$65)"&'64" 645"

58:%5))'-(" .5;5." -7" YWRQ?@!1" 34,)V" 3FMQ" %5[,'%5*5(6" 7-%" :%-65-.0)')" )55*)" 6-" B5" ,(';5%)$.V"

4-&5;5%V" 9$645:)'(" '+5(6'60V" 645" %$65" -7" 9.5$;$/5" $(+" 645" '(6%$95..,.$%" B54$;'-%" -7" 3FMQ" +'775%"

B56&55(":%'*$%0"JUR)"bC2?c1"

3FMQ")'/($.'(/"'("@"95..)"')"$))-9'$65+"&'64"+'775%5(6"'**,(5"7,(96'-()"),94"$)"$(6'/5(":%5)5(6$6'-(V"

$(6'B-+0":%-+,96'-(V"')-60:5"9.$))")&'694'(/V"906-G'(5")59%56'-("$(+"*-%51"D6"')"&5.."5)6$B.')45+"64$6"

3FMQ" $96';$6'-(" '(+,95)" 645" 58:%5))'-(" -7" *5*B%$(5EB-,(+" @" 95.." $96';$6'(/" 7$96-%" @JLLV" -(" 645"

),%7$95"-7"4,*$("@"95..)V".5$+'(/"6-"$("5(4$(95*5(6"'("@"95..":%-.'75%$6'-("bC2Cc1"

A8N2"2(+)-:()+"-)0"&$-66(.1()+""

1" " " Y:-(" .'/$(+" %59-/('6'-(V" 3FM)" $96';$65" +'775%5(6" +-&()6%5$*" )'/($.'(/"

:$64&$0)" B0" %59%,'6'(/" +'775%5(6" $+$:6-%" :%-65'()" ),94" $)" H0+PPV" H$." bH0+PPE$+$:6-%" .'G5c" $.)-"

G(-&(" $)" 3DMJUV" 3MDL" $(+" 3MJH" b3MDLEM5.$65+" J+$:6-%" H-.59,.5cV" 64%-,/4" ):59'7'9" 3DME3DM"

'(65%$96'-()"J3(+4$'"5[K;"S895:6"7-%"3FM?V"*-)6"3FM)"%59%,'6"H0+PP"$(+"'('6'$65"$"H0+PPE+5:5(+5(6"

)'/($.'(/":$64&$01"3FM<"$(+"3FMC")'/($.'(/V"'("$++'6'-(V"%5[,'%5)"645"9--:5%$6'-("-7"645"$+$:6-%"H$."

7$9'.'6$6'(/" 645" '(65%$96'-(" B56&55(" H0+PP" $(+" $96';$65+" 3FM)" %5),.6'(/" '(" )'/($." 6%$()+,96'-(1"

S(/$/5*5(6"-7"H0+PP"$96';$65)" DFE!M!E$))-9'$65+":%-65'(" G'($)5)" bDMJ_)cV" $..-&'(/" 645" '(65%$96'-("

&'64"6,*-%"(59%-)')"7$96-%"%595:6-%E$))-9'$65+"7$96-%"N"b3MJLNc1"3MJLN"')"$("S?",B'[,'6'(".'/$)5"64$6"

9$6$.0)5)" 645" :4-):4-%0.$6'-(" -7" Dv@" G'($)5" bD__cE\" $(+" HJU" G'($)5)" bHJU_)c1" bD__cE" \" G'($)5"

$96';$65)"645"9-*:.58"7-%*5+"B0"D__EuV"D__E\"$(+"WSHX"bWLEv@"5))5(6'$."*-+,.$6-%c".5$+'(/"6-"645"

+5/%$+$6'-(" -7" Dv@V" WLEv@" 6%$().-9$6'-(" 6-" 645" (,9.5,)V" $(+" '(+,96'-(" -7" 6%$()9%':6'-(" -7" 6$%/565+"

/5(5)k")'*,.6$(5-,).0V"HJU_)"$96';$6'-("')"9%'6'9$."7-%"$96';$6'-("-7"JUE!"$(+"64,)"645":%-+,96'-("-7"

'(7.$**$6-%0"906-G'(5)1"

Page 66: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

NC""

"

"

L'/,%5"!O^"H$**$.'$("3FM")'/($.'(/":$64&$0V"-0-#&'0"6$%7"_^P'(::"'&"-:;E"<=5M"

3FM?" $(+" 5(+-906-)5+" 3FMC" $96';$65" 3MDLE+5:5(+5(6" )'/($.'(/" bH0+PPE'(+5:5(+5(6c1" 3MDL"

'(65%$96'-(" &'64" 3FMC" %5[,'%5)" 645" $+$:6-%" 3MJH" $(+" 645(" $765%" 3MDL" %59%,'6)" 3MJLN" -%" MDU!" 6-"

$96';$65" WLEv@" )'*'.$%" 6-" 645" H0+PP" +5:5(+5(6" :$64&$01" 3MDL" 9$(" $.)-" %59%,'6" $(-645%" )'/($.'(/"

9-*:.58" 9-*:-)5+" -7" 3MJL?T3@_!TD__ED" .5$+'(/" 6-" 645" :4-):4-%0.$6'-(" -7" '(65%75%-(E%5/,.$6-%0"

7$96-%"?"bDML?cV"64,)"'(+,9'(/"645"58:%5))'-("-7"60:5"D"DLW"/5(5)"bC2Kc1"3&-"*-%5"6%$()9%':6'-("7$96-%)"

$%5" $96';$65+"+-&()6%5$*"-7" 3FM" )'/($.'(/" ),94" $)" 909.'9" JHUE%5):-()';5" 5.5*5(6" B'(+'(/" :%-65'("

RMS@"$(+"$96';$6-%":%-65'("JU!1"3-"(-65V"3FMC"%5:%5)5(6)"645"58$*:.5"-7"4-&"9-*:$%6*5(6$.'I$6'-("

-7"645"%595:6-%"9$("6%'//5%"+')6'(96")'/($.'(/":$64&$0)"bC2NV"C2Oc"$(+"&$)")4-&("6-"4$;5"645"*-)6"

9-*:.58" )'/($.'(/" $%%$(/5*5(6" -7" $.." 645" 3FM)1" D(+55+V" ,:-(" FUA" %59-/('6'-(V" 95.." ),%7$95" 3FMC"

$96';$65)" H0+PP" +5:5(+5(6" )'/($.'(/" :$64&$0" $(+" :%-E'(7.$**$6-%0" 906-G'(5" )59%56'-(k"

A,B)5[,5(6.0V"3FMC"')" '(65%($.'I5+"&'64'("5(+-)-*5)"'("$"+0($*'("$(+"9.$64%'(E+5:5(+5(6"*$((5%V"

7$;-%'(/" 3MJHE3MDL" 9-*:.58" %59%,'6*5(6" $(+" 60:5" D" DLW" :%-+,96'-(1" 3&-" (5&.0" +5)9%'B5+" 3DM"

$+$:6-%"*-.59,.5)" &5%5" '+5(6'7'5+" 6-" %5/,.$65" 3MDL" )'/($.'(/^" !c" 645" )65%'.5" u" $(+" $%*$+'..-E*-6'7"

Page 67: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

NK""

"

9-(6$'('(/":%-65'("AJMH!"64$6"')")4-&("6-"(5/$6';5.0"%5/,.$65"3MDLE+5:5(+5(6")'/($.'(/"'("4,*$()"

bC2PcV"$(+"')"%595(6.0")4-&("6-"9-(6%-."$8-($."+5/5(5%$6'-("'("B-64"*'95"$(+"7.'5)"bC2Qck"<c"645"@"95.."

$+$:6-%"7-%"UD?_"G(-&("$)"@RJU"-%"UD?_JU!":%-+,95+"B0"@"95..)V" '6":-))5))5)"$"3DM"%5.$65+"+-*$'(""

),//5)6'(/"'6)"'(;-.;5*5(6"'("*-+,.$6'(/"@"95.."$96';$6'-("B0"6-..".'G5"%595:6-%)1"D(+55+V"5$%.0"'(")'/($."

6%$()+,96'-(V"@RJU"*$0"5(/$/5"H0+PP";'$" '6)"3DM"+-*$'("$(+":-65(6'$..0"%5+,95"645"$;$'.$B'.'60"-7"

H0+PP"7-%"$96';$6'-("-7"WLEv@"645%5B0"$77596'(/"645"-,69-*5"-7"3FM")'/($.'(/k"@RJU"9$("$.)-"*5+'$65"

$96';$6'-("-7"UD?_TJG6":$64&$0"+-&()6%5$*"-7"3FM)"%5),.6'(/"'("645".'*'6$6'-("-7"906-G'(5")59%56'-("

$(+"'(7.$**$6'-("bC!2V"C!!c1"@5)'+5)"WLEv@"%5/,.$6'-(V"UD?_"')"+5)9%'B5+"6-"B5"5))5(6'$."'("*5+'$6'(/"

DMLEO"(,9.5$%"6%$().-9$6'-("$(+"60:5"D"DLW")59%56'-("'("4,*$(":#R)1""

345"6%$77'9"-7"6-..".'G5"%595:6-%)"')"*5+'$65+"B0"+'775%5(6"94$:5%-(5"*-.59,.5)1"3&-"),94":%-65'()"$%5"

/:QN"$(+"UMJ3C1">:QN"-%">MUQC"b>.,9-)5"%5/,.$65+":%-65'("-7"QC_#$c"')"$("SM":$%$.-/"-7"645"45$6"

)4-9G" :%-65'(" $(+" +5)9%'B5+" 6-" 94$:5%-(5" *,.6':.5" :%-65'(" ),B)6%$65)" '(9.,+'(/" 95.." ),%7$95" $(+"

'(6%$95..,.$%" 3FM)" b3FM<V" CV" KV" O" $(+" Qc1"H-%5-;5%V" 645)5" 3FM)" $%5" 7,(96'-($..0" +5:5(+5(6" -(" /:QN"

/';5("64$6"*$9%-:4$/5)".$9G'(/"/:QN"7$'."6-"%5):-(+"6-".'/$(+)"-7"9'65+"3FM)"bC!<c1"UMJ3CJ"%5)'+5)"'("

645"SM"$(+"')"'(;-.;5+"'("645"6%$77'9G'(/"-7"3FM!V"<"$(+"C"6-"645":.$)*$"*5*B%$(5"$(+"-7"3FMQ"6-"645"

5(+-)-*$." 9-*:$%6*5(6)" bC!?c1" 345" *-+5" -7" $96'-(" -7" 645)5" 6&-" 94$:5%-(5)" 9-()')6)" -(" +'%596"

'(65%$96'-("&'64" 645"3FM)"596-+-*$'()V":%-*-6'(/" 645'%" $::%-:%'$65"$))5*B.0"$(+" 6$%/56)" 645*" 6-"

645'%" ,.6'*$65" +5)6'($6'-(V" ,:-(" .'/$(+" %59-/('6'-(1" 3FM?" 6%$77'9" )55*)" 6-" B5" /:QN" $(+" UMJ3C"

'(+5:5(+5(6V"$(+"645"%5$)-("')"(-6"7,..0"5.,9'+$65+".5$;'(/"-:5("645":-))'B'.'60"-7"3FM?"%5[,'%5*5(6"

-%"(-6"7-%"-645%"94$:5%-(5)"7-%":%-:5%"7-.+'(/1"D(+55+"'(6%$95..,.$%"3FM?V"O"$(+"Q"$%5"7-,(+"'("645"SM"

'("%5)6'(/"+5(+%'6'9"95..)"$(+"*$9%-:4$/5)"$(+"$%5")4,66.5+"6-"645"5(+-)-*5)",:-("$96';$6'-(V"'("$("

YWRQ?@!" +5:5(+5(6" *$((5%1" YWRQ??@!V" ')" $" *,.6'6%$()*5*B%$(5" SM" :%-65'(" 64$6" ):59'7'9$..0"

'(65%$96)"&'64"645"6%$()*5*B%$(5"+-*$'()"-7"3FM?V"O"$(+"Q"$(+"64')"'(65%$96'-("')";'6$."7-%")'/($.'(/"

bC!CV" C!Kc1" D(" %5)6'(/" @" 95..)V" 3FMQ" ')" :%5)5(6" '(" )*$.." 9-*:$%6*5(6)" :-)'6';5" 7-%" 5$%.0" 5(+-)-*$."

*$%G5%)k" 64')" 9-()6'6,6';5" .-9$.'I$6'-(" -7" 3FMQ" '(" 5(+-)-*5)" '(" %5)6'(/" @" 95..)" 9-(6%$)6)" &'64" 645"

-B)5%;$6'-()" '(" #R)" $(+" *$9%-:4$/5)" &45%5" 3FMQ" ')" 9-(95(6%$65+" '(" 645" SM1" L-..-&'(/" @RM"

9%-)).'(G'(/"&'64" 645"$(6'/5("$.-(5"-%" 6-/5645%"&'64"R:>"#WJV"3FMQ"+')6%'B,6'-(" ')"$.65%5+k"3FMQ" ')"

%59%,'65+";'$"6,B,.'("(56&-%G)"6-"*,.6';5)'9,.$%"$,6-:4$/-)-*5)"&45%5"'6"9-.-9$.'I5)"&'64"645"@RMV"

$(+"'('6'$65)")'/($.'(/"bC!Nc1"34,)"'(6%$95..,.$%"3FMQ"6%$77'9")55*)"6-"%5.0"-("@RM")'/($.)k"%595(6.0V"645"

/%-,:" -7" @%'(G*$((" )4-&5+" 64$6" YWRQ?@!"*,6$6'-(" $.65%)" 645" 5(+-)-*$." .-9$.'I$6'-(" -7" 3FMQ" '("

%5)6'(/" @" 95..)" %5),.6'(/" '(" '6)" %565(6'-(" '(" 645" SMV" ),//5)6'(/" -(5" *-%5" 6'*5" $" 9%,9'$." %-.5" 7-%"

YWRQ?@!"94$:5%-(5" '(" 645"9-%%596" 7-.+'(/"$(+" 6%$77'9"-7"3FMQ" '(" 64%55"+'775%5(6" '**,(5"95.." 60:5)"

bC2?c1"J"*-%5"+56$'.5+"+5)9%':6'-("-7"YWRQ?@!"')"6-"B5"+5;5.-:5+"B5.-&1"

Page 68: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

NN""

"

A8N2"-)0"&B'($"B':#'$2"

"*'79$-)'"9%4)0"$'+4:-&%$2"

" " " " " R#!C" *-.59,.5" ')" -(5" 58$*:.5" -7" $" *5*B%$(5" B-,(+" 9-E

%595:6-%" '(;-.;5+" '(" 3FM" CV" O" $(+" Q" 6%'//5%5+" %5):-()5)1" R#!C" 9-,.+" $.)-" 58')6" $)" $" )-.,B.5"

/.09-:%-65'(" '(" 645" B.--+1" R#!C" &$)" :%'(9':$..0" $))-9'$65+" &'64" 3FMC" 6%'//5%5+" H0+PP" $(+" 3MDLE

+5:5(+5(6":$64&$0)"B0"7'%)6.0"B'(+'(/"FUA"$(+"645(":%-*-6'(/"3FMC"5(+-906-)')"bC!Oc1"R#!C"')"$.)-"

)4-&(" 6-" 9-()6'6,6';5.0" '(65%$96" &'64" 3FMO" $(+" Q" $(+" 45.:)" '(+,9'(/" :%-'(7.$**$6-%0" 906-G'(5"

)59%56'-(1" J(-645%" 58$*:.5" ')" 645" \<" '(65/%'(" %595:6-%" 7-%" 7'B%'(-/5("H$9E!" bR#!!BER+!PV" RM?V11c"

64$6" $%5" 4'/4.0" 58:%5))5+" -(" '(($65" 95..)1" R#!!B" ')" %595(6.0" )4-&(" 6-" (5/$6';5.0" %5/,.$65" 3FM"

)'/($.'(/" B0" $96';$6'(/" A0G" $(+" 64,)" :%-*-6'(/" +5/%$+$6'-(" -7" H0+PP" $(+" 3MDL" ;'$" RB.EB" bC!Pc1"

A,%:%')'(/.0V"H=R"9.$))"D"*-.59,.5)"&5%5"$.)-"7-,(+"'(;-.;5+"'("%5/,.$6'(/"3FM)"%5):-()5)"/(-"%5;5%)5"

)'/($.'(/k",:-("3FM"$96';$6'-(V"A%9"G'($)5":4-):4-%0.$65)"H=R"9.$))"D"'(6%$95..,.$%"+-*$'("64$6"'6)5.7"

'(65%$96)"&'64"645"60%-)'(5"G'($)5"L:)k"345(V"L:)"$..-&)"$"3MJLNE"$(+"3@_!E*5+'$65+"%59%,'6*5(6"-7"

645" :4-):4$6$)5" A=UE<" &4'94" '(65%75%5)" &'64" 3FM" )'/($.'(/" $(+" ),::%5))5)" '(($65" '(7.$**$6-%0"

%5):-()5)" bC!Qc1" L'($..0V" R#?NV" $" 6%$()*5*B%$(5" /.09-:%-65'(" 7-,(+" '(" .':'+" %$76)V" ')" %595(6.0"

'+5(6'7'5+"6-"$96"$)"$"(5&"9-%595:6-%"7-%"-8'+'I5+".-&"+5()'60".':-:%-65'("F#F"$(+"$*0.-'+E\":5:6'+5V"

$(+" 6-" 7$9'.'6$65"$))5*B.0"-7"3FM<E3FMN"-%"3FMCE3FMN"4565%-+'*5%)" 64%-,/4"A%9"G'($)5)V" .5$+'(/" 6-"

645"%5/,.$6'-("-7"3FM")'/($.'(/"bC<2c1"

X)&$-.'::4:-$"N'+4:-&%$2"

" " " " " YB'[,'6'(" *-+'70'(/" 5(I0*5)" ),94" $)" W%+:E!V" 45$6" )4-9G"

9-/($65" O2" l" '(65%$96'(/" :%-65'(" R=DUV" I'(9" 7'(/5%" :%-65'(" J<2" $(+" 3MDHK" b" $" MDW>" +-*$'(" S?"

,B'[,'6'(" .'/$)5c"4$;5"B55(")4-&(" 6-":%-;'+5" ):59'7'9'60"$(+" %5/,.$65" 645" '(65()'60"-7"3FM" )'/($.'(/"

:$64&$0)1" W%+:E!V" $(" S?" .'/$)5V" +'%596.0" B'(+)" $(+" :-.0,B'[,'6'($65)" H0+PP" $(+" 3@_!" :%-*-6'(/"

H0+PP" +5/%$+$6'-(" $(+" 3@_!" $96';$6'-(" .5$+'(/" 6-" $" :%575%5(6'$." 60:5" D" DLW" :%-+,96'-(" $(+" $"

+59%5$)5+" '(7.$**$6-%0" 906-G'(5" )59%56'-(" bC<!c1" R=DU" 7$9'.'6$65)" 645" 7-%*$6'-(" -7" $" 3FM" )'/($.'(/"

9-*:.58" B0" %59%,'6'(/V" :-.0,B'[,'6'($6'(/" $(+" $96';$6'(/" 60%-)'(5" G'($)5" A%9" $(+" $60:'9$." :%-65'("

G'($)5"R`"bUR_`c".5$+'(/"6-"DMJ_!V"3@_!"$(+"DML?TO"$96';$6'-("bC<<c1"J<2"'(4'B'6)"S?".'/$)5"$96';'6'5)"-7"

3MJLNV" 3MJL<" $(+" 9DJU!" B0" $(6$/-('I'(/" '(65%$96'-()"&'64" S<" ,B'[,'6'(" 9-(e,/$6'(/" 5(I0*5)V" $(+"

64,)" (5/$6';5.0" %5/,.$65)" '(7.$**$6'-(" bC<?c1" 3MDHK" 9$6$.0I5)" 645" )0(645)')" -7" ,B'[,'6'(" 94$'()"

%5),.6'(/" '(" 645"$96';$6'-("-7"3J_!"G'($)5"9-*:.58V"$(+"$" ),B)5[,5(6"$96';$6'-("-7"J:E!"$(+"WLEv@"

)'/($.'(/"bC<Cc1""

S(+-)-*5)V" 5(+-:.$)*'9" %56'9,.,*V" *'6-94-(+%'$" $(+" >-./'" $::$%$6,)" 9-(6$'(" %5/,.$6-%)" $(+"

9-7$96-%)" 64$6" :$%6'9':$65" '(" 3FME6%'//5%5+" '(($65" '**,(5" %5):-()5)1" J" %595(6" $(+" 5.5/$(6" )6,+0"

Page 69: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

NO""

"

%5;5$.)"$"(-("9.$))'9$."7,(96'-("7-%"'(6%$95..,.$%"H=R"9.$))"DD"*-.59,.5)"$)"$+$:6-%)"'("3FM?V"C"$(+"Q"

)'/($.'(/" :$64&$0" '(" *$9%-:4$/5)" $(+" #R)1" Y:-(" 3FM" 5(/$/5*5(6V" 5(+-)-*$." H=RDD" *-.59,.5)"

'(65%$96"&'64"645"@%,6-(h)"60%-)'(5"G'($)5"@6_";'$"645"9-)6'*,.$6-%0"*-.59,.5"R#C2"&4'94"*$'(6$'()"

@6_" $96';$6'-(1" X(95" :4-):4-%0.$65+V" @6G" '(65%$96)" &'64" H0+PP" $(+" 3MDL" $+$:6-%)" .5$+'(/" 6-"

5(4$(95+" :%-+,96'-(" -7" :%-E'(7.$**$6-%0" 906-G'(5)" $(+" 60:5" D" DLW)" bC<Kc1" J(-645%" 5(+-)-*$."

%5/,.$6-%"')"3J>"&4'94"')"$"):.'95";$%'$(6"-7"3MJH"64$6V",:-("FUA")6'*,.$6'-(V"+'):.$95)"645"$+$:6-%"

3MDL" 7%-*" 3MJH" $(+" '(4'B'6)" H0+PPE'(+5:5(+5(6" :$64&$0" bC<Nc1" D(" *'6-94-(+%'$V" 645" :%-65'("

HJMR=K"')"+5)9%'B5+"6-"B5"$"(-;5.":-)'6';5"%5/,.$6-%"-7"3FMO"B0"9$6$.0I'(/"645":-.0E,B'[,'6'($6'-("-7"

3JW_"%5),.6'(/"'("645"%5.5$)5"-7"'6)"'(4'B'6-%0"577596)"-("3MJLN"$(+"64,)":%-*-6'(/":%-'(7.$**$6-%0"

%5):-()5)"bC<Oc1"H'6-94-(+%'$."WFMa!"')"$.)-"),//5)65+"$)"$":-)'6';5"%5/,.$6-%"-7"3FMC"%5):-()5)k"'6"

+'))-9'$65)"7%-*"3MJLN"$(+"B'(+)"+'%596.0"6-"645"D__"9-*:.58".5$+'(/"6-"WLEv@"%5):-()';5"906-G'(5)1"

D("645"SMV">MUQC"$(+"UMJ3CJ"&5%5"'+5(6'7'5+"$)"*-+,.$6-%)"7-%"$":%-:5%"7-.+'(/"-7"3FM!V"<V"CV"O"$(+"

Q1" D(" 645">-./'V" 645"$(6';'%$.":%-65'("Z':5%'(V" '(+,95+",:-("3FMO"-%"Q" )6'*,.$6'-(" '(":#R)V" '(65%$96)"

&'64" DMJ_!"$(+"3MJLN" 6-" %59%,'6" 645*"6-" .':'+"B-+'5)"$(+" 64,)" 7$9'.'6$65)" DMJ_!",B'[,'6'($6'-("$(+"

DMLO"$96';$6'-("bC<Pc1"

"" AB'"`P!LM?5".-2'"

" " " " " " 345"YWREQ?":%-65'("&$)"7'%)6.0"+5)9%'B5+"'("R1S.5/$()"

$)"$"%5/,.$6-%0"),B,('6"-7"$"6%':$%6'65"6&-E:-%5":-6$))',*"94$((5."$(+"&$)")4-&("6-"B5"'(;-.;5+"'("

*,)9.5" 9-(6%$96'-("$(+"*-6'.'601" D(" 645"*$**$.'$(" 9-(6586V" 6&-":$%$.-/)"&5%5" '+5(6'7'5+"YWRQ?J"

$(+" YWRQ?@" 64$6" 4$;5" -(.0" !P|" $*'(-" $9'+" '+5(+'60" &'64" 645'%" R" 5.5/$()" 4-*-.-/" bC<QEC?!c1" D("

<22NV"645"/%-,:"-7"@5,6.5%"&$)"$B.5"6-"'+5(6'70"$"*,6$6'-("'("YWRQ?@!"/5(5V"9$..5+"?+"*,6$6'-(V"B0"

:5%7-%*'(/" 7-%&$%+" /5(56'9)" ,)'(/" 645" %$(+-*" /5%*.'(5"*,6$/5(" WE5640.EWE('6%-)-,%5$V" $..-&'(/"

645"+')9-;5%0"-7"6&-"(5&"7,(96'-()"7-%"YWRQ?@!",(%5.$65+"6-":-6$))',*"6%$():-%6"bC!Cc1""

345"*'))5()5")'(/.5"*,6$6'-("-7"=')"6-"J%/"&'64'("645"6%$()*5*B%$(5"+-*$'("Q"-7"YWRQ?@!":%-65'("

$B-.')45)" '(6%$95..,.$%"3FM?V"O"$(+"Q")'/($.'(/V"$(+" ')" 65%*5+"?+"-%" 6%':.5"#" 7-%" 645"6%':.5"9-*B'(5+"

)'/($.'(/" +57596)1" F$65%" -(V" 645" /%-,:" -7" =1U.-5/4" )4-&5+" 64$6" YWRQ?@!" '(65%$96)" :40)'9$..0" $(+"

):59'7'9$..0"&'64"3FM?V"OV"Q"$(+"!?";'$"645'%"6%$()*5*B%$(5"+-*$'()"'("645"SMV"$..-&'(/"645'%"6%$77'9"6-"

645"5(+-)-*5)",:-(")6'*,.$6'-("bC!Cc1"H-%5"%595(6")6,+'5)"$.)-"'(;-.;5+"YWRQ?@!"'("3FMP"+5.';5%0"

6-" 5$%.0" 5(+-)-*5)" bC?<cV" '(" 3FM!!" $96';$6'-(" $(+" %59-/('6'-("-7" 3-8-:.$)*$">-(+''" bC??cV" $(+" '("

3FM!?"58'6"7%-*"SM"bC?Cc1"=,*$("3-..".'G5"%595:6-%"?V",(.'G5"-645%"'(6%$95..,.$%"3FM)V"9$("B5"7-,(+"-("

645"95.."),%7$95"$)"&5.."$)"'("5(+-)-*5)V"+5:5(+'(/"-("645"95.."60:5k"6%$().-9$6'-("-7"3FM?"6-"645"95.."

),%7$95"')"$.)-"*5+'$65+"B0"YWRQ?@!"bC?Kc1"D(65%5)6'(/.0V"'("=YZSR"$(+"MJHXAE@.,5"@"95..".'(5)V"U-.0"

D^R")6'*,.$6'-(",:%5/,.$65)"645"58:%5))'-("-7"YWRQ?@!"64,)":%-*-6'(/"$"+'775%5(6'$."6%$().-9$6'-("-7"

Page 70: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

NP""

"

3FM?"/.09-)0.$65+"7-%*"6-"645"95.."),%7$95V"$(+"5(4$(9'(/"645"%5):-()';5(5))"6-"(,9.5'9"$9'+")5()'(/"

3FM)"B0"'(9%5$)'(/"645'%".'756'*5"bC?Nc1"

M5:-%6)" 7%-*" 645" /%-,:" -7" H'0$G5" +5*-()6%$65" 64$6" 3FMQ" 9-*:565)" &'64" 3FMO" 7-%" YWRQ?@!"

+5:5(+5(6" 6%$():-%6$6'-(" $(+" :%5+-*'($65)" -;5%" 3FMO" bC?Ock" 3FMQ" :%5+-*'($(95" ')" %5;5%)5+" 6-"

3FMO"&45("YWRQ?@!"B5$%)"$(-645%"*'))5()5"*,6$6'-("b#?CJcV"%5(+5%'(/"3FMO"40:5%%5):-()';5"$(+"

3FMQ"40:-%5):-()';5" '(" +5(+%'6'9" 95..)1"H'95"4-*-I0/-,)" 7-%" 64')"*,6$6'-(" ),775%" 7%-*"$" )0)65*'9"

.564$."'(7.$**$6'-("+,5"6-"5(4$(95+"3FMO"%5):-()5)"bC?Pc1"3-"(-65V"645"7'%)6"K2"$*'(-"$9'+"%5)'+,5)"

-7" YWRQ?@!" $::5$%" (595))$%0" 7-%" 3FMQ" 58:-%6" $(+" (-6" 3FMOV" ),//5)6'(/" 64$6" +')6'(96" %5/'-()" -7"

YWRQ?@!"$%5"%5[,'%5+"7-%"$))-9'$6'-("&'64"3FMO"$(+"3FMQ1"H-%5"):59'7'9$..0V"#P!<"$(+"SP!?"%5)'+,5)"

7-%" 3FMQ" $(+" #NQQ" $(+" SO2C" '(" 3FM?" )55*" 6-" B5" 9%,9'$." 7-%" 645" '(65%$96'-(" -7" 645)5" 3FM)" &'64"

YWRQ?@!"bC?Qc1">%5/-%0"@$%6-(h)".$BV"$/$'(V")4-&5+"64$6"3FMO"$(+"Q"YWRQ?@!E*5+'$65+"6%$77'9G'(/"

%-,65)"$%5"+')6'(96k"D("645"SMV"YWRQ?@!"')"$))-9'$65+"&'64"3FMQV"6%$77'9)"&'64"'6"64%-,/4">-./'"6-"645"

95.."),%7$95"&45%5"'6"%59%,'6)"$(+"$))-9'$65)"&'64"JU<";'$"$"taa}"*-6'7k"JU<"%59%,'6*5(6"')"(595))$%0"

7-%" 3FMQ" '(65%($.'I$6'-(" 6-" 645" 5(+-)-*5)k" 64')" JU<" +5:5(+5(6" 6%$77'9G'(/" 4$)" B55(" +5)9%'B5+" 7-%"

)5;5%$." :%-65'()" ),94" $)" FJHU!T<" $(+" H=R" 9.$))" DD1" L,%645%" 9-*:$%6*5(6$." ):59'$.'I$6'-(" ')"

/5(5%$65+"B0"JU?"&4'94"'(65%$96)"&'64"3FMQ"$(+"+'%596)"645"%595:6-%"6-"9-*:$%6*5(6)"+5+'9$65+"7-%"

60:5" D" DLW" )'/($.'(/1" 3FMOV" '()65$+V" $::5$%)" 6-" 5*:.-0" JUC" '(" $" +'%596" %-,65" -7" 6%$77'9" 6-" 645"

5(+-)-*5)V" 64,)" B0:$))'(/" 645" 95.." ),%7$95" .-9$.'I$6'-(1" 3FM!!V" !<" $(+" !?V" .'G5" 3FMOV" +-" (-6" ,)5"

YWRQ?@!TJU<":$64&$0k"6-"(-65V"64')"&-%G"&$)"$.."+-(5"'("6%$()75965+"95..".'(5)"bCC2c"J3(+4$'"5>K;"

"

"

L'/,%5"!P^"3%$77'9G'(/":$64&$0)"9-(6%-..'(/".-9$.'I$6'-("-7"5(+-)-*$."3FM)V"-0-#&'0"6$%7"8''"'&"-:;E"

<=5M"

Page 71: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

NQ""

"

345":40)'-.-/'9$."'(;-.;5*5(6"-7"YWRQ?@!"')"%5;5$.5+"'("*$(0"*'95"*-+5.)"$(+"'("4,*$()1"D(+55+V"

?+" *,6$6'-(" -7" YWRQ?@!" %5(+5%)" *'95" *-%5" ),)95:6'B.5" 6-" *$(0" '(7596'-()" .'G5" *-,)5"

906-*5/$.-;'%,)V" $" \45%:5)" ;'%,)V" 8(2&'$(-" 7%)%.G&%+')'2E" F&-#BG:%.%..42" I4$'42E" A%]%#:-27-"

W%)0(("$(+"A$G#-)%2%7'"!$4@("bC!CV"CC!V"CC<c1" D("4,*$()V"YWRQ?@!"+57'9'5(90"')"$))-9'$65+"&'64"$"

4'/4" ),)95:6'B'.'60" 6-" 45%:5)" )'*:.58" ;'%,)" 5(95:4$.'6')" '(7596'-(" bCC?ck" H-%5-;5%V" YWRQ?@!"

58:%5))'-("'("645"@"95..)"-7":$6'5(6)"&'64"$96';5")0)65*'9".,:,)"')"4'/4.0",:%5/,.$65+V"+5*-()6%$6'(/"

$("$99,*,.$6'-("-7"$,6-%5$96';5"@"95..)"58:%5))'(/"$(6'"(,9.5$%"$(6'B-+'5)"bCCCc1"D("$/%55*5(6"&'64"

64$6V" YWRQ?@!" +57'9'5(6" :$6'5(6)" +-" (-6" +'):.$0" $,6-%5$96';5" $(6'B-+'5)" '(" 645'%" )5%,*" b?!Qc"

),//5)6'(/"64$6"645"B.-9G$+5"-7"YWREQ?@":$64&$0"*$0"64&$%6"$,6-'**,('60"'("4,*$()1"

345")59-(+"7,(96'-("-7"YWRQ?@!"')"%5;5$.5+"'("645"$+$:6';5"'**,('60k"&45%5"YWRQ?@!"?+"*,6$6'-("

)5;5%5.0"+')%,:6)"H=R"9.$))"D"9%-))E:%5)5(6$6'-("$(+"H=R"9.$))"DD":%5)5(6$6'-("-7"58-/5(-,)"$(6'/5("

bC!Cc1" X(" 645" -645%" 4$(+V" $" 9-(6%$+'96-%0" )6,+0" )4-&)" 64$6" YWRQ?@!" ')" (-6" %5[,'%5+" 7-%" 9.$))" DD"

$(6'/5(":%5)5(6$6'-("'("4,*$("$(6'/5(":%5)5(6'(/"95..)"bCCKc1"D("64')"9-(6586V"-,%"%5),.6)"%5;5$."64$6"

YWRQ?@!"*,6$6'-("5(4$(95)"H=R"9.$))"DD"J/":%5)5(6$6'-("'("*,%'(5"@"95..)"b)55"M5),.6)":$%6ck"645)5"

9-(6%$+'96-%0" %5),.6)" -B6$'(5+" 9-,.+" B5" 58:.$'(5+" B0" 645" +'775%5(6" 60:5)" -7" $(6'/5()" ,)5+" $(+"

&45645%"645")6,+'5)"&5%5"+-(5"'("*'95"-%"4,*$(1"

" "

Page 72: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

O2""

"

#$*/6'*+

@$9G/%-,(+V"40:-645)')"$(+"$'*)"

" D(" 645" '(6%-+,96'-(":$%6V" D" 7-9,)5+"-(" 645"+'775%5(6"$):596)"-7"3-.." F'G5"M595:6-%" b3FM)c" 95.."

B'-.-/0"'("645"'**,(5"95..)V"'(9.,+'(/"645":-)'6'-('(/"-7"645"3FM)"6-"$..-&"645*"6-"$96"$)")5(6'(5.)"7-%"

UJHU"9-(6$'('(/":$64-/5()V"645"'(6%$95..,.$%"6%$77'9G'(/"-7"645"3FM)"$(+"645'%"SM"9-((596'-(V"$)"&5.."

645" 9-*:$%6*5(6$.'I$6'-(" -7" 3FM)" $(+" 645'%" .'/$(+)1" J.." 645)5" $):596)" &5%5" 5865()';5.0" )6,+'5+" '("

+5(+%'6'9"95..)V"&45%5$)";5%0"75&")6,+'5)"&5%5"9$%%'5+"-,6"9-(95%('(/"645"%5/,.$6'-("-7"645"6%$77'9G'(/"

$(+"645")'/($.'(/"-7"B-64"3FMO"$(+"3FMQ"'(":%'*$%0"@"95..)1""

"

D(":$%6"J" D" -7" 645" %5),.6)V"&5" )6,+0" 645" '*:.'9$6'-("-7"YWRQ?@!V" $" 3FM" 94$:5%-(5"*-.59,.5V" '(" 645"

%5/,.$6'-("-7"3FMO"$(+"3FMQ"7,(96'-(" '(":%'*$%0"@"95..)1"H-%5-;5%V"&5"&5%5"$B.5"6-" '+5(6'70"$"(5&"

%-.5"7-%"645"H=R"9.$))"DD"94$:5%-(5V"645"'(;$%'$(6"94$'("bD'cV"'("/-;5%('(/")5.596';5.0"3FMO"),B95..,.$%"

.-9$.'I$6'-("$(+")'/($.'(/"'(":%'*$%0"@"95..)1"g5"58$*'(5+"$)"&5.."645"9-()5[,5(95"-7"645"+57'9'5(90"

-7"D'"-("645"-,69-*5"-7"3FMO"+5:5(+5(6"'(($65"$(+"$+$:6';5"%5):-()5)"'("@"95..)1"

"

D(":$%6"J" DDV"&5"+5*-()6%$65"64$6"J):$%$/'(5"S(+-U5:6'+$)5"bJSUcV"&4'94"4$)"$"9%'6'9$."%-.5" '("3FMO"

$(+"Q":%-95))'(/V"*$6,%$6'-("$(+")'/($.'(/"'("+5(+%'6'9"95..)V" ')"$.)-"'*:-%6$(6" '("H=R"9.$))"DD"HX>"

bH05.'("X.'/-+5(+%-9065c":%5)5(6$6'-("B0"%5/,.$6'(/"9$645:)'("F"$96';'601"

"

D(":$%6"J"DDD"$(+"DZV"&5":%-;'+5"*564-+-.-/'9$.":%-6-9-.)"7-%"')-.$6'(/"5(+-)-*5)"-%T$(+".0)-)-*5)"

'(" #R)" $(+" 7-%" /5(5%$6'(/" H=R" 9.$))" DD" .'/$(+)" %5):596';5.01" 345" :,%'7'9$6'-(" -7" 5(+-)-*$." -%"

.0)-)-*$."-%/$(5..5)"')"B5(57'9'$."6-")6,+0"3FM)"9.5$;$/5"$(+"6-")9%55("645"58:%5))'-("-7":%-65'()"-7"

'(65%5)61"345":%-+,96'-("-7"H=R"9.$))"DD".'/$(+)"/5(5%$65+"B0"()"/(&$%"+'/5)6'-("&'64":%-65$)5)"5'645%"

:,%'7'5+"-%" 9-(6$'(5+" '(" .0)-)-*5)"$..-&)" 645" '+5(6'7'9$6'-("-7" ):59'7'9" 5(+-)-*$.":%-65$)5)"&4'94"

9-,.+"B5"6$%/565+"7-%"B5665%";$99'($6'-(1"

"

D("645")59-(+":$%6"-7"645"%5),.6)"bU$%6"@cV"D".')6"*0"9-(6%'B,6'-("6-"-645%":,B.'9$6'-()1"g5"&5%5"$B.5"6-"

+5)9%'B5" $" (-;5." %-.5" 7-%" D(),.'(E%5/,.$65+" $*'(-:5:6'+$)5" DMJU" '(" %5/,.$6'(/" 645" '(6%$95..,.$%"

6%$77'9G'(/"$(+")'/($.'(/"-7"3FMQ"'("+5(+%'6'9"95..)"bU$%6"@"Dc1"D(":$%6"@"DD"$(+"DDDV"&5")4-&"$"9%'6'9$."%-.5"

7-%"JSU" '("*-+,.$6'(/"3FMO"$(+"3FMK"%5):-()5)" '("+5(+%'6'9"95..)V"5:'645.'$."95..)V"$(+"*$9%-:4$/5)"

%5):596';5.01"

"

" " "

Page 73: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

O!""

"

5=>?+!++

D1"D(;$%'$(6"94$'("%5/,.$65)"3FMO"6%$77'9G'(/"$(+")'/($.'(/"'(":%'*$%0"@"

95..)"

" !5<42$3?#!$%&'(%)*+*!,-#!.%/!0/+123!4-#!51//6/789:;/*)!<$!%/+!$%/692=!>#!?@AB-!!"#$%&&'(!

!"#$%&'($)*3-"5.,9'+$65"645"%-.5"-7"'(;$%'$(6"94$'("'("%5/,.$6'(/"3FMO"7,(96'-("'(":%'*$%0"@"95..)""

+,%-./0123)"D6"')"&5.."5)6$B.')45+"64$6"645"6%$77'9"$(+"645"$96';$6'-("-7"(,9.5'9"$9'+")5()'(/"3-.."F'G5"

M595:6-%" b3FMc" $%5" ),Be5965+" 6-" %5/,.$6'-(" 6-" '*:%-;5" ):59'7'9" %59-/('6'-(" -7" *'9%-B'$." #WJ" $(+"

$;-'+" )5.7E#WJ" )5()'(/1" D(" @" 95..)V" $(+" ,(.'G5" *$9%-:4$/5)" $(+" +5(+%'6'9" 95..)V" 3FMQ" %5)'+5)" '("

5(+-)-*$." 9-*:$%6*5(6)" $6" 645" )65$+0" )6$65k" 64')" .-9$.'I$6'-(" ')" YWRQ?@!" +5:5(+5(6V" $)" $" i?+j"

*,6$6'-(" '(" 645" 6%$()*5*B%$(5" +-*$'(" -7" 645" 94$:5%-(5" *-.59,.5" YWRQ?@!" +')%,:6)" 3FMQ"

5(+-)-*$." .-9$.'I$6'-(V" %5),.6'(/" '(" 3FMQ" %5.-9$.'I$6'-(" '(" 645" SM1" 34,)V" YWRQ?@!" )5%;5)" $)" $"

94$:5%-(5"*-.59,.5"7-%"#WJ")5()'(/"3FMQ"'("@"95..)"B0":5%*'66'(/"'6)"9-%%596"7-.+'(/"$(+"6%$77'9G'(/"6-"

5(+-)-*$." 9-*:$%6*5(6)" 7%-*" &45%5" '6" )'/($.)1" X(" 645" -645%" 4$(+" $(+" )-" 7$%V" (-" )6,+'5)" &5%5"

%5:-%65+"9-(95%('(/"3FMO"B54$;'-%"'(":%'*$%0"@"95..)1"

D("$++'6'-("6-"645'%"9.$))'9$."7,(96'-("'("$(6'/5(":%5)5(6$6'-("$(+"645'%".5))5%"G(-&("$B'.'60"6-"$96"$)"

)'/($." 6%$()+,95%)V" *$e-%" 4')6-9-*:$6'B'.'60" 9-*:.58" 9.$))" DD" *-.59,.5)" $%5" %595(6.0" )4-&(" 6-"

:%-*-65"3-..EF'G5"%595:6-%"?V"C"$(+"Q")'/($.'(/"'("*$9%-:4$/5)"$(+"+5(+%'6'9"95..)1"34')"'(6%'/,'(/"%-.5"

%5[,'%5)" '(6%$95..,.$%" $))-9'$6'-(" &'64" 645" @%,6-(h)" 60%-)'(5" G'($)5" @6G" $(+" 645" 9-)6'*,.$6-%0"

*-.59,.5" R#C21" _(-&'(/" 645" 7,(+$*5(6$." %-.5" -7" '(;$%'$(6" 94$'(" bD'c" '(" 645" 9-%%596" 7-.+'(/" $(+"

6%$():-%6"-7"H=R"9.$))"DD"*-.59,.5)"7%-*"645"SM"6-"5(+-)-*$."9-*:$%6*5(6)"$(+"'("$(6'/5(".-$+'(/V"

&5"'(;5)6'/$65+"$":,6$6';5"7,(96'-("-7"D'"'("%5/,.$6'(/"5(+-)-*$."3FM")'/($.'(/"'(":%'*$%0"@"95..)1""

4$516&5)"g5"4$;5"-B)5%;5+"64$6"+57'9'5(90" '(" D'")'/('7'9$(6.0"5(4$(95+"3FMOE6%'//5%5+":%-+,96'-("-7"

:%-E'(7.$**$6-%0" 906-G'(5)" bDFEN" $(+" 3WLEuc" '(" :%'*$%0" *$6,%5" @" 95..)1" 34')" :45(-60:5" ')" -(.0"

%5)6%'965+"6-"3FMO"/';5("64$6"3FMCE"$(+"QE*5+'$65+"%5):-()5)"%5*$'("'(6$96"'("D'E+57'9'5(6":%'*$%0"@"

95..)1" D(;$%'$(6" 94$'(" +57'9'5(90" +'+" (-6" $77596" 645" 58:%5))'-(" :$665%(" -7" 3FMV" &4'94" 589.,+5+" 645"

:-))'B'.'60"64$6"645"5(4$(95*5(6"-7"3FMO"%5):-()5)"$94'5;5+"B0"645"+57'9'5(90"'("D'"&$)"+,5")'*:.0"6-"

$"4'/45%"58:%5))'-("-7"3FMO1"H-%5-;5%V"D'"+57'9'5(90"$.65%5+"3FMOV"B,6"(-6"3FMQV"+')6%'B,6'-("%5),.6'(/"

'("3FMO"%565(6'-("'("SME.'G5"9-*:$%6*5(6)V"&45%5$)"'("&'.+E60:5"bg3c"@"95..)V"3FMO".'G5"3FMQV"%5)'+5)"

'(" =<#Hp" D'p"H=RDDp" 5(+-)-*$." 9-*:$%6*5(6)1" 34')" %5),.6" ),//5)65+" $" 94$:5%-('(/" %-.5" -7" D'" B0"

*5+'$6'(/")5.596';5.0"3FMO"6%$77'9G'(/"7%-*"645"SM"6-"5(+-.0)-)-*5)1"D(65%5)6'(/.0V",:-(")6'*,.$6'-("

&'64" '6)" 9-/($65" .'/$(+V" 3FMO" 7-%*)" $" 9-*:.58" 6-/5645%" &'64" D'" $(+" '6)" $+$:6-%" *-.59,.5"H0+PPV"

),//5)6'(/"$(" '*:.'9$6'-("-7" D'" '(" 645")'/($.'(/"9-*:.58"+-&()6%5$*"3FMO1"Y(58:5965+.0V"YWRQ?@!"

Page 74: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

O<""

"

?+"*,6$6'-("+-5)"(-6"$77596"645"+')6%'B,6'-("-7"3FMO" '(":%'*$%0"@"95..)V"B,6"-(.0"$.65%)" '6)")'/($.'(/V"

4'/4.'/46'(/" $" %-.5" -7" YWRQ?@!" $)" $" )'/($.'(/" *-.59,.5" 7-%" B-64" 3FMO" $(+" Q" $(+" $)" $" 94$:5%-(5"

*-.59,.5"-(.0"7-%"3FMQ"'(":%'*$%0"@"95..)1"

H-%5-;5%V"&5")4-&"64$6"3FMO")6'*,.$6'-("5(4$(95+"H=R"9.$))"D"9%-))":%5)5(6$6'-("-7"$("58-/5(-,)"

$(6'/5(V"-;$.B,*'(V"'("g3"95..)V"B,6"),%:%')'(/.0"4$+"(-"577596"'("'(;$%'$(6"94$'("+57'9'5(6"95..)1"345)5"

-B)5%;$6'-()"%5;5$." 64$6"+57'9'5(90" '(" '(;$%'$(6"94$'(",:"%5/,.$65)"3FMOE*5+'$65+" '(($65"%5):-()5)"

;5%),)"$+$:6';5"%5):-()5)V"),//5)6'(/"$(",(:%595+5(65+"%-.5"-7"D'"'("*$'(6$'('(/"$"B$.$(95"B56&55("

B-64" '(($65"$(+"$+$:6';5" %5):-()5)1"34,)V"-,%" 7'(+'(/)":%-;'+5"$"(5&" 7,(96'-(" 7-%" '(;$%'$(6"94$'(V"

B56&55(")5;5%$.V"'("'**,(-.-/'9$.":%-95))5)"$(+"):59'7'9$..0"'("%5/,.$6'(/"3FMO"%5):-()5)"'("@"95..)1"

" "

Page 75: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

O?""

"

DD1"J):$%$/'(5"5(+-:5:6'+$)5"%5/,.$65)"HX>"$(6'/5(":%5)5(6$6'-("B0"

*-+,.$6'-("-7"9$645:)'("F"$96';'60"

" !5<42$3?@A!C6)*&&6/!D-E#!>1/)%F(%!G-#!</+1236/!,-#!81)%2%&&1!C-#!H1*I12%!$-!%/+!$%/692=!>-#!! ?@AB-!

! )*+,-',.-.&%/*!

!"#$%&'($)"3-"$++%5))"645"%-.5"-7"JSU"'("%5/,.$6'(/"9$645:)'("F"$96';'60"$(+"HX>"$(6'/5(":%5)5(6$6'-("

+,%-./0123)* H,.6':.5" A9.5%-)')" bHAc" ')" $" 94%-('9" '(7.$**$6-%0V" +5*05.'($6'(/" $(+"

(5,%-+5/5(5%$6';5" +')-%+5%" -7" 645" 95(6%$." (5%;-,)" )0)65*" bRWAc1" D6" $77596)" 0-,(/" $+,.6)" &'64" $("

'(9%5$)'(/" 75*$.5" :%5+-*'($(95" $(+" 9-()6'6,65)" 645" *-)6" '*:-%6$(6" 9$,)5" -7" (-(" 6%$,*$6'9"

(5,%-.-/'9$."+')$B'.'601"S8:5%'*5(6$."$,6-'**,(5"5(95:4$.-*05.'6')"bSJScV"645"$('*$."*-+5."7-%"HAV"

')" $" ;$.,$B.5" *564-+" 6-" )6,+0" 645" 4,*$(" +')5$)5" B0" '(e596'(/" HX>" bH05.'(" X.'/-+5(+%-9065"

>.09-:%-65'(c"$,6-"$(6'/5(1"HX>E:%-65'("'(+,95+"SJS":%'*5"B-64"R#Cp"3"95..)"b34!"$(+"34!Oc"$)"&5.."

$)"R#Pp"):59'7'9"3"95..)"bCCNc1"

JSUV" $(" $):$%$/'(5" ):59'7'9" 5(+-:%-65$)5V" ')" +5)9%'B5+" 6-" B5" '(;-.;5+" '(" H=R" 9.$))" DD" $(6'/5("

:%5)5(6$6'-(" B0" +'%596" :%-95))'(/" -7" +'775%5(6" $(6'/5()" ),94" $)" *'9%-B'$." 656$(,)" 6-8'9" $(6'/5(V"

*05.'("B$)'9":%-65'("$(+"3JME#WJ"B'(+'(/":%-65'("C?V"$(+"B0" '('6'$6'(/" 645":%-95))'(/"-7" '(;$%'$(6"

94$'("$..-&'(/"645"*$6,%$6'-("-7"9.$))"DD"*-.59,.5)1"H-%5-;5%V"JSU"')"%5[,'%5+"7-%"645"*$6,%$6'-("-7"

-645%":%-65$)5)"),94"$)"9$645:)'()"@V"#"$(+"F"'("640*'9"$(+"+5(+%'6'9"95..)1"g5"&$(65+"6-".--G"$6"645"

'(;-.;5*5(6"-7"JSU"'("HX>"H=R"9.$))"DD"$(6'/5(":%5)5(6$6'-(1"

4$516&5)*g5")4-&"64$6"JSU"+57'9'5(90"$.65%)"HX>"$(6'/5('9":%5)5(6$6'-("6-"3"95..)"()"/(&$%"$)"&5.."$)"

()" /(/%;" 345" %5+,95+"HX>" :%5)5(6$6'-(" '(" #R)" ')" $" 9-()5[,5(95" -7" '(9%5$)5+" 9$645:)'(" F" $96';'60"

+5):'65"645"7$96"64$6"9$645:)'("F"*$6,%$6'-("')"'(4'B'65+"'("JSU"+57'9'5(6"95..)1"D(9%5$)5+"9$645:)'("F"

$96';'60" .5$+)" 6-"$"+'%596"5(4$(95*5(6"-7"W_3"95.." 7,(96'-(1" D("$++'6'-(V"JSU"+57'9'5(6"*'95"+-"(-6"

+5;5.-:"SJS"'("9-*:$%')-("6-"9-(6%-."*'95"7-..-&'(/"HX>"'(e596'-(1"J.6-/5645%"645)5"%5),.6)")4-&"

645" '*:-%6$(95"-7"JSU" '("H=R" 9.$))" DD" %5)6%'965+"HX>"$(6'/5(":%5)5(6$6'-(" $(+" '6)" ,('[,5" %-.5" '("

%5/,.$6'(/"9$645:)'("F"$96';'601"

Page 76: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

OC""

"

Asparagine endopeptidase regulates MOG antigen presentation by modulation of

cathepsin L activity

Mira Tohmé*1,2,3, Renaud Colisson*4, Kamel Benlagha5, Stephen Anderton6, Cécile

Delarasse7, Mauro Teixera8 and Bénédicte Manoury&1,2

1 INSERM, Unité 1013, 75015, Paris, France

2 Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, 75015 Paris,

France

3 INSERM, Unité 932, Institut Curie, 75005, Paris, France

4 INSERM U851, Université de lyon, 21 Av Tony Garnier 69365 Lyon cedex 07

5 U580 Hôpital saint-vincent de paul 75013 Paris, France,

6 University of Edinburgh, Institute of Immunology and Infection Research, School of

Biological Sciences, Kings Buildings, West Mains Road, Edinburgh EH9 3JT UK,

7 University of Paris Sud, Institut de Biochimie et Biophysique Moléculaire et Cellulaire, Unité

Mixte de Recherche 8619, Centre National de la Recherche Scientifique, 91400 Orsay,

France

8 Universidade Federal de Minas Avenida Antonio Carlos Belo Horizonte 31270-0901 Brazil

Running Title: AEP-dependent MOG antigen presentation

Key words: AEP, MHC class II presentation/processing, cathepsin L, MOG

&Corresponding author: Dr Bénédicte Manoury, INSERM, Unité 1013, Hôpital Necker-Enfants

malades, 149 rue de Sèvres, 75743 Paris cedex 15, France, Phone: +33 (0) 1 44 49 53 75;

Fax: + 33 (0) 44 49 53 82; Email: [email protected]

* both authors contributed equally to the work

"

"

+

Page 77: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

OK""

"

!DK?>=J?+

L-%5'/(":%-65'("$(6'/5()"*,)6"B5"B%-G5("+-&("&'64'(".0)-)-*5)"6-"/5(5%$65"),'6$B.5":5:6'+5)"64$6"

&'.."7-%*"9-*:.585)"&'64"H=R"9.$))"DD"*-.59,.5)"7-%":%5)5(6$6'-("6-"3"95..)1"3-":5%7-%*"64')"6$)GV"$)"

&5.." $)" :%-95))'(/" -7" 645" '(;$%'$(6" 94$'(" 6-" $..-&" 645"*$6,%$6'-(" -7" 9.$))" DD"*-.59,.5)V" :%-65-.06'9"

5(I0*5)" $%5" %5[,'%5+1" J):$%$/'(5" 5(+-:5:6'+$)5" bJSUcV" $(" $):$%$/'(5" ):59'7'9" 5(+-:%-65$)5V"&$)"

)4-&("6-"B5"%5[,'%5+"7-%"$(6'/5(":%-95))'(/"$)"&5.."$)"D'"+5/%$+$6'-(1"g5"%5:-%6"45%5"64$6"*'95"$(+"

95..)"+57'9'5(6"7-%"JSU"/5(5")4-&"+57596"'("HX>"H=R"9.$))"DD"%5)6%'965+"$(6'/5(":%5)5(6$6'-(1"D("645"

$B)5(95" -7" JSUV"HX>" $(6'/5('9" :%5)5(6$6'-(" 6-" 3" 95..)" ')" +59%5$)5+" ()" /(&$%" $)"&5.." $)" ()" /(/%1" J)"

:%5;'-,).0" %5:-%65+V"-645%":%-65$)5)" ),94"$)" 9$645:)'()"@V"#"$(+" FV" '(;-.;5+" '("$(6'/5(":%-95))'(/"

$(+"3"95..")5.596'-(V"7$'."6-"B5":%-95))5+"'(6-"645'%"*$6,%5"7-%*)"'("640*'9"$(+"+5(+%'6'9"95..)".$9G'(/"

JSU"$96';'601"#5):'65" 64')V" 9$645:)'("F"$96';'60" ')" '(9%5$)5+" '("JSU"+57'9'5(6"*'95" .5$+'(/" 6-"$"+'%596"

5(4$(95*5(6"-7"W_3"95.."7,(96'-(1"J.6-/5645%V"645)5"%5),.6)")4-&"645"'*:-%6$(95"-7"JSU"'("645"H=R"

9.$))"DD":$64&$0"$(+"'6)",('[,5"%-.5"'("%5/,.$6'(/"-645%"90)65'(5":%-65$)5"$96';'6'5)1""

4=?G>C=I+=BO+VG?FAOK+

4CJG+=BO+JGII+H>GH=>=?CAB"

JSU"+57'9'5(6"*'95"&5%5"B%5+"'("$":$64-/5(E7%55"5(;'%-(*5(6"'("$99-%+$(95"&'64"=~:'6$."W59G5%"$(+"

D()6'6,6"R,%'5"/,'+5.'(5)1""R$645:)'("@"$(+"F"*'95"&5%5"G'(+.0"/';5("B0"#%"J($EH$%'$"F5((-("bD()6'6,6"

R,%'5V" YQ?<c1" " A'(/.5" 95.." ),):5()'-(" 7%-*" ):.55(V" .0*:4" (-+5" $(+" 640*,)" &5%5" /5(5%$65+" B0"

*594$('9$."+')%,:6'-("-7"645"6')),5)"$765%" '(9,B$6'-("&'64"!|"-7"9-..$/5($)5"$6"?O�R1"@-(5"*$%%-&"

95..)" &5%5" 4$%;5)65+" B0" 7.,)4'(/" 645" 75*,%" $(+" 6'B'$" -7" &'.+E60:5V" JSUE+57'9'5(6"*'95" ,)'(/" $" <KE

/$,/5" (55+.51" 3-" /5(5%$65" @H#R)V" B-(5"*$%%-&"&5%5" :.$65+" $6" !2E<28!2N" 95..)" :5%" :56%'" +')4" '("

9-*:.565" DH#H" b!2|LRAc" ),::.5*5(65+" &'64" <2|" -7" oKKP" ),:5%($6$(61" @-(5" *$%%-&)" &5%5"

%5:.$65+"$6"+$0"C"$6"!2O"95..)T:56%'"+')45)1"U%'*$%0"*$6,%5"@"95..)"&5%5"L%5)4"*5+'$"&$)"%5:.5(')45+"

5;5%0" ?" +$0)1" M5)6'(/" *$6,%5" D/HpTD/#

p" @" 95..)" -7" 645" ):.55(" &5%5" :,%'7'5+" B0" (5/$6';5" )5.596'-("

bH'.65(0'"@'-659c1"HX>"$(+"W_3"95.."40B%'+-*$)"&5%5"/5(5%$65+"$)":%5;'-,).0"+5)9%'B5+"bF',"56"$.1V"

!QQKk"@5(+5.$9"56"$.1V"!QQKc1""

5>A?GCBKZ+=B?CDAOCGK+=BO+A?FG>+>G=PGB?K+

HX>":%-65'("')"-B6$'(5+"$99-%+'(/.0"6-"645":%-6-9-.":%5;'-,).0"+5)9%'B5+"bJ*-%"56"$.1V"!QQCc1"HX>"

?KEKK" bHSZ>gtMAULAMZZ=FtMW>_c" ')" :%-+,95+" B0" D@UA" b3-,.-,)5V" L%$(95c1" M59-*B'($(6" 4,*$("

JSU"&$)" :%-+,95+" '(" R=X" 95..)" $(+" $,6-$96';$65+" $)" +5)9%'B5+" bF'" 56" $.1V" <22?c1" J(6'B-+0" $/$'()6"

HX>"&$)"$"G'(+"/'76" 7%-*"R1" F'('(/6-(" bJB5%+55(V"Y_c1"M59-*B'($(6" 9$645:)'()"@V"#V">V" FV" A"&5%5"

:,%94$)5+"7%-*"J645()"M5)5$%94"]"3594(-.-/0"bJ645()V">JV"YAJc1"M$BB'6"9$645:)'("F"$(6'B-+0"&$)"$"

Page 78: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

ON""

"

G'(+"/'76" 7%-*"J(("S%'9G)-(" bY(';5%)'60"-7"W-%64"R$%-.'($V"R4$:5."='..V"WRc1"JSU" '(4'B'6-%" bJSU'c"<VNE

+'*5640.EB5(I-'9"$9'+"?EB5(I0.-809$%B-(0.$*'(-ECE9$%B$*-0.E<E-8-EB,60."5)65%"&$)",)5+"$6"!2"µH"

$(+":%-;'+5+"B0"=1"X;5%G.5576"bF5'+5(V"W5645%.$(+)c1"uE>$.95%"$(+">$."α!1C"/$."αR5%"&5%5"$"G'(+"/'76"

7%-*"J.B5%6"@5(+5.$9"bA6"F-,')"YAJc1"

5>GH=>=?CAB+A[+!P\0A=?GO+"G=OK"

C"�"!2O"?"�*".$658"W=<EB5$+)"bU-.0)9'5(95c"&5%5"$96';$65+"&'64"P|"/.,6$%$.+540+5"7-%"<"4%"$6"%--*"

65*:5%$6,%5" bM3c1" @5$+)" &5%5" &$)45+" &'64" U@A" $(+" '(9,B$65+" -;5%('/46" bXTWc" &'64" +'775%5(6"

.'/$(+)^" !22"�/T*." -7" Lb$B′c<" /-$6" $(6'E*-,)5ED/H" bHU" B'-*5+'9$.)c" $(+" !22" �/T*." -7" H05.'("

X.'/-+5(+%-9065">.09-:-%-65'("HX>"-%"HX>":%-65'("$.-(51"

&B+]C?>A+OCPGK?CABK+

!2"�/"-7"HX>"&5%5"+'/5)65+"&'64"21!"�/"-7" %59-*B'($(6"9$645:)'()V"JSU"-%"!2"�/"-7"&'.+E60:5"-%"

JSUE+57'9'5(6" 95.." .0)$65)" &'64" -%" &'64-,6" !2" �H" -7" JSU'1" 345" %5$96'-(" B,775%" 9-(6$'(5+" K2" *H"

)-+',*"9'6%$65":="K1KV"K"*H"#33"$(+"21!|"R=JUA1"345"%5$96'-("&$)"$..-&5+"6-":%-955+" 7-%"C4"$6"

?O�R"$(+"645":%-+,96)"$($.0)5+"B0"A#AEUJ>S"$(+")6$'(5+"&'64"9--*$))'5"@.,51"

5F=PAKAV=I+4(9+OGP>=O=?CAB+=KK=U+

@H#R)"&5%5":,.)5+"7-%"!K"*'(,65)"&'64"HX>"9-$65+"B5$+)"$6"?O�R"$(+"94$)5+"7-%"+'775%5(6"6'*5)"

bN2"$(+"!P2"*'(,65)c"$6"?O�R1"R5..)"&5%5".0)5+"'("K2*H"3%')E=R."b:="O1Cc"),::.5*5(65+"&'64"!K2*H"

W$R.V" !*H"#33V"21K|"WUEC2"$(+"$" 9-9G6$'." -7":%-65$)5" '(4'B'6-%)" bM-945c1" L-%" LJRA"$($.0)')V" .$658"

B5$+)"&5%5")6$'(5+"&'64"$"*-(-9.-($."$(6'EHX>"$(+"$")59-(+$%0"$(6'E*-,)5"J.58$"CPP"bH-.59,.$%"

U%-B5)c1"

!B?CPGB+H>GKGB?=?CAB+=KK=UK+=BO+&VVEBC^=?CABK+

R5..)"7%-*"):.55(V"640*,)"-%"B-(5"*$%%-&"+$0"!2"&5%5":,.)5+"&'64"5'645%"HX>V"HX>"9-$65+"B5$+)V"

αE>$.$96-)0.95%$*'+5" -%" >$." α!C" /$." αR5%" 7-%" <C4" -%" +'775%5(6" 6'*5)" $(+" 645(" 7'85+" '(" 212K|"

/.,6$%$.+540+5"7-%"<2")591"R5..)"&5%5"[,5(945+"&'64"21!"H"-7"/.09'(5"$(+"645("5865()';5.0"&$)45+"

$(+"9-E9,.6,%5+"&'64"):59'7'9"3"95..)" 7-%"<C41"HX>"3"95..)"$%5"):59'7'9"7-%"645"?KEKK"+-*'($(6"HX>"

:5:6'+5"$(+"&5%5"G'(+.0 /';5("B0"A1"J(+5%6-("bY(';5%)'60"-7"S+'*B,%/4V"Y_c1"3%$()/5('9"X3EDD"R#C"3"

95..)" &5%5" 4$%;5)65+" 7%-*" 645" :5%':45%$." .0*:4" (-+5)" -7" 3RM" 6%$()/5('9" *'951" W_3" Zα!C" 95..)"

40B%'+-*$"&5%5"$"G'(+"/'76" 7%-*"J.B5%6"@5(+5.$9" " bA6"F-,')V"YAJc1"g'.+"60:5"-%"JSUE"+57'9'5(6"*'95"

&5%5" '**,('I5+" &'64" K2"µ/" -7" %HX>" 5*,.)'7'5+" '(" RLJ" '(" 5$94" 7--6:$+1" !2" +$0)" .$65%V" FW" &5%5"

4$%;5)65+"$(+"95..)"&5%5"-B6$'(5+"$765%"*594$('9$."+')%,:6'-("$(+")55+5+"$6"21K8!2KT&5.."'("QN"&5.."

Page 79: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

OO""

"

:.$65)"6-/5645%"&'64"+'775%5(6"9-(95(6%$6'-()"-7"%HX>1"R#Cp"3"95..)"&5%5":,%'7'5+",)'(/"645"H'.65(0'"

(5/$6';5")5.596'-("G'61"3"95.."$96';$6'-("&$)"$))5))5+"5'645%"B0"645":%5)5(95"'("645"),:5%($6$(6"-7"DFE<"

,)'(/"$("5(I0*5E.'(G5+"'**,(-)-%B5(6"$))$0"G'6"bU4$%*'(/5(c"-%"B0",:6$G5"-7"640*'+'(5"&4'94"&$)"

$++5+" 7-%" 645" .$)6" !N4" $(+" *5$),%5+" ,)'(/" $" .'[,'+" )9'(6'..$6'-(" βE9-,(65%" bF_@" g$..$9V" 3,%G,V"

L'(.$(+c1""

5>A?G=KG+=KK=UK+=BO+CVVEBADIA?+

R$645:)'("F"$96';'60"')"$))$05+",)'(/"$"):59'7'9":%-B5"&4'94"$765%"B'(+'(/"R$6F"9$6$.06'9")'65"7.,-%5)95"

$6"K<K"(H"&$;5.5(/64"bD**,(-945*')6%0V"YAJc1"R5..)"&5%5" .0)5+" '("K2"*H"3%')V"!K2"*H"W$9.V"!|"

WUC2"$(+"'(4'B'6-%"9-9G6$'.)"b@-54%'(/5%V"H$((45'*c"7-%"?2"*'("-("'951"g5"+565%*'(5+"645":%-65'("

9-(95(6%$6'-(",)'(/"$"@RJ"$)))$0"G'6" bU'5%95V"M-9G7-%+V" D.c1"A$*:.5)"&5%5" 7%$96'-($65+"B0"A#AEUJ>S"

$(+"6%$()75%%5+"6-"('6%-95..,.-)51"g5"+565965+"R$6F",)'(/":-.09.-($.":%'*$%0"$(6'B-+01"

5EIKG\0F=KG+=BO+&VVEBAH>GJCHC?=?CAB++

@H#R)"&5%5":%5'(9,B$65+"'("H56TR0)E7%55"#HSH"*5+',*"7-%"!41"R5..)"&5%5"645(":,.)5+"7-%"?2"*'("

&'64"21K"*R'"-7"?KAEH56TR0)"bJ*5%)4$*c"$(+"94$)5+"'(",(.$B5.5+"*5+',*"),::.5*5(65+"&'64"K"*H"

9-.+"*564'-('(5"'("645":%5)5(95"-%"$B)5(95"-7"JSU"'(4'B'6-%"7-%"645"'(+'9$65+"6'*5)1"R5..)"&5%5".0)5+"

'(" $"B,775%" 9-(6$'('(/"<2"*H"3%')E=RF" bU="O1KcV" !K2"*H"W$9.V" <*H"H/R.<V" !|"WUC2V" !|A#A"$(+"

'(4'B'6-%"9-9G6$'."bM-945c"$(+"45$65+"$6"QK�R"7-%"!2"*'(1""S$94")$*:.5"&$)"(-%*$.')5+"7-%"645")$*5"

(,*B5%"-7"95..)1"345"5.,65+":%-65'()"&5%5"+'.,65+" '(6-"!"*F"-7" .0)')"B,775%V":%59.5$%5+"&'64"*-,)5"

)5%,*"$(+"R$6F"&$)"'**,(-:%59':'6$65+",)'(/"$":-.09.-($."%$BB'6"$(6'B-+01"

$!$+CBOEJ?CAB+

H'95"&5%5" '(e5965+")191"&'64"K2"�/"-7"HX>"5*,.)'7'5+"&'64"D(9-*:.565"L%5,(+h)"J+e,;$(6"-("+$0"2"

$(+" O1" H'95" &5%5" *-('6-%5+" +$'.0" $(+" )9-%5+" $99-%+'(/" 6-" $" (5,%-.-/'9$." )9$.5^" 2V" (-%*$.k" !V"

:$%$.0)')"-%" ):$)6'9'60"-7" 645" 6$'.k" <V" '*:$'%5+" %'/46'(/" %57.58k"?V":$%5)')"-7"4'(+.'*B)k"CV":$%$.0)')"-7"

4'(+.'*B)"$(+"KV"+5$641"D(":$%$..5.V"645".-))"'("B-+0"&5'/46"&$)"$.)-"*5$),%5+1"

"

+

+

+

+

Page 80: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

OP""

"

#GKEI?K"

QCPE>G+1+

+

QCPE>G+1@"5>AJGKKCBP+A[+4(9+=B?CPGB,+ T!W+HX>":%-65'("&$)"+'/5)65+" ()" /(&$%"5'645%"&'64"+'775%5(6"

%59-*B'($(6" :%-65$)5)" b21!" �/c" -%" &'64" !2" �/" -7"g3" -%" JSU" +57'9'5(6" @H#R)" .0)$65)" C4" $6" ?O�R1"

#'/5)6'-()"&5%5"+-(5" '("K2*H"9'6%$65"B,775%"$6":="K1K1"345"%5$96'-()"&5%5")5:$%$65+"-("$"@')E3%')"

W,:$/5"/5."bW-;58c"$(+")6$'(5+"7-%"9--*$))'5"B.,51"T"W+g3"-%"JSU"+57'9'5(6"@H#R)"&5%5":,.)5+"7-%"

!K"*'("&'64"HX>"9-$65+"B5$+)"b/%$0"4')6-/%$*)c"$(+"645("94$)5+"7-%"+'775%5(6"6'*5)"bB.$9G".'(5)c1"

@H#R)" &5%5" .0)5+" $(+" HX>" 9-$65+" B5$+)" &5%5" %59-;5%5+1" HX>" $(6'/5('9" +5/%$+$6'-(" &$)"

*-('6-%5+"B0"7.-&"906-*56%0"B0",)'(/"):59'7'9"*-(-9.-($."$(6'EHX>"$(6'B-+01"+

!%).:42(%)a"345)5"%5),.6)")4-&"64$6"9$645:)'()"@"$(+"F"7,..0"+5/%$+5"HX>":%-65'(k"$B)5(95"-7"JSU"

$.)-" '(+,95)"HX>":%-65'("+5/%$+$6'-(1" D(" $++'6'-(V" $995.5%$65+":%-65-.0)')"-7"HX>" ')"-B)5%;5+" '("

JSU"+57'9'5(6"95..)"&45("9-*:$%5+"6-"g3"95..)1"

+

+

+

+

+

+

+

Page 81: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

OQ""

"

QCPE>G+:+

"

QCPE>G+ :@+ 4(9+ =B?CPGB+ H>GKGB?=?CAB+ '2* ('&/0* CK+ KG]G>GIU+ >GOEJGO+ CB+ !50K+ I=J_CBP+ !$5,+ !\QW+ JSU"

+57'9'5(6" @H#R)" bB.$9G" )[,$%5)cV" g3" b-:5(" .-)$(/5)c" @H#R)" &5%5" :,.)5+" &'64" 645" '(+'9$65+"

9-(95(6%$6'-()"-7"HX>"T!WV+):59'7'9"HX>":5:6'+5"b?KEKKc+T0W"-%"7-%"+'775%5(6"6'*5)"&'64+K2"�/T*F"-7"

HX>"$(6'/5(" $(+" 645(" 7'85+" T"W" B57-%5" B5'(/" 9-E9,.6,%5+"&'64"HX>" ):59'7'9" R#Cp"3" 95..)1" U%'*$%0"

*$6,%5"@"95..)"&5%5":,.)5+"&'64"B5$+)"9-$65+"&'64"HX>"$(6'/5("$.-(5"-%"6-/5645%"&'64"@RM".'/$(+"

-%"&'64"):59'7'9"HX>":5:6'+5"7-%"N"4-,%)V"&$)45+"$(+"'(9,B$65+"&'64"HX>"):59'7'9"R#Cp"3"95..)"T.W1"

@H#R)"+57'9'5(6"7-%"5'645%"9$645:)'("F"T$W"-%"9$645:)'("@"TQW+&5%5":,.)5++7-%"+'775%5(6"6'*5)"&'64+K2"

�/T*F" -7" HX>" $(6'/5(" $(+" 645(" 7'85+" B57-%5" B5'(/" 9-E9,.6,%5+" &'64" HX>" ):59'7'9" R#Cp"3" 95..)1+

J(6'/5(":%5)5(6$6'-("&$)"*5$),%5+"B0"DFE<"%5.5$)5"7%-*"HX>"3"95.."9.-(51"

!%).:42(%)a"J.6-/5645%V"645)5"%5),.6)")4-&"64$6"JSU"+57'9'5(90"'*:$'%)"HX>"$(6'/5(":%5)5(6$6'-("()"

/(&$%V"&45%5$)"9$645:)'("@"-%"F"+57'9'5(90"+-5)"(-6"'(7.,5(95"HX>"$(6'/5(":%5)5(6$6'-(1""

+

+

+

+

+

Page 82: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

P2""

"

QCPE>G+8+

+

+

QCPE>G+8@+ 72*('(0+4(9+H>AJGKKCBP+ CK+OGI=UGO+ CB+=DKGBJG+A[+!$5,+JSU"g3"-%"_X"*'95"&5%5" '(e5965+"

&'64"HX>" $(6'/5(" T!W+ 5*,.)'7'5+"&'64" RLJ" '(" 645" 7--6:$+)1" !2" +$0)" .$65%" .0*:4" (-+5)" bFWc"&5%5"

4$%;5)65+" $(+" %5)6'*,.$65+" ()" /(&$%" &'64" +'775%5(6" 9-(95(6%$6'-()" -7" %59-*B'($(6" HX>1" T"W+g3+

@H#R)" &5%5" :,.)5+" &'64" K2" �/T*F" -7" HX>" :%-65'(" 7-%" +'775%5(6" 6'*5)" $(+" 645(" 7'85+" $(+" 9-E

9,.6,%5+"&'64"R#Cp"3"95..)":,%'7'5+"7%-*"FW"7%-*"JSU"g3"-%"_X"HX>E'(e5965+"*'951"U%-.'75%$6'-("&$)"

*5$),%5+"B0"'(9-%:-%$6'-("-7"b?=c"640*'+'(5"$765%"O<"4-,%)1""

!%).:42(%)a"R#Cp"3"95..)"7%-*"JSU"_X"*'95"$%5":%'*5+"$6"$"%5+,95+".5;5."&45("9-*:$%5+"6-"g3"95..)"

9-(7'%*'(/"645"()"/(&$%"+$6$1"

"

"

"

"

"

"

+

+

LN AEP wt

LN AEP ko

0

50000

100000

150000

200000

1 10 100

MOG concentration (µg/ml)

CP

M (

Th

ymid

ine

inco

rpo

ratio

n) B A

0

5000

10000

15000

20000

0 60 120 240

Time (min)

MOG antigen

CD4+ AEP wt

CD4+ AEP ko

Page 83: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

P!""

"

QCPE>G+-+

"

QCPE>G+-@+0=?FGHKCB+6+=J?C]C?U+ CK+ CBJ>G=KGO+ CB+!$5+OG[CJCGB?+JGIIK,+ T!W"A945*$6'9";'5&"-7"9$645:)'("F"

:%-95))'(/1"R$645:)'("F"')")0(645)'I5+"$)"$":%-7-%*"$(+"645")'/($.":5:6'+5"')"%5*-;5+"$765%"%5$94'(/"

645"5(+-)-*51"U%-E9$645:)'("F" ')"645(":%-95))5+"6-"$")'(/.5"94$'("bARc"7-%*1"345"6&-"94$'("b45$;0"

$(+" .'/46" 94$'()c" 7-%*" ')" -B6$'(5+" $765%" 9.5$;$/5" -7" 645" )'(/.5" 94$'(1" T"W+ R$645:)'(" F" $96';'60" ')"

5(4$(95+"'("JSU"+57'9'5(6"@H#R)"b/%55(".'(5c"9-*:$%5"6-"g3"@H#R)"b%5+".'(5ck"9$645:)'("F"$96';'60"

&$)" $))$05+" ,)'(/" $" ):59'7'9" :%-B5" &4'94" $765%" B'(+'(/" R$6F" 9$6$.06'9" )'65" 7.,-%5)95" $6" K<K" (*"

&$;5.5(/64" +565965+" B0" 7.-&" 906-*56%01" T0W+ @H#R)+&5%5" :,.)5+" 7-%" ?2" *'(" &'64"?KAV" 94$)5+" 7-%"

+'775%5(6"6'*5)"$)"'(+'9$65+"&'64"-%"&'64-,6"JSU"'(4'B'6-%"$(+"645("645"+'775%5(6"7-%*)"-7"9$645:)'("F"

&5%5" '**,(-:%59':'6$65+" ,)'(/" $" ):59'7'9" $(6'B-+0" $/$'()6" 9$645:)'(" F1" JSU" '(4'B'6'-(" :%5;5(6)"

9$645:)'("F"*$6,%$6'-("'(6-"645"6&-"94$'("7-%*"),//5)6'(/"$("'(;-.;5*5(6"-7"JSU"'("/5(5%$6'(/"645"

*$6,%5" 7-%*" -7" 9$645:)'(" F1" T.W" 3-6$." .0)$65)" 7%-*"JSU"g3" $(+" _X" @H#R)" $(+" ):.5('9" #R)"&5%5"

'**,(-B.-665+"7-%"9$645:)'("F1"JSU"_X"95..)":-))5))"$("'**$6,%5")'(/.5"94$'("9$645:)'("F"&45%5$)"

9$645:)'("F"'("g3"95..)"58')6)"'("'6)"*$6,%5":%-95))5+"7-%*1" +F0*:4-B.$)6-'+"95..".'(5"A#!"95..)"bEc"-%"

-;5%58:%5))'(/"JSU"bpc"&5%5"),Be5965+"6-"&5)65%("B.-6"7-%"9$645:)'("F1"

!%).:42(%)a"J.6-/5645%V"645)5"%5),.6)")4-&"64$6"'("$B)5(95"-7"JSUV"9$645:)'("F"*$6,%$6'-(":%-95))"')"

'*:$'%5+1"A,%:%')'(/.0V" '**$6,%5")'(/.5"94$'(" 7-%*" b645":%5+-*'($(6" 7-%*" '("JSU"+57'9'5(6"95..)c" ')"

*-%5" $96';5" 64$(" 645" *$6,%5" 6&-E94$'(" 7-%*1" D(" $++'6'-(" $(+" $)" 58:5965+V" JSU" -;5%58:%5))'-("

%5),.6)"'("645"/5(5%$6'-("-7"645":%-95))5+"6&-E94$'("7-%*"-7"9$645:)'("F1"

SP

C

?AEP

Heavy chain Light chain

Procathepsin L

Single chain

Propeptide

Processing of cathepsin L

DSNKN

S

33

21

52

0 30min 3h o/n

WT

Proform

HeavyChain

Single Chain

+ AEP

inhibitor

0 3h

A

IP:CatL

D

B

Activecathepsin L

AEPWT

AEPKO

BMDCs

33

21

Single Chain

Heavy Chain

52

KOWTKOWT

BMDCs sDCs

SD1 cells - +

Page 84: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

P<""

"

QCPE>G+`"

""

"

QCPE>G+`@+)S'+ JGII+ =J?C]=?CAB+ CK+ GBF=BJGO+ CB+!$5+OG[CJCGB?+ JGIIK,+J(6'/5(":%5)5(6$6'-("$))$0)"&5%5"

:5%7-%*5+",)'(/"5'645%"g3" b&4'65" .-)$(/5)c" -%"JSU"+57'9'5(6"+5(+%'6'9" 95..)" bB.$9G" )[,$%5)c" :,.)5+"

&'64"6&-"+'775%5(6".':'+"$(6'/5()^"uE/$.$96-)0.95%$*'+5"T!W"-%">$."u"!VC"u"R5%"T"W+7-%"+'775%5(6"6'*5)"

$(+"645("7'85+"B57-%5"B5'(/"9-E9,.6,%5+"&'64"W$6,%$."_'..5%"3"bW_3c"95.."40B%'+-*$1"

!%).:42(%)a" >';5(" 64$6" 645" :%5)5(6$6'-(" -7" >$." u" !VC" u" R5%" $(6'/5(" 6-" W_3" 95..)" ')" )4-&(" 6-" B5"

+5:5(+5(6"-("9$645:)'("F"b_1"=-(50"56"$.1V"<22<cV"&5":5%7-%*5+".':'+"$(6'/5(":%5)5(6$6'-("$))$0)"6-"

W_3"95..)"6-"$))5))"645"$96';'60"-7"9$645:)'("F"'("JSU"&6"$(+"+57'9'5(6"+5(+%'6'9"95..)1"g5"-B)5%;5"64$6"

W_3" 95.." $96';$6'-(" ')" 5(4$(95+" '(" JSU" +57'9'5(6" 95..)" &45(" 9-*:$%5+" 6-" 9-(6%-." 95..)1" 34')"

5(4$(95*5(6"'("W_3"95..":%-.'75%$6'-("')"*-)6":%-B$B.0"+,5"6-"645"'(9%5$)5+"$96';'60"-7"9$645:)'("F1"

D(" $++'6'-(V" JSU" &6" $(+" JSU" +57'9'5(6" +5(+%'6'9" 95..)" :%5)5(6" uE/$.$96-)0.95%$*'+5V" &4'94" +'%596.0"

B'(+)"95.."),%7$95"R+!"*-.59,.5)V"$6"$")$*5".5;5."6-"W_3"95..)1"

+

+

+

+

+

+

+

+

IL-2

re

lea

se (

ng

/ml)

0

80

160

240

320

0 60 120 180 240 Time (min) Time (min)

0

70

140

210

280

350

0 60 120 180 240

α-Galcer Gal α1,4 gal αCer A B

Page 85: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

P?""

"

+

+

QCPE>G+<+

+

QCPE>G+<@+!$5+OG[CJCGB?+VCJG+OA+BA?+OG]GIAH+$!$+=[?G>+4(9+CBaGJ?CAB+NFGB+JAVH=>GO+?A+X'+VCJG,+

JSU"g3"$(+"_X"*'95"&5%5"'(e5965+"'("645"7--6:$+"&'64"K2�/"-7"HX>":%-65'("5*,.)'7'5+"'("R-*:.565"

L%5,(+h)"J+e,;$(61"345".-))"'("B-+0"&5'/46"T!W"$(+"SJS"+')5$)5")9-%5"T"W"&5%5"7-..-&5+"7-%"??"+$0)1""

!%).:42(%)a"JSU"+57'9'5(6"*'95"+-"(-6"+5;5.-:"SJS1"

" "

0 5 10 15 20 25 30 35

-15

-10

-5

0 WT KO

Days after EAE induction

∆ i

n B

od

y w

eig

ht

(%)

10 15 20 25 30 35 0

1

2

3

4

Days after EAE induction D

ise

ase

Sco

re

A B

Page 86: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

PC""

"

#GKEI?K+=BO+.CKJEKKCAB+

H05.'("X.'/-+5(+%-9065">.09-:%-65'("HX>"')"'*:-%6$(6"'("645":%-95))"-7"*05.'('I$6'-("-7"(5%;5)"'("

645" 95(6%$." (5%;-,)" )0)65*1" D(" :$64-.-/'9$." 9-(+'6'-()V" HX>" ')" $" 6$%/56" $,6-E$(6'/5(" $(+" '6)"

%59-/('6'-(" $(+" :%5)5(6$6'-(" 6-" ):59'7'9" 3" 95..)" .5$+" 6-" $,6-'**,(5E*5+'$65+" +5*05.'($6'-("

+')5$)5)"),94"$)"*,.6':.5")9.5%-)')1"

g5":%-;'+5"5;'+5(95"64$6"HX>":%-65'("')"6-6$..0"+'/5)65+"B0"9$645:)'("FV"9$645:)'("@"$(+"B0":%-65'("

.0)$65" 7%-*" JSU" +57'9'5(6" B-(5" *$%%-&" +5%';5+" +5(+%'6'9" 95..)" bL'/,%5" !JcV" ),//5)6'(/" 64$6" JSU"

+57'9'5(6" 95..)" :-))5))" 4'/45%" :%-65$)5)" $96';'60" :%-B$B.0" -7" 9$645:)'(" F" $(+" @" 64$6" $%5" $B.5" 6-"

+5/%$+5"HX>"$(6'/5(1"34')"%5),.6"9-%%5.$65)"&'64"645"$995.5%$65+"HX>"+5/%$+$6'-("-B)5%;5+"'("JSU"

+57'9'5(6" @H#R)" &45(" :,.)5+" &'64" HX>" $(6'/5(" 645(" 94$)5+" 7-%" +'775%5(6" 6'*5)" bL'/,%5" !@c1"

J.6-/5645%V" 645)5"-B)5%;$6'-()" ),//5)6" 64$6"+57'9'5(90" '("JSU"5(4$(95)"HX>":%-65'("+5/%$+$6'-(V"

&4'94"')"9-(7'%*5+"B0"$"+59%5$)5"-7"HX>"$(6'/5(":%5)5(6$6'-("6-"):59'7'9"3"95..)"B0"B-64"@H#R)"$(+"

@"95..)"()"/(&$%"bL'/,%5"<J"$(+"<#c1"D("$++'6'-(V"9$645:)'("F"-%"@"+57'9'5(90"+-5)"(-6"$77596"HX>"H=R"

9.$))"DD"$(6'/5(":%5)5(6$6'-("bL'/,%5"<#"$(+"<Lc1"H-%5-;5%V" ()"/(/%")6,+'5)"$.)-")4-&"$"+59%5$)5"'("3"

95..)" :%'*'(/" $(+" :%-.'75%$6'-(" '(" .0*:4" (-+5)" -7" JSU" +57'9'5(6"*'95" &45(" 94$..5(/5+" &'64"HX>"

$(6'/5("bL'/,%5"?J"$(+"?@c1""

J)":%5;'-,).0"%5:-%65+V"9$645:)'()"@V"#"$(+"FV"'(;-.;5+"'("$(6'/5(":%-95))'(/"$(+"3"95..")5.596'-(V"7$'."

6-" B5" :%-95))5+" '(" 645'%" *$6,%5" 7-%*)" '(" 640*'9" $(+" +5(+%'6'9" 95..)" .$9G'(/" JSU" $96';'601" D(+55+V"

9$645:)'("F"64$6"')")0(645)'I5+"$)"$":%-5(I0*5V"')":%-95))5+"7%-*"'6)"'**$6,%5")'(/.5"94$'("7-%*"6-"$"

*$6,%5"6&-E94$'("b45$;0"$(+".'/46"94$'()c"7-%*"bL'/,%5"CRc1"34')"*$6,%$6'-("')"JSU"+5:5(+5(6V"/';'(/"

64$6"'("JSU"+57'9'5(6"95..)V"645"*$6,%$6'-(":%-95))"')"B.-9G5+"$6"645")'(/.5"94$'("7-%*"bL'/,%5"CR"$(+"

C#c1"D(65%5)6'(/.0V"645"'**$6,%5"7-%*"b64$6"')"+-*'($(6"'("JSU"+57'9'5(6"95..)c"')"*-%5"$96';5"64$("645"

*$6,%5"7-%*"bL'/,%5"C@c"'(+'9$6'(/"64$6"JSU"%5/,.$65)"9$645:)'("F"*$6,%$6'-("$(+"$96';'601"R$645:)'("

F"')"%5[,'%5+"7-%"645"+5;5.-:*5(6"-7"W$6,%$."_'..5%"3"bW_3c"95..)"$(+"7-%"645":%5)5(6$6'-("-7".':'+)"6-"

W_3" 95..)" b=-(50" _" 56" $.1V" <22<c1" R-()5[,5(6.0V" 6-" $))5))" 9$645:)'(" F" $96';'60V" &5" :5%7-%*5+" .':'+"

:%5)5(6$6'-("$))$0)"6-"W_3"95..)1"J)"58:5965+V"$("5(4$(95*5(6"-7"W$6,%$."_'..5%"3"95..)":%-.'75%$6'-("

'(" JSU" +57'9'5(6" 95..)" &$)" -B)5%;5+" '(" 9-*:$%')-(" 6-" 9-(6%-." 95..)" bL'/,%5" K@c1" D(" $++'6'-(V" JSU"

+57'9'5(6"*'95"+-"(-6"+5;5.-:"SJS" bL'/,%5"NJ"$(+"N@c" '(+'9$6'(/" 64$6"*$0B5" '(9%5$)5+"9$645:)'(" F"

$96';'60"%5),.6)"'("645"9-*:.565"+5/%$+$6'-("-7"645"'**,(-+-*'($(6"HX>"5:'6-:5"'*:-%6$(6"'("SJS"

'(+,96'-(1""""

D(" 9-(9.,)'-(V" &5" +5*-()6%$65" 64$6" J):$%$/'(5" 5(+-:5:6'+$)5" ')" '*:-%6$(6" '("H=R" 9.$))" DD" HX>"

$(6'/5(":%5)5(6$6'-("B0"%5/,.$6'(/"9$645:)'("F"$96';'601"D(9%5$)5+"9$6F"$96';'60"$..-&)"645"$995.5%$65+"

+5/%$+$6'-(" -7" HX>" $(6'/5(V" %5),.6'(/" '(" %5+,95+" SJS" +')5$)5" '(+,96'-(1" 3$%/56'(/" JSUV" &'64" '6)"

Page 87: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

PK""

"

):59'7'9" '(4'B'6-%" b*b=<YYM=KE" 9-,.+" B5" $" 645%$:5,6'9$." -:6'-(" '(" 645" '(7.$**$6-%0" +5*05.'($6'(/"

+')5$)5"*,.6':.5")9.5%-)')1"

" "

Page 88: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

PN""

"

DDD1"D(6%$95..,.$%"3-..EF'G5"%595:6-%)"%59%,'6*5(6"$(+"9.5$;$/5"'("

5(+-)-*$."T".0)-)-*$."-%/$(5..5)"

!!!!! !5<42$3?!%/+!$%/692=!>-#!?@AB-!32:<5=B$0C$DCE745F5G7?!)*+,-'00+

+ +

Page 89: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! "!

Intracellular Toll-like receptors recruitment and cleavage in

endosomal/lysosomal organelles

Mira Tohmé1,2,3 and Bénédicte Manoury1,2,&

1 INSERM, Unité 1013, 75015, Paris, France

2 Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine, 75015 Paris,

France

3 INSERM, Unité 932, Institut Curie, 75005, Paris, France

&Corresponding author: Dr Bénédicte Manoury, INSERM, Unité 1013, Hôpital Necker-

Enfants malades, 149 rue de Sèvres, 75743 Paris cedex 15, France, Phone: +33 (0) 1 44

49 53 75; Fax: + 33 (0) 44 49 53 82; Email: [email protected]

Page 90: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! #!

Abstract

Microbial pathogens are recognized through multiple, distinct receptors such as

intracellular Toll like receptors (TLRs 3, 7, 8, 9 and 13) which reside in the endosomes and

lysosomes. TLRs are sensitive to chloroquine, a lysomotropic agent that neutralizes acidic

compartments indicating a role for endo/lysosomal proteases for their signalling. Indeed,

upon stimulation, full length TLR7 and 9 are cleaved into a C-terminal fragment and this

processing is highly dependent on a cysteine protease named Asparagine Endopeptidase

(AEP) in dendritic cells. A recruitment and a boost in AEP activity, which was induced

shortly after TLR7 and 9 stimulation, are shown to promote TLR7 and 9 cleavage and

correlate with an increased acidification in endosomes and lysosomes. Moreover, mutating

a putative AEP cleavage site in TLR7 or 9 strongly decreases their signalling in DCs

suggesting perhaps a direct cleavage of TLR7 and 9 by AEP. These results demonstrate

that TLR7 and 9 require a proteolytic cleavage for their signalling and identified a key

endocytic protease playing a critical role in this process.

Page 91: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! $!

Introduction

Toll like receptors (TLRs) are molecules, which recognize conserved molecules from

microorganisms and in dendritic cells (DCs), they are crucial in linking innate to adaptive

immunity. TLRs contain several leucine rich repeats (LRR) in an extracellular loop, a trans-

membrane domain and a cytosolic domain and are expressed either at the plasma

membrane or in the endosomal/lysosomal organelles. TLR stimulation is linked to MyD88

or TRIF-dependent signaling pathways that regulate the activation of different transcription

factors, such as NF-kB (Janeway and Medzhitov, 2002). Specific interaction between

TLRs and their ligands activates NF-kB resulting in enhanced inflammatory cytokine

responses, induction of DC maturation and expression of chemokine receptors. TLRs

expressed at the plasma membrane recognized Gram-negative bacteria and endosomal

TLRs sense viral and bacterial nucleic acids such as double/single-stranded RNA or DNA.

Endogenous ligands called DAMPs (for damage associated molecular patterns) may also

activate TLRs during self-tissues or cell damage. Recent findings have described the

importance of proteolysis for endosomal TLRs function (Ewald et al., 2008; Park et al.,

2008; Garcia-Cattaneo et al., 2012) and TLRs activation have been shown to boost MHCI

cross presentation in DCs (de Brito et al., 2011; Sathe et al., 2011). Upon stimulation, full-

length (FL) TLR9 is cleaved into a C-terminal (C-ter) fragment sufficient for signalling. This

cleavage is realized by several cathepsins in different cells, including macrophages, while

in DCs this cleavage is performed mainly by cathepsin K (CatK) and Asparagine

Endopeptidase (AEP). In CatK deficient DCs, TLR9 signaling is abrogated and in DCs

lacking AEP, TLR9 cleavage in phagosomal compartments as well as CD4+ antigen

specific T cell proliferation was greatly reduced upon CpG stimulation (Asagiri et al., 2008;

Sepulveda et al., 2009). TLR7 is also subjected to similar proteolytic maturation and

requires AEP for proper signaling (Maschalidi et al., 2012). Altogether these results

indicate that endosomal proteases, which are key players in generating peptides for the

MHC class II pathway (Riese et al., 1996; Nakagawa et al., 1999; Manoury et al., 1998;

Moss et al., 2005), play also an important role in intracellular TLRs activation

Page 92: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! %!

Purification of endosomes and lysosomes

Sucrose gradient fractionation !

All procedures, unless otherwise indicated are carried out at 4°C

1. 108 dendritic cells (DCs) are generated from mouse bone marrow by culturing

precursors for 7–10 days in Iscove’s Modified Dulbecco’s Medium (IMDM, Sigma,

I3390) supplemented with 10 FBS, 1% PS, 1% GLN and 10 ng/ml GM-CSF (Peprotech,

315-03).

2. Detach BMDCs (bone marrow derived dendritic cells) with PBS-EDTA 5 mM (10

minutes at 37°C).

3. After two washes in PBS, and one wash in Homogeneization Buffer (HB : 3 mM

imidazole, 8% sucrose, 1 mM DTT, 1 mM EDTA supplemented with 1 tablet of

proteases inhibitor coktail (Roche), pH 7.4), cells are homogenised with a cell craker in

HB buffer through a ball of 0,006 mm of clearance (ball number 6) in order to have 80%

of mortality.

4. Postnuclear supernatant (PNS) is prepared by centrifugation (1000 g for 10 min).

5. PNS is adjusted with 62% of sucrose solution in order to have a final concentration of

40.6% of sucrose.

6. A gradient of sucrose is prepared following this order from the bottom to the top:

2 mL of PNS containing endosomes and lysosomes

3 mL of 35% of sucrose

2 mL of 25% of sucrose

4 mL of HB

7. After ultracentrifugation for 90 minutes with no brake using the SW41 rotor, fractions are

collected. The interface/ring between the 35% and 25% sucrose corresponds to the

early endosomes while the one between the 25% of sucrose and the HB buffer

corresponds to the late endosomes.

8. The fractions are concentrated by ultracentrifugation using the TLA110 rotor for 30

minutes at 35000 rpm.

9. Pellets are resuspend in 50 µL of PBS and can be either frozen or used immediately for

a western blot.

Page 93: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! &!

Percoll gradient fractionation (lysosome purification)

Lysosomes purification !

1. DCs are prepared and homogenised as described in 2.1.1 and 1.2.

2. The homogenate is centrifuged at 2000 rpm for 10 min and the PNS is recovered and

underlaid with 23mL of 27% of percoll.

3. After centrifugation for 60 min at 23 000 rpm using the Ti45 rotor, fractions were

collected by upward displacement using a fractions collector.

4. Fractions are collected and assayed for β-hexosaminidase activity (check 2.2.2).

5. Positive fractions corresponding to lysosomes are pooled and centrifuged for 60 min at

40 000 rpm using the Ti70.2 rotor.

6. The ring obtained is recovered with a pasteur pipette and is subjected to one more

centrifugation using the TLS-55 rotor at 50 000 rpm for 60 min.

7. Pellet containing concentrated lysosomes is collected and frozen.

β-hexosaminidase assay

!1. Add 20 µL of the sample (fractions collected in 2.2.1.3) or the blank (27% percoll) to

80 µL of Homogeneisation Buffer HB, prewarmed at 37°C.

2. Prepare the standard curve using the 4-methylumbelliferone, starting concentration

at 1nmol.

3. Add 100 µL of substrate (4-methylumbelliferyl n-acetyl β-D-glucosamide)

4. Incubate 10 min at 37°C

5. Stop the reaction by adding 100 µL of stop buffer (0,1M glycine, pH 10.3), store in the

dark

6. Read fluorescence on a fluorimeter: excitation 360 nm, emission 450 nm

Endosomes and lysosome purification using magnetic beads

1. Detach BMDCs with PBS-EDTA 5 mM (10 minutes at 37°C).

2. Wash the cells with PBS 2x.

3. Resuspend the cells in 15 ml falcon tube (10.108 cells/1 ml) in IMDM alone.

4. Add 60 µL of magnetic nanoparticles (turbobeads of 20 nm of diameter, 10mg/mL)

for 30 min at 4° C.

5. The cells are incubated 20 minutes (pulse) in the water bath at 37°C

6. Stop the reaction by adding 10 ml cold PBS-BSA 0.1% and centrifuge for 10 min at

Page 94: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! '!

1300 rpm at 4°C.

7. Repeat step 6 3 times.

8. Resuspend the cells in 2 ml of complete IMDM medium and split the cells in 2

falcon tubes of 15 ml (1ml of cells each).

9. Add 10 ml cold PBS-BSA 0.1% for t=0 (pulse) and leave on ice, put the other tube

at 37°C for 100 minutes (chase).

10 T=0 correspond to early endosomes (20 minutes of pulse), t=120 minutes

correspond to lysosomes.

11 At the end of the chase, centrifuge the cells.

12 Now, perform the end of the experiment on ice.

13 Wash the cells in HB buffer.

14 Resuspend the cells in 1ml of HB buffer.

15 Break the cells using a 1ml syringe and a 22g needle. You need about 30 flushes to

break the cells. Check the breaking of the cells under a microscope (about 80% of

the cells should be dead).

16 Transfer the breaking cells into cold eppendorf tubes and place the eppendorf tubes

on the magnetic stand on ice.

17 Leave 5 minutes; aspirate the supernatant with a thin tip. Keep the SNT aside.

18 Wash the beads carefully with 1ml PBS-BSA 0,1% and repeat step 18 8x.

19 Resuspend the beads in 50 µL of lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl

0.5% NP40, 2 mM MgCl2, and a tablet of a cocktail of proteases inhibitors) and

leave on ice for 15 minutes.

20 Centrifuge at 12000 rpm for 15 min and freeze the supernatant.

Proteases assays

1. Buffer: 50 mM citrate buffer, pH 5.5, 1 mM DTT.

2. Protease activity assays are performed on a Mithras LB940 (Berthold

technologies) by measuring the release of fluorescent N-Acetyl-Methyl-Coumarin

(Nhmec) in citrate buffer (pH 5.5) at 37°C. Specific substrates are the following:

AEP: Z-Ala-Ala-Asn-NHMec for AEP, Z-Arg-Arg-NHMec for CatB, Z-Phe-Arg-

NHMec for CatB/L, Z-Val-Val-Arg-NHMec for CatS and Z-Gly-Pro-Arg-NHMec for

CatK.

3. Activity of the proteases is assessed using specific fluorometric substrates. 1 µg

of early or late endosomes are incubated with the different specific substrates

Page 95: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! (!

(see below) for different times. To calculate the specific activity of each protease

(µmole of substrate release per minute), a standard curve is obtained using

different concentrations of NHmec (from 0.2 to 2 µM).

4. Same assays are performed with purified endosomes or lysosomes from BMDCs

stimulated with intracellular TLRs ligands.

Intracellular TLRs processing

To check the purity of the endosomes and lysosomes obtained and to study TLR9

cleavage, proteins expressed in the endosomes and lysosomes are subjected to a

Western Blot (Burnette 1981).

1. Protein concentration is measured with a Colorimetric assay kit (Biorad )

2. Samples (5 µg of endosomes or lysosomes) are heated at 80°C for 10 minutes in

the reducing buffer (10 µl of 4X Laemli buffer supplemented with 8%of β-mercapto

ethanol).

3. Following electrophoresis, proteins are transferred on a PVDF membrane, pore

size 0,45 µm and they are stained with antibodies specific for the target proteins :

Rab 5 for early endosomes and cathepsin D for late endosomes. TLR9 cleavage is

also monitored (see Figure 1 Below).

Page 96: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! )!

Figure 1: Purity of endocytic compartments and TLR9 expression in endosomes.

Endosomes from wt (wild type) and AEP deficient BMDCs (AEP-/-

) were magnetically purified after 20 or 120

minutes. Protein expressed in total lysate (TL) or in endosomes (5 mg) were resolved by SDS-PAGE. TLR9

proteins in early (EE) and late (LE) endosomes from WT and AEP deficient BMDCs were detected by

immunoblot.

Immunodetection of early (Rab5) and late (Rab7) markers in endosomes.

FL TLR9: ful length TLR9

TLR9 N-ter: fragment corresponding to the N-terminal part of TLR9

Page 97: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! *!

References

!

Asagiri, M., T. Hirai, T. Kunigami, S. Kamano, H. J. Gober, K. Okamoto, K. Nishikawa, E. Latz, D. T. Golenbock, K. Aoki, K. Ohya, Y. Imai, Y. Morishita, K. Miyazono, S. Kato, P. Saftig, and H. Takayanagi. (2008). Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis Science 319, 624-627.

Burnette WN. (1981). “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate—polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A". Analytical Biochemistry 112, 195–203.

de Brito, C., Tomkowiak, M., Ghittoni, R., Caux, C., Leverrier, Y., and Marvel J. (2011) CpG promotes cross-presentation of dead cell-associated antigens br pre-CD8+alpha dendritic cells. J. Immunol. 186, 1503-1511.

Ewald, S. E., B. L. Lee, L. Lau, K. E. Wickliffe, G. P. Shi, H. A. Chapman, and G. M.

Barton. (2008). +,-!-./0102345!06!+0778749-!:-.-;/0:!*!4<!.7-3=-1!/0!>-5-:3/-!3!6?5./40537!:-.-;/0:@Nature 456:658-662.

Garcia-Cattaneo, A., F. X. Gobert, M. Muller, F. Toscano, M. Flores, A. Lescure, E. Del Nery, and P. Benaroch. (2012). Proc Natl Acad Sci U S A 109, 9053-9058.

Janeway, CA., and Medzhitov, R. (2002). Innate immune recognition. Annu Rev Immunol. 20,197-216.

Manoury, B., Hewitt, E.W., Morrice, N., Dando, P.M., Barrett, A.J., and Watts, C. (1998) An asparagynil endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396, 695-699.

Maschalidi S, Hässler S, Blanc F, Sepulveda F, Tohme M, Chignard M, van Endert P, Si-Tahar M, Descamps D and Manoury B. Asparagine Endopeptidase Controls Anti-Influenza Virus Immune Responses through TLR7 Activation. 2012 PLOS Pathog. Aug;8(8):e1002841 Moss, C.X., Villadangos, J.A., and Watts, C. (2005). Destructive potential of the

aspartyl protease cathepsin D in MHC class-restricted antigen processing. Eur J Immunol 35, 3442-3451.

Nakagawa, T., Roth, W., Wong, P., Nelson, A., Farr, A., Deussing, J., Villadangos, J.A., Ploegh, H., Peters, C., and Rudensky, A.Y. (1998). Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 280, 450-453.!

Park, B., Brinkmann, M.M., Spooner, E., Lee, C.C., Kim, Y.M., and Ploegh; H.H. (2008).

A:0/-07B/4.!.7-3=3>-!45!35!-5107B<0<0237!.02;3:/2-5/!4<!:-C?4:-1!60:!3./4=3/405!06!

+0778749-!:-.-;/0:!*@ Nat Immunol 9,1407-1414. Riese R.J, Wolf, P.R., Bromme, D., Natkin, L.R., Villadangos, J.A., Ploegh, H.L., and

Chapman, H.A. (1996). Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 4, 357-366.

Sathe, P., Pooley, J., Vremec, D., Mintern, J., Jin, J.O., Wu, L., Kwak, J.Y., Villadangos, J.A., and Shortman, K. (2011). The acquisition of antigne cross-presentation function by newly formed dendritic cell. J. Immunol. 186, 5184-5192.

Sepulveda F, Maschalidi S, Colisson R, Heslop L, sakka E, Ghirelli, C, Lennon-dumenil AM, Amigorena S, Cabanie L and Manoury B. Critical Role for Asparagine

Endopeptidase in endocytic TLR signalling in dendritic cells. 2009 Immunity Nov 20, 31 731-748.

!

!

!

Page 98: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

! "D!

!

!!

!

Page 99: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

PO""

"

DZ1"D(";'6%-"+'/5)6'-()"&'64":%-65$)5)":%-+,9'(/"H=R"9.$))"DD".'/$(+)"

""""""""""" 'AFVG+4,Z"H$)94$.'+'"A1"$(+"H$(-,%0"@1V"<2!<1"4G?FAOK+4AI+"CAI+QN2^K2QE!K1"

+

"

"

+

+

+

+

+

+

+

+

+

+

+

" +

Page 100: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

1

In Vitro Digestion With Proteases Producing MHC Class II Ligands

Running title: MHC class II peptides generation

Mira Tohmé1,2,3, Sophia Maschalidi1,2 and Bénédicte Manoury1,2

1Institut National de la Santé et la Recherche Médicale, Unité 1013, 75015

Paris, France

2Université Paris Descartes, Sorbonne Paris Cité, Faculté de médecine

René Descartes, 75015 Paris, France

3Institut Curie, Institut National de la Santé et la Recherche Médicale, Unité

932, 75005 Paris, France

Corresponding author :

Bénédicte Manoury, INSERM U1013, Hôpital Necker, 149 rue de Sèvres

75743 Paris cedex 15, France

E-mail address :

[email protected] Tel. +33144495375, Fax : +33144495382

Page 101: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

2

i.Summary

Proteases generate peptides that bind to MHC class II molecules to

interact with a wide diversity of CD4+ T cells. They are expressed in

dedicated organelles: endosomes and lysosomes of professional antigen

presenting cells (pAPCs) such as B cells, macrophages and dendritic cells.

The identification of endosomal proteases which produce antigenic peptides

is important for example for better vaccination and to prevent autoimmune

diseases. Here, we describe a panel of technics (in vitro digestion assays of

protein with recombinant proteases or purified endosomes/lysosomes, T cell

stimulation) to monitor the production of MHC class II ligands.

ii. Key words

MHC-II. Proteases. Endosomes/Lysosomes. Antigen processing. pAPCs.

I.Introduction

MHC class II molecules associate in the endoplasmic reticulum with a

chaperone protein: the invariant chain (1). Ii has many functions; one of

them is to deliver MHC class II complexes to endosomal/lysosomal

compartments (2). In these compartments, which also receive exogenous

antigens, proteases must perform two tasks: the generation of peptides that

will be loaded on MHC class II molecules and the proteolysis of Ii. Proteolytic

enzymes release amino acids and peptides from proteins and can be

grouped in different families based on their catalytic activities. They belong

to three major classes: aspartic, serine and cysteine families and are usually

dependent on acidic pH for their activities (3). The main enzymes present in

the endosomal/lysosomal pathway are the cathepsins (cathepsins B, C, D,

E, F, H, K, L, S) and AEP for asparagine endopeptidase. Processing of Ii is

mainly performed by cathepsin S in pAPCs (4, 5) and cathepsin L in cortical

thymic epithelial cells (6). For antigen processing, it appears that there is no

clear dependency on a single protease to generate a dedicate peptide but it

remains to be fully elucidated (7). Nonetheless, few exceptions have shown

that for example toxin tetanus C-fragment (TTCF) processing requires AEP

Page 102: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

3

(8). Proteases instead of generating peptides can also have the opposite

effect which is to destroy MHC class II ligands. Indeed, the immunodominant

peptide of a self antigen, myelin basic protein, is destroyed by AEP and a

myoglobin epitope is cleaved by cathepsins D (9, 10). Here, in this chapter,

we demonstrate that the production of MHC class II ligands generated by in

vitro digestion with proteases either purified or from lysosomes can be tested

by incubating fixed APCs together with recombinant or radiolabelled

antigens predigested with proteases and T cells.

2- Materials

We will take the example of TTCF and use the CD4+ T cell hybridomas as

readout but in principle any antigen with the specific T cell hybridoma can be

used with the same method.

2-1 Soluble antigens

Recombinant proteins such as TTCF or ovalbumin are either bought or

purified from E. Coli using standard procedures (11, 12).

2-2 T cell hybridoma

CD4+ T cells hybridoma are generated from standard procedures (13). For

example, TTCF specific T cell hybridomas were obtained by fusion between

spleens from TTCF injected mice and a thymoma lacking the expression of

the T cell receptor (14).

2-3 In vitro Digestion assays

TNT T7 or SP6 quick Coupled Transcription/Translation system

(Promega) and 35S methionine (Perkin Elmer).

Digestion buffer: 50 mM citrate buffer at pH 5.5 (mix 23.25 mL of 0.05 M

citric acid pH 5.5 with 76.75 mL of 0.05 M trisodium citrate pH 5.5), 0.1%

CHAPS, 1 mM DTT.

Page 103: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

4

2-4 Fluorometric assays

Recombinant proteases are supplied from Calbiochem.

Buffer: 50 mM citrate buffer, pH 5.5, 1 mM DTT.

Substrates: Protease activity assays are performed on a Mithras LB940

(Berthold technologies) by measuring the release of fluorescent N-Acetyl-

Methyl-Coumarin (Nhmec) in citrate buffer (pH 5.5) at 37°C. Specific

substrates for AEP (Z-Ala-Ala-Asn-NHMec), CatB (Z-Arg-Arg-NHMec),

CatB/L (Z-Phe-Arg-NHMec), CatG (Suc-Ala-Ala-Ala-Pro-Phe-NHMec), CatH

(Z-Arg-NHMec) and CatS (Z-Val-Val-Arg-NHMec) are from Bachem.The

substrate for CatK (Z-Gly-Pro-Arg-NHMec) is from Peptide Institute Inc.

2-5 Purification of endosomes and lysosomes

Magnetic nanoparticles are from Turbobeads.

Homogenization buffer (HB): 3 mM imidazole, 8% sucrose, 2 mM DTT and 5

µg/ml of DNase.

Wash buffer: PBS, 0.1% BSA.

Lysis buffer: 50 mM Tris PH7.4, 150 mM NaCl, 0.5% NP40, 2 mM MgCl2

and a tablet of cocktail inhibitors (Roche).

Magnetic stand for eppendorf tubes (Eppendorf).

2-6 10% Acrylamide Gels for SDS-PAGE

Buffer Lower TRIS 4X: 1.5 M Tris, 0.4% SDS, pH 8.8.

Buffer Upper TRIS 4X: 0.5 M Tris, 0.4% SDS, pH 6.8.

Poor resolving gel (10%): mix 6.7 ml (Stock Acrylamide/Bis 30%/0.8%) with

5 ml Lower 4X, 8.3 ml water, 70 µl Amonium persulfate (AP) 10% and 10 µl

Teemed. Add EtOH on top of the gel. It should take 30 minutes to

polymerise at room temperature. Once resolving gel is set, pour off EtOH.

Rinse with DI water. Poor stacking gel: mix 1.7 ml (Stock Acrylamide/Bis

30%/0.8%) with 1.25 ml Upper 4X, 7 ml water, 60 µl AP 10% and 20 µl

Page 104: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

5

Teemed. Load stacking solution onto the top of the resolving gel. Insert gel

comb carefully. It should take about 10-15 minutes to polymerize at room

temperature.

Running buffer: Tris 10 g, Glycine 144 g, SDS 10 g, in 1L of water.

2-7 Staining/Destaining buffer

Staining buffer: dissolve 0.6g of blue coomassie (Sigma) in 195 ml of

water and add 75 ml of propanol-2 together with 30 ml acetic acid.

Destained buffer: 10% acetic acid, 20% propanol-2 and 70% water.

3- Methods

3-1 cDNAs (0.5 µg) encoding the protein of interest are in vitro translated

with TNT mix, T7 buffer, T7 RNA polymerase, rabbit reticulocytes and 10 µCi

of methionine labeled with S35. Alternatively recombinant purified proteins

can be used as substrates.

3-1 Activity of the proteases is assessed using specific fluorometric

substrates. 10 ng of cathepsins B, D, G, K, B/L, S or AEP are incubated with

their specific substrates (see Materials) respectively for different times. To

calculate the specific activity of each protease (µmole of substrate release

per minute), a standard curve is obtained using different concentrations of

NHmec (from 0.2 to 2 µM).

3-3 Endosomes and lysosomes are purified using magnetic nanoparticles of

20 nm of diameter. 107 dendritic cells are incubated with 60 µl of magnetic

nanoparticles (10 mg/ml) for 30 minutes at 4°C, pulsed for 20 min at 37°C in

1ml of IMDM medium alone and chased for 100 min in 3 ml of complete

medium supplemented with 10% FCS and 10 ng/ml of rGM-CSF. Cells are

then washed 3 times with cold PBS, 0.1% BSA and resuspend in 1 ml of HB.

Cells are mechanically disrupted by passing them through a 25G needle for

about 30 times in order to have 80% mortality. Endosomes and lysosomes

Page 105: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

6

are purified by magnetic separation at 4°C on a magnetic eppendorf stand.

They are washed 10 times with cold PBS supplemented with a tablet of

cocktail inhibitors (Roche) and lysed in 50 µl of lysis buffer for 20 min on ice.

The endosomes/lysosomes are then centrifuged at 12000rpm at 4°C for 10

min to get rid of the magnetic particles and can be either frozen or used

immediately.

3-4 Radiolabelled proteins (5 µl of the reaction) or recombinant purified

proteins (10 µg )are incubated with proteases (1 to 15 U) or with purified

endosomes/lysosomes (1µg) from wild type cells or cells lacking different

cathepsins (B or D or G or K or L or S or AEP etc!) for 2 to 4 h in a final

volume of 30 µl in 50 mM citrate buffer pH 5.5, supplemented with 0.1%

CHAPS and 1mM DTT. The reaction is stopped by addition of lysis buffer

(10 µl of 4X Laemli buffer supplemented with 8%ofβ-mercapto ethanol).

3-5 Heat aliquots at 95°C for 10 min. Load samples

3-6 Following electrophoresis, open the gel plates with a spatula. For

radiolabelled samples, rinse the gel with water and incubate in a fixation

solution (staining buffer without coomassie) for 30 min to 1h. Rinse the gel

again with DI water and add the enhancer solution (Perkin Elmer) for 30 min.

Rinse the gel and dry it for 1h at 80°C. Develop the autoradiographic film

after few hours or an overnight exposure at -80°C. For recombinant proteins

digested in vitro, the gels are incubated in the staining buffer for 2h and

wash extensively with distained buffer.

3-7 In vitro digestion assays are stopped by adding the respective protease

inhibitors (20 µM MVO 26630 for AEP; 10 nM LHVS for cathepins B, L,S; 10

µM Boc-Phe-Leu-NHNH-CO-NHNH-Leu-Z for cathepsin K;10 µM inhibitor I

cat: 219372 for cathepsin G , 10 µM pepstatin A for cathepsins D, E). 2x106

of pAPCs (dendritic cells for example) are fixed with 200 µl of 0.1%

glutaraldehyde-PBS for 30 seconds at 37°C and the reaction is stopped by

adding 200µl of 0.2M Glycine, pH 7.4. Cells are extensively washed with a

Page 106: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

7

solution of RPMI 1640 supplemented with 1% FCS. They are then

distributed in 96 well plates (Flat bottom) at 5x104 cells in 50 µl per well. The

invitro digestion assays are added to the antigen presenting cells (50 µl)

together with100 µl of 105 T cells (ratio 2:1) for 24h. Stimulation of T cells is

measured by release of interleukine 2 using an ELISA kit (e-biosciences).

4- Notes

Note 1: To assess that the protease inhibitor you have used is indeed

specific for the protease you want to block, you can use the Fluorometric

assay to test it (see Materials 2-4).

Note 2: The in vitro digestion assays are most of the times performed in an

acidic pH (citrate buffer, pH 5.5). When added to the pAPCs, it can kill them.

To avoid this problem, you have to raise the pH of your buffer by adding few

drops of NaCl.

5- Ackowledgements

This work was supported by INSERM (ANR 2010 MIDI 008 01), an ARC

Ph.D. fellowship to S.M and an Institut Curie Ph.D. fellowship to M.T.

6- References

1- Kvist S, Wiman K, Claesson L, Peterson P.A, Dobberstein B (1982)

Membrane insertion and oligomericasselbly of HLA-DR histocompatibility

antigens. Cell 29: 61-69.

2- Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid S.L,

Quaranta V, Peterson P.A (1990) Intracellular transport of class II MHC

molecules directed by invaraint chain. Nature 348: 600-605.

3- Rawlings N.D,Barret A.J (1993) Biochem J 290:205-218.

4- Nakagawa T, Brissette W.H, Lira P.D, Griffiths R.J, Petrushova N, Stock

J, McNeish J.D, Eastman S.E, Howard E.D, Clarke S.R.M, et al (1999)

Impaired invariant chain degradation and antigen presentation and

Page 107: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

8

diminished collagen induced arthritis in cathepsin S null mice. Immunity 10:

207-217.

5- Riese R.J, Wolf P.R, Bromme D, Natkin L.R, Villadangos J.A, Ploegh H.L,

Chapman H.A (1996) Essential role for cathepsin S in MHC class II-

associated invariant chain processing and peptide loading. Immunity 4: 357-

366.

6- Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos

J.A, Ploegh H, Peters C, Rudensky A.Y (1998) Cathepsin L: critical role in Ii

degradation and CD4 T cell selection in the thymus. Science 280: 450-453.

7- C Watts (2011) The endosome-lysosomes pathway and information

generation in the immune system.Biochem etBiophysActa 8: 4-6.

8- Manoury B, Hewitt E.W, Morrice N, Dando P.M, Barrett A.J, Watts C

(1998) An asparagynil endopeptidase processes a microbial antigen for

class II MHC presentation. Nature 396: 695-699.

9- Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, Mazza

G, Wraith D.C, Watts C (2002) Destructive processing by asparagine

endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat.

Immunol 3:169-174.

10- Moss C.X, Villadangos J.A, Watts C (2005) Destructive potential of the

aspartyl protease cathepsin D in MHC class-restricted antigen processing.

Eur J Immunol 35: 3442-3451.

11- Schein C.H (1989) Production of soluble recombinant proteins in

bacteria. Nat Biotech 7: 1141-1149.

12- Mitraki A, King J (1989) Protein folding intermediates and inclusion

bodies formation. Nat Biotech 7: 690-697.

13- Lai M.Z, Ross D.T, Guillet J-G, Briner T.J, Gedter M.L, Smith J.A (1987)

T lymphocyte response to bacteriophage l repressor cI protein . recognition

of the same peptide presented by Ia molecules of different halotypes. J.

Immunol 139:3973-3977.

14- Matthews S.P, Werber I, Deussing C, Peters C, Reinheckel T, Watts C

(2010) Distinct proteases requirement for antigen presentation in vitro and in

vivo. J Immunol 184: 2423-2431.

Page 108: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

PP""

"

5=>?+"@+0AB?>CDE?CAB+?A+A?FG>+HEDICJ=?CABK+

D1"A6-%$/5"5(+-)-*5)"9-(6%-."3FMQ")'/($.'(/"'("+5(+%'6'9"95..)"

" >%J+62!K-E#!81&'%:L&!8-E!#!!5<42$3?#!$%&'(%)*+*!,-#!H69M9*!5-#!C(*F/%2+!$-#!>%9+!.-#!.%/!0/+123!4-#!!!!!!!

! $%/692=!>-E!%/+!,%N1%/9!5-E#!?@AB-!)*+,-',.-.&%/*+

!"#$%&'($)"3-"$))5))"645"'(;-.;5*5(6"-7"DMJU"5(+-)-*5)"'("3FMQ")'/($.'(/"'("+5(+%'6'9"95..)"

+,%-./0123)* D("+5(+%'6'9"95..)"$(+",:-(")6'*,.$6'-(V"3FMQ"6%$77'9)"7%-*"645"SM"64%-,/4"645">-./'"6-"

5$%.0" ZJHU?p" 5(+-)-*5)V" $" :%-95))" 7$9'.'6$65+" B0" YWRQ?@!1" J)" 645" 5(+-)-*5" *$6,%5)" $(+"

$9'+'7'5)V"3FMQ" ')"9.5$;5+"$(+"B59-*5)"9-*:565(6" 7-%")'/($.'(/"B0"%59%,'6'(/"645"$+$:6-%"*-.59,.5V"

H0+PPV" 6-"$96';$65" 645"WLEv@":$64&$0"$(+" 6-":%-+,95":%-E'(7.$**$6-%0"906-G'(5)1"3FMQ" ')" 7,%645%"

6%$().-9$65+"6-"FJHU!p"9-*:$%6*5(6)V"$("JUE?"*5+'$65+":%-95))V"&45%5"'6"5(/$/5)"*-.59,.5)"),94"

$)" 3MJL?" $(+" DMLO" $(+" '(+,95" 6%$()9%':6'-(" -7" DLW" /5(5)V" $)" JUE?" +57'9'5(90" )5.596';5.0" $B%-/$65)"

60:5"D"DLW"%5):-()5)V"&45%5$)":%-E'(7.$**$6-%0"%5):-()5)"%5*$'("'(6$961"34,)V".'/$(+"%59-/('6'-("B0"

3FMQ"$(+"645"7,(96'-($."-,69-*5"-7".'/$(+"B'(+'(/"')"/-;5%(5+"B0"645"),B95..,.$%".-9$6'-("-7"645"3FM"

$(+"'6)")'/($.'(/"*-.59,.5)1"

@5)'+5)" '6)" %5/,.$6-%0" %-.5" '(" +'$B565)V" DMJU" 5(I0*5" ')" $.)-" '*:.'9$65+" '(" 9%-))" :%5)5(6$6'-(" B0"

6%'**'(/" 58-/5(-,)" $(6'/5()" $(+" *-%5-;5%V" DMJU" 5(+-)-*5)" $%5" )4-&(" 6-" '(65%$96" &'64"

:4$/-)-*5)" $(+" :-))'B.0" :$%6'9':$65" '(" 645'%" *$6,%$6'-(1" >';'(/" 645" 9%,9'$." %-.5" -7" 3FMQ"

9-*:$%6*5(6$.'I$6'-(" '(" +57'('(/" 645" -,69-*5" -7" 645" %595:6-%" )'/($.'(/" '(" B-64" '(($65" )0)65*h)"

+5(+%'6'9"95..)"$(+"*$9%-:4$/5)"$(+"'("$+$:6';5h)")0)65*"@"95..)V"&5"&$(65+"6-"'(;5)6'/$65"&45645%"

3FMQ" %5$945)" DMJU" 5(+-)-*5)" ,:-(" .'/$(+" B'(+'(/" $(+" &45645%" DMJU" +57'9'5(90" +')6,%B)" 3FMQ"

)'/($.'(/1""""

8,'2* 9/$6':'2,/;* 4$516&5)* D(+55+" -,%" %5),.6)" )4-&" $(" ,:" %5/,.$6'-(" -7" 3FMQE6%'//5%5+" :%-E

'(7.$**$6-%0" 906-G'(5)" $(+" 60:5" D" DLW" )59%56'-(" '(" DMJU" +57'9'5(6" @H#R)" $(+" :#R)" ()" /(&$%;"

S(4$(95*5(6" '("906-G'(5)":%-+,96'-(" %5(+5%)" DMJU"+57'9'5(6"*'95"*-%5"),)95:6'B.5" 6-"+5$64",:-("

3FMQE+5:5(+5(6" D2'40%7%)-2" I'$4+()%2-" '(7596'-(1" 34')" :45(-60:5" 9-%%5.$65)" &'64" $("

5(4$(95*5(6" '("B-64"H0+PPTWLEκ@"$(+"H0+PPTDMLO"$))-9'$6'-(" '(" DMJU"+57'9'5(6" 95..)" ,:-("3FMQ"

5(/$/5*5(61"H-%5-;5%V" $"*').-9$.'I$6'-("-7" 3FMQ" ')" -B)5%;5+"$6" 645" )65$+0" )6$65" '(" DMJU"+57'9'5(6"

95..)^" 3FMQ" ')" 7-,(+"&'64'(" 5(+-.0)-)-*$." FJHU!" :-)'6';5" 9-*:$%6*5(6)V" &45%5$)" '("g3" @H#R)V"

3FMQ"%5)'+5)"'("645"SM1"34')"3FMQ"$B5%%$(6".-9$.'I$6'-("')":%-B$B.0"645"-%'/'("-7"645"4'/4")5()'6';'60"-7"

DMJU"+57'9'5(6"+5(+%'6'9"95..)"6-"3FMQ".'/$(+)1"

D(65%5)6'(/.0V"9-(7-9$."*'9%-)9-:0")4-&)"$"9-.-9$.'I$6'-("-7"ZJHU?p"5(+-)-*5)"bWLEκ@"5(+-)-*5)c"

$(+"FJHU!p"5(+-)-*5)"bDMLO"5(+-)-*5)c"'("DMJU"+57'9'5(6"95..)"),//5)6'(/"$"9%'6'9$."%-.5"7-%"DMJU"'("

Page 109: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

PQ""

"

*$'(6$'('(/" 645" '(65/%'60" -7" B-64" )'/($.'(/" 9-*:$%6*5(6)1" J.6-/5645%V" 645)5" +$6$" :%-;'+5" $" (5&"

7,(96'-("-7"DMJU"5(I0*5"'("%5/,.$6'(/"3FM)")'/($.'(/"$(+"6%$77'9"'("+5(+%'6'9"95..)1""

<02&/'"1&'02)*"

E H-('6-%'(/"645":%-E'(7.$**$6-%0"906-G'(5"$(+"'(65%75%-(")59%56'-("B0"B-(5"*$%%-&"+5%';5+"

$(+":.$)*$906-'+"+5(+%'6'9"95..)",:-(")6'*,.$6'-("&'64"3FM)".'/$(+)1"

E A6,+0'(/"645"6%$77'9G'(/"-7"3FMQ"B0"9-(7-9$."*'9%-)9-:0"

E U5%7-%*'(/" $" #,-.'(G" $))$0" 7-%" +56596'-(" -7" DMLOEH0#PP" '(6%$95..,.$%" :%-8'*'60" p"

[,$(6'7'9$6'-("

E H5$),%'(/"3FMQ"58:%5))'-("B0"7.-&"906-*56%0"'("DMJU"&6"$(+"+57'9'5(6"95..)"

" "

Page 110: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Q2""

"

DD1"J):$%$/'(5"5(+-:5:6'+$)5"')"%5[,'%5+"7-%"3FMO")'/($.'(/"$(+"'(7.,5(I$"

'(7596'-("

! $%&'(%)*+*!,-#!O%&&)12!,-#!>)%/'!P-#!,1L9)N1+%!P-#!!5<42$3?#!C(*F/%2+!$#!.%/70/+123!4-#!!

! ,*7H%(12!$-#!81&'%:L&!8-!%/+!$%/692=!>-#!?@A?-!HF5B$H/:<5G2CB$QRQST1A@@?QUA-!

*

!"#$%&'($)" 3-" +565%*'(5" J):$%$/'(5" S(+-:5:6'+$)5" %-.5" '(" D(7.,5(I$" '(7596'-(" $(+" 3FMOE6%'//5%5+"

'(7.$**$6-%0"%5):-()5)1!

*

+,%-./0123)+ D(7.,5(I$" '(7596'-(" ')" $" 9-**-(" +')5$)5" 64$6" '(+,95)" )5;5%5" $(+" $//%5))';5" '(($65"

%5):-()5)"64%-,/4"$("5895))';5":%-+,96'-("-7"906-G'(5)V"'("$"3FMOE+5:5(+5(6"7$)4'-(V".5$+'(/"6-"645"

$96';$6'-("-7":%-75))'-($."$(6'/5(":%5)5(6'(/"95..)"$(+"645"'('6'$6'-("-7"$+$:6';5"'**,('60"6-"9.5$%"645"

;'%,)1"3FMO")5()5)")'(/.5")6%$(+5+"MWJ"7%-*"D(7.,5(I$";'%,)5)"&'64'("645"5(+-)-*5)"%5),.6'(/"'("645"

'(+,96'-("-7"$(6'E;'%$."%5):-()5)1!

D(":%'*$%0"+5(+%'6'9"95..)V"$(+",:-(")6'*,.$6'-(V"7,..".5(/64"#WJE)5()'(/"3FMQ"6%$().-9$65)"7%-*"SM"6-"

5(+-.0)-)-*$." 9-*:$%6*5(6)" &45%5" '6" ')" ),Be5965+" 6-" $" 9.5$;$/5" '(6-" $" RE65%*'($." 7%$/*5(6"

),77'9'5(6"7-%")'/($.'(/1"34')":%-95))'(/"')"*5+'$65+"B0"9$645:)'("_"$(+"JSU1"g5"&$(65+"6-"'(;5)6'/$65"

&45645%" 3FMO" ')" $.)-" :%-95))5+" '(" $(" JSU" +5:5(+5(6" *$((5%" $(+" &45645%" 64')" :%-95))'(/"

9-(6%'B,65)"'(":%-6596'(/"$/$'()6"D(7.,5(I$"'(7596'-(1!

!

4$516&5)+g5")4-&"64$6"JSU"$96';'60" ')" 9%'6'9$." 7-%"3FMO":%-95))'(/"$(+")'/($.'(/" ()"/(/%" $(+" ()"/(&$%;"

H-%5-;5%V" JSU" ')" %5[,'%5+" 7-%" 3FMO"*5+'$65+" '(7.$**$6'-(V" 9%-))" :%5)5(6$6'-(" -7" 95.." $))-9'$65+E

$(6'/5()" $(+" 9%-))E:%'*'(/" -7" R#Pp"3" 95..)" ,:-(" D(7.,5(I$" Z'%,)" '(7596'-(1" 34,)V" J):$%$/'(5"

5(+-:5:6'+$)5" ')" 645" 7'%)6" +5)9%'B5+" :%-65$)5" 6-" B5" '(;-.;5+" '(" $(6'E'(7.,5(I$" ;'%,)" '**,(5"

%5):-()5)1"

*

<02&/'"1&'02)*

E U5%7-%*'(/"$"#,-.'(G"$))$0"6-"+56596"645"'(65%$96'-("B56&55("3FMO"%595:6-%"$(+"'6)"$+$:6-%"

*-.59,.5"H0+PP"p"[,$(6'7'9$6'-(*

E H5$),%'(/"JSU"$(+"9$645:)'()"@V"_V"F"$(+"A"$96';'60" '("B-(5"*$%%-&"+5%';5+"+5(+%'6'9"95..)"

6-6$.".0)$65V",:-("3FMO")6'*,.$6'-(*

"

"

* *

Page 111: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Asparagine Endopeptidase Controls Anti-Influenza VirusImmune Responses through TLR7 Activation

Sophia Maschalidi1,2, Signe Hassler1,2, Fany Blanc3,4, Fernando E. Sepulveda2,5, Mira Tohme1,2,6,

Michel Chignard3,4, Peter van Endert1,2, Mustapha Si-Tahar7,8, Delphyne Descamps1,2,

Benedicte Manoury1,2*

1 INSERM, Unite 1013, Paris, France, 2Universite Paris Descartes, Sorbonne Paris Cite, Faculte de Medecine, Paris, France, 3Unite de Defense Innee et Inflammation,

Institut Pasteur, Paris, France, 4 INSERM, Unite 874, Paris, France, 5 INSERM, Unite 768, Paris, France, 6 INSERM, Unite 932, Institut Curie, Paris, France, 7 INSERM, Unite 1100,

Tours, France, 8 Faculte de Medecine F. Rabelais, Tours, France

Abstract

Intracellular Toll-like receptors (TLRs) expressed by dendritic cells recognize nucleic acids derived from pathogens and playan important role in the immune responses against the influenza virus (IAV), a single-stranded RNA sensed by differentreceptors including TLR7. However, the importance of TLR7 processing in the development of anti-viral immune responsesis not known. Here we report that asparagine endopeptidase (AEP) deficient mice are unable to generate a strong anti-IAVresponse, as demonstrated by reduced inflammation, cross presentation of cell-associated antigens and priming of CD8+ Tcells following TLR7-dependent pulmonary infection induced by IAV. Moreover, AEP deficient lung epithelial- or myeloid-cells exhibit impaired TLR7 signaling due to defective processing of this receptor. Indeed, TLR7 requires a proteolyticcleavage by AEP to generate a C-terminal fragment competent for signaling. Thus, AEP activity is critical for TLR7 processing,opening new possibilities for the treatment of influenza and TLR7-dependent inflammatory diseases.

Citation: Maschalidi S, Hassler S, Blanc F, Sepulveda FE, Tohme M, et al. (2012) Asparagine Endopeptidase Controls Anti-Influenza Virus Immune Responsesthrough TLR7 Activation. PLoS Pathog 8(8): e1002841. doi:10.1371/journal.ppat.1002841

Editor: Andrew Pekosz, Johns Hopkins University - Bloomberg School of Public Health, United States of America

Received March 15, 2012; Accepted June 19, 2012; Published August 16, 2012

Copyright: ß 2012 Maschalidi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permitsunrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was supportedby grants from INSERM (ANR 2010 MIDI 008 01 to B. M and ANR 2008 NKTVir to M. S), an ARC PhD fellowship to S. M, an Institut Curie Ph.D. fellowship to M. T, FRMand ANR post-doc support respectively to S. H and D. D.

Competing Interests: The authors declare no competing financial interests..

* E-mail: [email protected]

Introduction

Influenza is a common respiratory disease where viral virulence

can either cause just a moderate sickness or a severe pathology

leading to hospitalisation or even death. There are studies

demonstrating that IAV infection induces severe and aggressive

innate response, manifested with excessive cytokine production by

alveolar macrophages and respiratory epithelial cells [1,2]. This

innate immune response triggers the activation of professional

antigen-presenting cells (APCs) leading to the initiation of adaptive

immunity to eradicate the virus. Thus, CD8+ T cell priming to

IAV requires antigen presentation by activated dendritic cells

(DCs) that express co-stimulatory molecules and promote T cell

differentiation and activation. Recent work has shown that tissue

resident DCs from the lung are responsible for the presentation of

exogenous antigens and subsequently the cross priming of T cells

in a Toll like receptor 7 (TLR7)-dependent fashion [3,4]. TLR7

senses single-stranded RNA from influenza viruses within the

endosomes and has been shown to be essential in the induction of

anti-viral immune responses to IAV [1,5,6,7,8].

Toll like receptors (TLRs) detect a wide variety of microbial

products and in DCs they are crucial in linking innate to adaptive

immunity [9]. TLRs contain several leucine rich repeats (LRR) in

an extracellular loop, a trans-membrane domain and a cytosolic

domain and are expressed either at the plasma membrane or in

the endosomal/lysosomal organelles. TLR stimulation is linked to

MyD88 or TRIF-dependent signaling pathways that regulate the

activation of different transcription factors, such as NF-kB [10].

Specific interaction between TLRs and their ligands activates NF-

kB resulting in enhanced inflammatory cytokine responses,

induction of DC maturation and expression of chemokine

receptors [11]. Little is known about how intracellular TLRs

(TLR3, 7, 9) and their ligands are targeted to the endocytic

pathway. Intracellular TLRs are sensitive to lysomotropic agents

that neutralize acidic compartments such as chloroquine or

concanamycin B indicating a role for endo/lysosomal proteases

for their signaling. Indeed, recent findings have described the

importance of proteolysis for TLR9 function [12,13]. It has been

shown that murine TLR9 is non functional until it is subjected to

proteolytic cleavage in the endosomes. Upon stimulation, full-

length (FL) TLR9 is cleaved into a C-terminal (C-ter) fragment

sufficient for signaling. Many proteases, mainly cathepsins, have

been shown to participate in this process in macrophages and in

different cell lines [12,13,14]. However, in primary DCs, cathepsin

K (CatK) and asparagine endopeptidase (AEP) are important in

TLR9 processing. In CatK deficient DCs, TLR9 signaling was

totally abrogated and in DCs lacking AEP, TLR9 cleavage in

phagosomal compartments as well as CD4+ antigen specific T cell

proliferation was greatly reduced upon CpG stimulation [15,16].

Still, it is unclear whether TLR7 is also subject to proteolysis

[12,13,17] and whether TLR7 processing is an important criterion

for the immune response to influenza infection

PLOS Pathogens | www.plospathogens.org 1 August 2012 | Volume 8 | Issue 8 | e1002841

Page 112: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Here, we describe for the first time that a protease, AEP, plays

an important role in anti-influenza virus immune responses.

Indeed, AEP-dependent TLR7 activation mediates inflammation,

cross presentation of cell-associated antigens and cross priming of

CD8+ T cells upon lung IAV infection. We demonstrate that AEP

activity is critical for TLR7 processing in vitro and signaling in vivo.

Altogether, these data indicate that endosomal processing is a

prerequisite for intracellular TLR signaling and identify AEP as a

major actor in anti-viral immunity.

Results

TLR7-dependent influenza virus inflammation and crosspresentation of cell associated antigens require AEPTo address the contribution of AEP in the innate immune

response to influenza virus-infection, wild type (wt) and AEP

deficient mice (AEP2/2) were infected with a sub-lethal dose of IAV

(100 pfu) and the inflammation was monitored in the lungs at days 4

and 8 post-infection [18]. In AEP2/2 mice, significant inhibition of

cytokine and chemokine secretion associated with influenza virus-

induced pneumonia, including keratinocyte chemo-attractant (KC),

interleukin 6 (IL-6), and interleukin 12 (IL-12), was detected

compared to wt mice (Figure 1A). In addition, interferon gamma

(IFN-c) and interferon alpha (IFN-a) production was also reduced in

AEP2/2 mice infected with IAV (Figure 1A and Figure S1A). No

difference in IFN-bmRNA expression was detected between wt and

AEP deficient mice (Figure S1B).

As NF-kB is the major pro-inflammatory transcriptional factor

and regulates the induction of most inflammatory cytokines [19],

we thus analyzed the contribution of the NF-kB pathway during

the in vivo IAV infection. We used an adenovirus containing an

NF-kB response element linked to a luciferase reporter gene (Ad-

NF-kB-luc) [20]. Control WT or AEP2/2 mice infected with Ad-

NF-kB-luc alone presented weak but similar bioluminescence

scores (data not shown). Wt mice co-infected with the Ad-NF-kB-luc and IAV developed an important inflammatory reaction in

lung tissue with a peak of NF-kB-activity at day 3, corresponding

to the maximum of viral replication. In contrast AEP2/2 mice

showed a moderate NF-kB activity (Figure 1B). Yet, the absence of

AEP did not diminish the accumulation of innate inflammatory

infiltrate characterized as macrophages/monocytes, granulocytes,

and dendritic cells upon IAV administration (Figure S1C).

Nonetheless, we noticed that the myeloperoxidase activity, which

mirrored the neutrophil degranulation, was decreased in the

broncho-alveolar lavage (BAL) of AEP2/2 mice compared to wt

mice (Figure S1D). To ascertain whether the difference in

inflammation we observed between wt and AEP2/2 mice was

due to a deficit in viral clearance, viral titers of influenza were

quantified either by mRNA expression of the M2 viral protein

(Figure 1C) and by plaque assays (Figure 1D) in the lungs on days

4 and 8 post infection. No significant difference was detected

between wt and AEP2/2 mice.

TLR7 has previously been shown to sense single-stranded RNA

from viruses including IAV [7]. To confirm the role of TLR7 in the

infectious model of IAV, we performed similar experiments in

TLR72/2mice.We found reduced level of proinflammatory cytokines

in the BAL of TLR72/2 infected mice and to a similar level as in

AEP2/2 infected mice in comparison to wt mice (Figure S2A).

Recently, studies have shown that cross presentation and cross

priming of CD8+ T cells can be enhanced by signaling through

TLRs expressed by DCs. Thus, we tested the hypothesis that

reduced antigen specific T cell proliferation will be detected in AEP

deficient cells and mice following IAV infection. We infected

splenocytes from Balb/C mice (H-2d) electroporated or not with

ovalbumin with the influenza virus PR8, and incubated them with

wt, AEP2/2 or TLR72/2 DCs together with T cells specific for

ovalbumin (OT-I cells). T cell proliferation was analyzed 3 days

later. To exclude that OVA processing was dependent on AEP, we

incubated splenocytes expressing OVA alone with wt or AEP2/2

DCs together with OT-I cells. As shown in Figure S3, OT-I

proliferation was comparable between wt and AEP2/2 cells. In wt

cells, T cell stimulation was increased when DCs were incubated

with IAV infected cells expressing OVA (Figure 2A, upper panel

and Figure S3) but not with BSA-electroporated cells. In contrast,

very weak proliferation of OT-I T cells was seen with AEP2/2 and

TLR72/2 DCs (Figure 2A, middle and lower panel). Similar results

were obtained when a synthetic ligand of TLR7 (imiquimod) instead

of IAV was used to trigger DCs activation (Figure 2A and Figure

S2). In the three cell types (wt, AEP2/2, TLR72/2) tested, OVA

control peptide (SIINFEKL) triggered similar proliferation

(Figure 2A). In addition, a synthetic ligand of TLR3 (poly(I:C))

did also elicit proliferation of OT-I T cells but to the same extent in

wt and AEP2/2 DCs (Figure S3).

To address in vivo whether antigens captured in the lungs could be

cross-presented and prime CD8+ T cells in the mediastinal lymph

nodes (mLNs) after influenza virus infection, we transferred CFSE

labeled OT-I cells specific for ovalbumin into wt or AEP2/2 mice

that had been previously infected with IAV. The mice were then

challenged with ovalbumin or PBS intranasally and 3 days later

proliferation of OT-I T cells in the draining lymph nodes (mLNs) and

in the spleen was analyzed. We detected OT-I T cells proliferation in

OVA-treated mice but not in PBS-treated mice (Figure 2B). T cells

proliferation was stronger in OVA-treated wt mice whereas OT-I

cells proliferate significantly less when injected in AEP2/2 (Figure 2B)

and TLR72/2 mice (data not shown). We conclude that AEP and

TLR7 have a critical role in cross presentation, cross priming and

cytokine secretion upon IAV infection.

Reduced TLR7 signaling in dendritic cells and in micedeficient for AEPThe findings that both AEP2/2 and TLR72/2 mice infected

with IAV secreted less proinflammatory cytokines and had a defect

Author Summary

Influenza A virus, a negative stranded RNA, can causesevere illness in humans and animals and stimulates manyreceptors including Toll like receptors 7 (TLR7). TLRsignaling induces maturation of dendritic cells and theproduction of a variety of inflammatory cytokines that arecrucial for both innate and adaptive immunity. TLR7 is anintracellular receptor, which resides in endosomes andsenses viruses to trigger host defence. Previous data haveshown that TLR9 requires proteolysis to be functional butit is unclear whether other intracellular TLRs (TLR3 andTLR7) are also subject to degradation. Here, we used aprotease deficient mouse model to show the in vivo

importance of TLR7 processing in influenza infection.Inflammation monitored by cytokine release and adaptiveimmunity measured by cross priming of CD8+ T cells wassignificantly reduced in infected protease-deficient animalsin comparison to control animals. We showed that TLR7requires a proteolytic cleavage by a cysteine endopepti-dase in order to be functional. Our findings indicate thatTLR7 processing mediated by a protease, asparagynilendopeptidase, is critical for inducing robust anti-influenzaimmune responses. Given our results, targeting TLR7response in the lungs through proteases may offer newtherapeutic potential in pulmonary infection.

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 2 August 2012 | Volume 8 | Issue 8 | e1002841

Page 113: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

in cross priming suggested that AEP might interfere with TLR7

signaling. To test this hypothesis, AEP2/2 and wt immune cells

from myeloid and non-myeloid origins were generated and TLR7

response was monitored. Wt, TLR7 and AEP deficient lung

epithelial cells, which are the first cells that will encounter IAV

after infection, were purified and stimulated with imiquimod or

IAV. Imiquimod response was totally abrogated in TLR72/2

epithelial cells demonstrating the expression of TLR7 in these

cells. In contrast, TLR72/2 epithelial cells were still able to secrete

cytokines following IAV infection probably because TLR7 also

respond to IAV via RIG-I (Figure S2B). Yet, AEP2/2 lung

epithelial cells showed a significant decrease in IL-6 and KC

production upon imiquimod or IAV infection as compared to wt

cells (Figure 3A). We further purified mouse plasmacytoid

dendritic cells (pDCs), key cells involved in the secretion of IFN-

a during viral infection. Upon imiquimod stimulation or IAV

infection, mouse AEP2/2 pDCs showed a significant reduction in

IFN-a production (Figure 3B). As expected, IAV stimulation was

dependent on TLR7 (Figure S4A). To address the role of other

proteases in TLR7 signaling, bone marrow derived DCs (BMDCs)

from AEP2/2, CatB2/2, CatK2/2, CatL2/2 and CatS2/2 mice

were generated and stimulated with TLR4 or TLR7 agonists. We

observed a significant decrease in IL-6 secretion by BMDCs

lacking AEP compared to wt cells upon intracellular TLR7

engagement (Figure 3C), but not when BMDCs deficient for CatB,

CatK, CatL and CatS were stimulated (Figure S4B). Similar

results were obtained in AEP2/2 DCs when IL-12p40 and tumor

necrosis a (TNF-a) were measured or when other TLR7 agonists

Figure 1. Reduced inflammation in IAV-infected AEP2/2 mice. (A) Broncho-alveolar lavage (BAL) fluid levels of KC, IL-6, IL-12 and IFN-c in wtand AEP deficient mice before (NI), 4 d and 8 d after intranasal injection of IAV PR8 strain (100 pfu/mice). (n = 8 animals; graphs show mean6 SEM oftwo independent experiments, * p,0.05, ** p,0.01). (B) NF-kB activity in the lungs of WT or AEP deficient mice infected with IAV. Mice were co-infected at d 0 with IAV (100 pfu) and Ad-NF-kB-luc (2.56108,pfu). Bioluminescence was measured after instillation of 50 ml of luciferine (500 mg/mL)and photon emission was captured at different times post-infection using the IVIS system. Graph shows fold increase of NF-kB activity that representsthe average radiance (photons/sec/cm2) of IAV+Ad-NF-kB-luc infected mice relatively to the average radiance corresponding to Ad-NF-kB-lucinfected mice (n = 7–10 animals, mean6 SEM of three independent experiments, * p,0.05). (C–D) Viral titers in lungs of wt and AEP2/2 mice 4 d and8 d post-viral challenge were determined by qRT-PCR performed on M2 viral protein (C) or by plaque assay (D). (pfu, plaque-forming units, n = 8animals; graphs show mean 6 SEM of two independent experiments).doi:10.1371/journal.ppat.1002841.g001

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 3 August 2012 | Volume 8 | Issue 8 | e1002841

Page 114: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

were used (Figure 3C). In addition, no differences in IL-6

production were detected between wt and cathepsin- or AEP-

deficient cells when plasma membrane TLR4 was triggered

(Figure S4C). AEP was shown to regulate cathepsin B, H, K and L

maturation [16,21,22]. We have previously reported that the

activity of these cysteine proteases is either not changed or

increased at the steady state in the absence of AEP [16].

Nevertheless, to be sure that the diminution in TLR7 signaling

we detected in AEP2/2 DCs was not influenced by reduced

cathepsin activity, we monitored cathepsins B, K, L and S

activities in the presence of imiquimod in wt and AEP2/2 cells.

Using fluorogenic substrates selective for CatB, CatB and CatL,

CatK or CatS, we found an increase in the activity of these

cysteine proteases in AEP2/2 DCs in comparison to wt cell

(Figure S4D). These data indicate that impaired TLR7 signaling in

AEP deficient DCs is not associated with reduced activity of other

cathepsins. In contrast, in cathepsin K deficient DCs, AEP activity

was decreased (Figure S4E) which might explain the weak but not

significant reduction of TLR7 signaling detected in cells lacking

CatK. Together these results demonstrate that cells from different

origins lacking AEP have diminished cytokine secretion upon

TLR7 activation and IAV infection.

To investigate the role AEP plays in TLR7-stimulation of DCs

in vivo, we next assessed the ability of AEP-deficient DCs to mature

phenotypically and to secrete pro-inflammatory cytokines. It was

previously reported that DCs are the main target of TLR

stimulation after two hours of TLR ligands injection in mice

[23]. DC maturation in the spleen was examined after intravenous

Figure 2. Impaired cross presentation in AEP deficient DCs and mice following IAV infection. (A) Proliferation of OT-I T cells cultured withDCs from wt, AEP2/2 or TLR72/2 incubated with splenocytes from Balb/C mice (H-2d) electroporated with OVA or BSA and infected with PR8 virus orstimulated with imiquimod. SIINFEKL was used as an OVA-peptide control. Results are representative of three independent experiments. (B)Proliferation of OT-I T cells in the mLNs and the spleen 72 h after adoptive transfer of CFSE-labeled (CD45.1) OT-I T cells into IAV-infected wt orAEP2/2 mice (CD45.2) and intranasal treatment with PBS (gray histogram) or 120 mg of OVA (white histogram) 24 h later. Cells are gated on CD45.1and histograms are representative of one mouse per group (left panel) and right panel represents the percentage of OT-I proliferating cells (n = 4animals, mean 6 SEM, * p,0.05, ** p,0.01).doi:10.1371/journal.ppat.1002841.g002

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 4 August 2012 | Volume 8 | Issue 8 | e1002841

Page 115: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

injection with imiquimod or LPS. In control mice, both LPS and

imiquimod induced an increased expression of CD40 and CD86

in the CD11c+ spleen cells. These responses were compromised in

AEP2/2 mice injected with imiquimod (Figure 4A). In addition,

we consistently observed attenuated IL-6 and IL-12p40 secretion

in the serum of AEP2/2 mice following TLR7 stimulation as

compared to wt mice (Figure 4B). To further investigate that the

decrease in TLR7 signaling observed in vivo was specific to AEP,

Figure 3. AEP activity is required for full cytokine production following TLR7 stimulation. (A, B) IL-6, KC or IFN-a secretions insupernatants of AEP+/+ (white bars) or AEP2/2 (black bars) lung primary epithelial cells (A) or pDCs activated (B) with 10 mg/mL of imiquimod or withthe IAV virus PR8 heat killed (HK) or live at a multiplicity of infection= 1 or 5 for 16 h or 24 h. (n = 2–3; mean 6 SEM, * p,0.05, ** p,0.01,*** p,0.001). (C) BMDCs from AEP2/2 mice (black bars) and from their wild type littermates (white bars) were stimulated with different TLR ligandsfor 16 h and secretion of IL-6, IL-12p40 and TNF-a in supernatants was measured by ELISA. (n = 2–6, mean6 SEM, * p,0.05, ** p,0.01, *** p,0.001).doi:10.1371/journal.ppat.1002841.g003

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 5 August 2012 | Volume 8 | Issue 8 | e1002841

Page 116: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

we performed the same experiments in CatB deficient mice as we

have noticed a little reduction in TLR7 stimulation in BMDCs

lacking CatB (Figure S4B). We noticed similar or even increase

expression of costimulatory molecules in spleen CD11c+ cells

purified from CatB2/2 mice and similar IL-6 secretion in the

serum of CatB2/2 mice, as compared to wt mice (Figures S5A and

S5B). We conclude that, in vivo, AEP is required for the secretion of

inflammatory cytokines and for the phenotypic maturation of

CD11c+ cells induced by TLR7 engagement.

AEP generates a TLR7 C-ter fragmentWe next addressed whether AEP could process TLR7 in vitro.

Radiolabelled mouse TLR7 was incubated with different recom-

binant cysteine (cathepsins B, K, L, S) and aspartic proteases

(cathepsin D) harboring the same enzymatic activity. Upon

incubation of TLR7 with different doses of recombinant AEP,

TLR7 FL was degraded to produce one major band of 60 kDa

size (Figure 5A). In vitro translated TLR7 digested with a higher

concentration of AEP showed two distinct bands migrating

approximately around 60 and 30 kDa (TLR7 fragments, Figure

S6A). As shown in Figure S6A, cathepsin L (CatL) and cathepsin S

(CatS) were also able to degrade totally full-length (FL) TLR7.

However, when decreasing CatL and CatS concentrations were

used to digest FL TLR7, no defined processing products were

detected (data not shown). In vitro digestion assays using human

TLR7 also showed processing of full-length TLR7 by AEP and

cathepsins L and S (Figure S6B). To verify whether the fragment

generated upon AEP digestion had the same size as a putative C-

terminal (C-ter) fragment, we predicted a candidate cleavage site

in TLR7 by homology with TLR9 [12] (Figure 5B) and translated

this C-ter cDNA in vitro (Figure 5C). Indeed, the putative candidate

TLR7 C-ter fragment migrated approximately at the same size as

the TLR7 product observed after TLR7 digestion by AEP

(Figures 5A and 5C). We next assessed if the TLR7 C-ter

fragment was produced in cells. We transfected fibroblasts with

cDNAs encoding HA-tagged full length or HA-tagged C-terminal

TLR7 and 48 hours later, transfected cells were lysed and blotted

with an antibody directed against HA. In cells stimulated with

imiquimod for 1 h, TLR7 full-length was detected as well as two

fragments migrating around 80 kDa and 60 kDa (Figure 5D). The

60 kDa processing fragment, which appeared upon imiquimod

incubation, migrated at the same size as the TLR7 C-ter we

designed in vitro (Figures 5C and 5D). In addition, to assess whether

the TLR7 C-ter fragment was produced in primary DCs, we

purified phagosomes from wt and AEP2/2 cells fed with magnetic

particles. At the steady state, TLR7 FL and C-ter were observed in

early (20 minutes) and late (120 minutes) phagosomes. In the

presence of imiquimod, TLR7 cleavage occurs more rapidly and

was already detectable after 20 min (Figure S7A).

Figure 4. Decreased cytokine and co-stimulatory molecule expression in AEP2/2 DCs in vivo upon TLR7 ligand sensing. (A) FACSanalysis of in vivomaturation of spleen CD11c+ cells 4 h after i.v. injection of 10 mg of imiquimod (left panel) or 1 mg of LPS (right panel) compared tono TLR ligand stimulation equivalent to 1. (B) IL-6 (left panel) and IL-12p40 (right panel) secretion were measured in serum of AEP+/+ or AEP2/2 mice2 h after i.v. injection with imiquimod or PBS. (n = 9 animals for imiquimod; n = 2 animals for PBS; mean 6 SEM for A and B, ** p,0.01, *** p,0.001).doi:10.1371/journal.ppat.1002841.g004

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 6 August 2012 | Volume 8 | Issue 8 | e1002841

Page 117: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Figure 5. AEP generates a TLR7 C-ter fragment in vitro and in primary DCs. (A) In vitro transcription and translation of mTLR7 FL followed by2 h digestion of radiolabelled mTLR7 FL with different doses of rAEP (3.25 to 15U) (left panel). ImageJ software quantification of TLR7 digestion with15U rAEP (right panel). Mean of three different experiments normalized to undigested TLR7. *** p,0.001 (ND: non-digested). (B) Schematicrepresentation of TLR7 protein and its cleavage fragments. (C) In vitro transcription and translation of mTLR7 FL and C-ter cDNAs labeled with S35. (D)Fibroblast were transfected with cDNAs encoding for HA-tagged TLR7 FL or C-ter together with UNC93B1. 48 h later, cells were stimulated withimiquimod for 1 h and western blot was performed with an anti-HA antibody. (E) Anti-TLR7 and MyD88 immunoblot of HPLC fractions of lysates fromAEP+/+ (left panel) or AEP2/2 BMDCs (right panel) treated with imiquimod (5 mg/mL) for 60 min. (C–E) Representative data from three independentexperiments. (F) Detection of MyD88 and TLR7 interaction using DuoLink in situ with anti-MyD88 and anti-TLR7 specific mAbs on AEP+/+ or AEP2/2

BMDCs stimulated or not with imiquimod for 30 min. PLA signals are shown in green and the nuclei in blue. Quantification of mean fluorescenceusing Image J software (n = 11), *** p,0.001.doi:10.1371/journal.ppat.1002841.g005

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 7 August 2012 | Volume 8 | Issue 8 | e1002841

Page 118: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

To investigate whether the TLR7 C-ter fragment is generated in

AEP2/2 cells and recruits the adaptor molecule MyD88, we

stimulated wt or AEP2/2 BMDCs with imiquimod and fraction-

ated TLR7 and MyD88 on the basis of size exclusion chroma-

tography as we previously did for TLR9 [16]. Similar chroma-

tography profiles were obtained for both cell types (data not

shown). After 60 min of imiquimod stimulation in wt cells, two

TLR7 products migrating around 80 kDa and 60 kDa (Figure 5E,

left panel) were detected. As before, the 60 kDa product had a

similar size as the TLR7 C-ter fragment we observed in the in vitro

translation assay (Figures 5C and 5D). In the absence of AEP, no

TLR7 processing fragment of 60 kDa was detected (Figure 5E,

right panel). We then monitored if MyD88 co-eluted with the C-

ter form of TLR7. Indeed, in wt cells we could detect MyD88 in

fraction 47 where TLR7 C-ter product was present (Figure 5E, left

panel). To look at MyD88-TLR7 interaction, we used the

DuoLink method that gives a signal if two different antibodies

are localized within 40 nm of each other. This method allows us to

detect and visualize TLR7 conjugated to MyD88. We could

confirm association between MyD88 and TLR7 in wt cells only

when the cells were stimulated with imiquimod (Figure 5F, upper

panel). In AEP2/2 cells, significatively less signal was detected

(Figure 5F, lower panel).

In conclusion, AEP generates a TLR7 processing fragment,

which is produced in wt cells upon imiquimod stimulation but not

in AEP2/2 DCs. In addition, a reduced association between

cleaved TLR7 and the adaptor protein MyD88 is observed in

AEP2/2 cells.

TLR7 C-terminal fragment is competent for signaling andis dependent on acidic pHWe next assessed whether the TLR7 C-ter fragment is

functional. TLR9 C-ter fragment containing a part of the ecto-,

trans-membrane and cytoplasmic domains has been shown to be

fully competent for signaling at a similar level as FL TLR9 [12].

We next wondered whether the same was true for TLR7. Indeed,

the C-terminal fragment of TLR7 was sufficient to initiate

signaling and even to a higher level than full-length TLR7 when

expressed in TLR72/2 DCs upon different doses of imiquimod

stimulation (Figures 6A, left panel, S7B and S7C). Neither the

empty vector nor the TLR7 N-ter fragment could restore

signaling in DCs lacking TLR7 (Figure 6A, left panel). As

expected, LPS-stimulated cells transfected with the same

constructs secreted similar amount of IL-6 (Figure 6A, right

panel). In addition, cells pretreated with the specific AEP

inhibitor (MV026630) failed to restore cytokine secretion in FL

TLR7-transfected TLR72/2 DCs (Figure 6B). On the contrary,

TLR7 C-terminal fragment did not require any further process-

ing because its signaling was not reduced when AEP was

inhibited (Figure 6B).

We next tested whether the C-terminal fragment of TLR7 could

restore full TLR7 signaling in DCs lacking AEP. AEP2/2 cells

were transfected with the cDNAs encoding TLR7 full-length

vector or the recombinant C-terminal TLR7 product. After TLR7

stimulation, diminished IL-6 secretion, as expected, was detected

when DCs lacking AEP were transfected with the cDNA encoding

full length TLR7 as compared to wt cells (Figure S8A, left panel).

On the contrary, TLR7 C-terminal fragment restored signaling in

AEP2/2 cells to the same level as in wt cells after imiquimod

stimulation as indicated by IL-6 secretion (Figure S8A, left panel).

As a control, LPS-stimulated cells transfected either with full-

length or C-terminal TLR7 plasmids produced same amount of

IL-6 (Figure S8A, right panel). However, we noticed that the

difference in TLR7 response between wt and AEP2/2 DCs

transfected with the cDNA encoding for the FL TLR7 was not as

significant as when AEP2/2 DCs were stimulated with imiqui-

mod. We suspect this might be due to the overexpression of the

TLR7 protein in these experiments. In summary, our results

suggest that TLR7 processing fragment is sufficient and necessary

for TLR7 activity.

AEP is a cysteine protease that requires acidic pH, like most of

the other cysteine and aspartic proteases, for its optimum activity

[24]. We and others have previously shown that the endosomal

pH of DCs is rather neutral and decreases only in lysosomal

compartments [16,25]. We then decided to monitor the pH in

endosomes (where most likely TLR7 traffics) and lysosomes of

DCs upon imiquimod stimulation using specific probes [25,26]. A

drastic drop of endosomal pH was detected upon imiquimod

stimulation, which persisted upon time and was also detected in

lysosomes, in comparison to unstimulated cells (Figure S8B). The

drop of pH upon imiquimod stimulation was also observed in

AEP deficient DCs (Figure S6B). This increase in endosomal/

lysosomal acidification correlates with a boost in AEP activity

measured in total cell lysate (Figure S8C). This enhancement of

AEP activity (about 2 fold) was particularly striking in phago-

somes where most likely cleavage of TLR7 occurred after

imiquimod stimulation (Figure S8D). Cathepsins B, K, L and S

activities were also increased upon TLR7 stimulation (Figure

S8E) indicating that it was not specific for AEP. To verify the

importance of endosomal acidification in TLR7 signaling, we

treated cells with concanamycin B (a drug interfering with pH

acidification by blocking the recruitment of the Vo subunit of the

V-ATPase complex) and measured IL-6 secretion after imiqui-

mod stimulation. Treatment with concanamycin B completely

abrogated TLR7 signaling but not TLR4 response as expected

(Figure 6C). Furthermore, endosomal acidic pH was still required

for the TLR7 C-ter product to signal suggesting that optimal

ligand receptor binding might occur at low pH [27] (Figure 6D)

and/or acidification might be required for a change of

conformation allowing the TLR7 C-ter fragment to bind the

adaptor molecule MyD88 and to signal. Thus, TLR7 processing

requires low pH and AEP activity.

Mutation of AEP cleavage site between LLR 14–15abrogates TLR7 signalingAEP cleaves native antigens at asparagine sites [28]. So, it is

tempting to speculate that AEP cleaves directly TLR7. Indeed,

the residues 450–479 in TLR7 situated between the two leucine

rich-regions (LRR 14–15) described to be susceptible for

proteolysis and to be a target for AEP cleavage in TLR9

[12,13,16], contain also an asparagine that can be a putative

cleavage site for AEP. To test this hypothesis, we mutated

asparagine residue 478 to glutamine. We first investigated the

intracellular localization of this mutant and wt TLR7 when

expressed in transfected in fibroblasts. To allow proper TLR

trafficking, wt or mutated TLR7 cDNAs were transfected

together with a cDNA encoding for the chaperone molecule,

UNC93B1 [29]. At the steady state, both wt and mutated TLR7

reside in the ER (Figure 7A, upper panel). Indeed, we could

observe colocalisation between UNC93B1 (an ER marker) and

both TLR7 constructs (Figure 7B, left panel). Upon imiquimod

stimulation, wt and mutated TLR7 traffic to LAMP positive

lysosomal compartments (Figure 7A, lower panel). No difference

in intracellular localization was observed between TLR7 wt and

the N478Q mutant suggesting that trafficking of TLR7 mutant is

not impaired (Figure 7B, right panel). We then tested whether this

mutant was able to signal following imiquimod stimulation when

expressed in fibroblasts and TLR72/2 DCs. We observed 70% to

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 8 August 2012 | Volume 8 | Issue 8 | e1002841

Page 119: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

90% of decrease in IL-6, KC and IL-12p40 secretion when

TLR7 mutant was activated with imiquimod but not with LPS

compared to wt TLR7 (Figures 7C, 7D and S7D). Transfection

efficiency assessed by cytometry was the same for both constructs

(20% in DCs and 90% in fibroblasts). Altogether these results

suggest a direct cleavage of TLR7 by AEP generating a C-

terminal fragment fully competent for signaling.

Discussion

Influenza A virus is the agent of one of the most common

infectious diseases and remains a major public health burden.

Numerous studies have shown that the main cause of death after

IAV infection is due to a ‘‘cytokine storm’’ or excessive secretion of

proinflammatory cytokines [1]. Indeed, pharmacological interven-

tion in order to limit cytokine responses and thus to reduce the

immunopathogenicity of influenza virus has been shown to be

beneficial for the host [1,30,31]. Signaling pathways in host IAV

infected cells can be induced by a variety of viral components,

among them double- and single-stranded RNA which are sensed

by the cytosolic RNA helicases, RIG-I, and the TLR family

members TLR7 and TLR3 [6,32,33,34]. So far, the therapeutic

approaches have targeted these last receptors.

Based on our previous results showing the critical role of AEP in

the processing and signaling of another intracellular TLR, TLR9,

it was tempting to speculate that AEP might be involved in TLR7

activation upon IAV infection. Interestingly, mice lacking AEP

were unable to generate a strong antiviral immune response when

challenged with the influenza virus strain PR8 described

previously to be recognized by TLR7 [5,6,7,8]. This was not

due to a deficit in viral clearance because the viral titers of IAV

remain the same in wt and AEP deficient mice. By contrast, lung

epithelial cells, that provide the first spatial barrier against this

respiratory virus, from AEP deficient mice responded much less to

that viral challenge. Moreover, plasmacytoid dendritic cells that

lack AEP expressed reduced amount of IFN-a compared to wt

cells, demonstrating that the response of the very first sentinels

upon viral infection is reduced in the absence of AEP. Besides this

attenuated innate immune response, we were able to observe that

the adaptive immune response in AEP deficient mice was also

severely impaired. CD8+ T cell priming to IAV requires antigen

presentation by activated DCs that express costimulatory mole-

cules, which in turn promote T cell-differentiation and activation.

We demonstrate that in AEP deficient mice the ability to initiate

an immunogenic CD8+ T cell response to an exogenous antigen

that is not synthetized by the antigen presenting cells was severely

Figure 6. TLR7 C-ter is functional and requires acidic environment. (A) IL-6 secretion in TLR72/2 BMDCs transfected with pcDNA3.1, FL, C-teror N-ter TLR7 cDNAs and stimulated with 5 mg/mL of imiquimod or 10 ng/mL of LPS for 16 h. (n = 3–4; mean 6 SEM, * p,0.05, ** p,0.01). (B) IL-6secretion in TLR72/2 BMDCs transfected with FL or C-ter TLR7 and stimulated with imiquimod as above and treated with or without 25 mMMV026630 (AEP inhibitor). (n = 3; mean 6 SEM, * p,0.05). (C) IL-6 secretion in BMDCs activated with either 5 mg/mL imiquimod or 10 ng/mL LPS for16 h, in the presence or not of 20 nM of concanamycin B. (n = 3; mean 6 SEM, ** p,0.01, *** p,0.001). (D) IL-6 secretion in TLR72/2 BMDCstransfected with FL or C-ter TLR7 and stimulated with imiquimod and treated as above. (n = 3; mean 6 SEM, * p,0.05).doi:10.1371/journal.ppat.1002841.g006

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 9 August 2012 | Volume 8 | Issue 8 | e1002841

Page 120: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

compromised. We ruled out the contribution of TLR3 [18] in our

work because TLR3 signaling does not require AEP (data not

shown) and we did not observe difference between wt and AEP2/

2 DCs in OVA cross presentation when TLR3 was stimulated

(Figure S3). Also, we cannot exclude the importance of the

inflammasome in IAV infection [33,35]. In our model, no

difference in IL-1b secretion was detected between wild type

and AEP deficient mice when the IAV PR8 strain was

administered, suggesting that AEP does not play a role in the

activation of the inflammasome (data not shown).

Figure 7. Mutating a putative AEP cleavage site abrogates TLR7 signaling. (A) Immunofluorescence microscopy of resting (top) orimiquimod activated (bottom) fibroblast co-transfected with FL or N478Q TLR7 HA-tagged and UNC93B1-cherry cDNAs and stained for TLR7 (green),LAMP1 (red) and UNC93B1 (red). One representative experiment out of three shown. (B) Quantification of colocalization using Image J software(n = 8). (C) KC secretion in fibroblasts transfected with FL or N478Q TLR7and stimulated overnight with 10 mg/mL imiquimod. (n = 2; mean 6 SEM,* p,0.05). (D) IL-6 secretion in TLR72/2 BMDCs transfected with FL or N478Q TLR7 and stimulated with TLR ligands as above. (n = 4; mean 6 SEM,** p,0.01).doi:10.1371/journal.ppat.1002841.g007

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 10 August 2012 | Volume 8 | Issue 8 | e1002841

Page 121: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Recent results have shown that TLR7 is also subject to

proteolytic degradation [17] but the proteases involved in this

process have not been identified and the functionality of this

product has not been determined. Indeed, no difference was

observed between control DCs and DCs lacking different single

cathepsins (Cathepsins B, K, L and S) in cytokines production

following TLR7 stimulation [12,13]. Furthermore, using Z-FA-

fmk, a broad inhibitor of cysteine proteases and caspases, in a

macrophage cell line, partial inhibition (about 30%) in TLR7

response was reported [17]. This altered signaling was not

observed when AEP was blocked. We have not tested macrophage

cell lines. However, using primary alveolar macrophages, we have

not observed any difference in cytokine secretion between AEP-

deficient macrophages and control cells following TLR7 stimula-

tion. Indeed, we and others have shown that DCs behave

differently from macrophages because they have evolved distinctly

to regulate endosomal acidification at the steady state and upon

TLR stimulation [16,25,36,37]. The experiments presented in this

paper establish that TLR7 processing is dependent on AEP in DCs

and epithelial cells. The in vitro cleavage of TLR7 by AEP, the

impaired cytokine secretion in DCs and in mice deficient for AEP

following TLR7 stimulation or in DCs expressing a TLR7 mutant

lacking the AEP cleavage site at position 478 support this

conclusion. Interestingly enough, both TLR7- and TLR9-

processing and -signaling depend on AEP. These two intracellular

TLRs necessitate UNC93B1 for their trafficking [29,38], share

sequence homology [39], have similar expression in certain DC

subtypes and both contribute to the development of some

autoimmune diseases like systemic lupus erythematous [40].

In conclusion, AEP plays a major role in TLR7 signaling in

primary epithelial and dendritic cells and contributes to the

induction of inflammation and CD8+ T cell activation during

influenza virus infection (Figure S9). Given our findings, targeting

TLR7 response in the lungs through AEP may offer new

therapeutic potential in pulmonary infection. Indeed, a specific

inhibitor of AEP (MV026630) is available and could be tested in

such inflammatory diseases.

Material and Methods

Ethics statementAnimals were housed in the Institut Pasteur animal facilities

accredited by the French Ministry of Agriculture to perform

experiments on live mice in appliance of the French and European

regulations on care and protection of the Laboratory Animals (EC

Directive 86/609, French Law 2001-486 issued on June 6, 2001).

Protocols were approved by the veterinary staff of the Institut

Pasteur animal facility (permit number 99.174) and were

performed in compliance with the NIH Animal Welfare Insurance

A5476-01 issued on 02/07/2007.

MiceAEP2/2 mice were generated in C. Peters’ lab (Freiburg) and

backcrossed 11 times on B6 background. Animals were bred in a

pathogen-free environment in accordance with the Institut Curie

guidelines. Cathepsin B, L, S deficient mice were a kind gift from

A.M. Lennon (Paris, France) and mice lacking cathepsin K were

kindly donated by P. Saftig (Germany).

Influenza virusInfluenza A/Puerto Rico/8 [mouse adapted] P2.3 (H1N1, PR8)

virus was generously provided by N. Naffakh (CNRS URA 3014,

Institut Pasteur, Paris, France), was prepared as previously

described [18] and the titer was expressed as plaque forming

units (pfu)/mL [41].

Cells and stimulationsFibroblasts were obtained from the skin of C57Bl/6J mice

following the protocol as previously described [42]. Bone marrow

derived DCs were generated from AEP2/2, CatB2/2, CatK2/2,

CatL2/2, CatS2/2, TLR72/2 mice and their wt littermates as

previously described [16]. Cell differentiation was controlled by

FACS (anti-CD11c, HL3, and anti-CD11b, M1/70, BD biosci-

ences). Splenic pDCs were isolated using mPDCA-1 selection kit

(Miltenyi Biotech, 90% of purity as determined by FACS).

Epithelial cells were isolated from the mouse lung as previously

described [43]. Plated cells in 96-well plate were treated

overnight with the TLR ligand (LPS (Sigma-Aldrich), Imiqui-

mod, poly(I:C), Resiquimod, or Gardiquimod, CL097 (Invivo-

gen)). In some experiments BM-DCs were pre-incubated with

ConB (20 nM, Sigma) for 20 min or for 1 h with the AEP specific

inhibitor: MV026630 (25 mM, laboratory of H. Overkleeft)

before adding the TLR agonist. Cytokines were measured in

supernatants using home-made (IFN-a) or commercial (TNF-a,

IL-6, IL-12p40, KC, IFN-c, RANTES, eBioscience or R&D

Systems) ELISA.

In vivo IAV modelMale mice were anesthetized by ketamine-xylazine and infected

intranasally with 50 ml of PBS containing 100 pfu of PR8 virus.

Airways were washed 460.5 mL of PBS, and the BAL was

collected to further determine cell differential counts (Beckman

Coulter) and FACS. Different cytokines were measured in BALs.

IFN-b protein expression was quantified by quantitative real-time

RT-PCR in total RNA extracted from lung tissue using the

RNeasy Mini Kit (Qiagen). Primer sequences were for murine

IFN-b gene F: 59CACAGCCCTCTCCATCAACT-39 and R: 59-

TCCCACGTCAATCTTTCCTC-39. In other experiments, re-

combinant adenovirus encoding for NF-kB-luciferase (Ad-NF-kB-

luc, Gene Transfer VectorCore, University of Iowa) was

intranasally co-injected (2.56108 pfu) with PR8 virus (100 pfu)

in order to analyze NF-kB activation in the lungs. Photon emission

of the luminescent construct transduced in the lungs was

quantified using the IVIS system (Xenogen Biosciences) after

intranasal injection of luciferine (50 ml, 500 mg/mL) as previously

described [20].

FACS analysisBAL cells were stained with Live/Dead fixable near-IR dead

cell stain kit (Invitrogen) in PBS for live/dead discrimination. Cells

were then incubated with anti-CD16/32 in PBS-1% BSA and

stained with PerCP-Cy5.5-anti-CD11b (clone M1/70), APC-anti-

CD11c (clone HL3), PE-Cy7-anti-Gr-1 (Ly-6G and Ly-6C, clone

RB6-8C5) (BD Biosciences). Cells were fixed with paraformalde-

hyde 2% and analyzed using a CYAN ADP cytometer (Beckman

Coulter) and with FlowJo software.

Quantification of M2 viral protein and particlesTotal RNA was extracted from lung tissue using the RNeasy

Mini Kit (Qiagen) and the M2 viral protein quantification

performed by quantitative real-time RT-PCR as previously

described [20]. Total proteins were extracted from lung tissue in

PBS in order to quantify the remained IAV by determining pfu

present in lung lysates with the method previously described

[41].

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 11 August 2012 | Volume 8 | Issue 8 | e1002841

Page 122: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

In vitro, in vivo cross-presentation and In vivo DCsstimulationIn vitro cross-presentation assays were performed as previously

described [44]. Briefly, splenocytes from Balb/C mice (H-2d) were

electroporated with 0.5 mg OVA or BSA and infected with PR8

virus (10 pfu) or stimulated with 10 mg/mL imiquimod or 100 mg/

mL poly(I:C) before irradiation (10 Gy) and incubation with DCs.

Then, CFSE labeled OT-I T cells were added to the culture and

the proliferation of T cells was monitored 3 days later. DCs

incubated with SIINFEKL (100 ng/mL) were used as a prolifer-

ation control. In vivo cross-presentation assays were performed as

previously described [4]. Briefly, CFSE labeled CD8+ T cells from

OT-I RAG (CD45.1+) mice were intravenously injected at day 4

into IAV-infected CD45.2+ recipient mice, a day later OVA or

PBS were administered intranasally and mice were sacrificed at

day 8 to monitor proliferation of T cells in the mLNs. Mice were

injected intravenously with TLR agonist or PBS alone and bled

2 h later. Serum cytokine was assessed by ELISA and splenic DCs

were stained with anti-CD11c-APC (HL3), anti-CD86-PE (GL1)

or anti-CD40-PE (3/23) (BD Biosciences) for flow cytometry

analysis.

Size chromatography exclusion, immunodetection andprotease activity506106 BM-DCs were stimulated with Imiquimod (10 mg/mL)

for 60 min. Cells were then lysed in a buffer (50 mM Tris pH 7.4,

150 mM NaCl, 5 mM MgCl2) with 0.5% NP40 for 30 min on ice

and centrifuged at 90000 rpm. The extract was applied to a G-200

Sephadex size exclusion column (Pharmacia). Fractions were

eluted using the previously buffer and 5 mg of protein were

immunoblotted for TLR7 (Imgenex) and MyD88 (Abcam)

expression. Protease activities were assayed on a Mithras LB940

(Berthold technologies) by measuring the release of fluorescent N-

Acetyl-Methyl-Coumarin in citrate buffer (pH 5.5) at 37uC as

previously described [16].

Endosomal pH measurementEndosomal pH measurement has been described [16]. Briefly,

cells were pulsed with 1 mg/mL of FITC- and Alexa-647-labelled

40 kDa dextrans (Molecular Probes) for 10 min at 37uC and

washed with cold PBS-1% BSA. Cells that have endocytosed the

probes were analyzed by FACS at different times.

Phagosome preparation506106 BMDCs were pulsed for 20 min at 37uC with magnetic

particles (Invitrogen) and then chased at 37uC for 100 min in the

presence or absence of imiquimod (10 mg/mL). Cells were then

washed with PBS and mechanically disrupted by passing them

through 25 g needle. Phagosomes were purified by magnetic

separation, washed, and lysed. Equal amounts of proteins were

submitted to separation on a 4–12% SDS NuPAGE Bis-Tris gels

(Invitrogen). Proteins were transferred on a PVDF membrane and

TLR7 immunodetection was realized with rabbit pAb anti-TLR7

(Imgenex).

ConstructsMurine TLR7 constructs (described in Table 1) containing

either the FL sequence, the C-terminal (aa 480–1052) or the N-

terminal part (aa 1–449) followed by a HA-tag were cloned into

pcDNA3.1 by PCR of the pUNO mTLR7-HA plasmid (Invivo-

gen). The full-length mTLR7 construct was mutagenized in its Asn

478 into Gln using the Quick change mutagenesis kit (Stratagene).

35S-labelling of TLR7 protein, digestion assays andtransfection in DCsTLR7 pcDNA3.1 plasmid was transcribed and translated in vitro

using TNT T7 quick Coupled Transcription/Translation system

(Promega) and 10 mCi 35S-methionine (Perkin Elmer). Digestion

assays were performed as previously described [16]. 106 BM-DCs at

day 6 were transfected with 1 mg of cDNA coding for TLR7-FL, -C-

ter or -N-ter using the mouse DC Amaxa kit (Lonza, Germany).

48 h later, cells were harvested and stimulated with TLR agonists.

ImmunofluorescenceCells were fixed with 4% paraformaldehyde for 10 min at RT,

and quenched in 100 mM glycine for 20 min. Fixed cells were

permeabilised and incubated with anti-HA (homemade) and anti-

CD107a LAMP1 (eBIO1, clone D4B) antibodies in PBS-0.2%

BSA-0.05% saponin. Immunofluorescence images were acquired

on a Leica confocal microscope.

Table 1. Sequences of primers used to TLR7 constructs.

Primer name Sequence

TLR7 Not I forward 59-ATA AGA ATG CGG CCG CAC CAT GGT GTT TTC GAT GTG GACA-39

TLR7 C-terminal Not I forward 59-ATA AGA ATG CGG CCG CGG AGC CAC CTT CTT TCT TGCC-39

HA Xho I reverse 59-CCG CTC GAG CGG TTA GGC GTA GTC TGG CAT GG-39

TLR7 N-terminal reverse (first step PCR) 59-AGT TTG AGC ATT AGG ACA AAAG-39

TLR7 N-terminal reverse (second step PCR), 59-CCG CTC GAG TTA GGC GTA GTC TGG CAC ATC ATA GGG GTA AGT TTG AGC AT-39

MHC class I leader sense 59-GGC CGC ACC ATG GTC CCG TGC ACG CTG CTC CTG CTG TTG GCA GCC GCC CTG GCTCCG ACT CAG ACC CGG GCC GGT ACC GC-39

MHC class I leader antisense 59-GGC CGC GGT CCG GCC CGG GTC TGA GTC GGA GCC AGG GCG GCT GCC AAC AGCAGG AGC AGC GTG CAC GGG ACC ATG GTGC-3

primers TLR7 mutant sense 59-TTG CAA ACT TTA ACA CAG GAA ACA TTT GTG TCA-39

TLR7 mutant antisense 59-TGA CAC AAA TGT TTC CTG TGT TAA AGT TTG CAA-39

The N-terminal insert was generated by two PCRs in order to add a HA-tag, using the first PCR product as template for the second PCR. In order to target the C-terminalconstructs to the ER, the leader sequence from murine MHC class I was added by synthesis. The leader-coding oligonucleotide was subsequently inserted in front of theC-terminal previously cloned into pcDNA3.1. The full-length mTLR7 construct was mutagenized in its Asn 478 into Gln using the Quick-change mutagenesis kit(Stratagene).doi:10.1371/journal.ppat.1002841.t001

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 12 August 2012 | Volume 8 | Issue 8 | e1002841

Page 123: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

DuolinkDuolink (OLINK) was performed according to the manufac-

turer’s instructions. Briefly, DCs were grown on coverslips and

then fixed in 4% paraformaldehyde for 10 min before permea-

bilization in PBS/0.05% saponin/0.2% BSA for 10 min. Cells

were then blocked in 3% BSA/PBS and primary antibodies were

incubated (anti-MyD88 and anti-TLR7). After washing the cells,

PLA probes were added, followed by hybridization, ligation, and

amplification for 90 min at 37uC. Nucleus (DAPI labelling) and

MyD88-TLR7 interactions (green) were visualised after incubation

with the detection solution. Slides were analyzed by confocal

microscopy. Quantification of mean fluorescence using Image J

software.

Statistical analysisStatistical significance was determined by unpaired t-test or two-

way ANOVA.

Supporting Information

Figure S1 The innate inflammatory infiltrate of IAV-infected lungs was not altered by the absence of AEP. (A)BAL fluid levels of IFN-a in wt or AEP2/2 mice before (NI), 4 d

or 8 d post-viral infection. (n = 4 animals; graphs show mean 6

SEM, * p,0.05). (B) IFN-b protein expression was quantified by

quantitative real-time RT-PCR in total RNA extracted from lungs

of wt or AEP2/2 mice before (NI), 4 d or 8 d post-viral infection.

(n = 4–8 animals; graphs show mean 6 SEM). (C) Flow cytometry

analysis of single-cell suspensions of wt or AEP2/2 mice-BAL

fluids before (NI), 4 d or 8 d post-viral infection. We analysed the

presence of macrophages/monocytes (CD11b+/Gr1Inter), neutro-

phils (CD11b+/Gr1high) and dendritic cells (CD11b+/CD11c+) in

BALs (n = 8 animals; graphs show mean 6 SEM of two

independent experiments). (D) Myeloperoxidase (MPO) activity

measured in BAL fluids from wt or AEP2/2 mice 4 d and 8 d

post-viral infection. (n = 8 animals; graphs show mean 6 SEM of

two independent experiments, ** p,0.01).

(TIF)

Figure S2 Reduced TLR7 response in mice- or lungepithelial cells- lacking TLR7 infected with IAV virus. (A)BAL fluid levels of cytokines (KC, IL-6, IL-12p40 and IFN-c) in wt

or TLR72/2 mice before (NI), 4 d or 8 d after intranasal injection

of IAV PR8 virus (100 pfu/mice). (n = 3–4 animals; graphs show

mean 6 SEM, * p,0.05, ** p,0.01). (B) IL-6 and RANTES

secretion in supernatants of wt (white bars) or TLR72/2 (gray

bars) lung primary epithelial cells activated with 5 mg/mL of

imiquimod or with the IAV PR8 (10 pfu) for 16 h or 24 h.

(TIF)

Figure S3 Similar cross presentation of OVA in WT orAEP2/2 DCs with or without TLR3 stimulation. Prolifer-ation of OT-I T cells cultured with DCs from wt or AEP2/2

incubated with splenocytes from Balb/C mice (H-2d) electropo-

rated with OVA and stimulated or not with 100 mg/mL poly(I:C)

or PR8 (10 pfu). Results are representative of two independent

experiments.

(TIF)

Figure S4 Cytokine production by AEP and cathepsindeficient pDCs, BMDCs upon TLR7 and TLR4 ligandstimuli. (A) IFN-a secretion in supernatants of AEP+/+, AEP2/2

or TLR72/2 pDCs activated with the IAV strain PR8 heat killed

(HK) or live at a multiplicity of infection= 1 or 5 for 16 h or 24 h.

(n = 2–3; mean 6 SEM). (B, C) BMDCs from AEP2/2, CatB2/2,

CatK2/2, CatL2/2, CatS2/2 mice (black bars) and from their

wild type littermates (white bars) were stimulated with increasing

concentrations of TLR agonist: imiquimod or resiquimod (B) for

TLR7 and LPS for TLR4 (C) for 16 h and secretion of IL-6 were

measured by ELISA. (n = 2–6, mean 6 SEM). (D) Protease

activities using specific substrates for CatB, CatB and CatL, CatK

and CatS were measured in protein lysates of imiquimod

stimulated DCs from wt (white symbols) and AEP-deficient mice

(black symbols). (n = 2–3). (E) Protease activity of different

cathepsins in total lysates from CatK2/2 and CatK+/+ BMDCs

was measured using specific fluorescent substrates.

(TIF)

Figure S5 Cytokine and co-stimulatory molecule ex-

pression in CatB2/2 and CatB+/+ DCs in vivo upon TLR7

sensing. (A) FACS analysis of in vivo maturation of spleen

CD11c+ cells 4 h after i.v. injection of 10 mg of imiquimod (left

panel) or 1 mg of LPS (right panel) compared to no TLR ligand

stimulation equivalent to 1. (B) IL-6 (left panel) and IL-12p40

(right panel) secretion were measured in serum of CatB+/+ or

CatB2/2 mice 2 h after i.v. injection with imiquimod or PBS.

(n = 7 animals for imiquimod; n = 2 animals for PBS; mean 6

SEM for A and B).

(TIF)

Figure S6 TLR7 is digested in vitro by AEP or cathep-

sins L or S. In vitro transcription and translation of murine (A) or

human (B) TLR7 FL followed by 2 h digestion of radiolabelled

TLR7 FL with 15 U of rAEP and cathepsins (ND: non-digested).

Data are representative of three experiments.

(TIF)

Figure S7 TLR7 C-ter is functional and its generation is

AEP-dependent. (A) Immunodetection of TLR7 proteins in

early (20 min) and late (120 min) phagosomes from wt BMDCs

unstimulated or stimulated with 10 mg/ml of imiquimod. (B)

TLR7 deficient DCs were transfected with cDNAs encoding for

the empty vector (pcDNA3.1), TLR7 FL or C-ter TLR7 fragment.

After 48 h, cells were stimulated with imiquimod for 16 h and IL-

12p40 was measured in the supernatants. The amount of IL-

12p40 produced by unstimulated cells was subtracted from

imiquimod-stimulated cells. (Graphs show mean 6 SEM, n= 3).

(C) IL-6 and IL-12p40 secretion in TLR72/2 BMDCs transfected

with pcDNA3.1, FL or C-ter TLR7 fragment and stimulated with

increasing concentrations of imiquimod for 16 h. (n = 4; mean 6

SEM). (D) IL-12p40 secretion in TLR72/2 BMDCs transfected

with FL or N478Q TLR7 and stimulated with 5 mg/mL

imiquimod for 16 h. (n = 4; mean 6 SEM, * p,0.05).

(TIF)

Figure S8 TLR7 C-ter fragment restores TLR7 response

in AEP2/2 DCs and TLR7 stimulation induces acidic pH.

(A) AEP deficient (black bars) and wt (white bars) DCs were

transfected with cDNAs encoding for the empty vector

(pcDNA3.1), TLR7 FL or C-ter TLR7 fragment. After 48 h,

cells were stimulated with imiquimod or LPS for 16 h and IL-6

was measured in the supernatants. The amount of IL-6 produced

by unstimulated cells was substracted from imiquimod-stimulated

cells. Graphs show mean 6 SEM, n=3, * p,0.05. (B) Kinetic of

endo/lysosomal pH in AEP+/+ and AEP2/2 BMDCs in the

presence or not of 10 mg/ml imiquimod and chased for different

times. (n = 2–5; mean 6 SEM, * p,0.05). (C, D) AEP activity in

total lysate (C) or in phagosomes (D) from wt BMDCs treated or

not with imiquimod (5 mg/mL) for the indicated time. (n = 3–4;

mean 6 SEM, ** p,0.01, *** p,0.001). (E) Protease activities

using specific substrates for CatB, CatB and CatL, CatK and CatS

were measured in protein lysates of imiquimod stimulated DCs

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 13 August 2012 | Volume 8 | Issue 8 | e1002841

Page 124: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

from wt mice (n = 2–3; mean 6 SEM, * p,0.05, ** p,0.01, ***

p,0.001).

(TIF)

Figure S9 Model for TLR7 processing and signaling.Single stranded RNA of viral origin (IAV) or chemical compounds

(imiquimod) are sensed by the intracellular receptor TLR7. After

binding on the cell surface, IAV is internalized into endosomes

where its genome is release in an acidic pH dependent fashion.

Following TLR7 ligand stimulation, which induces a drop of pH

in the endosomes and the recruitment of AEP, TLR7 translocates

with the help of UNC93B1 from the ER to the endosomes. In the

endosomes, TLR7 is cleaved in a C-terminal fragment where after

a conformational change binds the adaptor molecule MyD88.

This binding triggers the activation of NF-kB or IRF, their

translocation to the nucleus, and subsequently the production and

release of cytokines and chemokines in DCs.

(TIF)

Acknowledgments

We are grateful to S. Akira (Osaka, Japan) and N. Doyen (Institut Pasteur,

France) for providing the TLR72/2 mice and to the animal facility of the

Institut Curie for hosting AEP2/2 mice. We thank L. Saveanu for critical

reading of the manuscript and A. Bourhane who participated in the early

work on TLR7. The adenovirus containing the NF-kB response element

was kindly given by J.M Sallenave (Institut Pasteur, France). We also thank

V. Balloy and M. A Nicolas (Plateforme d’Imagerie Dynamique

Imagopole, Institut Pasteur, France) for the help with the IVIS system.

Author Contributions

Conceived and designed the experiments: SM SH FB FES DD BM.

Performed the experiments: SM SH FB FES DD. Analyzed the data: SM

SH FB FES DD. Contributed reagents/materials/analysis tools: MT MC

PVE MST. Wrote the paper: BM SM SH DD. BM supervised the project,

helped designed the experiments and edited the paper.

References

1. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, et al. (2011)Endothelial cells are central orchestrators of cytokine amplification duringinfluenza virus infection. Cell 146: 980–991.

2. La Gruta NL, Kedzierska K, Stambas J, Doherty PC (2007) A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol85: 85–92.

3. Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, et al. (2010) Influenza Ainfection enhances cross-priming of CD8+ T cells to cell-associated antigens in aTLR7- and type I IFN-dependent fashion. J Immunol 185: 6013–6022.

4. Ballesteros-Tato A, Leon B, Lund FE, Randall TD (2010) Temporal changes indendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+)T cell responses to influenza. Nat Immunol 11: 216–224.

5. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. (2004)Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc NatlAcad Sci USA 101: 5598–5603.

6. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, et al. (2007) Differentialrole of TLR- and RLR-signaling in the immune responses to influenza A virusinfection and vaccination. J Immunol 179: 4711–4720.

7. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innateantiviral responses by means of TLR7-mediated recognition of single-strandedRNA. Science 303: 1529–1531.

8. Jeisy-Scott V, Davis WG, Patel JR, Bowzard JB, Shieh WJ, et al. (2011)Increased MDSC accumulation and Th2 biased response to influenza A virusinfection in the absence of TLR7 in mice. PloS one 6: e25242.

9. Palm NW, Medzhitov R (2009) Pattern recognition receptors and control ofadaptive immunity. Immunol Rev 227: 221–233.

10. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innateimmunity: update on Toll-like receptors. Nat Immunol 11: 373–384.

11. Janeway CA, Jr., Medzhitov R (2002) Innate immune recognition. Annu RevImmunol 20: 197–216.

12. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, et al. (2008) Proteolyticcleavage in an endolysosomal compartment is required for activation of Toll-likereceptor 9. Nat Immunol 9: 1407–1414.

13. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, et al. (2008) The ectodomainof Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456:658–662.

14. Matsumoto F, Saitoh S, Fukui R, Kobayashi T, Tanimura N, et al. (2008)Cathepsins are required for Toll-like receptor 9 responses. Biochem Bioph ResCo 367: 693–699.

15. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, et al. (2008) CathepsinK-dependent toll-like receptor 9 signaling revealed in experimental arthritis.Science 319: 624–627.

16. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, et al. (2009)Critical role for asparagine endopeptidase in endocytic Toll-like receptorsignaling in dendritic cells. Immunity 31: 737–748.

17. Ewald SE, Engel A, Lee J, Wang M, Bogyo M, et al. (2011) Nucleic acidrecognition by Toll-like receptors is coupled to stepwise processing by cathepsinsand asparagine endopeptidase. The J Exp Med 208: 643–651.

18. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, et al. (2005) Involvement oftoll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280: 5571–5580.

19. Sen R, Baltimore D (1986) Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921–928.

20. Le Goffic R, Leymarie O, Chevalier C, Rebours E, Da Costa B, et al. (2011)Transcriptomic analysis of host immune and cell death responses associated withthe influenza A virus PB1-F2 protein. PLoS Pathog 7: e1002202.

21. Shirahama-Noda K, Yamamoto A, Sugihara K, Hashimoto N, Asano M, et al.(2003) Biosynthetic processing of cathepsins and lysosomal degradation are

abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem 278: 33194–33199.

22. Maehr R, Hang HC, Mintern JD, Kim YM, Cuvillier A, et al. (2005) Asparagineendopeptidase is not essential for class II MHC antigen presentation but isrequired for processing of cathepsin L in mice. J Immunol 174: 7066–7074.

23. Hou B, Reizis B, DeFranco AL (2008) Toll-like receptors activate innate andadaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms.Immunity 29: 272–282.

24. Li DN, Matthews SP, Antoniou AN, Mazzeo D, Watts C (2003) Multistepautoactivation of asparaginyl endopeptidase in vitro and in vivo. J Biol Chem278: 38980–38990.

25. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, et al. (2006) NOX2controls phagosomal pH to regulate antigen processing during crosspresentationby dendritic cells. Cell 126: 205–218.

26. Savina A, Peres A, Cebrian I, Carmo N, Moita C, et al. (2009) The smallGTPase Rac2 controls phagosomal alkalinization and antigen crosspresentationselectively in CD8(+) dendritic cells. Immunity 30: 544–555.

27. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, et al. (2004) Toll-likereceptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependentmanner. Eur J Immunol 4: 2541–2550.

28. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, et al. (1998) Anasparaginyl endopeptidase processes a microbial antigen for class II MHCpresentation. Nature 396: 695–699.

29. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, et al. (2006) The Unc93b1mutation 3d disrupts exogenous antigen presentation and signaling via Toll-likereceptors 3, 7 and 9. Nat Immunol 7: 156–164.

30. Ichinohe T, Iwasaki A, Hasegawa H (2008) Innate sensors of influenza virus:clues to developing better intranasal vaccines. Expert Rev Vaccines 7: 1435–1445.

31. Ehrhardt C, Seyer R, Hrincius ER, Eierhoff T, Wolff T, et al. (2010) Interplaybetween influenza A virus and the innate immune signaling. Microbes Infect 12:81–87.

32. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, et al. (2006)Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2: e53.

33. Thomas PG, Dash P, Aldridge JR, Jr., Ellebedy AH, Reynolds C, et al. (2009)The intracellular sensor NLRP3 mediates key innate and healing responses toinfluenza A virus via the regulation of caspase-1. Immunity 30: 566–575.

34. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, et al. (2011)TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendriticcell cross-presentation, CTL responses, and antiviral protection. J Immunol 186:2422–2429.

35. Pang IK, Iwasaki A (2011) Inflammasomes as mediators of immunity againstinfluenza virus. Trends Immunol 32: 34–41.

36. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES (2005) Differentiallysosomal proteolysis in antigen-presenting cells determines antigen fate. Science307: 1630–1634.

37. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I (2003) Activationof lysosomal function during dendritic cell maturation. Science 299: 1400–1403.

38. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL (2008) UNC93B1 deliversnucleotide-sensing toll-like receptors to endolysosomes. Nature 452: 234–238.

39. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, et al. (2005) Theevolution of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A 102: 9577–9582.

40. Barrat FJ, Coffman RL (2008) Development of TLR inhibitors for the treatmentof autoimmune diseases. Immunol rev 223: 271–283.

41. Matrosovich M, Matrosovich T, Garten W, Klenk HD (2006) New low-viscosityoverlay medium for viral plaque assays. Virol J 3: 63.

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 14 August 2012 | Volume 8 | Issue 8 | e1002841

Page 125: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

42. May T, Lindenmaier W, Wirth D, Mueller PP (2004) Application of a reversibleimmortalization system for the generation of proliferation-controlled cell lines.Cytotechnology 46: 69–78.

43. Raoust E, Balloy V, Garcia-Verdugo I, Touqui L, Ramphal R, et al. (2009)Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-

dependent signaling in murine alveolar macrophages and airway epithelial cells.PloS one 4: e7259.

44. Schulz O, Reis e Sousa C (2002) Cross-presentation of cell-associated antigensby CD8alpha+ dendritic cells is attributable to their ability to internalize deadcells. Immunology 107: 183–189.

Anti-IAV Immune Response Requires AEP

PLOS Pathogens | www.plospathogens.org 15 August 2012 | Volume 8 | Issue 8 | e1002841

Page 126: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Q!""

"

DDD1"3FMKV"DFE!\")59%56'-("$(+"$):$%$/'(5"5(+-:5:6'+$)5"$%5"9%'6'9$."

7$96-%)"7-%"$.;5-.$%"*$9%-:4$/5)":4$/-906-)')"]"B$965%'$."G'..'(/"

! 81&'%:L&! 8-#! 51! V%2&! $-#! >%))6=! .-#! >%2J*12! 8-#! $%&'(%)*+*! ,-#! !5<42$ 3?#! C(*F/%2+! $-#!

! D%:L(%)!D-#!$%/692=!>-!W!,%))1/%N1!K$-#!?@A?-$H.I8!A@XRYSTAZAX7?U-+

+

!"#$%&'($)+3-"$++%5))"645"%-.5"-7"3FMK"'("D2'40%7%)-2"I'$4+()%2-",:6$G5"$(+"9.5$%$(95"B0"$.;5-.$%"

*$9%-:4$/5)1+

*

+,%-./0123)+ D2'40%7%)-2* I'$4+()%2-" ')" $" /%$*" (5/$6';5" B$965%',*" 64$6" 9$,)5)" (-)-9-*'$."

:(5,*-('$"$(+" ')" '(;-.;5+" '("*$(0" 94%-('9" .,(/"+')-%+5%)1"D;"I'$4+()%2-" ')" %59-/('I5+"B0" 6-.." .'G5"

%595:6-%"K":%5)5(6"-("645"),%7$95"-7":4$/-9065)"),94"$)"$.;5-.$%"*$9%-:4$/5)"%5),.6'(/"'("906-G'(5)"

$(+"945*-G'(5)":%-+,96'-("$(+"'('6'$6'-("-7"'**,(5"%5):-()51"g5")-,/46"6-"'(;5)6'/$65"645"%-.5"-7"

3FMK"5(/$/5*5(6"'("B$965%'$.":4$/-906-)')"$(+"G'..'(/"B0"$.;5-.$%"*$9%-:4$/5)1+

*

4$516&5)+g5" )4-&" 64$6" 3FMKTH0+PP" )'/($.'(/" ')" 9%,9'$." 7-%"D;" I'$4+()%2-":4$/-906-)')" $(+" G'..'(/1"

34')" :%-95))" ')" *5+'$65+" B0" 645" *$6,%$6'-(" -7" 9$):$)5E!" $(+" DF" !E\" %5),.6'(/" '(" $(" '(9%5$)5+"

:4$/-.0)-)-*$." $9'+'7'9$6'-(" &4'94" '(+,95)" 645" 9-(),*:6'-(" -7" J):$%$/'(5" S(+-:5:6'+$)5"

+5*-()6%$65+"6-"B5"$"G50"7$96-%"'("D;"I'$4+()%2-"G'..'(/1"

*

<02&/'"1&'02)"H5$),%'(/"JSU"58:%5))'-("'("&'.+"60:5"b&6c":%'*$%0"$.;5-.$%"*$9%-:4$/5)"'(75965+"-%"

(-6"&'64"&6"-%"*,6$65+"U1"I'$4+()%2-"B0",)'(/"9-(7-9$."*'9%-)9-:0"p"[,$(6'7'9$6'-("

"

"

"

"

"

"

"

"

"

"

"

"

Page 127: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Toll-like receptor 5 (TLR5), IL-1β secretion, andasparagine endopeptidase are critical factors foralveolar macrophage phagocytosis and bacterial killingDelphyne Descampsa,b, Mathieu Le Garsa,b,c, Viviane Balloya,b, Diane Barbiera,b, Sophia Maschalidid,e,f, Mira Tohmed,e,f,g,Michel Chignarda,b, Reuben Ramphala,b,h, Bénédicte Manouryd,f,1, and Jean-Michel Sallenavea,b,c,1

aUnité de Défense Innée et Inflammation, Institut Pasteur, 75724 Paris, France; bInstitut National de la Santé et de la Recherche Médicale (INSERM) U874,75724 Paris, France; cUniversité Paris Diderot, Sorbonne Paris Cité (Cellule Pasteur), 75013 Paris, France; dINSERM U1013, Hôpital Necker-Enfants Malades,75015 Paris, France; eEcole Doctorale Gc2iD, Université Paris Descartes, 75006 Paris 5, France; fUniversité Paris Descartes, Sorbonne Paris Cité, Faculté deMédecine, 75015 Paris, France; gInstitut Curie, INSERM U932, 75005 Paris, France; and hDepartment of Medicine, University of Florida, Gainesville, FL 32610

Edited* by Ruslan Medzhitov, Yale University School of Medicine, New Haven, CT, and approved December 16, 2011 (received for review May 27, 2011)

A deficit in early clearance of Pseudomonas aeruginosa (P. aerugi-

nosa) is crucial in nosocomial pneumonia and in chronic lung infec-

tions. Few studies have addressed the role of Toll-like receptors

(TLRs), which are early pathogen associated molecular pattern

receptors, in pathogen uptake and clearance by alveolar macro-

phages (AMs). Here, we report that TLR5 engagement is crucial for

bacterial clearance by AMs in vitro and in vivo because unflagel-

lated P. aeruginosa or different mutants defective in TLR5 activa-

tion were resistant to AM phagocytosis and killing. In addition, the

clearance of PAK (a wild-type P. aeruginosa strain) by primary AMs

was causally associated with increased IL-1β release, which was

dramatically reduced with PAK mutants or in WT PAK-infected pri-

mary TLR5−/− AMs, demonstrating the dependence of IL-1β produc-

tion on TLR5. We showed that this IL-1β production was important

in endosomal pH acidification and in inducing the killing of bacteria

by AMs through asparagine endopeptidase (AEP), a key endosomal

cysteine protease. In agreement, AMs from IL-1R1−/− and AEP−/−

mice were unable to kill P. aeruginosa. Altogether, these findings

demonstrate that TLR5 engagement plays a major role in P. aeru-

ginosa internalization and in triggering IL-1β formation.

flagellin | interleukin-1 | lysosomal protease

The opportunist Gram-negative bacterium, Pseudomonas aer-uginosa, is particularly important in nosocomial pneumonia

and in chronic lung diseases such as cystic fibrosis (1). Alveolarmacrophages (AMs) lie at the forefront of lung defense againstpathogens such as P. aeruginosa. The main function of AMs isto clear pathogens (2), and a deficiency in early recognition ofP. aeruginosa by AMs has been suspected in these pathologies(3, 4). Research has shown that pathogen-associated molecularpatterns (PAMPs) are recognized by specific Toll-like receptors(TLRs) at the surface of phagocytes and mucosal epithelial cells.Surprisingly, although numerous studies have associated the li-gand-induced TLR engagement to cytokine and chemokineproduction from phagocytes (5, 6), comparatively fewer studieshave investigated the importance of TLRs in pathogen phago-cytosis and killing. Furthermore, these studies have mostly usedmacrophages from bone marrow-differentiated cells (BMDMs),few have used live bacteria, and even fewer have used flagellatedbacteria such as P. aeruginosa. Moreover most studies have usedprimed phagocytes (with LPS, zymosan) to boost pathogen up-take. Despite these caveats, the recruitment of membrane TLRsto phagosomes upon phagocytosis has been demonstrated (7–10), except for TLR5. TLR2, TLR4, and the adaptor moleculeMyD88 have been shown to be important molecules in pro-cessing of heat-killed Escherichia coli and Staphylococcus aureusby BMDMs in late endosomes and lysosomes (9–11), suggestingthat a blockade in phagosome maturation was occurring inphagocytes deleted for these molecules.

TLR5 is thought to be one of the key receptors implicated inthe recognition of P. aeruginosa (5, 8), but no information isavailable about whether this molecule is important for bacterialphagocytosis. Here, we sought to investigate specifically the in-volvement of TLR5 in P. aeruginosa phagocytosis and killing byAMs. We describe a pathway linking P. aeruginosa engagementto TLR5 through MyD88, followed by IL-1β release and theinvolvement of a lysosomal cysteine protease (asparagine endo-peptidase, AEP), all events concurring to AM-mediated P. aer-uginosa phagocytosis and bacterial killing.

Results

TLR5 Engagement Is Required for P. aeruginosa Clearance. To de-termine whether the TLR5 ligand flagellin/flagella were involvedin P. aeruginosa clearance by AMs, we infected murine alveolarMH–S cells with either WT P. aeruginosa strain PAK or PAKmutants deficient in the expression of flagellin, the primary fla-gellar subunit (the unflagellated PAKΔfliC), or expressing a fla-gellin monomer mutated in the TLR5-recognition site (PAKL88and PAKL94; Table S1). FACS analysis indicated that MH–Scells expressed TLR5 (Fig. S1A). In the first part of our study,both AM supernatants and cell lysates were pooled for P. aeru-ginosa numeration (killing assays). In that context, MH–S cellssignificantly killed PAK, whereas no clearance of PAKΔfliC orflagellin-mutated PAKL88 or PAKL94 was observed, regardlessof the duration of infection or the multiplicity of infection (MOI)used (Fig. 1A and Fig. S1B). These results were confirmed inprimary WT AMs (Fig. 1B). In all of these experiments, thebacterial counts of all mutants continued to increase, in contrastto WT PAK. Moreover, AMs from TLR5−/−mice were unable tokill PAK, compared with WT AMs (Fig. 1C), whereas the bac-terial clearance ability of AMs from TLR4−/− mice was not im-paired. Importantly, MyD88−/− mice, the TLR5 mRNA levels ofwhich were comparable to those of WT mice (Fig. S1C), werealso unable to eliminate bacteria, underscoring the role ofMyD88 in TLR5 signaling.The resistance of unflagellated PAKΔfliC to AM killing clearly

pointed to the P. aeruginosa flagellum as the organelle mainlyimplicated in AM stimulation (12). However, our data did notrule out that the flagellin monomer might be responsible for AM

Author contributions: D.D., M.C., R.R., B.M., and J.-M.S. designed research; D.D., M.L.G.,

V.B., D.B., S.M., M.T., and B.M. performed research; S.M., M.T., R.R., B.M., and J.-M.S.

contributed new reagents/analytic tools; D.D., M.L.G., S.M., M.T., M.C., B.M., and J.-M.S.

analyzed data; and D.D., B.M., and J.-M.S. wrote the paper.

The authors declare no conflict of interest.

*This Direct Submission article had a prearranged editor.

1To whom correspondence may be addressed. E-mail: [email protected] or

[email protected].

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.

1073/pnas.1108464109/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1108464109 PNAS | January 31, 2012 | vol. 109 | no. 5 | 1619–1624

IMMUNOLO

GY

Page 128: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

induction of bacterial killing. We, therefore, used an unflagel-lated PAK mutant, PAKD (Table S1), which, unlike PAKΔfliC,is still able to release high amounts of flagellin in the supernatant(Fig. S2A). Fig. 1D shows that PAKD, despite its ability to signalthrough TLR5 (TNFα output, 1201 ± 454 pg/mL vs. 2473 ± 487pg/mL for WT PAK), was completely resistant to primary AMkilling. Bacteria centrifuged onto cells to force bacteria–cellcontact, did not increase PAKD killing by primary AMs, rein-forcing the importance of specific functional flagellum–TLR5interaction for P. aeruginosa clearance.The implication of TLR5 recognition in P. aeruginosa clear-

ance was further confirmed in vivo. Following intratrachealP. aeruginosa administration, we showed that 67% of theWT PAKinoculum was recovered in WT mice bronchoalveolar lavage(BAL) 2 h postinfection, whereas 101% of the same inoculumremained after mouse TLR5−/− infection (Fig. 1E). Moreover,all of the original PAKL94 inoculum remained and continued toproliferate after infection of WT mice (124%), suggesting a delayin bacterial clearance, compared with WT PAK. Importantly,these differences cannot be attributed to variations in the cellularcomposition of the airspaces (97−100% of AMs and 0−3% ofneutrophils), and the total cell counts were not significantlydifferent regardless of the bacteria strains used, thereby impli-cating solely the AMs in the events described.

TLR5/MyD88 Signaling Is Important for P. aeruginosa Phagocytosis.

Because bacterial clearance could not be explained either bybactericidal activity of AM-infected supernatants (Table S2) orby AM cytotoxicity, we assessed whether the differential killingbetween WT and PAK mutants was attributable to different AMuptake. MH–S cells were incubated with bacteria for 1 h, fol-lowed by antibiotic treatment, and then the amount of phago-cytosed bacteria was determined in cell lysates only. Fig. 2Ashows a deficit in phagocytosis for PAKL88 and PAKL94 com-pared with WT PAK, whereas mutant CFU counts increased insupernatants. Using FITC-labeled bacteria (Fig. 2B), FACSanalysis showed a near complete absence of labeling in MH–Scells with PAKΔfliC-FITC, i.e., an almost complete deficit ofphagocytosis, whereas PAKL88-FITC and PAKL94-FITC pre-sented an intermediate phenotype of AM uptake, with PAKL88-

FITC being less phagocytosed than PAKL94-FITC. To confirmthat the P. aeruginosa uptake is dependent upon flagellum–TLR5(and not flagellin–TLR5) interaction, we performed phagocyto-sis assays with PAKD. In Fig. S2B, PAKD (despite high levelsof secreted flagellin; Fig. S2A) was less phagocytosed than WTP. aeruginosa, even when bacteria–cell contact was increasedby centrifugation, demonstrating that bacterial internalization isnot attributable to flagellin/TLR5 engagement. Immunoblottingof intracellular flagellin also reflected differences in bacterial

TLR4/

Ba

cte

ria

l g

row

th

aft

er

AM

in

fec

tio

n (

%)

PAK

PAK fliC

PAKL88

PAKL94

MH S cells Primary AM

******

***

***

***

***

Centrifugation

PAK

PAKD

***

WT TLR5 /Mice

PAK PAKL94 PAKRe

ma

inin

g b

ac

teri

al

ino

cu

lum

in

BA

L (

%) ***

*

Ba

cte

ria

l g

row

th

aft

er

AM

in

fec

tio

n (

%)A D

C E

B

Ba

cte

ria

l g

row

th

aft

er

AM

in

fec

tio

n (

%)

***

Primary AM WT

TLR5/

WT

MyD88

/

WT

*** ***

- +

Fig. 1. P. aeruginosa clearance by AMs is dependent on efficient TLR5-Flagella interaction. MH–S cells (A) or primary AMs (B) were infected for 4 h with WT

PAK, PAKΔfliC, PAKL88, or PAKL94 mutants [MOI: 0.1 (B) or 10 (A)]. (C) Primary WT, TLR5−/−, TLR4−/−, or MyD88−/− AMs were infected for 4 h with WT PAK

(MOI: 0.1). (D) Primary AMs were infected for 4 h with either WT PAK or PAKD (MOI: 0.1) with or without centrifugation. (A–D) CFU were quantified in AM

supernatants pooled with cell lysates. Results are means ± SD of three experiments (**P < 0.01; ***P < 0.001) and are expressed as percentages as follows:

(CFU counts recovered without AMs − CFU counts recovered after AM infection) × 100. (E) WT or TLR5−/− mice were infected intratracheally with 105 CFU

of PAK or PAKL94. BALs were performed 2 h later and plated on LB agar plates to quantify total CFU counts. Results are means ± SD of three experiments

(*P < 0.05; ***P < 0.001) and are expressed as percentage of surviving bacteria in BAL = (total CFU counts in BAL/ CFU counts of inoculum) × 100.

Ba

cte

ria

l p

ha

go

cy

tic

Ind

ex

(%

)

Phagocytosed FITC-bacteria

Ce

ll c

ou

nts

******

***

No bacteria

PAK-FITC

PAK fliC-FITC

PAKL88-FITC

PAKL94-FITC

Primary AM

Ba

cte

ria

l p

ha

go

cy

tic

Ind

ex

(%

)

WT TLR5 / WT MyD88 / WT TLR4 /

***

***

A B

C

PAK

PAKL88

PAKL94

Fig. 2. Phagocytosis of P. aeruginosa by AMs is dependent on TLR5-MyD88

signaling. (A and C) MH–S cells were infected for 1 h with WT PAK, PAKL88,

or PAKL94 mutants (A), or primary WT, TLR5−/−, MyD88−/−, or TLR4−/− AMs

were infected with WT PAK (MOI: 10) for 1 h (C). After stimulation, cells

were washed and treated with tobramycin and the number of ingested

bacteria was determined by counting CFU from AM lysates on LB agar plates.

Results are means ± SD of three experiments (***P < 0.001) and are

expressed as percentages of relative phagocytosis index = (CFU counts in

mutant PAK-treated cells/CFU counts in WT PAK-treated cells) × 100. (B)

FACS analysis of MH–S cells following 1 h infection with FITC-labeled WT or

FITC-mutant P. aeruginosa strains. Results are representative of three in-

dependent experiments.

1620 | www.pnas.org/cgi/doi/10.1073/pnas.1108464109 Descamps et al.

Page 129: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

uptake (Fig. S2A). Phagocytosis was shown to be TLR5 receptor-specific, because centrifugation did not significantly abolish dif-ferences in AM uptake between WT PAK and mutants (Fig. S2B–D). Moreover, competition experiments with P. aeruginosaflagellin significantly reduced PAK binding (Fig. S2E). Finally,such a deficit in P. aeruginosa phagocytosis was shown in TLR5−/−

and MyD88−/− primary AMs (Fig. 2C). In contrast, TLR4 wasshown to play no role in P. aeruginosa internalization by primaryAMs. Taken together, these observations established the impor-tance of flagellum/TLR5–MyD88 engagement for P. aeruginosaphagocytosis of primary AMs.

IL-1β Production Is Dependent on TLR5 Signaling.Although PAKL94was not killed, it was shown to be better phagocytosed thanPAKL88, suggesting that other intracellular PAMP receptorsmight be important in the detection and the killing of P. aeru-ginosa by AMs. Because the intracellular PAMP receptor ICEprotease-activating factor (IPAF) participates in the processingof pro-IL-1β to IL-1β through caspase-1/inflammasome-de-pendent activation in P. aeruginosa-infected macrophages (13,14), we measured mature secreted IL-1β levels in primary AMsupernatants as a potential index of inflammasome involvement.We observed that high levels of IL-1β were associated with AM-mediated PAK killing and low IL-1β levels were detected withPAKL94 infection (Fig. 3A). The reduction of IL-1β by PAKL94-treated AMs was associated with a delay and a reduction in pro-IL-1β (31 kDa) production, leading to an important inhibition inmature IL-1β conversion (17 kDa) 4 h postinfection (Fig. 3B).We have demonstrated that purified flagellin was able to inducethe pro-IL-1β synthesis but not the caspase-1 p10 and, therefore,was not involved in the mature IL-1β generation (Fig. S3 A–C).The dependence of IL-1β production on TLR5 was furtherdemonstrated by using PAK-infected primary TLR5−/− AMs.Indeed, for these cells, a significant reduction of IL-1β secretionwas observed, compared with WT AMs, caused by a delay in pro-IL-1β production 2 h postinfection and a decrease in mature IL-1β conversion (Fig. 3 C and D).

Importantly, the deficiency in mature IL-1β conversion ob-served in PAKL94-infected WT AMs was correlated with a re-duction in mature caspase-1 p10 production (Fig. S4A), whereasthis was not the case with PAK-infected TLR5−/− AMs, com-pared with WT AMs (Fig. S4B).

IL-1β Is Required for P. aeruginosa Bacterial Killing. To examine theconnection between IL-1β production and bacterial killing, westudied AM infection with PAKΔpscF, a PAK mutant deficientin the type III secretion system (T3SS) (14), which has beendescribed to block the caspase-1-dependent processing of IL-1β(15). Whereas TNFα secretion was similar between WT PAK-and PAKΔpscF-infected AMs, released IL-1β levels were un-detectable in supernatants after infection of primary AMs withthis mutant (Fig. 4A). Western blot analysis showed that, al-though PAKΔpscF induced high levels of pro-IL-1β, mature IL-1β was not produced (Fig. 4B). This is likely attributable to itsinability to activate caspase-1, as evidenced by the absence of thecaspase-1 p10 subunit in PAKΔpscF-infected AMs 4 h post-infection (Fig. S4C). Importantly, although PAKΔpscF was asefficiently phagocytosed by AMs (125% ± 28%) as WT PAK(100% ± 25%), this nonmature IL-1β producer was not killedby primary AMs (Fig. 4C), validating a link between defectivekilling and a major reduction of IL-1β secretion.Importantly, Fig. 4D showed that exogenously added IL-1β

restored PAKL94 killing to levels equivalent to that of WT PAK.We also demonstrated that IL-1 receptor antagonist (IL-1RA),an inhibitor of IL-1β signaling, was able to inhibit MH–S cellkilling of WT PAK (Fig. 4E), without affecting IL-1β release(3867 ± 649 pg/mL with IL-1RA vs. 3393 ± 309 pg/mL withoutIL1-RA; 5 × 105 AMs). To reinforce that point, we performedadditional experiments on primary AMs from IL-1R1−/− mice.Fig. 4F clearly demonstrated that primary IL-1R1−/− AMs wereunable to kill WT P. aeruginosa, compared with WT AMs. Fur-thermore, we measured the same amount of IL-1β in AMs fromIL-1R1−/− (333 ± 144 pg/mL) and WT (271 ± 34 pg/mL) mice,demonstrating the autocrine feedback of IL-1β on P. aeruginosaclearance by primary AMs.

IL-1β-Induced Bacterial Killing Is Dependent on AEP. Because bac-terial fate is ultimately determined in acidic phagolysosomecompartments, we then set out to determine the mechanismsresponsible for PAK killing in AMs. We showed that blockingphagolysosome acidification by bafilomycin A (BafA) treatment(Fig. S5A), an inhibitor of vacuolar type H+-ATPase, inhibitedsignificantly PAK killing in primary AMs (Fig. S5B), whereas IL-1β release was unaffected (Fig. S5C). Using specific probes tomeasure the pH in endolysosomes, we showed that exogenousadministration of IL-1β significantly reduced the pH in MH–Scell endosomes (Fig. 5A), suggesting that IL-1β-mediated acidi-fication of AM phagolysosomes may be a key element in thecontrol of bacterial killing.Because most of the lysosomal cysteine proteases are de-

pendent on a low pH for their activities, we chose to study therole of the protease AEP in PAK clearance. Using confocalmicroscopy, AEP staining was detected in endosomal EEA1+

vesicles in noninfected primary AMs. In contrast, AEP labelingwas significantly decreased upon PAK challenge, whereas a re-duction of staining was much less pronounced in PAKL94-infected AMs (Fig. 5B). Immunoblotting (Fig. 5C) and enzy-matic activity assays using AEP-specific fluorogenic substrate(Fig. 5D) confirmed a significant AEP consumption in WT PAK-infected AMs 4 h postinfection, whereas this was not the casewith PAKL94-infected primary AMs. However, exogenouslyadded IL-1β restored AEP consumption in PAKL94-infectedAMs 3 h postinfection (Fig. 5 C and D). AEP consumptionwas associated with mature IL-1β secretion but was independentof bacterial uptake, because PAKΔpscF, which is efficiently

0

0.5

1

1.5

2

2.5

0

0.5

1

1.5

2

PA

K

Primary AM WT TLR5 /

-IL1

17 kD

-Pro-IL1

31 kD

- 2 h 4 h 2 h 4 h

PAK PAKL94

IL-1

ActinPA

KP

AKfliC

PA

KL

88

PA

KL

94

[IL

1-

] (n

g/m

L)

C D

BA

-IL1

17 kD

-Pro-IL1

31 kD

Actin

n.d n.d

******

[IL

1-

] (n

g/m

L)

***

n.d n.d

PA

K

- 2 h 4 h - 2 h 4 h

PAK PAK

TLR5 /

IL-1

WT

NI

NI

NI

Fig. 3. IL-1β production in primary AMs is dependent on TLR5. A total of 105

primary AMs fromWT (A and B) or TLR5−/− (C and D) mice were infected with

WT PAK, PAKL88, or PAKL94 (MOI: 1). IL-1β secretion was measured in

supernatants 4 h postinfection (A and C). Results are means ± SD of three

experiments (***P < 0.001). NI, noninfected cells; nd, not detected. Lysates

obtained from primary WT (B) or TLR5−/− (D) AMs infected with bacteria

were analyzed by immunoblotting for pro-IL-1β processing. Equal loading

was controlled for by β-actin detection. Results are representative of three

independent experiments.

Descamps et al. PNAS | January 31, 2012 | vol. 109 | no. 5 | 1621

IMMUNOLO

GY

Page 130: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

phagocytosed but unable to produce IL-1β, did not affect AEPexpression during infection (Fig. S6A).Furthermore we showed that recombinant AEP can exert

a dose-dependent direct lytic activity on P. aeruginosa at pH 6(Fig. S6B). Finally, the importance of AEP activity in AM-mediated bacterial killing of P. aeruginosa was confirmed inprimary AEP−/− AMs. Although PAK was phagocytosedat comparable levels in primary AEP−/− AMs and WT AMs(Fig. S6C), we observed that primary AEP−/− AMs were un-able to kill PAK, compared with WT AMs (Fig. 5E). Theabsence of killing by primary AEP−/− AMs was not caused bya deficiency in pro-IL-1β processing, because these cells didnot secrete less mature IL-1β compared with WT AMs (Fig. S6D and E).

Discussion

Using nonopsonic conditions, thus mimicking resting and naïveconditions in the alveolar space, we show that TLR5 and MyD88(but not TLR4) are of paramount importance for P. aeruginosaphagocytosis and killing. Indeed, P. aeruginosa mutants for theTLR5-recognition site of flagellin monomer domain D1 [PAKL88or PAKL94 (16, 17)] were resistant to AM killing, and primaryTLR5−/− AMs were unable to clear P. aeruginosa. Importantly, inthese unprimed conditions, bacterial flagellum was shown to bekey for AM–P. aeruginosa interaction because unflagellatedmutants, PAKΔfliC or PAKD (the latter secreting flagellin in thesupernatant), were equally resistant to AM killing. Crucially, theimportance of flagellum/TLR5 interaction on bacterial killing was

IL1

-(n

g/m

L)

NI

IL-1- 2 h 4 h 2 h 4 h

PAK PAK pscF

-IL1

17 kD

-Pro-IL1

31 kD

Actin

E F

A B C

D

TN

F(n

g/m

L)

0

1

2

3

n.d n.d

PAKPAK

pscF

n.d0

1

2

3

**

PAK

PAK pscF

PAK

0 10IL-1

(ng/mL)

* *

PAKL94

0 10

Ba

cte

ria

l g

row

th

aft

er

AM

in

fec

tio

n (

%)

0 20 200IL-1RA

(ng/mL)

**

Ba

cte

ria

l g

row

th

aft

er

AM

in

fec

tio

n (

%)

***

Primary AM WT IL-1R1 /

Ba

cte

ria

l g

row

tha

fte

r A

M i

nfe

cti

on

(%

)

Ba

cte

ria

l g

row

th

aft

er

AM

in

fec

tio

n (

%)

Fig. 4. IL-1β secretion is required for AMs to kill P.

aeruginosa. (A) Primary WT AMs (105) were infected

with WT PAK or PAKΔpscF mutant (MOI: 1) for 4 h. TNFα

or IL-1β was measured in supernatants. Results are

means ± SD of three experiments. NI, noninfected cells;

nd, not detected. (B) Lysates from infected AMs were

assessed for pro-IL-1β processing. Equal loading was

controlled by β-actin detection. Results are representa-

tive of three independent experiments. (C) Primary WT

AMs were infected with WT PAK or PAKΔpscF (MOI: 0.1)

for 4 h. (D and E) MH–S cells were infected with WT PAK

or PAKL94 mutant (MOI: 0.1) for 4 h in the presence or

not of IL-1β or IL-1 receptor antagonist (IL-1RA). (F) Pri-

mary WT or IL-1R1−/− AMs were infected for 4 h with WT

PAK (MOI: 0.1). (C–F) CFU were quantified in super-

natants pooled with cell lysates. Results are means ± SD

of three experiments (*P < 0.05; **P < 0.01) and are

expressed as in Fig 1.

A B

C D E

Fig. 5. AEP protease is essential for P. aeruginosa killing by primary AMs. (A) Kinetics of endolysosomal pH in MH–S cells ± IL-1β (10 ng/mL) was measured.

Results are means ± SD of three experiments. (B) Confocal microscopy of AEP was measured in primary WT AMs infected or not for 3 h with WT PAK or

PAKL94. Quantification was performed using Image J software (n = 5). (C) Immunoblotting AEP expression in lysates from WT PAK- or PAKL94-infected

primary WT AMs (MOI: 1) with or without IL-1β. Equal loading was controlled by β-actin detection. Results are representative of three independent

experiments. (D) AEP activity was measured in lysates fromWT PAK- or PAKL94-infected MH–S cells (MOI: 10) with a fluorometer by assessing the hydrolysis of

the specific substrate for AEP. (A–D) Unpaired t test (*P < 0.01; **P < 0.005; ***P < 0.0001). NI, noninfected cells. (E) Primary WT or AEP−/− AMs were infected

with WT PAK (MOI: 0.1) for 4 h. CFUs were quantified in supernatants pooled with cell lysates. Results are means ± SD of three experiments (***P < 0.001) and

are expressed as in Fig 1.

1622 | www.pnas.org/cgi/doi/10.1073/pnas.1108464109 Descamps et al.

Page 131: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

confirmed by using primary TLR5−/−, TLR4−/−, or MyD88−/−

AMs, as well as in vivo, where we demonstrated that 2 h post-infection, TLR5 expression on AMs was the most important factorin clearing bacteria and in containing pulmonary infection.Flagellum/TLR5-mediated killing was not related to AM-se-

creted antimicrobial activity, but was associated with TLR5-de-pendent intracellular entry, because PAK mutants for the TLR5-recognition sites L88 and L94 were less phagocytosed by MH–Scells than WT PAK. The necessity of TLR5/MyD88 engagementfor P. aeruginosa phagocytosis was also confirmed by using pri-mary TLR5−/− and MyD88−/− AMs. Importantly, TLR4 signal-ing did not play any role in P. aeruginosa uptake by primary AMs.Loss of bacterial motility (18) was not a relevant factor in ourmodel. Indeed, PAKL88 and PAKL94 are fully motile bacteria(16); however, none of the mutants was killed by AMs. More-over, after centrifugation to force bacteria–cell contact, flagellin-mutated bacteria or unflagellated mutants were still considerablyless phagocytosed than WT bacteria, demonstrating that thephagocytic phenotype was not attributable to a mobility-deficit orflagellin/TLR5 engagement but was related to diminished spe-cific flagellum/TLR5 interaction.Unexpectedly, the use of PAKL88 and PAKL94 revealed

differences in P. aeruginosa phagocytosis and killing. Indeed,although both mutants were equally resistant to AM killing,PAKL88 stayed mostly extracellular, whereas PAKL94 was bet-ter phagocytosed by AMs, albeit not as efficiently as WT PAK.Although a short stretch of 10 aa (N-88-LQRIRDLALQ-97) inthe flagellin monomer was known to be crucial for TLR5 rec-ognition (16–18), our data demonstrate that the L88 residue isimportant for binding/recognition by TLR5 and intracellularentry, whereas the L94 residue may be more important for in-tracellular downstream events. Indeed, Franchi et al. (14) dem-onstrated that PAKL94 was much less efficient at inducingmature IL-1β than WT PAK in BMDMs, presumably because ofa reduced interaction of bacteria with the intracellular receptorIPAF. These data demonstrated that L94 was a critical residuefor the engagement of the inflammasome via IPAF, in additionto residues present at the C terminus of the D0 domain of fla-gellin monomer (14, 17, 19). Alternatively, other Nod-likereceptors such as Naip5 (19, 20) may also be involved in thedifferential binding of flagellin L94.Another important finding of our study is that TLR5 is im-

portant for production of IL-1β in AMs. The latter result con-trasts with that of Franchi and coworkers (14, 21), who studied P.aeruginosa and Salmonella infection of BMDMs and showed,without studying the effect on phagocytosis and bacterial killing,that TLR5 was redundant and that IPAF and ASC were thetwo inflammasome constituents regulating IL-1β synthesis. Twothings may explain this discrepancy: first, whereas these authorsused BMDMs, we have used AMs; second, and crucially,whereas they primed BMDMs with LPS before bacterial in-fection to increase pro-IL-1β production, our protocol did notinvolve priming, and the production of mature IL-1β occurredfollowing a single event of P. aeruginosa infection (4 h). In ourstudy, TLR5 is essential for bacterial internalization, production,and processing of pro-IL-1β (presumably through IPAF). In thestudy mentioned above (14, 21), BMDM priming with LPSprobably bypassed the need for TLR5 through other receptors(e.g., TLR4) for pro-IL-1β generation. The latter events in-volving inflammasome activation most likely occurred in a simi-lar fashion in both studies.The role of inflammasome has been mainly investigated using

intracellular bacteria (Legionella, Shighella) (22, 23), but rela-tively few studies have addressed this issue in AMs infected withextracellular bacteria (e.g., P. aeruginosa). How can P. aerugi-nosa, then, activate the inflammasome if this bacterium fate isdestruction in the phagolysosome? No system to evade thephagolysosome has been described for P. aeruginosa. However,

a cytosolic leakage/transport of bacterial constituents is a possi-bility. The main vector for this transfer may be the T3SS, andthe main ligand may be flagellin itself, although most studiesused, for their demonstration, elegant but artificial transfectionmethods to introduce flagellin in the cytosol to activate IPAF.Indeed, we showed that extracellularly added flagellin, althoughable to produce pro-IL-1β, is unable to activate procaspase-1and, consequently, to induce the mature IL-1β secretion.Moreover, PAKΔpscF, a mutant deficient in T3SS unable toengage IPAF (13, 14), was not killed by AMs and completelyfailed to induce the mature IL-1β production (although pro-IL-1β was produced), despite the presence of flagellum and itsproper internalization. This demonstrates that IL-1β processingneeds both the flagellum and T3SS to activate the inflamma-some. Crucially, IL-1β production is not merely a bystander inthe killing process but is causative because WT AMs treated withIL-1RA or AMs from IL-1R1−/− mice could not kill P. aerugi-nosa. This clearly demonstrates the existence of an autocrineloop, involving IL-1β production, IL-1β/IL-1R interaction, andsubsequent P. aeruginosa clearance. It has been shown recentlythat the IL-1β processing (procaspase-1/pro-IL-1β) may, in fact,be operative in lysosomes (24, 25), bringing this machinery inclose contact with incoming bacteria and, presumably, decreasingthe time of reaction for mature IL-1β production upon bacterialcontact. Moreover, this vesicular localization of procaspase-1/caspase-1 may explain why IL-1β release precedes cell lysis, be-cause in the time frame of our experiments, no pyroptosis/celllysis was observed. However, it is possible that AMs may beinherently more resistant to pyroptosis because this cell typeperforms a crucial sentinel role within tissues. Interestingly,Carvalho et al. have shown that IL-1RA is produced by AMs inresponse to flagellin after 4 h, suggesting that this counter-regulatory molecule is only secreted at a late time point in thephagocytic process and may not impair bacterial clearance (26).We went a step further in the dissection of the mechanism by

showing that IL-1β increased phagolysosomal acidification. Be-cause the latter is critical for the activation of cysteine proteasesinvolved in bacterial degradation (27), we studied specificallyone of them, AEP, which controls the activation of other lyso-somal cysteine proteases (28). By using three independenttechniques, we observed a reduction of AEP levels upon in-fection with WT PAK, but not with PAKL94 or PAKΔpscF orpurified flagellin (Fig. S3D). AEP was shown to be a key factorparticipating in AM-mediated P. aeruginosa killing becauseAEP−/− AMs were unable to kill WT PAK.In summary (Fig. S7), we describe a phagocytic pathway,

demonstrating the role of TLR5 in AM phagocytosis after P.aeruginosa early infection. This occurs in a T3SS-dependentfashion, leading to caspase-1 and IL-1β maturation. The latterinduces, after acidification of the phagolysosome, the consump-tion of AEP, a protease that we demonstrate to be a key factor inP. aeruginosa killing. Our results give a mechanistic insight intoearly events following P. aeruginosa infection of AMs in the lungand extend our understanding of the crucial role of TLR5 in thedefense of the lung against this important pathogen (29, 30–32).

Materials and MethodsMouse Primary AMs and MH–S Cells. TLR4−/−, TLR5−/−, MyD88−/− (S. Akira,

Osaka University, Osaka, Japan), and IL-1R1−/− mice (CDTA) were back-

crossed 8 times with C57BL/6J. C57BL/6J mice (Janvier) were used as control

mice. Care and use of the mice was in accordance with Institut Pasteur

guidelines in compliance with the European Animal Welfare regulations.

Mouse primary AMs were isolated after lung washing with PBS (33). AMs

were plated in complete RPMI medium (supplemented with 2 mM L-gluta-

mine, 1% antibiotic, and 5% inactivated FBS). After 2 h, medium was re-

moved and AMs were incubated overnight with fresh medium. Mouse AM

cell line MH–S (CRL-2019; ATCC) was maintained in complete RPMI medium

supplemented with 1% sodium pyruvate. Primary AMs or MH–S cells were

placed into serum- and antibiotic-free RPMI for 5 h before infection.

Descamps et al. PNAS | January 31, 2012 | vol. 109 | no. 5 | 1623

IMMUNOLO

GY

Page 132: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Bacterial Strains.WT strain PAK (from S. Lory, HarvardMedical School, Boston,

MA) is a commonly studied P. aeruginosa strain. All modified mutants used

were derived from PAK (Table S1). Bacteria were grown overnight in LB

broth at 37 °C and then transferred to fresh medium and grown by shaking

at 100 rpm for 4–5 h to mid-log phase. The culture was centrifuged at 3,000

× g and the pellet was washed and resuspended in PBS. The OD600nm was

adjusted to give the desired inoculum. Inoculum was verified by serial

dilutions plated on LB agar to determine the number of colony-forming unit

(CFU). Bacterial growth of each PAK strain used in this study was shown to

be identical.

Bacterial Clearance Assay. A total of 105 AMs were infected with bacteria

(MOI: 0.1). After 2–4 h, supernatants were collected and cells were lysed with

0.1% Triton X-100 (a concentration that did not affect PAK viability) in H2O

in sequential washes to harvest total bacteria. To quantify total viable

bacteria, pooled cell supernatants and lysates were diluted and plated on LB

agar to determine CFU scores. Results are expressed as percentages as fol-

lows: (CFU counts recovered without AMs − CFU counts recovered after AM

infection) × 100. For specific experiments, centrifugation was performed (80

× g; 4 min) to ensure synchronous contact between WT or nonmotile

P. aeruginosa and AMs. To test bacterial clearance in vivo, mice were anes-

thetized by ketamine-xylazine intramuscular injection, and then infected

intratracheally with 105 CFU (50 μL). Mice were euthanized 2 h later. BAL

fluids (2 × 250 μL pooled) were performed, diluted, and plated on LB agar

plates to quantify total CFU counts. The percentage of surviving bacteria in

BAL was assessed as follows: (total CFU counts in BAL/CFU counts of in-

oculum) × 100. Total cell counts were measured with a Coulter Beckman

Counter. Cell differential counts were determined after cytospin centrifu-

gation and staining with Diff-Quik products (Medion Diagnostics).

Phagocytosis Assay. A total of 5 × 105 AMs were infected with bacteria (MOI:

10) to 1 h. Free and adherent bacteria were removed by washing cells with

PBS and were killed with tobramycin treatment (40 μg/mL; 30 min). Then, cells

were washed and lysed in H2O containing 0.1% Triton X-100. The number of

bacteria in lysates was determined by counting CFU on LB agar plate. The

percentage of relative phagocytosis index was assessed as follows: (CFU

counts in mutant PAK-treated cells/CFU counts in WT PAK-treated cells) × 100.

In other experiments, bacteria were labeled with 0.1 mg/mL FITC (Sigma) in

Na2CO3 buffer, pH 9.5, at 37 °C while shaking at 100 rpm for 1 h. After in-

cubation and treatment as described above, cells were resuspended in PBS-

EDTA 2 mM, and then fixed in 3% PFA. To quantify phagocytosed bacteria,

fixed cells were used for FACS analysis of cell-associated fluorescence.

ELISA. IL-1β and TNFα were assayed after stimulation using DuoSet ELISA

(R&D Systems). Recombinant murine IL-1β and IL-1RA were purchased from

Peprotech.

Endosomal pH Measurement. Endosomal pH measurement assays have been

described previously (28). MH–S cells were pulsed with 1 mg/mL FITC- and

Alexa-647-labeled 40-kDa dextrans (Molecular Probes) for 10 min at 37 °C

and washed with PBS with 1% BSA. Cells were chased and analyzed by FACS,

via a FL1/FL4 gate selective for cells that have endocytosed the probes.

AEP Protease Activity. Protease activity assays were performed on a FluoStar

Optima (BMG Labtech) by measuring the release of fluorescent N-acetyl-

methyl-coumarin in citrate buffer (pH 5.5) or PBS (pH 7.4) at 37 °C after

incubation of AEP or total lysates with its specific substrate (Z-Ala-Ala-Asn-

NHMec; Bachem).

AEP Immunofluorescence. Primary AMs were seeded on poly-L-lysine-coated

glass coverslips. Cells were infected with bacteria (MOI: 10) for 3 h, washed,

fixed with 4% PFA, and quenched by adding 0.1 M glycine. Cells were per-

meabilized in PBS/0.05% saponin/0.2% BSA, washed, and then incubated

with anti-AEP Ab. The coverslips were mounted with Fluoromount G and

were analyzed by confocal microscopy (Zeiss confocal microscope LSM 700).

For Z-stack acquisition, several images were acquired.

Statistics. Data are presented as means ± SD. A one-way ANOVA with

Fischer’s protected least significant difference test was conducted.

ACKNOWLEDGMENTS. We acknowledge B. Solhonne for her assistance,Prof. Z. Xing (Centre for Gene Therapeutics, McMaster University, Hamilton,Canada) for useful discussions, and Bernhard Ryffel for providing IL-1R1−/−

mice (Unité Mixte de Recherche 6218, Centre National de la Recherche Sci-entifique, Orléans, France). We thank Vaincre la Mucoviscidose for fundingthis work.

1. Mogayzel PJ, Jr., Flume PA (2010) Update in cystic fibrosis 2009. Am J Respir Crit Care

Med 181:539–544.

2. Gordon S (2007) The macrophage: Past, present and future. Eur J Immunol 37(Suppl

1):S9–S17.

3. Di A, et al. (2006) CFTR regulates phagosome acidification in macrophages and alters

bactericidal activity. Nat Cell Biol 8:933–944.

4. Deriy LV, et al. (2009) Disease-causing mutations in the cystic fibrosis transmembrane

conductance regulator determine the functional responses of alveolar macrophages.

J Biol Chem 284:35926–35938.

5. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity:

Update on Toll-like receptors. Nat Immunol 11:373–384.

6. Medzhitov R (2007) Recognition of microorganisms and activation of the immune

response. Nature 449:819–826.

7. Underhill DM, et al. (1999) The Toll-like receptor 2 is recruited to macrophage

phagosomes and discriminates between pathogens. Nature 401:811–815.

8. Ozinsky A, et al. (2000) The repertoire for pattern recognition of pathogens by the

innate immune system is defined by cooperation between toll-like receptors. Proc

Natl Acad Sci USA 97:13766–13771.

9. Blander JM, Medzhitov R (2004) Regulation of phagosomematuration by signals from

toll-like receptors. Science 304:1014–1018.

10. Blander JM, Medzhitov R (2006) On regulation of phagosome maturation and anti-

gen presentation. Nat Immunol 7:1029–1035.

11. Doyle SE, et al. (2004) Toll-like receptors induce a phagocytic gene program through

p38. J Exp Med 199:81–90.

12. Mahenthiralingam E, Speert DP (1995) Nonopsonic phagocytosis of Pseudomonas

aeruginosa by macrophages and polymorphonuclear leukocytes requires the pres-

ence of the bacterial flagellum. Infect Immun 63:4519–4523.

13. Miao EA, Ernst RK, Dors M, Mao DP, Aderem A (2008) Pseudomonas aeruginosa ac-

tivates caspase 1 through Ipaf. Proc Natl Acad Sci USA 105:2562–2567.

14. Franchi L, et al. (2007) Critical role for Ipaf in Pseudomonas aeruginosa-induced cas-

pase-1 activation. Eur J Immunol 37:3030–3039.

15. Jyot J, et al. (2011) Type II secretion system of Pseudomonas aeruginosa: In vivo evi-

dence of a significant role in death due to lung infection. J Infect Dis 203:1369–1377.

16. Verma A, Arora SK, Kuravi SK, Ramphal R (2005) Roles of specific amino acids in the N

terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the

innate immune response. Infect Immun 73:8237–8246.

17. Smith KD, et al. (2003) Toll-like receptor 5 recognizes a conserved site on flagellin

required for protofilament formation and bacterial motility. Nat Immunol 4:

1247–1253.

18. Amiel E, Lovewell RR, O’Toole GA, Hogan DA, Berwin B (2010) Pseudomonas aeru-

ginosa evasion of phagocytosis is mediated by loss of swimming motility and is in-

dependent of flagellum expression. Infect Immun 78:2937–2945.

19. Miao EA, et al. (2010) Innate immune detection of the type III secretion apparatus

through the NLRC4 inflammasome. Proc Natl Acad Sci USA 107:3076–3080.

20. Lightfield KL, et al. (2011) Differential requirements for NAIP5 in activation of the

NLRC4 inflammasome. Infect Immun 79:1606–1614.

21. Franchi L, et al. (2006) Cytosolic flagellin requires Ipaf for activation of caspase-1 and

interleukin 1beta in salmonella-infected macrophages. Nat Immunol 7:576–582.

22. Amer A, et al. (2006) Regulation of Legionella phagosome maturation and infection

through flagellin and host Ipaf. J Biol Chem 281:35217–35223.

23. Suzuki T, et al. (2007) Differential regulation of caspase-1 activation, pyroptosis, and

autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog 3:e111.

24. Andrei C, et al. (2004) Phospholipases C and A2 control lysosome-mediated IL-1 beta

secretion: Implications for inflammatory processes. Proc Natl Acad Sci USA 101:

9745–9750.

25. Wewers MD (2004) IL-1beta: An endosomal exit. Proc Natl Acad Sci USA 101:10241–

10242.

26. Carvalho FA, Aitken JD, Gewirtz AT, Vijay-Kumar M (2011) TLR5 activation induces

secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-as-

sociated tissue damage. Mucosal Immunol 4:102–111.

27. Bird PI, Trapani JA, Villadangos JA (2009) Endolysosomal proteases and their in-

hibitors in immunity. Nat Rev Immunol 9:871–882.

28. Sepulveda FE, et al. (2009) Critical role for asparagine endopeptidase in endocytic

Toll-like receptor signaling in dendritic cells. Immunity 31:737–748.

29. Balloy V, et al. (2007) The role of flagellin versus motility in acute lung disease caused

by Pseudomonas aeruginosa. J Infect Dis 196:289–296.

30. Feuillet V, et al. (2006) Involvement of Toll-like receptor 5 in the recognition of

flagellated bacteria. Proc Natl Acad Sci USA 103:12487–12492.

31. Ramphal R, Balloy V, Huerre M, Si-Tahar M, Chignard M (2005) TLRs 2 and 4 are not

involved in hypersusceptibility to acute Pseudomonas aeruginosa lung infections. J

Immunol 175:3927–3934.

32. Sutterwala FS, et al. (2007) Immune recognition of Pseudomonas aeruginosa medi-

ated by the IPAF/NLRC4 inflammasome. J Exp Med 204:3235–3245.

33. Gonçalves de Moraes VL, Singer M, Vargaftig BB, Chignard M (1998) Effects of roli-

pram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced

inflammation in mouse lung. Br J Pharmacol 123:631–636.

1624 | www.pnas.org/cgi/doi/10.1073/pnas.1108464109 Descamps et al.

Page 133: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Q<""

"

.&*0/**&()+!).+5$#*5$0'&%$*+

H0"+')9,))'-("&'.."B5"7-9,)5+"-("645"%5/,.$6'-("-7"3FMO"$(+"3FMQ")'/($.'(/"$(+"6%$77'9G'(/"*$'(.0"'("@"

95..)1"

g5" $%5" e,)6" B5/'(('(/" 6-" ,(+5%)6$(+" 645" 9-*:.58" 95.." B'-.-/0" 64$6" ,(+5%.'5)" 645" 7,(96'-(" -7" 645"

'*:-%6$(6" 7$*'.0"-7":$665%(" %59-/('6'-(" %595:6-%)V" 645"3-..EF'G5"M595:6-%)" b3FMc1"J" 9-**-(" 645*5"

64$6"')"5*5%/'(/"9-(95%('(/"645"%5/,.$6'-("-7"3FM")'/($.'(/"')"-(5"'("&4'94"645"),B95..,.$%".-9$6'-("-7"

645"3FM"+'96$65)"'6)"7,(96'-(1"345":-)'6'-('(/"-7"645"3FM"6-"$..-&"645*"6-"$96"$)")5(6'(5.)"7-%"UJHUE

9-(6$'('(/" :$64-/5()V" 645'%" '(6%$95..,.$%" 6%$77'9G'(/" $(+" 645'%" 9-*:$%6*5(6$.'I$6'-(" 6-/5645%" &'64"

645'%".'/$(+)V"9-()6'6,65"9%'6'9$."75$6,%5)"'("3FM")'/($.'(/"-,69-*51""

72(06($:$2&*0=*>?<@A+B*'2*CD4E*,23*@*&/,=='%-'2.*,23*5'.2,6'2.*'2*+*%$665*

345"95..,.$%"*594$(')*)"B0"&4'94"3FM)".'/$(+)"$%5"+5.';5%5+"6-"645"'(6%$95..,.$%"3FM"'("@"95..)"$%5"(-6"

7,..0",(+5%)6--+"$(+"$%5"-7"B'/"'(65%5)61"D("9-(6%$)6"6-"+5(+%'6'9"95..)"b#R)c"$(+"*$9%-:4$/5)V"@"95..)"

$%5" :--%.0" :'(-906'9" $(+" :4$/-906'9" 95..)1" R-()5[,5(6.0V" @" 95..)" %5.0" -(" 645" @RM" 7-%" 645" $(6'/5("

,:6$G5",(+5%":40)'-.-/'9$."9-(95(6%$6'-("-7"$(6'/5(V"),//5)6'(/" 64$6" 645" '(6%$95..,.$%"3FM" '("@"95..)"

*$0" +5:5(+" -(" +5.';5%0" -7" 645'%" .'/$(+V" B0" 645" @RM" &4'94" 7,(96'-()" $)" $(" $(6'/5(E)9$;5(/'(/"

%595:6-%1" D(" <22PV" 645" /%-,:" -7" A,I$(" U'5%95"&$)" 645" 7'%)6" 6-" )4-&" 645" '(6%$95..,.$%" .-9$.'I$6'-(" -7"

3FMQ"'("%5)6'(/":%'*$%0"@"95..)V"7-,(+"'(":,(96$65E$::5$%'(/")*$.."9-*:$%6*5(6)"64$6"$%5":-)'6';5"7-%"

5$%.0"5(+-)-*$."*$%G5%)"SSJ!"$(+"6%$()75%%'("%595:6-%1"H-%5-;5%V"6450")4-&5+"64$6"7-..-&'(/"@RM"

9%-)).'(G'(/"&'64"645"$(6'/5("$.-(5"-%" 6-/5645%"&'64"R:>"#WJV"3FMQ"&$)"%59%,'65+"6-"*,.6'.$*5..$%"

*,.6';5)'9,.$%" FJHU!p" $,6-:4$/-)-*5)" &45%5" '6" 9-.-9$.'I5+" &'64" 645" $(6'/5(EB-,(+" '(65%($.'I5+"

@RM1"#)MWJE)5()'(/"3FM?"&$)"$.)-"%59%,'65+"6-"645"@RM"9-(6$'('(/"$,6-:4$/-)-*5)V"),//5)6'(/"64$6"

B0"'(+,9'(/"645"6%$77'9G'(/"-7"$6".5$)6"3FM?"$(+"3FMQ"6-"645"$,6-:4$/-)-*5V"645"@RM"$..-&)"645)5"3FM"

6-"/$'("$995))"6-"645'%".'/$(+"bC!Nc1"345".-9$.'I$6'-("-7"3FMQ"'("645"5(+-)-*5)"$6"645")65$+0")6$65"'("@"

95..)" 9-(6%$)6)" &'64" 645" -B)5%;$6'-()" '(" #R)" $(+"*$9%-:4$/5)" &45%5" 3FMQ" ')" 9-(95(6%$65+" '(" 645"

5(+-:.$)*'9" %56'9,.,*" '(" ,()6'*,.$65+" 95..)1" D6" ')" -(.0" ,:-(" R:>" #WJ" )6'*,.$6'-(" 64$6" 3FMQ"

%5.-9$.'I5)"6-/5645%"&'64"'6)"94$:5%-(5"*-.59,.5"YWRQ?@!"6-"645"5(+-)-*5)"&45%5"'6"')"),Be5965+"6-"

:%-65-.0)')"7-%"-:6'*$.")'/($.'(/1"YWRQ?@!"')"$.)-"%5[,'%5+"7-%"3FM?V"OV"PV"!!V"!<"$(+"!?"7,(96'-("'("

+5(+%'6'9" 95..)" $(+" *$9%-:4$/5)" B0" 9-(6%-..'(/" 645'%" 6%$77'9" 7%-*" 645" SM" 6-" 5(+-.0)-)-*5)" $(+" $"

)'(/.5"*,6$6'-("&'64'("'6)"6%$()*5*B%$(5"+-*$'("65%*5+"?+"')"),77'9'5(6"7-%"$B-.')4'(/"'(6%$95..,.$%"

3FM")'/($.'(/1""

t56V" (-" )6,+'5)"&5%5" %5:-%65+" 9-(95%('(/" 645" '(;-.;5*5(6"-7"YWRQ?@!" '(" '(6%$95..,.$%" 3FM)" 6%$77'9"

$(+")'/($.'(/" '("@"95..)",(6'." .$65"<2!<"&45("645"/%-,:"-7"@%'(G*$((")4-&5+"$("$.65%$6'-("-7"3FMQ"

Page 134: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

Q?""

"

5(+-)-*$.".-9$.'I$6'-("'("YWRQ?@!E?+"*,6$65+"%5)6'(/"@"95..)"&45%5"3FMQ"&$)"7-,(+"'()65$+"'("645"

SMV" 4'/4.'/46'(/" -(5"*-%5" 6'*5" $" 9%'6'9$." %-.5" 7-%"YWRQ?@!" '(" 3FMQ" 6%$77'9" '(" :%'*$%0" @" 95..)" bC2?c1"

D(+55+V"'("-,%"9,%%5(6")6,+0V"&5"9-(7'%*5+"645"%5[,'%5*5(6"-7"YWRQ?@!"7-%"3FMQ"9-%%596"7-.+'(/"$(+"

6%$77'9" '(" :%'*$%0" @" 95..)1" ?+EYWRQ?@!" *,6$6'-(" $77596)" 3FMQ" :%-:5%" 7-.+'(/" '(" :%'*$%0" @" 95..)"

%5),.6'(/"'("$B-.')4*5(6"-7"3FMQE6%'//5%5+"%5):-()5)",:-("R:>"#WJ")6'*,.$6'-("&45%5$)"'("g3"95..)V"

3FMQ"%5)'+5)"'("=<#Hp"D'p"H=RDDp"5(+-)-*$."9-*:$%6*5(6)"$(+":$%6'$..0".-9$.'I5)"&'64"YWRQ?@!1"D("

$++'6'-(V" '(" -,%" 4$(+)V" @RM" 5(/$/5*5(6" +'+" (-6" $77596" 645" ),B" 95..,.$%" .-9$.'I$6'-(" -7" 3FMQV" '("

9-(6%$)6" 6-" U'5%95h)" -B)5%;$6'-(V"&4'94" 589.,+5)" 645" %-.5" -7" 645" @" 95.." %595:6-%" '(" /-;5%('(/" 3FMQ"

.-9$.'I$6'-(1""

D("-,%")6,+0V"&5"&$(65+"6-"'(;5)6'/$65"&45645%"MWJ")5()'(/"3FMO"')"%5/,.$65+"'("645")$*5"*$((5%"$)"

3FMQ" '(":%'*$%0"@" 95..)" )'(95"(-":%5;'-,)" )6,+'5)"4$;5":-'(65+" 64')"-,61"J)"58:5965+V"YWRQ?@!"?+"

*,6$6'-(" +'+" $.65%" 3FMOE6%'//5%5+" :%-E'(7.$**$6-%0" 906-G'(5)" :%-+,96'-(" B,6" '(65%5)6'(/.0" +'+" (-6"

$77596" 3FMO" 5(+-)-*$." .-9$.'I$6'-(1" 34,)" 3FMO" %5)'+5)" '(" =<#Hp" D'p" H=RDDp" 5(+-)-*$."

9-*:$%6*5(6)" '(" B-64" g3" $(+" YWRQ?@!" ?+" *,6$65+" @" 95..)" $6" 645" )65$+0" )6$65" $(+" ,:-(" 3FMO"

-%T$(+"@RM"5(/$/5*5(61"34')"'(+'9$65)"$")5.596';5"%5[,'%5*5(6"7-%"YWRQ?@!"'("*5+'$6'(/"3FMQ"$(+"

(-6" 3FMO" 6%$77'9" '(" :%'*$%0" @" 95..)1" X,%" 9,%%5(6" )6,+0" B%'(/)" 5;'+5(95" 64$6" YWRQ?@!" ?+"*,6$6'-("

$B%-/$65)" 3FMOE6%'//5%5+" %5):-()5)" '(" :%'*$%0" @" 95..)" $(+" 64')" ')" (-6" +,5" 6-" $" +')%,:6'-(" -7" 3FMO"

+')6%'B,6'-(" $)" ')" 645" 9$)5" 7-%" 3FMQV" B,6" %$645%" 6-" $" :%-B$B.5" +'%596" '(;-.;5*5(6" -7"YWRQ?@!" $)" $"

)'/($.'(/"*-.59,.5"+-&()6%5$*"3FMO1"34')"40:-645)')V"4-&5;5%V"(55+)"6-"B5"9-(7'%*5+"B0"$")56"-7"

58:5%'*5(6)"+5*-()6%$6'(/"$"%59%,'6*5(6"-7"YWRQ?@!"*-.59,.5"6-"645")'/($.'(/"9-*:.58"9-(6$'('(/"

3FMO"$(+"'6)"$+$:6-%"*-.59,.5"H0+PP1"

73$2&'='%,&'02*0=*72(,/',2&*%F,'2*,5*,*%F,G$/02$*:06$%16$*=0/*CD4E*'2*+*%$665**

8(4"c" '&" -:;" +5*-()6%$65+" 64$6" .-))"-7"H=R" 9.$))" DD" %5),.6)" '(" %5+,95+"H0+PPE+5:5(+5(6" $(+"3MDLE

+5:5(+5(6" 3FM?V" C" $(+" Q" )'/($.'(/" '(" *$9%-:4$/5)" $(+" +5(+%'6'9" 95..)" bC<Kc1" D(" )5$%94" -7" $"

*594$(')*" 6-" 58:.$'(" 64')" :45(-*5(-(V" 645" $,64-%)" :5%7-%*5+" $" )9%55(" -7" G'($)5)" G(-&(" 6-" B5"

'(;-.;5+" '(" 3FM" )'/($.'(/1" 34')" %5;5$.5+" '*:$'%5+" :4-):4-%0.$6'-(" -7" 645" @%,6-(h)" 60%-)'(5" G'($)5"

b@6Gc"7-..-&'(/"3FM?V"C"$(+"Q")6'*,.$6'-("-7":5%'6-(5$."*$9%-:4$/5)"7%-*"=<ETE"*'95"&45("9-*:$%5+"

&'64" =<pTp" 95..)" ),//5)6'(/" 64$6" H=R" 9.$))" DD" *-.59,.5)" 7$9'.'6$65" 3FME6%'//5%5+" '(7.$**$6-%0"

%5):-()5)" B0" %5/,.$6'(/" 645" $96';'60" -7" @6G" G'($)51" H-%5-;5%V" 6450" )4-&5+" 64$6" $96';$6'-(" -7" @6G"

G'($)5" %5[,'%5)" R#C2V" $" 7'(+'(/" 64$6" ')" 9-()')65(6" &'64" :%5;'-,)" )6,+'5)" '(" '(($65" @!" 95..)" 64$6"

+5*-()6%$65+"64$6"R#C2".'/$6'-("%5),.65+"'("$96';$6'-("-7"@6G"bCCOc1"34,)V",:-("3FM")6'*,.$6'-(V"H=R"

9.$))" DD"*-.59,.5" 7,(96'-()"$)"$("$+$:6-%"*-.59,.5"B0" 7-%*'(/"$"9-*:.58"&'64"@6G"$(+"R#C2" '(" 645"

5(+-)-*51"34')"9-*:.58"$..-&)"$"),)6$'(5+"$96';$6'-("-7"@6G"G'($)5"64$6" '(65%$96)"&'64"645"$+$:6-%"

Page 135: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

QC""

"

*-.59,.5)"H0+PP"$(+"3MDL"7-%"$"7,%645%"5(4$(95*5(6"-7"3FM"%5):-()5)1"34')")6,+0"5(9-,%$/5+",)"6-"

'(;5)6'/$65"645":%-B$B.5"%-.5"-7"H=R"DD"*-.59,.5)"'("3FM)"6%'//5%5+"%5):-()5)"'("@"95..)1"X,%"%5),.6)"

)4-&5+"(-"+'775%5(95"'("3FMCV"O"$(+"Q"l"'(+,95+":%-E'(7.$**$6-%0"906-G'(5)")59%56'-("'("B-64"H=R"

9.$))" DD"g3"$(+"+57'9'5(6":%'*$%0"@" 95..)1" A,%:%')'(/.0V" D(;$%'$(6" 94$'("-%" D'V" $" 9%'6'9$." 94$:5%-(5" 7-%"

H=R"9.$))"DD"*-.59,.5)"$(+"%595(6.0")4-&("6-"7$9'.'6$65"645"6%$77'9"-7"H=R"9.$))"D"*-.59,.5)"7%-*"645"

SM" 6-" 5(+-.0)-)-*5)" b<ONcV" %5/,.$65)" )5.596';5.0" 3FMOE+5:5(+5(6" %5):-()5)" '(" :%'*$%0" @" 95..)1" D("

$++'6'-(V"&5")4-&"64$6" '(" 645"$B)5(95"-7" D'V"3FMO" ')" 7-,(+" '("SM" .'G5"9-*:$%6*5(6)"&45%5$)" '("g3"

95..)"3FMO"9-.-9$.'I5)"6-/5645%"&'64"D'"'("=<#Hp"H=RDDp"9-*:$%6*5(6)1"D("9-(6%$)6V"3FMQ"+')6%'B,6'-("

$(+"%5):-()5)"%5*$'("'(6$96"'("D'"+57'9'5(6"@"95..)1"J.6-/5645%V"645)5"%5),.6)"%5;5$."$"94$:5%-('(/"%-.5"

7-%" '(;$%'$(6"94$'(" '("+'%596'(/V"(-6"-(.0"H=R"9.$))" D"$(+" DD"*-.59,.5)V"B,6"$.)-"3-.."F'G5"M595:6-%"O"

7%-*"645"SM"6-"645"5(+-)-*5)1"34,)V"3FMO"$(+"Q"$%5"%5/,.$65+"+'775%5(6.0"'(":%'*$%0"@"95..)"$(+"%5.0"

-("6&-"+'775%5(6"*-.59,.5)V"D'"$(+"YWRQ?@!"%5):596';5.0V"7-%"645'%"6%$77'9G'(/1"

H'==$/$2&',6*/$.16,&'02*0=*CD4E*,23*CD4@**

34')"+'775%5(6'$."%5/,.$6'-("-7"3FMO"$(+"3FMQ"%5):-()5)"+5*-()6%$65+"B0"-,%")6,+0"'(":%'*$%0"@"95..)"

')"$.)-"-B)5%;5+"'("-645%"9$)5)1"D(+55+V"DLWEu")6'*,.$6'-("%5(+5%)"4,*$("@"95..)"40:5%"%5):-()';5"6-"

3FMO" B0" )5.596';5.0" ,:E%5/,.$6'(/" '6)" 58:%5))'-(" &45%5$)" 3FMQ" $(+" YWRQ?@!" 58:%5))'-(" &5%5" (-6"

$775965+k"*-%5-;5%V" +57'9'5(90" '(" DLW" u" $(+" \" %595:6-%" bDLWJMc" $)" &5.." $)" DLW" %5/,.$6-%0" 7$96-%" Q"

bDMLQV"$("DLW")'/($.'(/"*-.59,.5c"+57'9'5(90"$B%-/$65"@"95.."$96';$6'-(")5.596';5.0"64%-,/4"3FMO1"X(5"

*-%5")6,+0":5%7-%*5+"B0"645"/%-,:"-7"oR1"R$*B'5%")4-&)"64$6"ZDAJV"$"*'6-94-(+%'$."6%$()*5*B%$(5"

:%-65'("5))5(6'$."7-%"MFME*5+'$65+"%5):-()5)"6-"906-)-.'9"MWJV"%5/,.$65)")5.596';5.0"3FMO"58:%5))'-(1"

34,)V" ZDAJ" +57'9'5(6" @" 95..)" :-))5))" %5+,95+" 3FMO" 58:%5))'-(" 64$6" 9-%%5.$65)" &'64" '*:$'%5+" 3FMO"

$/-(')6E'(+,95+" ,:%5/,.$6'-(" -7" $96';$6'-(" *$%G5%)" ),94" $)" R#NQ" $(+" R#PNV" 95.." :%-.'75%$6'-(V"

:%-+,96'-("-7"DLWEuV"3WL"$(+"DFE!<V"$)"&5.."$)"WLEv@"$96';$6'-(1"D("9-(6%$)6V"ZDAJ"+57'9'5(90"+-5)"(-6"

$77596"3FMQ"58:%5))'-("-%"$96';$6'-("'(":%'*$%0"@"95..)"b?KKV"?KNV"CCPc1"J.6-/5645%V"645)5"%5),.6)":,6"'("

5;'+5(95" +'775%5(6'$." *594$(')*)" 64$6" %5/,.$65" MWJE)5()'(/" 3FMO" -(" -(5" 4$(+" $(+" #WJE)5()'(/"

3FMQ"-("645"-645%"4$(+"'("@"95..)V"+5):'65")'*'.$%"),B95..,.$%"+')6%'B,6'-("$(+"+-&()6%5$*")'/($.'(/"

:$64&$0")4$%5+"B0"645)5"6&-"%595:6-%)1"34')"+'775%5(6'$."%5/,.$6'-("')"7,%645%"5*:4$)'I5+"'(")0)65*'9"

.,:,)"$,6-'**,(5"5%0645*$6-),)" bAFSc"+')5$)5"&45%5" 645" %59-/('6'-("-7"(,9.5$%"$,6-"$(6'/5()"B0"

3FMO"$(+"3FMQ"'("@"95..)"%5),.6)"'("645":%-+,96'-("-7";$%'-,)"$,6-$(6'B-+'5)1"=-&5;5%V"645"$($.0)')"-7"

.,:,)E:%-(5"*'95"+57'9'5(6"'("3FMO"-%"3FMQ"%5;5$.5+"64$6"645"%-.5"-7"3FMQ"'("AFS"')"%$645%":%-6596';5V"

'("9-(6%$)6"6-"3FMO"64$6":-))5))"$":$64-/5('9"%-.5"bCCQc1"345"+'775%5(6'$."%5/,.$6'-("')"$.)-"%57.5965+"'("

645"+'))'*'.$%'60"'("645"(5,%-'(7.$**$6-%0"%5):-()5"5.'9'65+"B0"3FMO"$(+"3FMQ")'/($.'(/V"%5),.6'(/"'("

+'775%5(95)"'("645"$B'.'60"-7"3FMO"$(+"Q"$/-(')6)"6-":%-;'+5":%-6596'-("'("645"95(6%$."(5%;-,)")0)65*"

bRWAc" +,%'(/" ;'%$." '(7596'-(1"g4'.5" )6'*,.$6'-(" -7" 3FMQ" %5),.65+" '(" $" )6%-(/" '(7.$**$6-%0" 906-G'(5"

Page 136: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

QK""

"

%5):-()5" &'64" %59%,'6*5(6" -7" '(7.$**$6-%0" 95..)" 6-" 645" RWA" $(+" '(+,95+" +5$64" '(" *'95V" 3FMO"

)6'*,.$6'-(V"'("9-(6%$)6V"6%'//5%)"DLWE\"%5):-()5)V"$"*'('*$."'(7.$**$6'-("$(+"(-"-B)5%;$B.5"9.'('9$."

)'/()"bCK2c1"

@5)'+5"@"95..)V"$"+'775%5(6'$."%5/,.$6'-("-7"3FMO"$(+"Q"%5):-()5)"')"$.)-"-B)5%;5+"'("-645%"95.."60:5)1"

D(+55+V"'("+5(+%'6'9"95..)V"645")$*5"94$:5%-(5"*-.59,.5"YWRQ?@!"')"%5):-()'B.5"-7"645":%-:5%"6%$77'9"

-7" B-64" 3FMO" $(+"3FMQ" 7%-*" 645"SM" 6-" 5(+-.0)-)-*5)",:-(" .'/$(+" )6'*,.$6'-(V" B,6" )6'..V"YWRQ?@!"

7$;-%)"645"6%$():-%6$6'-("-7"3FMQ"-;5%"3FMO"$(+"64')"3FMQ":%5+-*'($(95" ')" %5;5%)5+"6-"3FMO"&45("

YWRQ?@!" B5$%)" $" *'))5()5" *,6$6'-(" b#?CJcV" %5(+5%'(/" 3FMO" 40:5%" %5):-()';5" $(+" 3FMQ" 40:-"

%5):-()';51" H-%5-;5%" $(+" ;5%0" %595(6.0V" 645" /%-,:" -7" @$%6-(" +5*-()6%$65)" 645" 58')65(95" -7" 6&-"

+')6'(96" %-,65)" 64$6" *5+'$65" YWRQ?@!E+5:5(+5(6" 6%$77'9G'(/" -7" 3FMO" $(+" 3FMQ" '(" MJg<NC"

*$9%-:4$/5"95..".'(51"D("645"SMV"YWRQ?@!"$))-9'$65)"&'64"3FMQ"$(+"6%$77'9)"&'64"'6"64%-,/4"645">-./'"

6-"645"95.."),%7$951"J6"645"95.."),%7$95V"645"$+$:6-%"JU<"')"645("%59%,'65+"$..-&'(/"3FMQ"'(65%($.'I$6'-("

'("645"5(+-)-*5)1"3FMO"'()65$+V"5*:.-0)"645"$+$:6-%"JUC"'("$"+'%596"%-,65"-7"6%$77'9"7%-*"645"3%$()"

>-./'"W56&-%G"b3>Wc"6-"645"5(+-)-*5)"$(+"64,)"B0:$))5)"645"95.."),%7$95" .-9$.'I$6'-("bCC2c1"345)5"

7'(+'(/)" %5;5$." 64$6" $.64-,/4" 645" )$*5" 94$:5%-(5" *-.59,.5" iYWRQ?@!j" 9-(6%-.)" 645" -;5%$.."

6%$77'9G'(/" -7" B-64" 3FMO" $(+" Q" '(" B-(5"*$%%-&" +5%';5+" +5(+%'6'9" 95..)" $(+"*$9%-:4$/5" 95.." .'(5)V"

+'775%5(6":$64&$0)")55*"6-"9-(6%-."3FMO"$(+"3FMQ".-9$.'I$6'-("$(+"*$0"B5"%5):-()'B.5"-7"+5.';5%'(/"

645" %595:6-%)" 6-" +')6'(96" 9-*:$%6*5(6)" &'64" +'775%5(6" $995))" 6-" .'/$(+)" -%" &'64" +')6'(96" )'/($.'(/"

:%-:5%6'5)1"

"7'*3$='%'$2%;*1G/$.16,&$5*CD4E*G/0I'2=6,::,&0/;*%;&0-'2$*/$5G025$5*

D("64')":%5)5(6")6,+0V"&5")4-&"64$6"'(":%'*$%0"@"95..)V"645"$B)5(95"-7"'(;$%'$(6"94$'("%56$'()"3FMO"'("

SME.'G5" 9-*:$%6*5(6)" 64$6" $%5" :-)'6';5" 7-%" 9$.%56'9,.'(1" Y(58:5965+.0V" 64')" %565(6'-(" %5(+5%)" 3FMO"

40:5%"%5):-()';5"6-"'6)".'/$(+V"&4'94"9-(6%$)6)"&'64"645"-B)5%;$6'-()"'("+5(+%'6'9"95..)"&45%5"+57596"

'("3FMO"%5):-()5)"')"-B)5%;5+"+,5"6-"$"7$'.,%5"'("'6)":%-:5%"6%$77'9G'(/"6-"5(+-)-*$."9-*:$%6*5(6)1"

D(65%5)6'(/.0V"$"9-((596'-("B56&55("3FMO")6'*,.$6'-("$(+"9$.%56'9,.'("4$)"B55("9$%%'5+"-,6"'("$";5%0"

%595(6"&-%G":5%7-%*5+"B0"645"/%-,:"-7"R1"o577%'5)"&45%5"645"$,64-%)"+5)9%'B5"$"(5&"*594$(')*"64$6"

5(4$(95)" :4$/-906-)')" -7" $:-:6-6'9" B-+'5)" B0" *05.-'+" 95..)1" @%'57.0V" ,:-(" 3FMO" )6'*,.$6'-(V" @6G"

G'($)5" ')" $96';$65+" $(+" $))-9'$65)" &'64" 645" *-.59,.$%" 94$:5%-(5" 9$.%56'9,.'(" bRM3c" %5),.6'(/" '(" '6)"

:4-):4-%0.$6'-("$(+"$96';$6'-(1"345"$))-9'$6'-("-7"@6G"$(+"RM3"')"'*:-%6$(6"7-%"*5+'$6'(/"645"6%$77'9"

-7" RM3" 6-&$%+)" 645" 95.." ),%7$95"&45%5" '6" 9-" .-9$.'I5)"&'64"R#Q!" %5),.6'(/" '(" 645" 7-%*$6'-("-7" RM3E

R#Q!"9-*:.58"&4'94" )5%;5)"$)"$" 9%,9'$."+-9G'(/" )'65" 7-%"-:)-('()"&4'94"9-$6"$:-:6-6'9" 95..)" bCK!c1"

34,)V" ,:-(" 3FMO" )6'*,.$6'-(V" @6G" G'($)5" %5/,.$65)" 9$.%56'9,.'(" :4-):4-%0.$6'-(" $(+" $96';$6'-("

%5),.6'(/" '(" $(" 5(4$(95+" ,:6$G5" -7" $:-:6-6'9" +5B%')1" H-%5-;5%V" @6G" G'($)5" ')" $.)-" )4-&(" 6-" B5"

Page 137: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

QN""

"

'(;-.;5+"'(":%-*-6'(/"-:6'*$."3FMOE"$(+"3FMQE+%';5("906-G'(5":%-+,96'-("'("*$9%-:4$/5)"bCK<c"$(+"

@" 95..)" bCK?V" CKCc1" J.6-/5645%V" 645)5" 7'(+'(/)" 9-,.+" 58:.$'(" 645" ,:E%5/,.$6'-(" -7" 3FMOE*5+'$65+"

906-G'(5" :%-+,96'-(" -B)5%;5+" '(" '(;$%'$(6" 94$'(" +57'9'5(6" @" 95..)"&45%5" 3FMO" ')" 7-,(+" 9-" .-9$.'I5+"

&'64" 9$.%56'9,.'(" B0" $" *594$(')*" '(;-.;'(/" $" 40:5%" $96';$6'-(" -7" @6G" G'($)5V" $" 40:-645)')" 6-" B5"

:%-;5+1" =0:5%" $96';$6'-(" -7" 3FMO" %5):-()5)" 7%-*" 645" SM" 9$(" $.)-" B5" 58:.$'(5+" B0" $" /%5$65%"

'(65%$96'-("&'64" 645" $+$:6-%"*-.59,.5"H0+PP" -%" 5;5(" B0" 645" %59%,'6*5(6" -7" -645%" (-(" '+5(6'7'5+"

*-.59,.5)"6-"645")'/($.'(/"9-*:.58"$..-&'(/"$("$*:.'7'9$6'-("-7"645")'/($.1"345)5"40:-645)5)"$%5"056"

6-"B5"'(;5)6'/$65+1"

GJ*,23*CD45*/$.16,&'02*

345" %5[,'%5*5(6" 7-%" $(" $9'+'9" :=" 6-" 9-(;50" $(" $::%-:%'$65" 5(;'%-(*5(6" 7-%" .'/$(+E3FM" B'(+'(/" '("

5(+-)-*5)"&$)"7'%)6.0")4-&("B0"$")6,+0":5%7-%*5+"B0"M'6I"56"$.1"&45%5"6450"+5*-()6%$65"64$6"R:>"

#WJ" B'(+'(/" 6-" 3FMQ" &$)" )6%-(/5%" &45(" .-&5%'(/" 645" :=" 6-" N1KEK1K" 9-*:$%5+" 6-" 645" &5$G"

'(65%$96'-(" -B)5%;5+" $6" (5,6%$." :=" '(" =,*$(" S*B%0-('9" _'+(50" b=S_c<Q?" 95..)" b?QNc1" X(5" *-%5"

5;'+5(95"7-%":=E+5:5(+5(6".'/$(+"B'(+'(/"')"645"58')65(95"-7"9-()5%;5+"%5)'+,5)"'("645"586%$95..,.$%"

+-*$'("-7"4,*$("3FMP"64$6"$%5"9%'6'9$."7-%":="+5:5(+5(6"B'(+'(/"-7"%5)'[,'*-+"bCKKc1"=-&5;5%V".'66.5"

')"G(-&("$B-,6"4-&"3FMO".'/$(+)"b7-%"58$*:.5" '*'[,'*-+c"9$("%5$94"3FMOE%5)'+5(6"9-*:$%6*5(6)1"

345"/%-,:"-7"A-.+$'('"&$)"$B.5"6-"6%$9G"645"),B95..,.$%".-9$.'I$6'-("-7"$")*$.."*-.59,.5"3FMO"$/-(')6"'("

4,*$(" :.$)*$906-'+" +5(+%'6'9" 95..)" B0" .$B5.'(/" 645" .'/$(+" &'64" 7.,-%-:4-%5)1" D(65%5)6'(/.0V" 3FMO"

$/-(')6)"9-.-9$.'I5+"&'64"FJHU!V"R#N?"$(+"=FJE#M"'("645"H=R"9.$))"DD".-$+'(/"9-*:$%6*5(6"bHDDRc"

-7" :#R)1" @.-9G'(/" 5(+-)-*$." $9'+'7'9$6'-(" &'64" B$7'.-*09'(" JV" $(" $(6$/-(')6" -7" 645" ;$9,-.$%" 60:5"

:%-6-("J3U$)5V")6%-(/.0"'(4'B'65+"645".-9$.'I$6'-("-7"3FMO"$/-(')6)"B,6".576"$(",($.65%5+".-9$.'I$6'-("

-7"R:>@1"34,)"$9'+'9":="7-,(+"'("645"HDDR"-7":#R)"')"645"+%';'(/"7-%95"7-%"3FMO"$/-(')6)"$99,*,.$6'-("

'(" .0)-)-*$." 9-*:$%6*5(6)1" D(+55+V" 3FMO" .'/$(+)" $%5" :%5+'965+" 6-" B5" :-)'6';5.0" 94$%/5+" $(+" 64,)"

%5$94"4'/4"9-(95(6%$6'-()"'("$9'+'9"9-*:$%6*5(6)"9-*:$%'(/"6-"645"%5)6"-7"645"95..1"34')"9-,.+")5%;5"

6-"+%';5" .-&"$77'('60" '(65%$96'-()"-7"3FMO"&'64" '6)" .'/$(+"$B-;5"645"64%5)4-.+"(595))$%0"7-%")'/($.'(/"

bCKNcK*=-&5;5%V"4-&"645".'/$(+"iD*'[,'*-+j"%5$945)"SME.'G5"9-*:$%6*5(6)"64$6"B5$%"$"(5,6%$.":="6-"

$96';$65"3FMO"'("'(;$%'$(6"94$'("_X"@"95..)"$(+"6%'//5%":%-E'(7.$**$6-%0"906-G'(5")59%56'-("')")6'.."$("

-:5("[,5)6'-(1"3-" '(;5)6'/$65"&45645%"$9'+'7'9$6'-("-7"5(+-)-*$."9-*:$%6*5(6)" '(":%'*$%0"@"95..)"

-99,%)" ,:-(" .'/$(+" %59-/('6'-(V" &5" 9-,:.5+" 645" $(6'/5(E9-$65+" B5$+)" 6-" R0:45%" KV" $" +05" &4-)5"

7.,-%5)95(95"'(9%5$)5)"$6"$9'+'9":="$(+"&5"'(9,B$65+"645*"&'64"D'"g3"-%"D'"_X"@"95..)"'("645":%5)5(95"

-%"$B)5(95"-7"3FMO".'/$(+1"Y:-("95.."9-(6$96V"J/E9-$65+"B5$+)"$9[,'%5"$")6%-(/"7.,-%5)95(95"+,5"6-"

645":-.$%'I5+")59%56'-("-7".0)-)-*5)"$..-&'(/"645"%5.5$)5"-7"40+%-.$)5)"64$6"577'9'5(6.0"586%$96"645"J/1"

g5"-B)5%;5+"64$6"645":5%95(6$/5"-7"@"95..)"64$6"B5$%"7.,-%5)95(95"')"4'/45%"'("645"$B)5(95"-7"D'"$(+"

+-5)"(-6"+'775%",:-("3FMO")6'*,.$6'-(" J3(+4$'"IK;"34,)V" .0)-)-*$."9-*:$%6*5(6)"7%-*"D'E+57'9'5(6"@"

Page 138: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

QO""

"

95..)"4$;5"$"*-%5"$9'+'9":=" '(" 9-*:$%'(/" 6-"g3"95..)1"=-&5;5%V"B-64" 9-*:$%6*5(6)"$9'+'70" 6-" 645"

)$*5".5;5."'("645":%5)5(95"-%"$B)5(95"-7"3FMO".'/$(+1"J.6-/5645%"645)5"%5),.6)")4-&"$"65(+5(90"7-%"

*-%5" $9'+'9" 5(;'%-(*5(6" '(" D'" +57'9'5(6" @" 95..)1" @,6" '7" $(+" 4-&" 64')" 7$96" '(7.,5(95)" 645" SME.'G5"

9-*:$%6*5(6)"B54$;'-%"$(+"'("6,%("3FMO"%5):-()5)V"(55+"6-"B5"'(;5)6'/$65+"

" "

"3(+4$'"I"a"!%)6%.-:"7(.$%2.%#G"2B%Q2"7%$'"6:4%$'2.')&"-)&(,X+*"!G#B'$"T"9'-02"-&"&B'"-)&(+')V?".'::"

$'.'#&%$" ()&'$6-.'" ()" X(\_"0'6(.(')&" ?" .'::2"QB')" .%7#-$'0" &%"dA" .'::2Z" AB'" B(2&%+$-7"%)" &B'" $(+B&"

2B%Q2"-"e4-)&(6(.-&(%)"%6"&B'"6:4%$'2.').'"%6"!G#B'$"T"9'-02"()"9%&B"X("dA"-)0"\_"#$(7-$G"?".'::2"()"

&B'"#$'2').'"%$"-92').'"%6"A8N[":(+-)0;"

H,.6':.5" )6,+'5)" 4$;5" +5)9%'B5+" :%-95))'(/" $)" $" 9%,9'$." )65:" 7-%" 3FM" $96';$6'-(1" D(+55+V" +'775%5(6"

:%-65$)5)" 4$;5" B55(" '(;-.;5+" '(" /5(5%$6'(/" $" 6%,(9$65+" B,6" 7,(96'-($." 7-%*"-7" 645" %595:6-%" ,:-("

.'/$(+"%59-/('6'-(1"H-%5-;5%V":%-65$)5)"%5[,'%5"$".-&":="'("645"5(+-)-*$."9-*:$%6*5(6)"7-%"645'%"

-:6'*$." $96';'601" X,%" /%-,:" 4$+" )4-&5+" 64$6" J):$%$/'(5" S(+-:5:6'+$)5" -%" JSUV" $(" 5(+-)-*$."

90)65'(5":%-65$)5V" ')"645"*$'(":%-65$)5"%5):-()'B.5"7-%"3FMO":%-95))'(/V"%5),.6'(/"'("645"/5(5%$6'-("

-7" 3FMO" RE65%*'($." 7%$/*5(6" 9-*:565(6" 7-%" )'/($.'(/" '(" B-(5" *$%%-&" +5%';5+" $(+" :.$)*$906-'+"

+5(+%'6'9" 95..)" $)" &5.." $)" '(" 5:'645.'$." 95..)" b?NQc1" A,%:%')'(/.0V" &5" &5%5" ,($B.5" 6-" +56596" $(0"

+'775%5(95" '("906-G'(5")59%56'-("B56&55("JSU"+57'9'5(6":%'*$%0"@"95..)"$(+"9-(6%-." 95..)",:-("3FMO"

)6'*,.$6'-(V"589.,+'(/"$"%-.5"-7"JSU"'("%5/,.$6'(/"3FMO")'/($.'(/"'(":%'*$%0"@"95..)"$(+",(+5%.'('(/"$"

+'775%5(6'$." %5/,.$6'-(" -7" 3FMO" %5):-()5)" B56&55(" @" 95..)" $(+" #R)1"g5" 645(" '(;5)6'/$65+"&45645%"

-645%":%-65$)5)"*'/46"B5"'(;-.;5+"'("3FMO":%-95))'(/"'("@"95..)1"A'(/.5"9$645:)'()"b9$645:)'("@"-%"A"-%"

Fc"+57'9'5(6"@"95..)"+'+"(-6")4-&"$(0")'/('7'9$(6"+57596"'("3FMO")'/($.'(/"J3(+4$'"?K;"34,)V"'("-,%"4$(+)"

&5" &5%5" (-6" $B.5" 6-" '+5(6'70" $" ):59'7'9" 5(+-)-*$." :%-65$)5" 64$6" ')" '*:-%6$(6" 7-%" 3FMO" )'/($.'(/1"

=-&5;5%V" $++'6'-($." 58:5%'*5(6)" (55+" 6-" B5" :5%7-%*5+" ,)'(/" B%-$+" :%-65'(" '(4'B'6-%)" .'G5"

.5,:5:6'(5V"-%"+-,B.5"+57'9'5(6":%-65$)5)"*'95"$(+"95..)V"$)"&5.."$)"+%,/)"64$6"'(65%75%5"&'64"645":="

.'G5"9-(9$($*09'("@V"'("-%+5%"6-")6,+0"645":="+5:5(+5(90"$(+"6-"'+5(6'70"645":%-65$)5)"'(;-.;5+"'("

3FMO":%-95))'(/"'("@"95..)1""

2"

!2"

<2"

?2"

C2"

K2"

N2"

O2"

P2"

Q2"

R0:45%"E" R0:45%"p"b+A[+"+JGIIK+

g3"

g3"D*'"

D'"_X"

D'"_X"D*'"

Page 139: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

QP""

"

R-(95%('(/"3FMQV"645"/%-,:"-7"@%'(G*$(("&$)"645"7'%)6"6-"+5)9%'B5"3FMQ":%-95))'(/"'(":%'*$%0"@"95..)1"

3-" :5%7-%*" 645)5" )6,+'5)V" 6450" /5(5%$65+" 6%$()/5('9"*'95" 64$6" 58:%5))" $"*,%'(5" 3FMQE>LU" 7,)'-("

:%-65'(" 6-" 7$9'.'6$65"B'-945*'9$."$($.0)')1"345"$,64-%)" )4-&5+" 64$6" 9$645:)'("F" '(4'B'6-%"B.-9G)" 645"

:%-95))'(/" -7" 7,.." .5(/64" 3FMQ" '(6-" 645" RE65%*'($." 7,(96'-($." 7%$/*5(6" '(" @" 95..)1" D(65%5)6'(/.0V" $"

)'/('7'9$(6" :--." -7" 3FMQ" ')" $.%5$+0" 9.5$;5+" '(" ,()6'*,.$65+" @" 95..)V" &4'94" 9-%%5.$65)" &'64" '6)"

5(+-)-*$." .-9$.'I$6'-(1" 345" $,64-%)" $.)-" )4-&5+" $" +'775%5(6" G'(56'9" '(" /5(5%$6'(/" 3FMQ" RE65%*'($."

7%$/*5(6" '(" :%'*$%0" @" 95..)" $(+" '(" B-(5" *$%%-&" +5%';5+" *$9%-:4$/5)" b@H#H)c1" @0" :5%7-%*'(/"

:,.)5T94$)5"58:5%'*5(6)V"6450")4-&5+"64$6"9.5$;$/5"-7"3FMQ"-99,%)"$765%"?"4-,%)"-7"94$)5"'("@H#H)"

&45%5$)"$"3FMQ"RE65%*'($." 7%$/*5(6" ')"+565965+"$)"5$%.0"$)"!1K"4-,%"-7"94$)5" '("@"95..)1"H-%5-;5%V"

645"9.5$;$/5"%$65"-7"3FMQ"'("@"95..)"')"(-6"'(9%5$)5+",:-("3FMQ"-%"@"95.."%595:6-%")6'*,.$6'-("$(+"')":="

+5:5(+5(61"J.6-/5645%V"645)5"%5),.6)"4'/4.'/46"645"'*:-%6$(95"-7")6,+0'(/"3FM"*-.59,.$%"6%$77'9G'(/"'("

+'775%5(6" 95..)" $)" 3FM" B54$;5" +'775%5(6.0" +5:5(+'(/" -(" 645" 6$%/56" 95.." bC2?c1" t56V" (-" 5;'+5(95"&$)"

%5:-%65+"9-(95%('(/"3FMO"9.5$;$/5" '(":%'*$%0"@"95..)1" D("$++'6'-(V"&5"&5%5"(-6"$B.5"6-" '+5(6'70"645"

i5(+-)-*$.j":%-65$)5"'(;-.;5+"'("645"%5/,.$6'-("-7"3FMO"%5):-()5)"'(":%'*$%0"g3"@"95..)1"g45645%"

-%"(-6V" 645"$B)5(95"-7" '(;$%'$(6"94$'("$77596)"3FMO":%-95))'(/":-))'B.0"B0"i$("SM" %5)'+5(6":%-65'(j"

.'G5"7,%'(V"DMJU"-%"SMJU"5(I0*5)"-%"-645%)V"')")6'.."6-"B5"58:.-%5+1"

"

3(+4$'"?a"F(7(:-$"X8Y".G&%1()'"#$%04.&(%)"()"IUDE"!-&FE"!-&?"-)0"!-&8"\_"#$(7-$G"?".'::2"QB')"

.%7#-$'0"&%"dA".'::2;"

7'*,*5'.2,6'2.*:06$%16$*30L25&/$,:*0=*CD4E*'2*+*%$665M*

L%-*" +,-.'(G" 58:5%'*5(6)V" &5" &5%5" $B.5" 6-" )4-&" 64$6" 3FMO" 7-%*)" $" 9-*:.58" 6-/5645%" &'64" '6)"

$+$:6-%" *-.59,.5" H0+PP" $(+" '(;$%'$(6" 94$'(" ,:-(" )6'*,.$6'-(V" ),//5)6'(/" $" :%-B$B.5" %-.5" 7-%"

'(;$%'$(6" 94$'(V" (-6" -(.0" '(" +'%596'(/" 3FMO" 7%-*" 645" SM" 6-" 5(+-)-*$." 9-*:$%6*5(6)V" B,6" $.)-" B0"

9-(6%'B,6'(/"6-"645")'/($.'(/"9-*:.58"+-&()6%5$*"-7"3FMO1"34')" ')"(-6"$";5%0"),%:%')'(/"40:-645)')V"

/';'(/"64$6"R#OC"*-.59,.5"4$)"B55("$.%5$+0"94$%$965%'I5+"$)"$("$995))-%0E)'/($.'(/"*-.59,.5"7'%)6.0"

B0" '(+,9'(/" $" :$64&$0" .5$+'(/" 6-" 645" $96';$6'-(" -7" 6%$()9%':6'-("*5+'$65+" B0" 645" W7Ev@" :NKTM5.J"

4-*-+'*5%" $(+" '6)" 9-$96';$6-%" 3JL" DD" !2K" %5),.6'(/" '(" @" 95.." +5;5.-:*5(6" $(+" *$6,%$6'-(V" $(+"

Page 140: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

QQ""

"

)59-(+.0V"B0"'(+,9'(/"$")'/($.'(/"9$)9$+5"64$6"'(;-.;5)"A0G"60%-)'(5"G'($)5"$(+"645"UD?_TJG6":$64&$0"

.5$+'(/" 6-" @" 95.." :%-.'75%$6'-(" $(+" ),%;';$." ,:-(" 5(/$/5*5(6" bCKOc1" #565%*'('(/" 645" )'65" -7"

'(65%$96'-(" B56&55(" 3FMO" $(+" D'" ')" ,(+5%" '(;5)6'/$6'-(1" 3-" (-65V" 645" 906-)-.'9" +-*$'(" -7" '(;$%'$(6"

94$'(" ')" )4-&(" 6-"B5" '(;-.;5+" '(" '6)" )'/($.'(/" 7,(96'-(1"g45645%" 645"WE65%*'($." 7%$/*5(6"-7" D'" 64$6"

9-(6$'()" 645"+'.5,9'(5EB$)5+" 6$%/56'(/"*-6'7)" %5):-()'B.5"-7"+'%596'(/" D'EH=RDD" 9-*:.585)" 7%-*" 645"

SM"6-"5(+-)-*5)" '("$("JU!V"<"-%"?"+5:5(+5(6"*$((5%V" ')"$.)-" '(;-.;5+" '("*5+'$6'(/"3FMO"6%$77'9" '("

:%'*$%0"@"95..)"$(+"&45645%"645"906-)-.'9"6$'."-7"D'"b64$6"9-(6$'()"645")'/($.'(/"7,(96'-(c"')"'*:-%6$(6"

'("3FMO"+-&()6%5$*")'/($.'(/"$%5"056"6-"B5"$++%5))5+1""

L,%645%*-%5V"$(+"B5)'+5)"'6)"9.$))'9$."7,(96'-("'("94$:5%-('(/"H=R"9.$))"DD"$(+"%595(6.0"H=R"9.$))"D"

*-.59,.5)V" '(;$%'$(6"94$'("4$)"$.)-"B55(")4-&("6-"%5/,.$65")5.596';5.0"3FMO"%5):-()5)" '(":%'*$%0"@"

95..)1" D(65%5)6'(/.0V" D'" +57'9'5(90" 7$;-%)" 3FMOE6%'//5%5+" '(($65" %5):-()5)" b:%-E'(7.$**$6-%0" 906-G'(5"

)59%56'-(c";5%),)"3FMOE6%'//5%5+"$+$:6';5"%5):-()5)"bH=R"9.$))"D"9%-))":%5)5(6$6'-(cV"4'/4.'/46'(/"$("

5895:6'-($."$(+",(:%595+5(65+"%-.5"-7"D'"'("*$'(6$'('(/"$"B$.$(95"B56&55("B-64"'(($65"$(+"$+$:6';5"

%5):-()5)1" H-%5-;5%V" $" +'775%5(6'$." 58:%5))'-(" -7" '(;$%'$(6" 94$'(" ')" -B)5%;5+" '(" 645" :%5)5(95" -%"

$B)5(95"-7"3FMO1"D(+55+"'("$B)5(95"-7"3FMOV"'(;$%'$(6"94$'("58:%5))'-("$6"645"95.."),%7$95"')"'(9%5$)5+"

&45(" 9-*:$%5+" 6-" 9-(6%-." 95..)" J3(+4$'" !K1" 34')" '(+'9$65)" $" :%-B$B.5" i;'95E;5%)$j" %5/,.$6'-(" -7"

.-9$.'I$6'-("$(+"6%$77'9"B56&55("645"6&-"*-.59,.5)"3FMO"$(+"D'1""

"

3(+4$'"!a"!'::"24$6-.'"X("']#$'22(%)"()"A8N["dA"-)0"\_"#$(7-$G"?".'::2"

D("9-(9.,)'-(V"&5"4$;5"$($.0I5+"3FMO"7,(96'-("'(":%'*$%0"@"95..)"$(+"+5)9%'B5+"645"9%'6'9$."%-.5"64$6"

'(;$%'$(6"94$'(":.$0)"'("3FMO")'/($.'(/1"D(+55+V"&5"&5%5"$B.5"6-")4-&"64$6"'(;$%'$(6"94$'("+57'9'5(90"

$.65%)"3FMO":%-:5%".-9$.'I$6'-("$(+"9$,)5)"'6)"%565(6'-("'("645"SMV".5$+'(/"6-"$("58$95%B$6'-("-7"3FMO"

'(($65"B,6"(-6"$+$:6';5"7,(96'-(1"34,)"'(;$%'$(6"94$'("58:%5))'-(V"7-,(+"9%'6'9$."'("+'775%5(6"+')5$)5)"

.'G5" 94%-('9" '(7.$**$6-%0"+')5$)5)V" +'$B565)" $(+" 9$(95%V" $.)-"*-+,.$65)" 3FMOE6%'//5%5+" %5):-()5)1"

345)5" 7'(+'(/)" :%-;'+5" $" 645%$:5,6'9$." 6--." B0" 6$%/56'(/" D'" '(" :$64-.-/'9$." )'6,$6'-()" &45%5" 3FMO"

:$64&$0"')"+0)%5/,.$65+V"'(9.,+'(/"*'9%-B'$."'(7596'-()V"+'$B565)"$(+".,:,)1"

!

Extracellular Ii

TLR7KO TLRTLR

TLR7WT

Page 141: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!22""

"

"&"6&(9#!537+"

!1" A'.;5%)65'(" JH" b<22?c" #$%&'(')*" $(+" '**,(-.-/0^" 7%-*" H5694('G-77" 6-" @,%(561" P-&4$'"

(774)%:%+G"Cb!c^?EN1"

<1" H5+I4'6-;"M"]"o$(5&$0"RJV"o%1"b<22<c"#59-+'(/"645":$665%()"-7")5.7"$(+"(-()5.7"B0"645"'(($65"

'**,(5")0)65*1"F.(').'"<QNbKKNNc^<QPE?221"

?1" f$).-77"H" b<22<c" J(6'*'9%-B'$." :5:6'+5)" -7"*,.6'95..,.$%" -%/$(')*)1"P-&4$'" C!KbNPO2c^?PQE

?QK1"

C1" U$(/B,%("H_"]"H,..5%ESB5%4$%+"=o"b!QPCc"345"$.65%($6';5":$64&$0"-7"9-*:.5*5(61"F#$()+'$"

2'7()-$2"()"(774)%#-&B%:%+G"Ob<E?c^!N?E!Q<1"

K1" F$&"A_JM_@H"b!QQKc"R-*:.5*5(61"D$'22"<(+"5+'6'-("X87-%+"Y(';5%)'601"

N1" L,e'6$"3"b<22<c"S;-.,6'-("-7"645".596'(E9-*:.5*5(6":$64&$0"$(+"'6)"%-.5"'("'(($65"'**,('601"

P-&4$'"$'/('Q2;"X774)%:%+G"<bKc^?CNE?K?1"

O1" #5/("ASV"34'5."AV"]"o5()5(',)"oR"b<22Oc"W5&":5%):596';5)"-("*$(($(EB'(+'(/".596'(E*5+'$65+"

9-*:.5*5(6"$96';$6'-(1"X774)%9(%:%+G"<!<bCEKc^?2!E?!!1"

P1" f':75."UL"]"AG5%G$"R"b<22Qc"R-*:.5*5(6"%5/,.$6-%)"$(+"'(4'B'6-%0":%-65'()1"P-&4$'"$'/('Q2;"

X774)%:%+G"Qb!2c^O<QEOC21"

Q1" =$.'(" RV" H-%$" oMV" A,*5(" RV" ]" ;-(" J(+%'$(" Y=" b<22Kc" D(" ;';-" '*$/'(/" -7" .0*:4-9065"

6%$77'9G'(/1"I))4-:"$'/('Q"%6".'::"-)0"0'/':%#7')&-:"9(%:%+G"<!^KP!EN2?1"

!21" >5..5%6"H" b<22<c"Zb#co" %59-*B'($6'-(^"MJ>":%-65'()V" %5:$'%" 7$96-%)V" $(+" %5/,.$6'-(1"I))4-:"

$'/('Q"%6"9(%.B'7(2&$G"O!^!2!E!?<1"

!!1" F'6*$(" >gV" M$)6" oUV" ]" L,/*$((" A#" b<2!2c" 345" -%'/'()" -7" ;5%65B%$65" $+$:6';5" '**,('601"

P-&4$'"$'/('Q2;"X774)%:%+G"!2bPc^KC?EKK?1"

!<1" R--:5%"H#"]"J.+5%"HW"b<22Nc"345"5;-.,6'-("-7"$+$:6';5"'**,(5")0)65*)1"!'::"!<CbCc^P!KE

P<<1"

!?1" o,(6" 3V" A9$(+5..$" SV" ]" F,+5&'/" @" b<22Pc" L-%*" 7-..-&)" 7,(96'-(^" .0*:4-'+" 6')),5"

*'9%-$%94'6596,%5"'("$(6'*'9%-B'$."'**,(5"+575(951"P-&4$'"$'/('Q2;"X774)%:%+G"Pb!2c^ONCE

OOK1"

!C1" F5@'5(" 3g" ]" 35++5%" 3L" b<22Pc" @" .0*:4-9065)^" 4-&" 6450" +5;5.-:" $(+" 7,(96'-(1" ?:%%0"

!!<bKc^!KO2E!KP21"

!K1" 3')5.',)"J"]"_$B$6"SJ"b!Q?Pc"S.596%-:4-%5)')"-7"D**,(5"A5%,*1"F.(').'"POb<<N<c^C!NEC!O1"

!N1" W-))$.">o"]"F5+5%B5%/"o"b!QKPc"J(6'B-+0":%-+,96'-("B0")'(/.5"95..)1"P-&4$'"!P!bCN<2c^!C!QE

!C<21"

!O1" S+5.*$(">H"]">$..0" oJ" b!QNCc"J"H-+5." 7-%" 645" O)"J(6'B-+0"H-.59,.51"D$%.''0()+2" %6" &B'"

P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"K!^PCNEPK?1"

!P1" U-%65%" MM" b!QN?c" R45*'9$." A6%,96,%5" -7" >$**$E>.-B,.'(" $(+" J(6'B-+'5)1" ?$(&(2B" 7'0(.-:"

94::'&()"!Q^!QOE<2!1"

!Q1" R--:5%" H#" M#" b!QNNc" 345" 7,(96'-()" -7" 645" 640*,)" )0)65*" $(+" 645" B,%)$" )0)65*" '(" 645"

94'9G5(1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"b!<?c^OKE!2<1"

<21" R--:5%"H#"UMV">--+"MJ"b!QNKc"#5.'(5$6'-("-7"645"640*'9"$(+"B,%)$.".0*:4-'+")0)65*)"'("645"

94'9G5(1"P-&4$'"<2K^!C?E!CN1"

<!1" H'..5%"oL"]"H'6945..">L"b!QNPc"R5.."6-"95.."'(65%$96'-("'("645"'**,(5"%5):-()51"D1"=5*-.0)'(E

7-%*'(/"95..)" '("(5-($6$..0"640*596-*'I5+"*'95"%59-()6'6,65+"&'64"640*,)"-%"64-%$9'9"+,96"

.0*:4-9065)1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!<PbCc^P2!EP<21"

<<1" H'6945..">L"]"H'..5%"oL"b!QNPc"R5.."6-"95.."'(65%$96'-("'("645"'**,(5"%5):-()51"DD1"345")-,%95"

-7"45*-.0)'(E7-%*'(/"95..)"'("'%%$+'$65+"*'95"/';5("B-(5"*$%%-&"$(+"640*,)"-%"64-%$9'9"+,96"

.0*:4-9065)1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!<PbCc^P<!EP?O1"

<?1" R--*B)"MMV"L5'()65'("JV"]"g'.)-("J@"b!QNQc"D**,(-/.-B,.'("+565%*'($(6)"-("645"),%7$95"-7"

4,*$(".0*:4-9065)1"8-).'&"<bON?!c^!!KOE!!N21"

Page 142: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2!""

"

<C1" =$0$G$&$"_V"=$%+0"MMV"=5%I5(B5%/"FJV"]"=5%I5(B5%/"FJ"b!QPKc"U%-/5('6-%)"7-%"F0E!"@"95..)"

$%5" +')6'(96" 7%-*" :%-/5('6-%)" 7-%" -645%" @" 95..)1" AB'" S%4$)-:" %6" ']#'$(7')&-:" 7'0(.()'"

!N!bNc^!KKCE!KNP1"

<K1" H-(659'(-EM-+%'/,5I" SV" F5$645%)" =V" ]" #-%)4G'(+" _" b<22Nc" D+5(6'7'9$6'-(" -7" $" @E!" @" 95..E

):59'7'5+":%-/5('6-%1"P-&4$'"(774)%:%+G"Ob?c^<Q?E?2!1"

<N1" >%'77'("#XV"=-.-+'9G"WSV"]"M-64)65'(" 3F" b<2!!c"=,*$("@!" 95..)" '(",*B'.'9$." 9-%+" $(+"$+,.6"

:5%':45%$." B.--+" 58:%5))" 645" (-;5." :45(-60:5" R#<2p" R#<Op" R#C?p" R#O21" AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"<2Pb!c^NOEP21"

<O1" H$%6'(" LV" X.';5%" JHV"]" _5$%(50" oL" b<22!c"H$%/'($." I-(5" $(+" @!" @" 95..)" ,('65" '(" 645" 5$%.0"

%5):-()5"$/$'()6"3E'(+5:5(+5(6"B.--+EB-%(5":$%6'9,.$65"$(6'/5()1"X774)(&G"!CbKc^N!OEN<Q1"

<P1" @$.$I)"HV"H$%6'(" LV" f4-," 3V" ]" _5$%(50" o" b<22<c" @.--+" +5(+%'6'9" 95..)" '(65%$96"&'64" ):.5('9"

*$%/'($."I-(5"@"95..)"6-"'('6'$65"3E'(+5:5(+5(6"'**,(5"%5):-()5)1"X774)(&G"!Ob?c^?C!E?K<1"

<Q1" S4%5()65'("HM"]"W-6.50"RJ"b<2!2c"345"'*:-%6$(95"-7"($6,%$."D/H^")9$;5(/5%V":%-6596-%"$(+"

%5/,.$6-%1"P-&4$'"$'/('Q2;"X774)%:%+G"!2b!!c^OOPEOPN1"

?21" H-%%')" J" ]"H-..5%" >" b!QNPc" M5/,.$6'-(" -7" 95..,.$%" $(6'B-+0" )0(645)')" 577596" -7" $+-:6';5.0"

6%$()75%%5+" $(6'B-+0E:%-+,9'(/" ):.55(" 95..)" -(" 95..,.$%" $(6'B-+0" )0(645)')1" S%4$)-:" %6"

(774)%:%+G"!2!b?c^C?QECCK1"

?!1" -:;"JH'"b!QQOc"A,::%5))';5"%-.5"-7"@"95..)"'("94%-('9"9-.'6')"-7"3"95.."%595:6-%"u"*,6$(6"*'951"

S;']#;*'0"b!PNc^!OCQl!OKN1"

?<1" U'..$'" A" ]" R$%'$::$" J" b<22Qc" 345" 7-..'9,.$%" ;5%),)" *$%/'($." I-(5" @" .0*:4-9065" 95.." 7$65"

+59')'-(1"P-&4$'"$'/('Q2;"X774)%:%+G"Qb!!c^ONOEOOO1"

??1" H$9G$0" L" ]" A94(5'+5%" U" b<22Qc" R%$9G'(/" 645" @JLL" 9-+51" P-&4$'" $'/('Q2;" X774)%:%+G"

QbOc^CQ!EK2<1"

?C1" X�>$%%$"JE"'&"-:;"b!QQ2c"U%-+,96'-("-7"906-G'(5)"B0"*-,)5"@"95..)^"@".0*:4-*$)"$(+"(-%*$."@"

95..)":%-+,95"'(65%.5,G'("!21"X)&'$)-&(%)-:"(774)%:%+G"<bQc^P<!EP?<1"

?K1" @,%+'(" WV" U5%-((5" RV" @$(945%5$," oV" ]" M-,))56" L" b!QQ?c" S:)65'(E@$%%" ;'%,)" 6%$()7-%*$6'-("

'(+,95)" @" .0*:4-9065)" 6-" :%-+,95" 4,*$(" '(65%.5,G'(" !21" AB'" S%4$)-:" %6" ']#'$(7')&-:"

7'0(.()'"!OOb<c^<QKE?2C1"

?N1" F,(+" LS" ]" M$(+$.." 3#" b<2!2c" S77596-%" $(+" %5/,.$6-%0" @" 95..)^" *-+,.$6-%)" -7" R#Cp" 3" 95.."

'**,('601"P-&4$'"$'/('Q2;"X774)%:%+G"!2bCc^<?NE<CO1"

?O1" t$($B$" _V" @-,$I'I" o#V"H$6),)4'6$" 3V" 3),B$6$" 3V" ]" 35++5%" 3L" b<22Qc" 345" +5;5.-:*5(6" $(+"

7,(96'-("-7"%5/,.$6-%0"@"95..)"58:%5))'(/"DFE!2"b@!2"95..)c"%5[,'%5)"$(6'/5("%595:6-%"+';5%)'60"

$(+"3FM")'/($.)1"S%4$)-:"%6"(774)%:%+G"!P<b!<c^OCKQEOCO<1"

?P1" S;$()" o>E" '&" -:;" b<22Oc"W-;5." ),::%5))';5" 7,(96'-(" -7" 6%$()'6'-($." <" @" 95..)" '(" 58:5%'*5(6$."

$%64%'6')1"S%4$)-:"%6"(774)%:%+G"!OPb!<c^OPNPEOPOP1"

?Q1" H$,%'" R" ]" S4%5()65'(" HM" b<22Pc" 345" �)4-%6�" 4')6-%0" -7" %5/,.$6-%0" @" 95..)1" A$')02" ()"

(774)%:%+G"<Qb!c^?CEC21"

C21" H$6),*-6-"HE"'&"-:;" b<2!!c"345"9$.9',*")5()-%)"A3DH!"$(+"A3DH<"9-(6%-."@"95.."%5/,.$6-%0"

7,(96'-("64%-,/4"'(65%.5,G'(E!2":%-+,96'-(1"X774)(&G"?CbKc^O2?EO!C1"

C!1" @.$'%"UJE"'&"-:;"b<22Qc"A5.596';5"6$%/56'(/"-7"@"95..)"&'64"$/-(')6'9"$(6'ER#C2"')"$("577'9$9'-,)"

)6%$65/0" 7-%" 645"/5(5%$6'-("-7" '(+,95+" %5/,.$6-%0"3<E.'G5"@"95..)"$(+" 7-%" 645"),::%5))'-("-7"

.,:,)"'("HMFT.:%"*'951"S%4$)-:"%6"(774)%:%+G"!P<bNc^?CQ<E?K2<1"

C<1" L'..$6%5$," AV" A&55('5" R=V" H9>5$940" HoV" >%$0" #V" ]" J(+5%6-(" AH" b<22<c" @" 95..)" %5/,.$65"

$,6-'**,('60"B0":%-;')'-("-7"DFE!21"P-&4$'"(774)%:%+G"?b!2c^QCCEQK21"

C?1" *'I-/,)4'"J"HS"b<22<c"94%-('9" '(65)6'($." '(7.$**$6-%0"9-(+'6'-("/5(5%$65)"DFE!2E:%-+,9'(/"

%5/,.$6-%0"@"95.."),B)56"94$%$965%')5+"B0"R#!+",:%5/,.$6'-("X774)(&G"!N^<!QE<?21"

CC1" M-(56"RE"'&"-:;"b<2!2c"M5/,.$6-%0"@"95..)")4$:5"645"+5;5.-:*5(6"-7"34<"'**,(5"%5):-()5)"'("

@JF@T9" *'95" '(75965+" &'64" F5')4*$('$" *$e-%" 64%-,/4" DFE!2" :%-+,96'-(1" S%4$)-:" %6"

(774)%:%+G"!PCb<c^PPNEPQC1"

CK1" >'..$("Z"]"#5;$(50"S" b<22Kc"M5/,.$6-%0"3" 95..)"*-+,.$65"34<" %5):-()5)" '(+,95+"B0"@%,/'$"

:$4$(/'"64'%+E)6$/5".$%;$51"X)6'.&(%)"-)0"(774)(&G"O?bOc^C2?CEC2C<1"

Page 143: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2<""

"

CN1" W5;5)" UE" '&" -:;" b<2!2c" A'/($.'(/" ;'$" 645" H0#PP" $+$:6-%" :%-65'(" '(" @" 95..)" ),::%5))5)"

:%-6596';5"'**,('60"+,%'(/"A$.*-(5..$"60:4'*,%',*"'(7596'-(1"X774)(&G"??bKc^OOOEOQ21"

CO1" >'..$("ZV"F$&%5(95"MJV"]"#5;$(50"S"b<22Kc"@"95..)":.$0"$"%5/,.$6-%0"%-.5"'("*'95"'(75965+"&'64"

645"F?"-7"@%,/'$":$4$(/'1"X)&'$)-&(%)-:"(774)%:%+G"!ObCc^?O?E?P<1"

CP1" _.$,)">>V"=,*:4%50"o=V"_,(G."JV"]"#-(/&-%64"#g"b!QP2c"345"7-..'9,.$%"+5(+%'6'9"95..^"'6)"%-.5"

'("$(6'/5(":%5)5(6$6'-("'("645"/5(5%$6'-("-7"'**,(-.-/'9$."*5*-%01"X774)%:%+(.-:"$'/('Q2"

K?^?E<P1"

CQ1" H$(+5." 3SV" U4'::)" MUV" JBB-6" JV" ]" 35&" o>" b!QP2c" 345" 7-..'9,.$%" +5(+%'6'9" 95..^" .-(/" 65%*"

$(6'/5("%565(6'-("+,%'(/"'**,('601"X774)%:%+(.-:"$'/('Q2"K?^<QEKQ1"

K21" R$%%-.." HR" b!QQPc" 345" %-.5" -7" 9-*:.5*5(6" $(+" 9-*:.5*5(6" %595:6-%)" '(" '(+,96'-(" $(+"

%5/,.$6'-("-7"'**,('601"I))4-:"$'/('Q"%6"(774)%:%+G"!N^KCKEKNP1"

K!1" z'("#E" '&" -:;" b<222c" L9" /$**$" %595:6-%" DD@" -(" 7-..'9,.$%" +5(+%'6'9" 95..)" %5/,.$65)" 645" @" 95.."

%59$.."%5):-()51"S%4$)-:"%6"(774)%:%+G"!NCb!<c^N<NPEN<OK1"

K<1" _$.+e'$("SUV">%56I"oSV"J(+5%)-("JXV"A4'"tV"]"A4$&"A"b<22!c"A:$6'$."$(+"*-.59,.$%"-%/$('I$6'-("

-7" .0*:4"(-+5"3"95.."9-%658^"$" .$B0%'(64'(5"9$;'60"B-,(+5+"B0"$("5:'645.',*E.'G5"*-(-.$05%"

-7" 7'B%-B.$)6'9" %56'9,.$%" 95..)" $(94-%5+" 6-" B$)5*5(6" *5*B%$(5E.'G5" 586%$95..,.$%" *$6%'81"

X)&'$)-&(%)-:"(774)%:%+G"!?b!2c^!<C?E!<K?1"

K?1" _,*$%$%$6(5" #AV" @$I'(" =V" ]" H$9F5(($(" DR" b!QP!c" H$%/'($." I-(5)^" 645" *$e-%" @" 95.."

9-*:$%6*5(6"-7"%$6"):.55()1"U4$%#'-)"C%4$)-:"%6"(774)%:%+G"!!b!!c^PKPEPNC1"

KC1" H$%6'("L"]"_5$%(50" oL" b<22<c"H$%/'($.EI-(5"@"95..)1"P-&4$'" $'/('Q2;" X774)%:%+G"<bKc^?<?E

??K1"

KK1" @-4()$9G" oL" ]" @%-&(" So" b!QPNc" 345" %-.5" -7" 645" ):.55(" '(" %5)')6$(95" 6-" '(7596'-(1" I))4-:"

$'/('Q"%6"7'0(.()'"?O^CQEKQ1"

KN1" R$4$.$("H#"]"U$%G5%"D"b<22Pc"R4-%5-/%$:40"-7"95.."*-6'.'60"$(+"'(65%$96'-("+0($*'9)"'*$/5+"

B0"6&-E:4-6-("*'9%-)9-:0"'(".0*:4-'+"-%/$()1"I))4-:"$'/('Q"%6"(774)%:%+G"<N^KPKEN<N1"

KO1" >5%*$'(" MWV" H'..5%" HoV" #,)6'(" HFV" ]" W,))5(I&5'/" HR" b<22Nc" #0($*'9" '*$/'(/" -7" 645"

'**,(5")0)65*^":%-/%5))V":'67$..)"$(+":%-*')51"P-&4$'"$'/('Q2;"X774)%:%+G"NbOc^CQOEK2O1"

KP1" =$%&--+" WS" ]" @$6')6$" L#" b<2!2c" S$%.0" 5;5(6)" '(" @" 95.." $96';$6'-(1" I))4-:" $'/('Q" %6"

(774)%:%+G"<P^!PKE<!21"

KQ1" U$:5" _JV" R$6%-(" #HV" D6$(-" JJV" ]" o5(G'()" H_" b<22Oc" 345" 4,*-%$." '**,(5" %5):-()5" ')"

'('6'$65+" '(" .0*:4" (-+5)" B0" @" 95..)" 64$6" $9[,'%5" )-.,B.5" $(6'/5(" +'%596.0" '(" 645" 7-..'9.5)1"

X774)(&G"<NbCc^CQ!EK2<1"

N21" M--I5(+$$."ME"'&"-:;" b<22Qc"R-(+,'6)"*5+'$65" 6%$():-%6"-7" .-&E*-.59,.$%E&5'/46"$(6'/5("6-"

.0*:4"(-+5"7-..'9.5)1"X774)(&G"?2b<c^<NCE<ON1"

N!1" @$6')6$"L#"]"=$%&--+"WS"b<22Qc"345"&4-V"4-&"$(+"&45%5"-7"$(6'/5(":%5)5(6$6'-("6-"@"95..)1"

P-&4$'"$'/('Q2;"X774)%:%+G"Qb!c^!KE<O1"

N<1" >%$G-,'"JE"'&"-:;" b!QQQc"345" '**,(-.-/'9$." )0($:)5^"$"*-.59,.$%"*$94'(5"9-(6%-..'(/"3"95.."

$96';$6'-(1"F.(').'"<PKbKC<Kc^<<!E<<O1"

N?1" _,:75%" JV" A&$'(" AFV"]" A'(/5%" Ao" b!QPOc" 345" ):59'7'9" +'%596" '(65%$96'-(" -7" 45.:5%" 3" 95..)" $(+"

$(6'/5(E:%5)5(6'(/" @" 95..)1" DD1" M5-%'5(6$6'-(" -7" 645" *'9%-6,B,.5" -%/$('I'(/" 95(65%" $(+"

%5-%/$('I$6'-("-7"645"*5*B%$(5E$))-9'$65+"906-)G5.56-("'()'+5"645"B-,(+"45.:5%"3"95..)1"AB'"

S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!NKbNc^!KNKE!KP21"

NC1" H$%6'(5IEU-*$%5)" F" ]" >-%+-(" A" b<22Oc" J(6'/5(" :%5)5(6$6'-(" 645" *$9%-:4$/5" &$01" !'::"

!?!bCc^NC!ENC?1"

NK1" o,(6" 3E" '&" -:;" b<22Oc" A,B9$:),.$%" )'(,)" *$9%-:4$/5)" '(" .0*:4" (-+5)" 9.5$%" .0*:4EB-%(5"

;'%,)5)"$(+":%5)5(6"645*"6-"$(6';'%$."@"95..)1"P-&4$'"CK2bO!NNc^!!2E!!C1"

NN1" z'"=V"S/5("o>V"=,$(/"JtV"]">5%*$'("MW"b<22Nc"S86%$7-..'9,.$%"$96';$6'-("-7".0*:4"(-+5"@"95..)"

B0"$(6'/5(EB5$%'(/"+5(+%'6'9"95..)1"F.(').'"?!<bKOP2c^!NO<E!NON1"

NO1" @5%/6-.+" JV" #5)$'" ##V" >$;4$(5" JV" ]" R.0(5)" M" b<22Kc" R5.." ),%7$95" %5909.'(/" -7" '(65%($.'I5+"

$(6'/5(":5%*'6)"+5(+%'6'9"95..":%'*'(/"-7"@"95..)1"X774)(&G"<?bKc^K2?EK!C1"

Page 144: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2?""

"

NP1" @5%(50"RE"'&"-:;" b!QQQc"J"*5*B5%"-7"645"+5(+%'6'9"95.." 7$*'.0"64$6"5(65%)"@"95.." 7-..'9.5)"$(+"

)6'*,.$65)":%'*$%0"$(6'B-+0"%5):-()5)"'+5(6'7'5+"B0"$"*$((-)5"%595:6-%"7,)'-(":%-65'(1"AB'"

S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!Q2bNc^PK!EPN21"

NQ1" F-:5)ER$%;$.4-"3V"L--65"oV"]"_5$%(50"oL"b<22Kc"H$%/'($."I-(5"@"95..)"'(".0*:4-9065"$96';$6'-("

$(+"%5/,.$6'-(1"!4$$')&"%#()(%)"()"(774)%:%+G"!Ob?c^<CCE<K21"

O21" R45("FFV"L%$(G"JHV"J+$*)"oRV"]"A65'(*$("MH"b!QOPc"#')6%'B,6'-("-7"4-%)5%$+')4":5%-8'+$)5"

b=MUcE$(6'E=MU" '**,(5" 9-*:.585)" '(" *-,)5" ):.55(" &'64" ):59'$." %575%5(95" 6-" 7-..'9,.$%"

+5(+%'6'9"95..)1"AB'"S%4$)-:"%6".'::"9(%:%+G"OQb!c^!PCE!QQ1"

O!1" 35&" o>V" U4'::)" MUV" ]"H$(+5." 3S" b!QP2c" 345" *$'(65($(95" $(+" %5/,.$6'-(" -7" 645" 4,*-%$."

'**,(5"%5):-()5^":5%)')6'(/"$(6'/5("$(+"645"%-.5"-7"7-..'9,.$%"$(6'/5(EB'(+'(/"+5(+%'6'9"95..)"

$)"$995))-%0"95..)1"X774)%:%+(.-:"$'/('Q2"K?^!OKE<2!1"

O<1" U4$("3>V">%'/-%-;$"DV"XG$+$"3V"]"R0)65%"o>"b<22Oc"A,B9$:),.$%"5(9-,(65%"$(+"9-*:.5*5(6E

+5:5(+5(6" 6%$():-%6" -7" '**,(5" 9-*:.585)" B0" .0*:4" (-+5" @" 95..)1" P-&4$'" (774)%:%+G"

PbQc^QQ<E!2221"

O?1" _.$,)" >>"]"=,*:4%50" o=" b!QOOc" 345" /5(5%$6'-(" -7"*5*-%0" 95..)1" D1" 345" %-.5" -7" R?" '(" 645"

/5(5%$6'-("-7"@"*5*-%0"95..)1"X774)%:%+G"??b!c^?!EC21"

OC1" U$:$*'94$'."HE" '&" -:;" b!QOKc" R-*:.5*5(6" +5:5(+5(95" -7" .-9$.')$6'-(" -7" $//%5/$65+" D/>" '("

/5%*'($."95(6%5)1"F.-)0()-/(-)"C%4$)-:"%6"(774)%:%+G"CbCc^?C?E?CO1"

OK1" t-)4'+$" _V" ;$(" +5(" @5%/" 3_V" ]" #'eG)6%$" R#" b!QQ?c" 3&-" 7,(96'-($..0" +'775%5(6" 7-..'9,.$%"

+5(+%'6'9"95..)"'(")59-(+$%0".0*:4-'+"7-..'9.5)"-7"*-,)5"):.55(V"$)"%5;5$.5+"B0"RM!T<"$(+"L9M"

/$**$"DDE*5+'$65+"'**,(5E9-*:.58"6%$::'(/1"X774)%:%+G"P2b!c^?CE?Q1"

ON1" J..5("R#"]"R0)65%"o>"b<22Pc"L-..'9,.$%"+5(+%'6'9"95.."(56&-%G)"-7":%'*$%0"7-..'9.5)"$(+"/5%*'($."

95(65%)^":45(-60:5"$(+"7,(96'-(1"F'7()-$2"()"(774)%:%+G"<2b!c^!CE<K1"

OO1" R$%%$)9-"tM"]"@$6')6$"L#"b<22Oc"@"95..)"$9[,'%5":$%6'9,.$65"$(6'/5("'("$"*$9%-:4$/5E%'94"$%5$"

$6"645"B-,(+$%0"B56&55("645"7-..'9.5"$(+"645"),B9$:),.$%")'(,)"-7"645".0*:4"(-+51"X774)(&G"

<Ob!c^!N2E!O!1"

OP1" R'($*-(">V"f$94$%'$4"HJV"F$*"XHV"L-))"LgV" o%1V"]"R0)65%" o>" b<22Pc"L-..'9,.$%" )4,66.'(/"-7"

*$%/'($."I-(5"@"95..)"7$9'.'6$65)"$(6'/5("6%$():-%61"P-&4$'"(774)%:%+G"Qb!c^KCEN<1"

OQ1" U$,."gS"]"A5+5%"MJ"b!QQCc"F0*:4-9065"%5):-()5)"$(+"906-G'(5)1"!'::"ONb<c^<C!E<K!1"

P21" H-(G)"RMV"L%5'B5%/"@JV"_,:75%"=V"A9'$G0"WV"]"_,:75%"J"b!QQPc"34%55E+'*5()'-($.")5/%5/$6'-("

-7"),:%$*-.59,.$%"$96';$6'-("9.,)65%)"'("3"95..)1"P-&4$'"?QKbNNQOc^P<EPN1"

P!1" R$%%$)9-"tMV"L.5'%5"AoV"R$*5%-("3V"#,)6'("HFV"]"@$6')6$"L#"b<22Cc"FLJE!TDRJHE!"'(65%$96'-("

.-&5%)"645"64%5)4-.+"-7"@"95.."$96';$6'-("B0"7$9'.'6$6'(/"@"95.."$+45)'-("$(+")0($:)5"7-%*$6'-(1"

X774)(&G"<2bKc^KPQEKQQ1"

P<1" U-665%" 3JV">%5B5" _V" L%5'B5%/" @V"]" _,:75%" J" b<22!c" L-%*$6'-(" -7" ),:%$*-.59,.$%" $96';$6'-("

9.,)65%)"-(" 7%5)4"58" ;';-"R#Pp" 3" 95..)" $765%" 5(/$/5*5(6"-7" 645"3" 95.." $(6'/5(" %595:6-%" $(+"

R#P" B0" $(6'/5(E:%5)5(6'(/" 95..)1" D$%.''0()+2" %6" &B'" P-&(%)-:" I.-0'7G" %6" F.(').'2" %6" &B'"

`)(&'0"F&-&'2"%6"I7'$(.-"QPb<<c^!<N<CE!<N<Q1"

P?1" A6'(949-*B5"oR"@>V"@--64"AV">%'77'64)">H"b<22!c"645"'**,(-.-/'9$.")0($:)5"-7"R3F"9-(6$'()"

$")59%56-%0"+-*$'("$(+"*5*B%$(5"B%'+/5)1"X774)(&G"!K^OK!EON!1"

PC1" H$%.'("A#E"'&"-:;"b!QQ2c"J")-.,B.5"7-%*"-7"'(65%95..,.$%"$+45)'-("*-.59,.5E!"'(4'B'6)"%4'(-;'%,)"

'(7596'-(1"P-&4$'"?CCbN<N!c^O2EO<1"

PK1" F-"R>V"F,"33V"]"R0)65%" o>" b<22?c" D(65/%'(E+5:5(+5(95"-7" .0*:4-9065"5(6%0" '(6-" 645"):.5('9"

&4'65":,.:1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!QOb?c^?K?E?N!1"

PN1" _--:*$(">E"'&"-:;"b!QQ!c"J+45)'-("-7"4,*$("@"95..)"6-"7-..'9,.$%"+5(+%'6'9"95..)"'(;-.;5)"B-64"

645" .0*:4-9065" 7,(96'-(E$))-9'$65+" $(6'/5(" !T'(65%95..,.$%" $+45)'-(" *-.59,.5" !" $(+" ;5%0"

.$65" $(6'/5(" CT;$)9,.$%" 95.." $+45)'-(" *-.59,.5" !" :$64&$0)1" AB'" S%4$)-:" %6" ']#'$(7')&-:"

7'0(.()'"!O?bNc^!<QOE!?2C1"

PO1" _,)4('%"WV"F',"FV"]"H$9U45%)-(">>"b!QQPc"#5(+%'6'9"95..)"$(+"%5)6'(/"@"95..)"7-%*"9.,)65%)"'("

;'6%-" $(+" '(" ;';-^" 3" 95.." '(+5:5(+5(95V" :$%6'$." FLJE!" +5:5(+5(95V" $(+" %5/,.$6'-(" B0" 9%-))E

.'(G'(/"),%7$95"*-.59,.5)1"S%4$)-:"%6"(774)%:%+G"!N2bCc^!OOCE!OP!1"

Page 145: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2C""

"

PP1" _--:*$(">E"'&"-:;"b!QQCc"J+45)'-("64%-,/4"645"FLJE!"bR#!!$TR#!PcEDRJHE!"bR#KCc"$(+"645"

ZFJEC" bR#CQ+cEZRJHE!" bR#!2Nc" :$64&$0)" :%5;5(6)" $:-:6-)')" -7" /5%*'($." 95(65%" @" 95..)1"

S%4$)-:"%6"(774)%:%+G"!K<bPc^?ON2E?ONO1"

PQ1" L%55+*$("JAE"'&"-:;" b!QQ2c"J+45)'-("-7"4,*$("@"95..)" 6-"/5%*'($."95(65%)" '(";'6%-" '(;-.;5)"

ZFJEC"$(+"DWRJHE!!21"F.(').'"<CQbCQO<c^!2?2E!2??1"

Q21" t,)577"HDE"'&"-:;"b<2!!c"U-.$%'I5+")59%56'-("-7".0)-)-*5)"$6"645"@"95..")0($:)5"9-,:.5)"$(6'/5("

586%$96'-("6-":%-95))'(/"$(+":%5)5(6$6'-(1"X774)(&G"?Kb?c^?N!E?OC1"

Q!1" M564"H"b!QPQc"J(6'/5("%595:6-%"6$'."9.,51"P-&4$'"??PbN<!Cc^?P?E?PC1"

Q<1" _,%-)$G'" 3" b!QQQc" >5(56'9" $($.0)')" -7" @" 95.." $(6'/5(" %595:6-%" )'/($.'(/1" I))4-:" $'/('Q" %6"

(774)%:%+G"!O^KKKEKQ<1"

Q?1" >%5/'$('('" 3AE" '&" -:;" b<22Cc" S(;'%-(*5(6$." $(+" -(6-/5(56'9" 9-(6%-." -7" $99,*,.$6'-(" -7"

B%$94095%'(5V" $" B'-$96';5" '(+-.5" $.G$.-'+" 7%-*" U)094-6%'$" B%$94095%$)1" S%4$)-:" %6" .B'7(.-:"

'.%:%+G"?2b!2c^<2<?E<2?N1"

QC1" #5L%$(9-" JF" b!QQOc" 345" 9-*:.58'60" -7" )'/($.'(/" :$64&$0)" $96';$65+" B0" 645" @RM1" !4$$')&"

%#()(%)"()"(774)%:%+G"Qb?c^<QNE?2P1"

QK1" _,%-)$G'"3"]"_,%-)$G'"H"b!QQOc"3%$():4-):4-%0.$6'-("-7"@%,6-(�)"60%-)'(5"G'($)5"-("60%-)'(5"

KK!" ')" 9%'6'9$." 7-%" @" 95.." $(6'/5(" %595:6-%" 7,(96'-(1" AB'" S%4$)-:" %6" 9(%:%+(.-:" .B'7(2&$G"

<O<b<Kc^!KKQKE!KKQP1"

QN1" M564" H" ]"g'5($(+)" o" b!QQOc" D('6'$6'-(" $(+" :%-95))'(/" -7" )'/($.)" 7%-*" 645" @" 95.." $(6'/5("

%595:6-%1"I))4-:"$'/('Q"%6"(774)%:%+G"!K^CK?ECOQ1"

QO1" A94$%5(B5%/"JHV"=,*:4%'5)"FJV"]"M$&.'(/)"#o"b<22Oc"R$.9',*")'/($..'(/"$(+"95..E7$65"94-'95"

'("@"95..)1"P-&4$'"$'/('Q2;"X774)%:%+G"Ob!2c^OOPEOPQ1"

QP1" M-..'"ZE"'&"-:;"b<22<c"J*:.'7'9$6'-("-7"@"95.."$(6'/5("%595:6-%")'/($.'(/"B0"$"A0GTD3JH":-)'6';5"

755+B$9G".--:1"*%:'.4:-$".'::"!2bKc^!2KOE!2NQ1"

QQ1" S(/5.G5"HV"S(/5.)"WV"#'66*$(("_V" A6-%G"@V"]"g'5($(+)" o" b<22Oc"R$b<pc" )'/($.'(/" '("$(6'/5("

%595:6-%E$96';$65+"@".0*:4-9065)1"X774)%:%+(.-:"$'/('Q2"<!P^<?KE<CN1"

!221" R$*B'5%"oRV">$,.+"A@V"H5%%5.."_3V"]"Z'.5("@o"b<22Oc"@E95.."$(5%/0^"7%-*"6%$()/5('9"*-+5.)"6-"

($6,%$..0"-99,%%'(/"$(5%/'9"@"95..)�"P-&4$'"$'/('Q2;"X774)%:%+G"ObPc^N??ENC?1"

!2!1" A94,.I5EF,54%*$(("o"]">4-)4"A"b<22Nc"J(6'/5(E%595:6-%")'/($.'(/"6-"(,9.5$%"7$96-%"G$::$"@1"

X774)(&G"<KbKc^O2!EO!K1"

!2<1" F$(I$;5994'$" J" b!QPKc" J(6'/5(E):59'7'9" '(65%$96'-(" B56&55(" 3" $(+" @" 95..)1" P-&4$'"

?!CbN2!!c^K?OEK?Q1"

!2?1" M-9G" _FV" @5($95%%$7" @V" ]" JBB$)" J_" b!QPCc" J(6'/5(" :%5)5(6$6'-(" B0" 4$:65(E):59'7'9" @"

.0*:4-9065)1" D1" M-.5" -7" ),%7$95" '**,(-/.-B,.'(" %595:6-%)1" AB'" S%4$)-:" %6" ']#'$(7')&-:"

7'0(.()'"!N2bCc^!!2<E!!!?1"

!2C1" R4$6,%;5+'" JV" H$%6I" MV" #-%&$%+" #V" g$')B5%/" HV" ]" U'5%95" A_" b<2!!c" S(+-906-)5+" @RM)"

)5[,5(6'$..0" %5/,.$65" HJU_" $(+" JG6" )'/($.'(/" :$64&$0)" 7%-*" '(6%$95..,.$%" 9-*:$%6*5(6)1"

P-&4$'"(774)%:%+G"!<b!!c^!!!QE!!<N1"

!2K1" 3-.$%"U"]"U'5%95"A_"b<2!2c"J"9-(7-%*$6'-(E'(+,95+"-.'/-*5%'I$6'-("*-+5."7-%"@"95.."%595:6-%"

*'9%-9.,)65%'(/"$(+")'/($.'(/1"!4$$')&"&%#(.2"()"7(.$%9(%:%+G"-)0"(774)%:%+G"?C2^!KKE!NQ1"

!2N1" L.5'%5" AoE" '&" -:;" b<22Nc" @" 95.." .'/$(+" +')9%'*'($6'-(" 64%-,/4" $" ):%5$+'(/" $(+" 9-(6%$96'-("

%5):-()51"F.(').'"?!<bKOOCc^O?PEOC!1"

!2O1" @%56)945%"JV"S+&$%+)"_V"]"L54-("M>"b<22<c"SMH":%-65'()"$(+"*5%.'(^"'(65/%$6-%)"$6"645"95.."

9-%6581"P-&4$'"$'/('Q2;"*%:'.4:-$".'::"9(%:%+G"?bPc^KPNEKQQ1"

!2P1" 3%5$(-%" @E" '&" -:;" b<2!2c" 345"*5*B%$(5" )G5.56-(" 9-(6%-.)" +'77,)'-(" +0($*'9)" $(+" )'/($.'(/"

64%-,/4"645"@"95.."%595:6-%1"X774)(&G"?<b<c^!POE!QQ1"

!2Q1" 3%5$(-%"@V"#5:-'."#V"@%,9GB$,5%"JV"]"@$6')6$"L#"b<2!!c"#0($*'9"9-%6'9$."$96'("%5*-+5.'(/"B0"

SMH" :%-65'()" 9-(6%-.)" @RM" *'9%-9.,)65%" -%/$('I$6'-(" $(+" '(65/%'601" AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"<2PbKc^!2KKE!2NP1"

!!21" A94(0+5%"3E"'&"-:;"b<2!!c"@"95.."%595:6-%E*5+'$65+"$(6'/5("/$645%'(/"%5[,'%5)",B'[,'6'(".'/$)5"

RB."$(+"$+$:6-%)">%B<"$(+"#-GE?" 6-" %59%,'6"+0(5'(" 6-" 645")'/($.'(/"*'9%-9.,)65%1" X774)(&G"

?CbNc^Q2KEQ!P1"

Page 146: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2K""

"

!!!1" F-)'(/" HE" '&" -:;" b<2!?c" 345" #-GE?T>%B<" :%-65'(" )'/($." *-+,.5" $665(,$65)" F0(" G'($)5E

+5:5(+5(6" $96';$6'-("-7" A0G" G'($)5" '("@" 95.." $(6'/5(" %595:6-%"*'9%-9.,)65%)1"AB'" S%4$)-:" %6"

9(%:%+(.-:".B'7(2&$G"<PPbCc^<?2?E<?!?1"

!!<1" L5$%-(" #3" ]" R$%65%" M=" b!QQKc" 345" R#!QTRM<T3JUJE!" 9-*:.58" -7" @" .0*:4-9065)^" .'(G'(/"

($6,%$."6-"$9[,'%5+"'**,('601"I))4-:"$'/('Q"%6"(774)%:%+G"!?^!<OE!CQ1"

!!?1" @%--G)"AMV"_'%G4$*"UHV"L%55B5%/"FV"]"R$%65%"M=" b<22Cc"@'(+'(/"-7" 906-:.$)*'9":%-65'()" 6-"

645" R#!Q" '(6%$95..,.$%" +-*$'(" ')" 4'/4" $77'('60V" 9-*:56'6';5V" $(+" *,.6'*5%'91" S%4$)-:" %6"

(774)%:%+G"!O<b!<c^OKKNEOKNC1"

!!C1" g5B5%" HE" '&" -:;" b<22Pc" U4-):4-.':$)5" RE/$**$<" $(+" Z$;" 9--:5%$65" &'64'(" )'/($.'(/"

*'9%-9.,)65%)" 6-" :%-:$/$65" @" 95.." ):%5$+'(/" '(" %5):-()5" 6-"*5*B%$(5EB-,(+" $(6'/5(1" AB'"

S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"<2KbCc^PK?EPNP1"

!!K1" A$6-"AV"H'..5%"JAV"=-&$%+"HRV"]"35++5%"3L"b!QQOc"M5/,.$6'-("-7"@".0*:4-9065"+5;5.-:*5(6"

$(+"$96';$6'-("B0"645"R#!QTR#<!TR#P!TF5,"!?"9-*:.58"%5[,'%5)"645"906-:.$)*'9"+-*$'("-7"

R#!Q1"S%4$)-:"%6"(774)%:%+G"!KQbOc^?<OPE?<PO1"

!!N1" H$66'.$"U_E"'&"-:;" b<2!?c"345"$96'("$(+"656%$):$('("(56&-%G)"-%/$('I5"%595:6-%"($(-9.,)65%)"

6-"%5/,.$65"@"95.."%595:6-%E*5+'$65+")'/($.'(/1"X774)(&G"?Pb?c^CN!ECOC1"

!!O1" H$9G$0"LV"A94(5'+5%"UV"M5((5%6"UV"]"@%-&('(/"o"b<22?c"@JLL"JW#"JUMDF^"$"6,6-%'$."-("@"95.."

),%;';$.1"I))4-:"$'/('Q"%6"(774)%:%+G"<!^<?!E<NC1"

!!P1" H$9G$0"L"]"F5,(/"="b<22Nc"345"%-.5"-7"645"@JLLTJUMDF")0)65*"-("3"95.."7,(96'-(1"F'7()-$2"()"

(774)%:%+G"!PbKc^<PCE<PQ1"

!!Q1" R4,"Z3V"S(/4$%+"UV"M'5*5G$)65(">V"]"@5%5G"R"b<22Oc" D(";'6%-"$(+"'(";';-"$96';$6'-("'(+,95)"

@JLL"$(+"JUMDF"58:%5))'-("'("@"95..)1"S%4$)-:"%6"(774)%:%+G"!OQbQc^KQCOEKQKO1"

!<21" A9$:'('"UV"@$II-('" LV"]"R$))$65..$"HJ" b<22Pc"M5/,.$6'-("-7"@E95..E$96';$6'(/" 7$96-%" b@JLLcT@"

.0*:4-9065")6'*,.$6-%"b@F0Ac"58:%5))'-("'("4,*$("(5,6%-:4'.)1"X774)%:%+G":'&&'$2"!!Nb!c^!E

N1"

!<!1" @-,.5" HgE" '&" -:;" b<22Cc" 3-..E.'G5" %595:6-%" QE+5:5(+5(6" $(+" E'(+5:5(+5(6" +5(+%'6'9" 95.."

$96';$6'-("B0"94%-*$6'(E'**,(-/.-B,.'(">"9-*:.585)1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"

!QQb!<c^!N?!E!NC21"

!<<1" H$9G$0" L" ]" A94(5'+5%" U" b<22Pc" 3JRDV" $(" 5('/*$6'9" @JLLTJUMDF" %595:6-%V" &'64" (5&"

,($::%59'$65+"B'-945*'9$."$(+"B'-.-/'9$.":%-:5%6'5)1"!G&%1()'"f"+$%Q&B"6-.&%$"$'/('Q2"!Qb?E

Cc^<N?E<ON1"

!<?1" g--+.$(+" M3E" '&" -:;" b<22Pc"H,.6':.5" )'/($.'(/" :$64&$0)" :%-*-65" @" .0*:4-9065" )6'*,.$6-%"

+5:5(+5(6"@E95.."/%-&64"$(+"),%;';$.1"?:%%0"!!!b<c^OK2EON21"

!<C1" U$6G5"JV"H59G.5(B%$,G5%" DV"S%+e,*5(6E@%-*$/5"=V"35*:)6"UV"]"3$%$G4-;)G0"J"b<22Nc"@JLL"

9-(6%-.)" @" 95.."*56$B-.'9" 7'6(5))" 64%-,/4" $" U_R" B56$E" $(+" JG6E+5:5(+5(6"*594$(')*1" AB'"

S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"<2?b!!c^<KK!E<KN<1"

!<K1" @5()-("HoE"'&"-:;"b<22Pc"R,66'(/"5+/5^"645"+5:5(+5(95"-7":.$)*$"95..)"$(+"'(+5:5(+5(95"-7"

*5*-%0"@"95..)"-("@JLL"$(+"JUMDF1"S%4$)-:"%6"(774)%:%+G"!P2bNc^?NKKE?NKQ1"

!<N1" R5%,66'"JV"U,/$"DV"]"R-.)"H"b<2!!c"D(($65"9-(6%-."-7"@"95.."%5):-()5)1"A$')02"()" (774)%:%+G"

?<bKc^<2<E<!!1"

!<O1" H$9G$0"L"]"3$(/05"A>"b<22Cc"345"%-.5"-7"645"@JLLTJUMDF")0)65*"'("@"95.."4-*5-)6$)')"$(+"

.0*:4-'+"9$(95%)1"!4$$')&"%#()(%)"()"#B-$7-.%:%+G"CbCc^?COE?KC1"

!<P1" >$%)'+5"UE"'&"-:;"b!QQPc"Z'),$.'I$6'-("-7"):59'7'9"@"$(+"3".0*:4-9065"'(65%$96'-()"'("645".0*:4"

(-+51"F.(').'"<P!bK?O?c^QNEQQ1"

!<Q1" _$&$B5"3V"H$6),)4'*$"HV"=$)4'*-6-"WV"D*$'I,*'"_V"]"=$)5/$&$"t"b<2!!c"R#C2TR#C2".'/$(+"

'(65%$96'-()" '(" '**,(5" %5):-()5)" $(+" :,.*-($%0" '**,('601" P-+%G-" C%4$)-:" %6" 7'0(.-:"

2.(').'"O?b?ECc^NQEOP1"

!?21" R$)6'/.'" SE" '&"-:;" b!QQCc"R#C2E+57'9'5(6"*'95"/5(5%$65+"B0" %59-*B'($6'-(E$96';$6'(/"/5(5E<E

+57'9'5(6" B.$)6-90)6" 9-*:.5*5(6$6'-(1"D$%.''0()+2" %6" &B'"P-&(%)-:"I.-0'7G"%6" F.(').'2" %6"

&B'"`)(&'0"F&-&'2"%6"I7'$(.-"Q!b<Kc^!<!?KE!<!?Q1"

!?!1" o$B$%$"==V"g5(/"tV"A$(('G-;$"3V"]">54$"MA"b<22Qc"3MJL<"$(+"3MJL?"'(+5:5(+5(6.0"*5+'$65"

D/"9.$))")&'694'(/"+%';5("B0"R#C21"X)&'$)-&(%)-:"(774)%:%+G"<!bCc^COOECPP1"

Page 147: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2N""

"

!?<1" XI9$(" SV" M$,65%" DV" >$%'B0$(" FV" #'..-(" AMV" ]" >54$" MA" b<2!!c" 3-..E.'G5" %595:6-%" QV"

6%$()*5*B%$(5" $96';$6-%" $(+" 9$.9',*E*-+,.$6'(/" 909.-:4'.'(" .'/$(+" '(65%$96-%V" $(+" R#C2"

)0(5%/'I5" '(" 9$,)'(/" @E95.." $96';$6'-(1" AB'" S%4$)-:" %6" -::'$+G" -)0" .:()(.-:" (774)%:%+G"

!<Pb?c^N2!EN2Q"5N2!EN2C1"

!??1" >5::5%6" 3#" ]" F':)G0" US" b!QPKc" J(6'/5(" :%5)5(6$6'-(" B0" '(65%75%-(E/$**$E6%5$65+"

5(+-645.'$." 95..)" $(+" 7'B%-B.$)6)^" +'775%5(6'$." $B'.'60" 6-" 7,(96'-(" $)" $(6'/5(E:%5)5(6'(/" 95..)"

+5):'65"9-*:$%$B.5"D$"58:%5))'-(1"S%4$)-:"%6"(774)%:%+G"!?KbNc^?OK2E?ON<1"

!?C1" H,.+5%" #oE" '&" -:;" b<2!!c" J(6'/5(" :%5)5(6$6'-(" $(+" H=R" 9.$))" DD" 58:%5))'-(" B0" 4,*$("

5)-:4$/5$." 5:'645.'$." 95..)^" %-.5" '(" 5-)'(-:4'.'9" 5)-:4$/'6')1" AB'" I7'$(.-)" C%4$)-:" %6"

#-&B%:%+G"!OPb<c^OCCEOK?1"

!?K1" A94-(57,))" JE" '&" -:;" b<2!2c" Y:%5/,.$6'-(" -7" 9$645:)'(" A" '(" :)-%'$6'9" G5%$6'(-9065)1"

U]#'$(7')&-:"0'$7-&%:%+G"!QbPc^5P2EPP1"

!?N1" M5'64"gV"F5'B,(+>,6EF$(+*$(("AV"]"g$.+B,%/5%"oH"b<22Kc"M5/,.$6'-("-7"H=R"9.$))"DD"/5(5"

58:%5))'-("B0"645"9.$))"DD"6%$()$96';$6-%1"P-&4$'"$'/('Q2;"X774)%:%+G"Kb!2c^OQ?EP2N1"

!?O1" U$,." UE" '&" -:;" b<2!!c" J" >5(-*5E&'+5" *,.6'+'*5()'-($." MWJ'" )9%55(" %5;5$.)" :$64&$0)"

9-(6%-..'(/"H=R"9.$))"DD"$(6'/5(":%5)5(6$6'-(1"!'::"!CKb<c^<NPE<P?1"

!?P1" R45*$.'"HV"M$+6G5"_V"#5)e$%+'()"HV"]"S(/.')4"F"b<2!!c"J.65%($6';5":$64&$0)"7-%"H=R"9.$))"D"

:%5)5(6$6'-(^" $" (5&" 7,(96'-(" 7-%" $,6-:4$/01" !'::4:-$" -)0" 7%:'.4:-$" :(6'" 2.(').'2" a" !*8F"

NPbQc^!K??E!KC!1"

!?Q1" @05%)+-%75%"RJV"#':$-.-"MoV"U56I-.+"AoV"]"Y($(,5"SM"b<22Cc"L-..-&'(/"'**,('I$6'-("$(6'/5("

B59-*5)"9-(95(6%$65+"'("$".'*'65+"(,*B5%"-7"JUR)"'(9.,+'(/"@"95..)1"S%4$)-:"%6"(774)%:%+G"

!O?b!!c^NN<OENN?C1"

!C21" R$6%-("#HV"D6$(-"JJV"U$:5"_JV"H,5..5%"#FV"]"o5(G'()"H_"b<22Cc"Z'),$.'I'(/"645"7'%)6"K2"4%"-7"

645":%'*$%0"'**,(5"%5):-()5"6-"$")-.,B.5"$(6'/5(1"X774)(&G"<!b?c^?C!E?CO1"

!C!1" J.,;'4$%5"ZMV"_4$*.'94'"JJV"g'..'$*)">3V"J+-%'('"FV"]"W5,B5%/5%"HA"b!QQOc"J995.5%$6'-("-7"

'(6%$95..,.$%"6$%/56'(/"-7"$(6'/5("B0"645"@E95.."$(6'/5("%595:6-%^"'*:-%6$(95"+5:5(+)"-("645"

($6,%5"-7"645"$(6'/5(E$(6'B-+0"'(65%$96'-(1"AB'"U*?_"C%4$)-:"!Nb!<c^?KK?E?KN<1"

!C<1" R45(/"URV"A655.5"RMV">,"FV"A-(/"gV"]"U'5%95"A_"b!QQQc"H=R"9.$))"DD"$(6'/5(":%-95))'(/"'("@"

95..)^" $995.5%$65+" '(6%$95..,.$%" 6$%/56'(/" -7" $(6'/5()1" S%4$)-:" %6" (774)%:%+G" !N<b!<c^O!O!E

O!P21"

!C?1" g-.7"UM"]"U.-5/4"=F"b!QQKc"=-&"H=R"9.$))"DD"*-.59,.5)"$9[,'%5":5:6'+5"9$%/-^"B'-)0(645)')"

$(+" 6%$77'9G'(/" 64%-,/4" 645" 5(+-906'9" :$64&$01" I))4-:" $'/('Q" %6" .'::" -)0" 0'/':%#7')&-:"

9(%:%+G"!!^<NOE?2N1"

!CC1" W$G$/$&$" 3t" ]" M,+5()G0" Jt" b!QQQc" 345" %-.5" -7" .0)-)-*$." :%-65'($)5)" '(" H=R" 9.$))" DDE

*5+'$65+"$(6'/5(":%-95))'(/"$(+":%5)5(6$6'-(1"X774)%:%+(.-:"$'/('Q2"!O<^!<!E!<Q1"

!CK1" Z'..$+$(/-)" oJE" '&" -:;" b!QQQc" U%-65$)5)" '(;-.;5+" '(" H=R" 9.$))" DD" $(6'/5(" :%5)5(6$6'-(1"

X774)%:%+(.-:"$'/('Q2"!O<^!2QE!<21"

!CN1" g$66)" R" b<22!c" J(6'/5(" :%-95))'(/" '(" 645" 5(+-906'9" 9-*:$%6*5(61" !4$$')&" %#()(%)" ()"

(774)%:%+G"!?b!c^<NE?!1"

!CO1" #%$G5"FV"H9>-;5%(E@%'(+')'"SHV"]"#%$G5"oM"b<22Nc"@RM",B'[,'6'($6'-("9-(6%-.)"@RME*5+'$65+"

$(6'/5(":%-95))'(/"$(+":%5)5(6$6'-(1"?:%%0"!2Pb!?c^C2PNEC2Q?1"

!CP1" _$6G5%5" @V" M-)$" AV" ]" #%$G5" oM" b<2!<c" 345" A0GEB'(+'(/" ,B'[,'6'(" .'/$)5" 9ERB." *5+'$65)"

)'/($.'(/E+5:5(+5(6" @" 95.." %595:6-%" ,B'[,'6'($6'-(" $(+" @" 95.." %595:6-%E*5+'$65+" $(6'/5("

:%-95))'(/"$(+":%5)5(6$6'-(1"AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<POb<2c^!NN?NE!NNCC1"

!CQ1" Z$)9-66-" LE" '&" -:;" b<22Oc" 345" $96'(EB$)5+" *-6-%" :%-65'(" *0-)'(" DD" %5/,.$65)" H=R" 9.$))" DD"

6%$77'9G'(/" $(+" @RME+%';5(" $(6'/5(" :%5)5(6$6'-(1" AB'" S%4$)-:" %6" .'::" 9(%:%+G" !ONbOc^!22OE

!2!Q1"

!K21" F$(G$%"#E"'&"-:;" b<22<c"#0($*'9)"-7"*$e-%"4')6-9-*:$6'B'.'60"9-*:.58"9.$))"DD"9-*:$%6*5(6)"

+,%'(/" @" 95.." %595:6-%E*5+'$65+" 95.." $96';$6'-(1" AB'" S%4$)-:" %6" ']#'$(7')&-:" 7'0(.()'"

!QKbCc^CN!ECO<1"

!K!1" W$6G$()G'" SE" '&"-:;" b<2!?c"@"R5..)"Y)5"H594$('9$." S(5%/0" 6-"#')9%'*'($65"J(6'/5("J77'('6'5)1"

F.(').'1"

Page 148: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2O""

"

!K<1" =-.6" XoV" >$..-" LV" ]" >%'77'64)" >H" b<22Nc" M5/,.$6'(/" )59%56-%0" .0)-)-*5)1" S%4$)-:" %6"

9(%.B'7(2&$G"!C2b!c^OE!<1"

!K?1" @.-66" So"]">%'77'64)">H" b<22<c" A59%56-%0" .0)-)-*5)1"P-&4$'" $'/('Q2;"*%:'.4:-$" .'::" 9(%:%+G"

?b<c^!<<E!?!1"

!KC1" L%'5+%'94)"@E"'&"-:;" b<22?c"340%-'+"7,(96'-()"-7"*-,)5"9$645:)'()"@V"_V"$(+"F1"AB'"S%4$)-:"%6"

.:()(.-:"()/'2&(+-&(%)"!!!b!!c^!O??E!OCK1"

!KK1" Z$)'.e5;$"XE"'&"-:;"b<22Oc"S*5%/'(/"%-.5)"-7"90)65'(5"9$645:)'()"'("+')5$)5"$(+"645'%":-65(6'$."

$)"+%,/"6$%/56)1"!4$$')&"#B-$7-.'4&(.-:"0'2(+)"!?bCc^?POEC2?1"

!KN1" =-(50"_"]"M,+5()G0"Jt"b<22?c"F0)-)-*$."90)65'(5":%-65$)5)"%5/,.$65"$(6'/5(":%5)5(6$6'-(1"

P-&4$'"$'/('Q2;"X774)%:%+G"?bNc^CO<ECP<1"

!KO1" 3,%G"#"]">,(9$%">"b<22?c"F0)-)-*$."90)65'(5":%-65$)5)"b9$645:)'()c^":%-*')'(/"+%,/"6$%/56)1"

I.&-".$G2&-::%+$-#B(.-;"F'.&(%)"OE"?(%:%+(.-:".$G2&-::%+$-#BG"KQbU6"<c^<2?E<!?1"

!KP1" =)'(/" FR" ]" M,+5()G0" Jt" b<22Kc" 345" .0)-)-*$." 90)65'(5" :%-65$)5)" '("H=R" 9.$))" DD" $(6'/5("

:%5)5(6$6'-(1"X774)%:%+(.-:"$'/('Q2"<2O^<<QE<C!1"

!KQ1" R45(" oHE" '&" -:;" b!QQOc" R.-('(/V" ')-.$6'-(V" $(+" 94$%$965%'I$6'-(" -7"*$**$.'$(" .5/,*$'(V" $("

$):$%$/'(0."5(+-:5:6'+$)51"AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<O<b!<c^P2Q2EP2QP1"

!N21" R45("oHV"#$(+-"UHV"A65;5()"MJV"L-%6,($6-"HV"]"@$%%566"Jo"b!QQPc"R.-('(/"$(+"58:%5))'-("-7"

*-,)5".5/,*$'(V"$".0)-)-*$."5(+-:5:6'+$)51"AB'"?(%.B'7(.-:"C%4$)-:"??K"b"U6"!c^!!!E!!O1"

!N!1" H$(-,%0"@E"'&"-:;"b<22?c"J):$%$/'(5"5(+-:5:6'+$)5"9$("'('6'$65"645"%5*-;$."-7"645"H=R"9.$))"

DD"'(;$%'$(6"94$'("94$:5%-(51"X774)(&G"!PbCc^CPQECQP1"

!N<1" F'"#WV"H$6645&)"AUV"J(6-('-,"JWV"H$II5-"#V"]"g$66)"R"b<22?c"H,.6')65:"$,6-$96';$6'-("-7"

$):$%$/'(0." 5(+-:5:6'+$)5" '(" ;'6%-" $(+" '(" ;';-1" AB'" S%4$)-:" %6" 9(%:%+(.-:" .B'7(2&$G"

<OPbC2c^?PQP2E?PQQ21"

!N?1" A4'%$4$*$EW-+$" _E" '&" -:;" b<22?c" @'-)0(6456'9" :%-95))'(/" -7" 9$645:)'()" $(+" .0)-)-*$."

+5/%$+$6'-(" $%5" $B-.')45+" '(" $):$%$/'(0." 5(+-:5:6'+$)5E+57'9'5(6" *'951" AB'" S%4$)-:" %6"

9(%:%+(.-:".B'7(2&$G"<OPb?Kc^??!QCE??!QQ1"

!NC1" H$54%" ME" '&" -:;" b<22Kc" J):$%$/'(5" 5(+-:5:6'+$)5" ')" (-6" 5))5(6'$." 7-%" 9.$))" DD"H=R" $(6'/5("

:%5)5(6$6'-(" B,6" ')" %5[,'%5+" 7-%" :%-95))'(/" -7" 9$645:)'(" F" '("*'951" S%4$)-:" %6" (774)%:%+G"

!OCb!!c^O2NNEO2OC1"

!NK1" H$(-,%0" @E" '&" -:;" b!QQPc" J(" $):$%$/'(0." 5(+-:5:6'+$)5" :%-95))5)" $" *'9%-B'$." $(6'/5(" 7-%"

9.$))"DD"H=R":%5)5(6$6'-(1"P-&4$'"?QNbNO!<c^NQKENQQ1"

!NN1" =5%)G-&'6I" o=E"'&"-:;" b<2!<c"J):$%$/'(0."5(+-:5:6'+$)5"9.5$;5)"3#UEC?" '("B%$'(1"D$%&'%7(.2"

!<b!KE!Nc^<CKKE<CN?1"

!NO1" H$(-,%0" @E" '&" -:;" b<22<c" #5)6%,96';5" :%-95))'(/" B0" $):$%$/'(5" 5(+-:5:6'+$)5" .'*'6)"

:%5)5(6$6'-("-7"$"+-*'($(6"3"95.."5:'6-:5"'("H@U1"P-&4$'"(774)%:%+G"?b<c^!NQE!OC1"

!NP1" A6%,B'("HV"F-(/"SXV"]"H$94"@"b!QPNc"3&-"7-%*)"-7"645"D$"$(6'/5(E$))-9'$65+"'(;$%'$(6"94$'("

%5),.6"7%-*"$.65%($6';5"'('6'$6'-()"$6"6&-"'(E:4$)5"JY>)1"!'::"CObCc^N!QEN<K1"

!NQ1" A6%,B'(" HV" @5%65" RV" ]" H$94" @" b!QPNc" J.65%($6';5" ):.'9'(/" $(+" $.65%($6';5" '('6'$6'-(" -7"

6%$().$6'-(" 58:.$'(" 645" 7-,%" 7-%*)" -7" 645" D$" $(6'/5(E$))-9'$65+" '(;$%'$(6" 94$'(1" AB'" U*?_"

C%4$)-:"Kb!?c^?CP?E?CPP1"

!O21" A94,6I5" HUV" U565%)-(" UJV" ]" o$9G)-(" HM" b!QQCc" J(" WE65%*'($." +-,B.5E$%/'('(5" *-6'7"

*$'(6$'()" 60:5" DD" *5*B%$(5" :%-65'()" '(" 645" 5(+-:.$)*'9" %56'9,.,*1" AB'" U*?_" C%4$)-:"

!?bOc^!NQNE!O2K1"

!O!1" M-*$/(-.'" U" ]" >5%*$'(" MW" b!QQKc" D(4'B'6'-(" -7" '(;$%'$(6" 94$'(" bD'cE9$.(58'(" '(65%$96'-("

%5),.6)" '(" 5(4$(95+" +5/%$+$6'-(" -7" D'" B,6" +-5)" (-6" :%5;5(6" 645" $))5*B.0" -7" $.:4$" B56$" D'"

9-*:.585)1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!P<bNc^<2<OE<2?N1"

!O<1" @'e.*$G5%)"HoV"@5($%-94"UV"]"U.-5/4"=F" b!QQCc"H$::'(/" 7,(96'-($." %5/'-()" '(" 645" .,*5($."

+-*$'(" -7" 645" 9.$))" DDE$))-9'$65+" '(;$%'$(6" 94$'(1" AB'" S%4$)-:" %6" ']#'$(7')&-:" 7'0(.()'"

!P2b<c^N<?EN<Q1"

!O?1" X,"goV"R$*5%-("U=V"34-*$)"#tV"]"@5%/5%-("oo"b!QQ?c"J))-9'$6'-("-7"7-.+'(/" '(65%*5+'$65)"

-7"/.09-:%-65'()"&'64"9$.(58'("+,%'(/":%-65'("*$6,%$6'-(1"P-&4$'"?NCbNCC2c^OO!EOON1"

Page 149: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2P""

"

!OC1" A94$'77"g3V"=%,)G$"_JV"o%1V"H9R-,%6"#gV">%55("HV"]"A94&$%6I"@#"b!QQ<c"=FJE#M"$))-9'$65)"

&'64"):59'7'9")6%5))":%-65'()"$(+" ')" %56$'(5+" '("645"5(+-:.$)*'9"%56'9,.,*"'(" '(;$%'$(6"94$'("

(5/$6';5"95..)1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!ONb?c^NKOENNN1"

!OK1" J(+5%)-("_A"]"R%5))&5.."U"b!QQCc"J"%-.5"7-%"9$.(58'("bDUQ2c" '("645"$))5*B.0"-7"9.$))"DD"H=R"

*-.59,.5)1"AB'"U*?_"C%4$)-:"!?b?c^NOKENP<1"

!ON1" @-((5%-6" RE" '&" -:;" b!QQCc" J))-9'$6'-(" &'64" @'U" $(+" $//%5/$6'-(" -7" 9.$))" DD" H=R"*-.59,.5)"

)0(645)'I5+"'("645"$B)5(95"-7"'(;$%'$(6"94$'(1"AB'"U*?_"C%4$)-:"!?bCc^Q?CEQCC1"

!OO1" @'G-77" S_V" >5%*$'(" MWV" ]" M-B5%6)-(" So" b!QQKc" J..5.'9" +'775%5(95)" $77596'(/" '(;$%'$(6" 94$'("

+5:5(+5(90"-7"H=R"9.$))"DD"),B,('6"$))5*B.01"X774)(&G"<b?c^?2!E?!21"

!OP1" M-945"UJV"H$%G)"HAV"]"R%5))&5.."U"b!QQ!c"L-%*$6'-("-7"$"('(5E),B,('6"9-*:.58"B0"=FJ"9.$))"

DD"/.09-:%-65'()"$(+"645"'(;$%'$(6"94$'(1"P-&4$'"?KCbN?K<c^?Q<E?QC1"

!OQ1" A6,*:6(5%ER,;5.5665" U" ]" @5($%-94" U" b<22<c"H,.6':.5" %-.5)" -7" 645" '(;$%'$(6" 94$'(" '("H=R"

9.$))"DD"7,(96'-(1"?(%.B(7(.-"'&"9(%#BG2(.-"-.&-"!KC<b!E?c^!E!?1"

!P21" =-7*$(("HgE" '&"-:;" b!QQQc"345" .5,9'(5EB$)5+")-%6'(/"*-6'7)" '(" 645"906-:.$)*'9"+-*$'("-7"

645" '(;$%'$(6"94$'("$%5"%59-/('I5+"B0"645"9.$64%'("$+$:6-%)"JU!"$(+"JU<"$(+"645'%"*5+',*"

94$'()1"AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<OCbK!c^?N!K?E?N!KP1"

!P!1" H-66$"JE" '&" -:;" b!QQKc" A6%,96,%5E$96';'60" %5.$6'-()4':" -7" 645" .5,9'(5EB$)5+" )-%6'(/"*-6'7)" '("

645" 906-)-.'9" 6$'." -7" 645" *$e-%" 4')6-9-*:$6'B'.'60" 9-*:.58E$))-9'$65+" '(;$%'$(6" 94$'(1" AB'"

S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<O2bCKc^<O!NKE<O!O!1"

!P<1" f4-(/" >V" M-*$/(-.'" UV" ]" >5%*$'(" MW" b!QQOc" M5.$65+" .5,9'(5EB$)5+" 906-:.$)*'9" 6$%/56'(/"

)'/($.)" '(" '(;$%'$(6" 94$'(" $(+" *$e-%" 4')6-9-*:$6'B'.'60" 9-*:.58" 9.$))" DD" *-.59,.5)" 9-(6%-."

5(+-906'9" :%5)5(6$6'-(" -7" +')6'(96" +565%*'($(6)" '(" $" )'(/.5" :%-65'(1" AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"!PKb?c^C<QEC?P1"

!P?1" A'*-()5(" JE" '&" -:;" b!QQQc" U-.$%'I5+" 6%$():-%6" -7" H=R" 9.$))" DD" *-.59,.5)" '(" H$+'(E#$%B0"

9$('(5"G'+(50"95..)" ')"+'%5965+"B0"$" .5,9'(5EB$)5+")'/($." '(" 645"906-:.$)*'9" 6$'."-7" 645"B56$E

94$'(1"S%4$)-:"%6"(774)%:%+G"!N?bKc^<KC2E<KCP1"

!PC1" U'(56"ZV"Z5%/5..'"HV"H$%6'("MV"@$GG5"XV"]"F-(/"SX"b!QQKc"J(6'/5(":%5)5(6$6'-("*5+'$65+"B0"

%5909.'(/"-7"),%7$95"=FJE#M"*-.59,.5)1"P-&4$'"?OKbNK?<c^N2?EN2N1"

!PK1" M-945" UJV" 35.56)G'" RFV" A6$(/" SV" @$GG5" XV" ]" F-(/" SX" b!QQ?c" R5.." ),%7$95" =FJE#ME'(;$%'$(6"

94$'(" 9-*:.585)" $%5" 6$%/565+" 6-" 5(+-)-*5)" B0" %$:'+" '(65%($.'I$6'-(1" D$%.''0()+2" %6" &B'"

P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"Q2b!Pc^PKP!EPKPK1"

!PN1" >,:6$"AWV"_.-)65%"HHV"M-+'-(-;"#>V"]"@$GG5"X"b<22Nc"M5E%-,6'(/"-7"645"'(;$%'$(6"94$'("6-"

645"+'%596" )-%6'(/":$64&$0"B0" '(6%-+,96'-("-7"$("JU?EB'(+'(/"*-6'7" 7%-*"FDHU" DD1"U4$%#'-)"

C%4$)-:"%6".'::"9(%:%+G"PKbNc^CKOECNO1"

!PO1" M'5)5"MoE"'&"-:;"b!QQNc"S))5(6'$."%-.5"7-%"9$645:)'("A"'("H=R"9.$))"DDE$))-9'$65+"'(;$%'$(6"94$'("

:%-95))'(/"$(+":5:6'+5".-$+'(/1"X774)(&G"CbCc^?KOE?NN1"

!PP1" W$G$/$&$"3E"'&"-:;"b!QQPc"R$645:)'("F^"9%'6'9$."%-.5"'("D'"+5/%$+$6'-("$(+"R#C"3"95..")5.596'-("'("

645"640*,)1"F.(').'"<P2bK?N<c^CK2ECK?1"

!PQ1" 3-.-)$"SE"'&"-:;"b<22?c"R$645:)'("Z"')"'(;-.;5+"'("645"+5/%$+$6'-("-7"'(;$%'$(6"94$'("'("4,*$("

640*,)" $(+" ')" -;5%58:%5))5+" '(" *0$)645('$" /%$;')1" AB'" S%4$)-:" %6" .:()(.-:" ()/'2&(+-&(%)"

!!<bCc^K!OEK<N1"

!Q21" @$('$"oE"'&"-:;"b<22?c"=,*$("9$645:)'("AV"B,6"(-6"9$645:)'("FV"+5/%$+5)"577'9'5(6.0"H=R"9.$))"

DDE$))-9'$65+" '(;$%'$(6"94$'(" '("(-(:%-75))'-($."JUR)1"D$%.''0()+2"%6" &B'"P-&(%)-:"I.-0'7G"

%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!22b!!c^NNNCENNNQ1"

!Q!1" A4'" >UE" '&" -:;" b<222c" M-.5" 7-%" 9$645:)'(" L" '(" '(;$%'$(6" 94$'(" :%-95))'(/" $(+" *$e-%"

4')6-9-*:$6'B'.'60" 9-*:.58" 9.$))" DD" :5:6'+5" .-$+'(/" B0" *$9%-:4$/5)1" AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"!Q!bOc^!!OOE!!PN1"

!Q<1" J;;$" MM" ]" R%5))&5.." U" b!QQCc" D(" ;';-" $(+" '(" ;'6%-" 7-%*$6'-(" $(+" +'))-9'$6'-(" -7" =FJE#M"

9-*:.585)"&'64"'(;$%'$(6"94$'(E+5%';5+":5:6'+5)1"X774)(&G"!bQc^ON?EOOC1"

!Q?1" #5(I'(" F_"]"R%5))&5.." U" b!QQKc"=FJE#H" '(+,95)" RFDU" +'))-9'$6'-(" 7%-*"H=R" 9.$))" DD" $.:4$"

B56$"+'*5%)"$(+"7$9'.'6$65)":5:6'+5".-$+'(/1"!'::"P<b!c^!KKE!NK1"

Page 150: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!2Q""

"

!QC1" A.-$("ZAE"'&"-:;"b!QQKc"H5+'$6'-("B0"=FJE#H"-7"+'))-9'$6'-("-7":5:6'+5)"7%-*"=FJE#M1"P-&4$'"

?OKbNK?Cc^P2<EP2N1"

!QK1" A$(+5%)-("LV" 34-*$)"RV"W557e5)" oV"]"3%-&)+$.5" o" b!QQNc"J))-9'$6'-("B56&55("=FJE#H"$(+"

=FJE#M"'(";';-1"X774)(&G"Cb!c^POEQN1"

!QN1" _%-:)4-75%"=E"'&"-:;"b!QQNc"S+'6'(/"-7"645"=FJE#ME:5:6'+5"%5:5%6-'%5"B0"=FJE#H1"AB'"U*?_"

C%4$)-:"!Kb<<c^N!CCEN!KC1"

!QO1" g5B5%"#JV"S;$;-.+"@#V"]"o5()5("US"b!QQNc"S(4$(95+"+'))-9'$6'-("-7"=FJE#MEB-,(+":5:6'+5)"

'("645":%5)5(95"-7"=FJE#H1"F.(').'"<OCbK<POc^N!PEN<21"

!QP1" _%-:)4-75%"=V"J%(+6"AXV"H-.+5(4$,5%">V"=$**5%.'(/">oV"]"Z-/6"J@"b!QQOc"=FJE#H"$96)"$)"$"

*-.59,.$%" 94$:5%-(5" $(+" %5)9,5)" 5*:60" =FJE#M" *-.59,.5)" $6" .0)-)-*$." :=1" X774)(&G"

Nb?c^<Q?E?2<1"

!QQ1" A4$94$%" D" ]" L.$;5.." MJ" b!QQNc" M5[,'%5*5(6" 7-%" '(;$%'$(6" 94$'(" '(" @" 95.." *$6,%$6'-(" $(+"

7,(96'-(1"F.(').'"<OCbK<PCc^!2NE!2P1"

<221" _5(60">V"H$%6'("g#V"Z$("_$5%"FV"]"@'G-77"S_"b!QQPc"H=R"9.$))"DD"58:%5))'-("'("+-,B.5"*,6$(6"

*'95".$9G'(/"'(;$%'$(6"94$'("$(+"#H"7,(96'-()1"S%4$)-:"%6"(774)%:%+G"!N2b<c^N2NEN!C1"

<2!1" _5(60" >"]" @'G-77" S_" b!QQQc" @JF@T9" '(;$%'$(6" 94$'("*,6$(6"*'95" +'):.$0" %5.$6';5.0" 577'9'5(6"

*$6,%$6'-(" -7" R#Cp" 3" 95..)" '(" 645" :5%':45%0" $(+" )59-(+$%0" :%-.'75%$6';5" %5):-()5)" 5.'9'65+"

,:-(":5:6'+5"94$..5(/51"S%4$)-:"%6"(774)%:%+G"!N?b!c^<?<E<C!1"

<2<1" M$e$/-:$.$(">V"A*$%6"H_V"_%9-"RoV"]"#$;'+"RA"b<22<c"S8:%5))'-("$(+"7,(96'-("-7"6%$()/5('9"

=FJE#z"*-.59,.5)"$(+" .0*:4-9065"+5;5.-:*5(6" '("*'95" .$9G'(/" '(;$%'$(6"94$'(1" S%4$)-:"%6"

(774)%:%+G"!NQbCc^!OOCE!OP?1"

<2?1" H$6I$" #E" '&" -:;" b<22<c" D(;$%'$(6" 94$'(" '(+,95)" @" 95.." *$6,%$6'-(" '(" $" :%-95))" 64$6" ')"

'(+5:5(+5(6"-7" '6)" 94$:5%-('9"$96';'601"D$%.''0()+2"%6" &B'"P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"

&B'"`)(&'0"F&-&'2"%6"I7'$(.-"QQbKc^?2!PE?2<?1"

<2C1" H$6I$"#V"g-.)65'("XV"#'G)65'("MV"]"A4$94$%"D"b<22!c"D(;$%'$(6"94$'("'(+,95)"@"95.."*$6,%$6'-("

B0" $96';$6'(/" $" 3JLbDDc!2KEWLEG$::$@E+5:5(+5(6" 6%$()9%':6'-(" :%-/%$*1" AB'" S%4$)-:" %6"

9(%:%+(.-:".B'7(2&$G"<ONb<Qc^<O<2?E<O<2N1"

<2K1" #'G)65'(" MV" f4-," AV" ]" 3e'$(" M" b!QQNc" =,*$(" 3JLDD" !2K" ')" $" 95.." 60:5E):59'7'9" 3LDD#" ),B,('6"

%5.$65+"6-"43JLDD!?21"!'::"POb!c^!?OE!CN1"

<2N1" f'**5%*$(("ZAE"'&"-:;" b!QQQc"S(/$/5*5(6"-7"@"95.." %595:6-%" %5/,.$65)" 645" '(;$%'$(6"94$'(E

+5:5(+5(6"H=R"9.$))"DD":%5)5(6$6'-(":$64&$01"S%4$)-:"%6"(774)%:%+G"!N<bKc^<CQKE<K2<1"

<2O1" @5')(5%"#ME" '&"-:;" b<2!?c"345" '(6%$*5*B%$(5":%-65$)5"A::.<$" ')" %5[,'%5+" 7-%"@"95.." $(+"#R"

+5;5.-:*5(6" $(+" ),%;';$." ;'$" 9.5$;$/5" -7" 645" '(;$%'$(6" 94$'(1"AB'" S%4$)-:" %6" ']#'$(7')&-:"

7'0(.()'"<!2b!c^<?E?21"

<2P1" A94(5::5(45'*" oE" '&" -:;" b<2!?c" 345" '(6%$*5*B%$(5" :%-65$)5" AUUF<$" :%-*-65)" @" 95.."

+5;5.-:*5(6"$(+"9-(6%-.)"5(+-)-*$."6%$77'9"B0"9.5$;$/5"-7"645"'(;$%'$(6"94$'(1"AB'"S%4$)-:"

%6"']#'$(7')&-:"7'0(.()'"<!2b!c^C!EKP1"

<2Q1" @54(G5" oE" '&" -:;" b<2!!c" A'/($.E:5:6'+5E:5:6'+$)5E.'G5" <$" bAUUF<$c" ')" 6$%/565+" 6-"

.0)-)-*5)T.$65" 5(+-)-*5)" B0" $" 60%-)'(5" *-6'7" '(" '6)" RE65%*'($." 6$'.1" 3U?F" :'&&'$2"

KPKb!Qc^<QK!E<QKO1"

<!21" H$%6'("FE"'&"-:;"b<22Pc"M5/,.$65+"'(6%$*5*B%$(5":%-65-.0)')"-7"@%'<"bD6*<Bc"B0"J#JH!2"$(+"

AUUF<$TAUUF<B1"AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<P?b?c^!NCCE!NK<1"

<!!1" _'%G'("ZE"'&"-:;"b<22Oc"345"L$)".'/$(+"'(6%$95..,.$%"+-*$'("')"%5.5$)5+"B0"J#JH!2"$(+"AUUF<$"

9.5$;$/5"'("3E95..)1"!'::"0'-&B"-)0"0(66'$')&(-&(%)"!CbQc^!NOPE!NPO1"

<!<1" L%'5+*$((" SE" '&" -:;" b<22Nc" AUUF<$" $(+" AUUF<B" :%-*-65" '(6%$*5*B%$(5" :%-65-.0)')" -7"

3WL$.:4$"'("$96';$65+"+5(+%'6'9"95..)"6-"6%'//5%"DFE!<":%-+,96'-(1"P-&4$'".'::"9(%:%+G"PbPc^PC?E

PCP1"

<!?1" @5%/*$((" =E" '&" -:;" b<2!?c" @" 95.." ),%;';$.V" ),%7$95" @RM" $(+" @JLLM" 58:%5))'-(V" R#OC"

*56$B-.')*V"$(+"R#PE"+5(+%'6'9"95..)"%5[,'%5"645"'(6%$*5*B%$(5"5(+-:5:6'+$)5"AUUF<J1"AB'"

S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"<!2b!c^?!EC21"

<!C1" F5(/" FE" '&" -:;" b<22?c" HDL" )'/($." 6%$()+,96'-(" '('6'$65+" B0" B'(+'(/" 6-" R#OC1" AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"!QOb!!c^!CNOE!CON1"

Page 151: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!2""

"

<!K1" R$.$(+%$"3"]"M-/5%"3" b<22?c"H$9%-:4$/5"*'/%$6'-(" '(4'B'6-%0" 7$96-%^"$" %5/,.$6-%"-7" '(($65"

'**,('601"P-&4$'"$'/('Q2;"X774)%:%+G"?b!2c^OQ!EP221"

<!N1" W$,e-G$)"HLV"H-%'("HV"J(+5%)-("HAV"U565%)-("HV"]"H'..5%"o"b!QQ?c"345"94-(+%-'6'("),.7$65"

7-%*"-7"'(;$%'$(6"94$'("9$("5(4$(95")6'*,.$6'-("-7"3"95.."%5):-()5)"64%-,/4"'(65%$96'-("&'64"

R#CC1"!'::"OCb<c^<KOE<NP1"

<!O1" R%')6'($" R5%[,566'" HV" =-;)5:'$(" SV" A$%($9G'" A=V" ]" >-%5(" W@" b<22Pc" A$.*-(5..$" 5(65%'9$"

)5%-;$%"S(65%'6'+')"+$*"*,6$(6"'(+,95)".-&"WXAE<"$(+"RXaE<"58:%5))'-("'("*$9%-:4$/5)";'$"

$665(,$6'-(" -7" HJU_" $(+" WLEG$::$@" :$64&$0)1"*(.$%9'2" -)0" ()6'.&(%)" V" X)2&(&4&" D-2&'4$"

!2b!CE!Kc^!C?!E!C?Q1"

<!P1" g5B5%" RE" '&" -:;" b<22Pc" A6%,96,%$." +565%*'($(6)" -7" HDL" 7,(96'-()" '(" RaRM<E*5+'$65+"

'(7.$**$6-%0"$(+"$645%-/5('9" .5,G-9065"%59%,'6*5(61"D$%.''0()+2"%6"&B'"P-&(%)-:"I.-0'7G"

%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2KbC<c^!N<OPE!N<P?1"

<!Q1" @5%(4$/5(" oE" '&" -:;" b<22Oc" HDL" ')" $" (-(9-/($65" .'/$(+" -7" RaR" 945*-G'(5" %595:6-%)" '("

'(7.$**$6-%0"$(+"$645%-/5('9"95.."%59%,'6*5(61"P-&4$'"7'0(.()'"!?bKc^KPOEKQN1"

<<21" g-(/" U" ]" M,+5()G0" Jt" b!QQNc" U45(-60:5" $(+" 7,(96'-(" -7" R#Cp" 3" 95..)" '(" *'95" .$9G'(/"

'(;$%'$(6"94$'(1"S%4$)-:"%6"(774)%:%+G"!KNbNc^<!??E<!C<1"

<<!1" L$,%5EJ(+%5">E"'&"-:;"b<22Pc"M5/,.$6'-("-7"+5(+%'6'9"95.."*'/%$6'-("B0"R#OCV"645"H=R"9.$))"DDE

$))-9'$65+"'(;$%'$(6"94$'(1"F.(').'"?<<bKQ2Pc^!O2KE!O!21"

<<<1" X.';5%" oE" '&" -:;" b<22Oc" J))-9'$6'-(" -7" 645" *$9%-:4$/5" *'/%$6'-(" '(4'B'6-%0" 7$96-%" /5(5"

:-.0*-%:4')*)"&'64"'(7.$**$6-%0"B-&5."+')5$)51"W4&"KNb!c^!K2E!K!1"

<<?1" F54*$(("FSE"'&"-:;" b<22Qc"J"HDL"4$:.-60:5" ')"$))-9'$65+"&'64"645"-,69-*5"-7":$6'5(6)"&'64"

)5;5%5")5:)')^"$"9$)5"9-(6%-.")6,+01"S%4$)-:"%6"&$-)2:-&(%)-:"7'0(.()'"O^!221"

<<C1" W,(5I"RE"'&"-:;"b<22Oc"D(;-.;5*5(6"-7"*$9%-:4$/5"*'/%$6'-("'(4'B'6-%0"7$96-%"/5(5"'("95.'$9"

+')5$)5"),)95:6'B'.'601"W')'2"-)0"(774)(&G"Pb<c^!NPE!O21"

<<K1" =-.-)4'6I" o" b<2!2c" 345" %45,*$6-'+" $%64%'6')" =FJE#M@!" )4$%5+" 5:'6-:51" !4$$')&" %#()(%)" ()"

$B'47-&%:%+G"<<b?c^<Q?E<QP1"

<<N1" H$%6'(EZ5(6,%$"oFE"'&"-:;"b<22Qc"D(9%5$)5+"R#OC"58:%5))'-("'("4,*$("$645%-)9.5%-6'9":.$[,5)^"

9-(6%'B,6'-("6-"'(7.$**$6-%0"%5):-()5)"'(";$)9,.$%"95..)1"!-$0(%/-2.4:-$"$'2'-$.B"P?b?c^KPNE

KQC1"

<<O1" F$:65%" AE" '&" -:;" b<2!!c" J" %-.5" 7-%" 645" @E95.." R#OCT*$9%-:4$/5" *'/%$6'-(" '(4'B'6-%0" 7$96-%"

:$64&$0" '(" 645" '**,(-*-+,.$6'-(" -7" )0)65*'9" .,:,)" 5%0645*$6-),)" B0" $" 645%$:5,6'9"

6-.5%-/5('9":5:6'+51"X774)%:%+G"!?<b!c^POEQK1"

<<P1" t-)4'0$*$"tV"J%$'"_V"XG'"3V"]"=$66-%'"3"b<222c"S8:%5))'-("-7"'(;$%'$(6"94$'("$(+":%-E9$645:)'("

F"'("J.I45'*5%�)"B%$'(1"P'4$%2.(').'":'&&'$2"<Q2b<c^!<KE!<P1"

<<Q1" @%0$("_oE"'&"-:;"b<22Pc"S8:%5))'-("-7"R#OC"')"'(9%5$)5+"'("(5,%-7'B%'..$%0"6$(/.5)"'("J.I45'*5%�)"

+')5$)51"*%:'.4:-$")'4$%0'+')'$-&(%)"?^!?1"

<?21" @-%/45)5" L"]" R.$(940" LD" b<2!!c" R#OC^" $(" 5*5%/'(/" -::-%6,('60" $)" $" 645%$:5,6'9" 6$%/56" '("

9$(95%"$(+"$,6-'**,(5"+')5$)51"U]#'$&"%#()(%)"%)"&B'$-#'4&(."&-$+'&2"!Kb?c^<?OE<K!1"

<?!1" g$(/"WV"g5B5%"SV"]"@.,*"oA"b<22Qc"#'*'(')45+"'(6%$95..,.$%"'(;$%'$(6"94$'("58:%5))'-("$765%"

;$99'('$";'%,)"'(7596'-(1"S%4$)-:"%6"(774)%:%+G"!P?b?c^!KC<E!KK21"

<?<1" JB5.5" M" ]" 3$*:5" M" b<22Cc" 345" J@R)" -7" '**,(-.-/0^" )6%,96,%5" $(+" 7,(96'-(" -7" 3JUV" 645"

6%$():-%65%"$))-9'$65+"&'64"$(6'/5(":%-95))'(/1"DBG2(%:%+G"!Q^<!NE<<C1"

<??1" J+$*)"So"]"F,-*$"JH"b<2!?c"345"$+$:6$B.5"*$e-%"4')6-9-*:$6'B'.'60"9-*:.58"bH=Rc"7-.+^"

)6%,96,%5" $(+" 7,(96'-(" -7" (-(9.$))'9$." $(+" H=R" 9.$))" DE.'G5" *-.59,.5)1" I))4-:" $'/('Q" %6"

(774)%:%+G"?!^K<QEKN!1"

<?C1" @e-%G*$("UoE"'&"-:;"b!QPOc"A6%,96,%5"-7"645"4,*$("9.$))"D"4')6-9-*:$6'B'.'60"$(6'/5(V"=FJEJ<1"

P-&4$'"?<QbN!?Qc^K2NEK!<1"

<?K1" =$))$(" D" ]" J4*$+" L" b<2!!c" A6%,96,%$." +';5%)'60" -7" 9.$))" D" H=RE.'G5" *-.59,.5)" $(+" '6)"

'*:.'9$6'-()" '(" B'(+'(/" ):59'7'9'6'5)1" I0/-).'2" ()" #$%&'()" .B'7(2&$G" -)0" 2&$4.&4$-:" 9(%:%+G"

P?^<<?E<O21"

Page 152: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!!""

"

<?N1" R$%$*5.-" ooV" R$)6%-" XJV" +5" U%$6E>$0" >V" ]" U$%-+'" Jo" b<22Cc" 345" 5(+-:.$)*'9" %56'9,.,*"

/.,9-)0.6%$()75%$)5"%59-/('I5)"(5$%.0"($6';5"/.09-:%-65'("7-.+'(/" '(65%*5+'$65)1"AB'"S%4$)-:"

%6"9(%:%+(.-:".B'7(2&$G"<OQbCCc^CN<P2ECN<PK1"

<?O1" M'665%" RV" z,'%'(" _V" _-&$%'G" HV" ]" =5.5(',)" J" b<22Kc" H'(-%" 7-.+'(/" +57596)" 6%'//5%" .-9$."

*-+'7'9$6'-(" -7" /.09-:%-65'()" B0" 645" SM" 7-.+'(/" )5()-%" >31" AB'" U*?_" C%4$)-:" <CbQc^!O?2E

!O?P1"

<?P1" A-.+$"3V">$..'"RV"_$,7*$("MoV"]"H-.'($%'"H"b<22Oc"A,B)6%$65E):59'7'9"%5[,'%5*5(6)"7-%"Y>3!E

+5:5(+5(6"%5.5$)5"7%-*"9$.(58'(1"*%:'.4:-$".'::"<Ob<c^<?PE<CQ1"

<?Q1" M-9G" _FE" '&" -:;" b!QQCc" D(4'B'6-%)" -7" 645" :%-65$)-*5" B.-9G" 645" +5/%$+$6'-(" -7" *-)6" 95.."

:%-65'()"$(+"645"/5(5%$6'-("-7":5:6'+5)":%5)5(65+"-("H=R"9.$))"D"*-.59,.5)1"!'::"OPbKc^ON!E

OO!1"

<C21" >-.+B5%/" JFV" R$)9'-" UV" A$%'9" 3V" ]" M-9G" _F" b<22<c" 345" '*:-%6$(95" -7" 645" :%-65$)-*5" $(+"

),B)5[,5(6":%-65-.06'9")65:)"'("645"/5(5%$6'-("-7"$(6'/5('9":5:6'+5)1"*%:'.4:-$"(774)%:%+G"

?Qb?ECc^!COE!NC1"

<C!1" t5&+5.." ogV"J(6-(" FRV"]"@5(('(G" oM" b!QQNc"#57596';5" %'B-)-*$." :%-+,96)" b#M'U)c^" $"*$e-%"

)-,%95"-7"$(6'/5('9":5:6'+5)"7-%"H=R"9.$))"D"*-.59,.5)�"S%4$)-:"%6"(774)%:%+G"!KObKc^!P<?E

!P<N1"

<C<1" t5&+5.." og" ]" W'994'66$" RZ" b<22Nc" 345" #M'U" 40:-645)')" +595(('$.^" ),::-%6V" 9-(6%-;5%)0V"

%57'(5*5(6"$(+"5865()'-(1"A$')02"()"(774)%:%+G"<ObPc^?NPE?O?1"

<C?1" F5;" JE" '&" -:;" b<2!2c" R-*:$%6*5(6$.'I5+" H=R" 9.$))" D" $(6'/5(" :%-95))'(/" 5(4$(95)"

'**,(-),%;5'..$(95" B0" 9'%9,*;5(6'(/" 645" .$&" -7"*$))" $96'-(1"D$%.''0()+2" %6" &B'"P-&(%)-:"

I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2Ob!Kc^NQNCENQNQ1"

<CC1" J:945%" AE" '&" -:;" b<2!!c"H$e-%" )-,%95" -7" $(6'/5('9" :5:6'+5)" 7-%" 645"H=R" 9.$))" D" :$64&$0" ')"

:%-+,95+" +,%'(/" 645" :'-(55%" %-,(+" -7" *MWJ" 6%$().$6'-(1" D$%.''0()+2" %6" &B'" P-&(%)-:"

I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2Pb<Pc^!!KO<E!!KOO1"

<CK1" ;$("S(+5%6"U"b<2!!c"U%-;'+'(/" .'/$(+)"7-%"H=R"9.$))" D"*-.59,.5)1"!'::4:-$"-)0"7%:'.4:-$" :(6'"

2.(').'2"a"!*8F"NPbQc^!CNOE!CNQ1"

<CN1" _$&$4$%$"HV"t-%G"DJV"=5$%("JV"L$%7$("#V"]"M-9G"_F"b<22Qc"J($.0)')"-7"645"%-.5"-7"6%':5:6'+0."

:5:6'+$)5"DD"'("H=R"9.$))"D"$(6'/5(":%5)5(6$6'-("'(";';-1"S%4$)-:"%6"(774)%:%+G"!P?b!2c^N2NQE

N2OO1"

<CO1" t-%G"DJV"@4,6$('"WV"f5(+I'$("AV">-.+B5%/"JFV"]"M-9G"_F"b<22Nc"3%':5:6'+0.":5:6'+$)5"DD"')"645"

*$e-%":5:6'+$)5"(55+5+"6-"6%'*".-(/"$(6'/5('9":%59,%)-%)V"B,6"')"(-6"%5[,'%5+"7-%"*-)6"H=R"

9.$))"D"$(6'/5(":%5)5(6$6'-(1"S%4$)-:"%6"(774)%:%+G"!OOb?c^!C?CE!CC?1"

<CP1" A5%&-.+"3V">-(I$.5I"LV"_'*"oV"o$9-B"MV"]"A4$)6%'"W"b<22<c"SMJJU"9,)6-*'I5)":5:6'+5)"7-%"H=R"

9.$))"D"*-.59,.5)"'("645"5(+-:.$)*'9"%56'9,.,*1"P-&4$'"C!QbNQ2Nc^CP2ECP?1"

<CQ1" A$%'9" 3E" '&" -:;" b<22<c" J(" DLWE/$**$E'(+,95+" $*'(-:5:6'+$)5" '(" 645" SMV" SMJU!V" 6%'*)"

:%59,%)-%)"6-"H=R"9.$))"DE:%5)5(65+":5:6'+5)1"P-&4$'"(774)%:%+G"?b!<c^!!NQE!!ON1"

<K21" A$;5$(," FE" '&" -:;" b<22Kc" R-(95%65+" :5:6'+5" 6%'**'(/" B0" 4,*$(" SMJU!" $(+" SMJU<"

$*'(-:5:6'+$)5"9-*:.585)"'("645"5(+-:.$)*'9"%56'9,.,*1"P-&4$'"(774)%:%+G"NbOc^NPQENQO1"

<K!1" _--:*$(("oXV"U-)6"HV"W557e5)"ooV"=$**5%.'(/">oV"]"H-*B,%/"L"b!QQNc"3%$().-9$6'-("-7".-(/"

:5:6'+5)" B0" 6%$():-%65%)" $))-9'$65+" &'64" $(6'/5(" :%-95))'(/" b3JUc1" U4$%#'-)" C%4$)-:" %6"

(774)%:%+G"<NbPc^!O<2E!O<P1"

<K<1" Z-.G5%" R" ]" F,:$)" JW" b<22<c" H-.59,.$%" 5;-.,6'-(" -7" :%-65$)-*5)1" !4$$')&" &%#(.2" ()"

7(.$%9(%:%+G"-)0"(774)%:%+G"<NP^!E<<1"

<K?1" H54(5%6"HV"A-**5%"3V"]"o$%-)94"S"b<2!2c"SMJ#",B'[,'6'(" .'/$)5)^"*,.6'7,(96'-($."6--.)" 7-%"

:%-65'(" [,$.'60" 9-(6%-." $(+"&$)65" +'):-)$." '(" 645" 5(+-:.$)*'9" %56'9,.,*1"?(%U22-G2" a" )'Q2"

-)0"$'/('Q2"()"7%:'.4:-$E".'::4:-$"-)0"0'/':%#7')&-:"9(%:%+G"?<b!2c^Q2KEQ!?1"

<KC1" @5(/6)-(" H=" ]" o-$I5'%-" RJ" b<2!2c" M-.5" -7" $" %'B-)-*5E$))-9'$65+" S?" ,B'[,'6'(" .'/$)5" '("

:%-65'("[,$.'60"9-(6%-.1"P-&4$'"CNObO?!Cc^CO2ECO?1"

<KK1" @$%7-%+" #" b<2!!c" A6%,96,%5V" 7,(96'-(" $(+"*594$(')*" -7" 645" $($:4$)5" :%-*-6'(/" 9-*:.58"

bJURTRc1"g4-$&'$:G"$'/('Q2"%6"9(%#BG2(.2"CCb<c^!K?E!Q21"

Page 153: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!<""

"

<KN1" @$+5%"H"]" A65..5%" =" b<22Qc" M5/,.$6'-(" -7" 95.." +5$64" B0" 645" ,B'[,'6'(E:%-65$)-*5" )0)65*1"

!4$$')&"%#()(%)"()".'::"9(%:%+G"<!bNc^POPEPPC1"

<KO1" U'&G-" g" ]" o5(6)94" A" b<22Nc" U%-65$)-*5E*5+'$65+" :%-65'(" :%-95))'(/" B0" B'+'%596'-($."

+5/%$+$6'-("'('6'$65+"7%-*"$("'(65%($.")'651"P-&4$'"2&$4.&4$-:"f"7%:'.4:-$"9(%:%+G"!?bPc^NQ!E

NQO1"

<KP1" _'))5.5;" JLV" JG-:'$(" 3WV"g--" _HV"]" >-.+B5%/" JF" b!QQQc" 345" )'I5)" -7" :5:6'+5)" /5(5%$65+"

7%-*":%-65'(" B0"*$**$.'$(" <N" $(+" <2" A" :%-65$)-*5)1" D*:.'9$6'-()" 7-%" ,(+5%)6$(+'(/" 645"

+5/%$+$6';5" *594$(')*" $(+" $(6'/5(" :%5)5(6$6'-(1" AB'" S%4$)-:" %6" 9(%:%+(.-:" .B'7(2&$G"

<OCbNc^??N?E??O!1"

<KQ1" H$,:'(EL,%.-&"o"b<2!<c"U%-65$)-*5)"$(+":%-65'("9-(e,/$6'-("$9%-))"+-*$'()"-7".'751"P-&4$'"

$'/('Q2;"*(.$%9(%:%+G"!2b<c^!22E!!!1"

<N21" >5(/"L"]"3$()50"gU"b<2!<c"A'*'.$%"65*:-%$."$(+"):$6'$."%59%,'6*5(6"-7"($6';5"!QA"$(+"<2A"

:%-65$)-*5" ),B,('6)" 6-" 6%$()9%':6'-($..0" $96';5" 94%-*$6'(1" D$%.''0()+2" %6" &B'" P-&(%)-:"

I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2Qb!Nc^N2N2EN2NK1"

<N!1" _.-56I5." UH" b<22!c" J(6'/5(" :%-95))'(/" B0" 645" :%-65$)-*51"P-&4$'" $'/('Q2;"*%:'.4:-$" .'::"

9(%:%+G"<b?c^!OQE!PO1"

<N<1" A'e6)" So"]"_.-56I5." UH" b<2!!c" 345" %-.5"-7" 645":%-65$)-*5" '(" 645"/5(5%$6'-("-7"H=R"9.$))" D"

.'/$(+)"$(+"'**,(5"%5):-()5)1"!'::4:-$"-)0"7%:'.4:-$":(6'"2.(').'2"a"!*8F"NPbQc^!CQ!E!K2<1"

<N?1" W'66$" 3E" '&" -:;" b<2!2c" 340*-:%-65$)-*5" )4$:5)" '**,(-9-*:565(6" %5:5%6-'%5" -7" R#Pp" 3"

95..)1"X774)(&G"?<b!c^<QEC21"

<NC1" @5;$("Ho"b!QONc"R%-))E:%'*'(/"7-%"$")59-(+$%0"906-6-8'9"%5):-()5"6-"*'(-%"="$(6'/5()"&'64"

=E<" 9-(/5('9" 95..)" &4'94" +-" (-6" 9%-))E%5$96" '(" 645" 906-6-8'9" $))$01" AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"!C?bKc^!<P?E!<PP1"

<NK1" o,(/"AE"'&"-:;"b<22<c"D(";';-"+5:.56'-("-7"R#!!9p"+5(+%'6'9"95..)"$B%-/$65)":%'*'(/"-7"R#Pp"3"

95..)"B0"58-/5(-,)"95..E$))-9'$65+"$(6'/5()1"X774)(&G"!Ob<c^<!!E<<21"

<NN1" M-+%'/,5I"JV"M5/($,.6"JV"_.5'e*55%"HV"M'99'$%+'ER$)6$/(-.'"UV"]"J*'/-%5($"A"b!QQQc"A5.596';5"

6%$():-%6" -7" '(65%($.'I5+" $(6'/5()" 6-" 645" 906-)-." 7-%"H=R" 9.$))" D" :%5)5(6$6'-(" '(" +5(+%'6'9"

95..)1"P-&4$'".'::"9(%:%+G"!bNc^?N<E?NP1"

<NO1" J9G5%*$("JFV">'-+'('"JV"]"R%5))&5.."U" b<22Nc"J"%-.5" 7-%" 645"5(+-:.$)*'9"%56'9,.,*":%-65'("

%56%-6%$().-9$6'-(" *$94'(5%0" +,%'(/" 9%-)):%5)5(6$6'-(" B0" +5(+%'6'9" 95..)1" X774)(&G"

<KbCc^N2OEN!O1"

<NP1" D*$'"3E"'&"-:;" b<2!!c"=5$6")4-9G":%-65'("Q2"b=AUQ2c"9-(6%'B,65)"6-"906-)-.'9"6%$().-9$6'-("-7"

586%$95..,.$%" $(6'/5(" 7-%" 9%-))E:%5)5(6$6'-(" B0" +5(+%'6'9" 95..)1" D$%.''0()+2" %6" &B'" P-&(%)-:"

I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2Pb?Qc^!N?N?E!N?NP1"

<NQ1" >,5%*-(:%5I"UE"'&"-:;"b<22?c"SME:4$/-)-*5"7,)'-("+57'(5)"$("H=R"9.$))"D"9%-))E:%5)5(6$6'-("

9-*:$%6*5(6"'("+5(+%'6'9"95..)1"P-&4$'"C<KbNQKNc^?QOEC2<1"

<O21" R5B%'$(" DE" '&" -:;" b<2!!c" A59<<B" %5/,.$65)" :4$/-)-*$." *$6,%$6'-(" $(+" $(6'/5("

9%-)):%5)5(6$6'-("B0"+5(+%'6'9"95..)1"!'::"!CObNc^!?KKE!?NP1"

<O!1" L'%$6" SE" '&" -:;" b<22Oc" 345" %-.5" -7" 5(+-:.$)*'9" %56'9,.,*E$))-9'$65+" $*'(-:5:6'+$)5" !" '("

'**,('60"6-"'(7596'-("$(+"'("9%-))E:%5)5(6$6'-(1"S%4$)-:"%6"(774)%:%+G"!OPbCc^<<C!E<<CP1"

<O<1" A$;5$(,"FE"'&"-:;"b<22Qc"DMJU"'+5(6'7'5)"$("5(+-)-*$."9-*:$%6*5(6"%5[,'%5+"7-%"H=R"9.$))"D"

9%-))E:%5)5(6$6'-(1"F.(').'"?<KbKQ?Oc^<!?E<!O1"

<O?1" A45(" FV" A'/$." FoV" @-5)" HV" ]" M-9G" _F" b<22Cc" D*:-%6$(6" %-.5" -7" 9$645:)'(" A" '(" /5(5%$6'(/"

:5:6'+5)" 7-%" 3JUE'(+5:5(+5(6"H=R" 9.$))" D" 9%-)):%5)5(6$6'-(" '(" ;';-1" X774)(&G" <!b<c^!KKE

!NK1"

<OC1" H5%I-,/,'"WV" _%$6I5%"MV" A$;5$(," FV"]" ;$("S(+5%6" U" b<2!!c"J":%-65$)-*5E+5:5(+5(6V" 3JUE

'(+5:5(+5(6" :$64&$0" 7-%" 9%-))E:%5)5(6$6'-(" -7" :4$/-906-)5+" $(6'/5(1" U*?_" $'#%$&2"

!<b!<c^!<KOE!<NC1"

<OK1" F'I55" >E" '&" -:;" b<22?c" R-(6%-." -7" +5(+%'6'9" 95.." 9%-))E:%5)5(6$6'-(" B0" 645" *$e-%"

4')6-9-*:$6'B'.'60"9-*:.58"9.$))"D"906-:.$)*'9"+-*$'(1"P-&4$'"(774)%:%+G"Cb!!c^!2NKE!2O?1"

<ON1" @$)4$" >E" '&" -:;" b<2!<c" J" R#OCE+5:5(+5(6" H=R" 9.$))" D" 5(+-.0)-)-*$." 9%-))E:%5)5(6$6'-("

:$64&$01"P-&4$'"(774)%:%+G"!?b?c^<?OE<CK1"

Page 154: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!?""

"

<OO1" f-," FE" '&" -:;" b<22Qc" 345" >3U$)5" M$B?BT?9E:-)'6';5" %5909.'(/" ;5)'9.5)" $%5" '(;-.;5+" '(" 9%-))E

:%5)5(6$6'-("'("+5(+%'6'9"95..)1"D$%.''0()+2"%6"&B'"P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"

F&-&'2"%6"I7'$(.-"!2Nb?Oc^!KP2!E!KP2N1"

<OP1" _5" t" ]" _$::" oJ" b!QQNc" S8-/5(-,)" $(6'/5()" /$'(" $995))" 6-" 645" *$e-%" 4')6-9-*:$6'B'.'60"

9-*:.58" 9.$))" D" :%-95))'(/":$64&$0" '("@" 95..)" B0" %595:6-%E*5+'$65+",:6$G51"AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"!PCb?c^!!OQE!!PC1"

<OQ1" o'$(/"gV" F5+5%*$("HHV"=$%+'(/" RZV"]" A'5/" AL" b<2!!c" U%5)5(6$6'-(" -7" )-.,B.5" $(6'/5()" 6-"

R#Pp" 3" 95..)" B0" R:>" -.'/-+5-80(,9.5-6'+5E:%'*5+" 4,*$(" ($';5" @" 95..)1" S%4$)-:" %6"

(774)%:%+G"!PNbCc^<2P2E<2PN1"

<P21" =5'6" JE" '&" -:;" b<22Cc" R:>E#WJ" $'+5+" 9%-))E:%'*'(/" B0" 9%-))E:%5)5(6'(/" @" 95..)1" S%4$)-:" %6"

(774)%:%+G"!O<b?c^!K2!E!K2O1"

<P!1" 3-B'$("JJV"=$%+'(/"RZV"]"R$($+$0"#="b<22Kc"H09-B$965%',*"6,B5%9,.-)')"45$6")4-9G"7,)'-("

:%-65'("5(4$(95)"9.$))"D"H=R"9%-))E:%-95))'(/"$(+"E:%5)5(6$6'-("B0"@".0*:4-9065)1"S%4$)-:"

%6"(774)%:%+G"!OCbQc^K<2QEK<!C1"

<P<1" M-B)-(" WRV" #-($94'5" JHV" ]" H-&$6" JH" b<22Pc" A'*,.6$(5-,)" :%5)5(6$6'-(" $(+" 9%-))E

:%5)5(6$6'-("-7"'**,(5E)6'*,.$6'(/"9-*:.58E$))-9'$65+"9-/($65"$(6'/5("B0"$(6'/5(E):59'7'9"

@"95..)1"U4$%#'-)"C%4$)-:"%6"(774)%:%+G"?PbKc^!<?PE!<CN1"

<P?1" M'694'5"#AV"t$(/"oV"=5%*$()"DLV"]"M-(945)5"L"b<22Cc"@EF0*:4-9065)"$96';$65+"B0"R#C2".'/$(+"

'(+,95"$("$(6'/5(E):59'7'9"$(6'E6,*-,%"'**,(5"%5):-()5"B0"+'%596"$(+"'(+'%596"$96';$6'-("-7"

R#Pbpc"3E95..)1"F.-)0()-/(-)"C%4$)-:"%6"(774)%:%+G"N2bNc^KC?EKK!1"

<PC1" H$%'(-" SV" 3$(" @V" @'(/5" FV" H$9G$0" RMV" ]" >%50" A3" b<2!<c" @E95.." 9%-))E:%5)5(6$6'-(" -7"

$,6-.-/-,)"$(6'/5(":%59':'6$65)"+'$B565)1"O(-9'&'2"N!b!!c^<PQ?E<Q2K1"

<PK1" @-)[,5" JV" L$*'/.'566'" HV" g50%'94" JAV" >-,.)6-(" RV" ]" U.$(5..5)" Z" b<2!!c" =-*5-)6$6'9"

:%-.'75%$6'-(" 7$'.)" 6-" 577'9'5(6.0" %5$96';$65" =DZE!" .$65(6.0" '(75965+" 95(6%$." *5*-%0" R#Cp" 3"

95..)1"D8%F"#-&B%+')2"Ob!2c^5!22<<PP1"

<PN1" _5..5%"AJE"'&"-:;"b<22Qc"L-..'9,.$%"$(+"*$%/'($."I-(5"@"95..)"7$'."6-"9%-))E:%5)5(6"H=R"9.$))"DE

%5)6%'965+"5:'6-:5)"+5%';5+"7%-*";'%$.":$%6'9.5)1"S%4$)-:"%6"(774)%:%+G"!P<b!2c^N<N!EN<NN1"

<PO1" H'.-"DE"'&"-:;"b<2!?c"#0($*'9"'*$/'(/"%5;5$.)":%-*')9,-,)"9%-))E:%5)5(6$6'-("-7"B.--+EB-%(5"

$(6'/5()"6-"($';5"R#Pp"3"95..)"'("645"B-(5"*$%%-&1"?:%%01"

<PP1" 3),e'*-6-" H" ]" =$66-%'" J" b<22Kc" 345" -806-9'($)5" ),B7$*'.0" -7" H!" $*'(-:5:6'+$)5)1"

?(%.B(7(.-"'&"9(%#BG2(.-"-.&-"!OK!b!c^QE!P1"

<PQ1" A$;5$(,"F"]";$("S(+5%6"U"b<2!<c"345"%-.5"-7"'(),.'(E%5/,.$65+"$*'(-:5:6'+$)5"'("H=R"9.$))"D"

$(6'/5(":%5)5(6$6'-(1"3$%)&('$2"()"(774)%:%+G"?^KO1"

<Q21" g5'*5%)4$,)"HE" '&" -:;" b<2!<c" R-(;5(6'-($." +5(+%'6'9" 95..)" %5[,'%5" DMJUEM$B!C" 5(+-)-*5)"

7-%"577'9'5(6"9%-))E:%5)5(6$6'-(1"S%4$)-:"%6"(774)%:%+G"!PPbCc^!PC2E!PCN1"

<Q!1" H$%6'(5I"+5" .$"3-%%5"tE"'&"-:;" b<2!2c"S;-.,6'-("-7"645":5(6%$8'("7$*'.0^"645"(5&"5(6%0"U3aC1"

S%4$)-:"%6"(774)%:%+G"!PCbQc^K2KKEK2NC1"

<Q<1" >,:6$">"]" A,%-.'$" J" b<22Oc" R-..596'()^" )5(6'(5.)" -7" '(($65" '**,('601"?(%U22-G2" a" )'Q2" -)0"

$'/('Q2"()"7%:'.4:-$E".'::4:-$"-)0"0'/':%#7')&-:"9(%:%+G"<QbKc^CK<ECNC1"

<Q?1" @-66$II'"@V"#-('"JV">$%.$(+$"RV"]"H$(6-;$('"J"b<2!2c"J("'(65/%$65+";'5&"-7"4,*-%$."'(($65"

'**,('60^":5(6%$8'()"$)"$":$%$+'/*1"I))4-:"$'/('Q"%6"(774)%:%+G"<P^!KOE!P?1"

<QC1" t-(50$*$"HE"'&"-:;" b<22Kc"A4$%5+"$(+",('[,5"7,(96'-()"-7" 645"#S8#T=EB-8"45.'9$)5)"MD>EDV"

H#JKV"$(+"F>U<"'("$(6';'%$."'(($65"'**,('601"S%4$)-:"%6"(774)%:%+G"!OKbKc^<PK!E<PKP1"

<QK1" R4'," t=V" H$9*'..$(" o@V" ]" R45(" fo" b<22Qc" MWJ" :-.0*5%$)5" DDD" +56596)" 906-)-.'9" #WJ" $(+"

'(+,95)"60:5"D"'(65%75%-()"64%-,/4"645"MD>ED":$64&$01"!'::"!?Pb?c^KONEKQ!1"

<QN1" JB.$))5%"JE"'&"-:;"b<22Qc"MD>EDE+5:5(+5(6")5()'(/"-7":-.0b+J^+3c"64%-,/4"645"'(+,96'-("-7"$("

MWJ":-.0*5%$)5"DDDE6%$()9%'B5+"MWJ"'(65%*5+'$651"P-&4$'"(774)%:%+G"!2b!2c^!2NKE!2O<1"

<QO1" W$G4$5'"UV">5('("UV"R';$)"JV"]"=')9-66"o"b<22Qc"MD>EDE.'G5"%595:6-%)^")5()'(/"$(+"%5):-(+'(/"6-"

MWJ";'%,)"'(7596'-(1"F'7()-$2"()"(774)%:%+G"<!bCc^<!KE<<<1"

<QP1" 3$G5,94'" X" ]" JG'%$" A" b<22Pc" H#JKTMD>ED" $(+" ;'%,)" %59-/('6'-(1" !4$$')&" %#()(%)" ()"

(774)%:%+G"<2b!c^!OE<<1"

Page 155: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!C""

"

<QQ1" t$($'"=V"A$;'6)G0"#V"3$*,%$"3V"]"3$('/,94'"3"b<22Qc"M5/,.$6'-("-7"645"906-)-.'9"#WJE)5()'(/"

)0)65*"'("'(($65"'**,('60^"$"9,%%5(6";'5&1"!4$$')&"%#()(%)"()"(774)%:%+G"<!b!c^!OE<<1"

?221" =$0$)4'" 3E" '&" -:;" b<2!2c" #WJE+5:5(+5(6" $96';$6-%" -7" DLWE%5/,.$6-%0" 7$96-%)" 5(4$(95)" 645"

6%$()9%':6'-(" -7"=DZE!" 64%-,/4"WLEG$::$@1"*(.$%9'2" -)0" ()6'.&(%)" V" X)2&(&4&" D-2&'4$" !<b!<E

!?c^Q?OEQCO1"

?2!1" =-%(,(/"ZE"'&"-:;" b<22Qc"JDH<"%59-/('I5)"906-)-.'9"+)#WJ"$(+"7-%*)"$"9$):$)5E!E$96';$6'(/"

'(7.$**$)-*5"&'64"JAR1"P-&4$'"CKPbO<?Oc^K!CEK!P1"

?2<1" _$:$%$G')"HV"U4'.:-66"#oV"]"L5%%5%-"MF" b<22Oc"H$**$.'$("WFM":%-65'()k"+')9%'*'($6'(/" 7-5"

7%-*"7%'5(+1"X774)%:%+G"-)0".'::"9(%:%+G"PKbNc^CQKEK2<1"

?2?1" _,*$%" =V" _$&$'" 3V" ]" JG'%$" A" b<2!!c" U$64-/5(" %59-/('6'-(" B0" 645" '(($65" '**,(5" )0)65*1"

X)&'$)-&(%)-:"$'/('Q2"%6"(774)%:%+G"?2b!c^!NE?C1"

?2C1" H,I'-"HE"'&"-:;" b<22Qc"S8:%5))'-("$(+"7,(96'-("-7" 6-.." .'G5"%595:6-%)" '("94%-('9" .0*:4-906'9"

.5,G$5*'$"95..)1"?$(&(2B"C%4$)-:"%6"B-'7-&%:%+G"!CCbCc^K2OEK!N1"

?2K1" X�W5'.."FJ"b<2!!c"A0(5%/')*"B56&55("WX#E.'G5"%595:6-%)"$(+"3-..E.'G5"%595:6-%)"'("4,*$("@"

.0*:4-9065)1"S%4$)-:"%6":'41%.G&'"9(%:%+G"PQb<c^!O?E!OK1"

?2N1" g-%+5("JfE"'&"-:;"b<22Qc">%55("5;-.,6'-("$(+"+0($*'9"$+$:6$6'-()"%5;5$.5+"B0"/5(-*5)"-7"

645"*$%'(5":'9-5,G$%0-65)"H'9%-*-($)1"F.(').'"?<CbKQ<Cc^<NPE<O<1"

?2O1" @%-&(" >#" b<22Nc" #596'(E!^" $" )'/($..'(/" (-(E3FM" :$665%(E%59-/('6'-(" %595:6-%1" P-&4$'"

$'/('Q2;"X774)%:%+G"Nb!c^??EC?1"

?2P1" o$(5&$0"RJV"o%1"b!QPQc"J::%-$94'(/"645"$)0*:6-65�"S;-.,6'-("$(+"%5;-.,6'-("'("'**,(-.-/01"

!%:0"F#$()+"H-$9%$"2G7#%2(-"%)"e4-)&(&-&(/'"9(%:%+G"KC"U6"!^!E!?1"

?2Q1" >$0"Wo"]"_5'64"Lo"b!QQ!c"#%-)-:4'.$"3-.."$(+"DFE!"%595:6-%1"P-&4$'"?K!bN?<Kc^?KKE?KN1"

?!21" =5/,0" JV" @$.+$%'" R3V" H$994'$" >V" 35.7-%+" oFV" ]" H5..'" H" b!QQ<c" J*'(-" $9'+)" 9-()5%;5+" '("

'(65%.5,G'(E!"%595:6-%)" bDFE!M)c"$(+"645"#%-)-:4'.$"6-..":%-65'("$%5"5))5(6'$." 7-%" DFE!M")'/($."

6%$()+,96'-(1"AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<NObCc^<N2KE<N2Q1"

?!!1" F5*$'6%5" @V" W'9-.$)" SV" H'94$,6" FV" M5'944$%6" oHV" ]" =-77*$((" oJ" b!QQNc" 345" +-%)-;5(6%$."

%5/,.$6-%0" /5(5" 9$))5665" ):$6I.5T3-..T9$96,)" 9-(6%-.)" 645" :-65(6" $(6'7,(/$." %5):-()5" '("

#%-)-:4'.$"$+,.6)1"!'::"PNbNc^QO?EQP?1"

?!<1" H5+I4'6-;" MV" U%5)6-(E=,%.B,%6" UV" ]" o$(5&$0" RJV" o%1" b!QQOc" J" 4,*$(" 4-*-.-/,5" -7" 645"

#%-)-:4'.$"3-..":%-65'(")'/($.)"$96';$6'-("-7"$+$:6';5"'**,('601"P-&4$'"?PPbNNC2c^?QCE?QO1"

?!?1" U-.6-%$G" JE" '&" -:;" b!QQPc" #57596';5" FUA" )'/($.'(/" '(" R?=T=5o" $(+" RKO@FT!2A9R%" *'95^"

*,6$6'-()"'("3.%C"/5(51"F.(').'"<P<bK?QNc^<2PKE<2PP1"

?!C1" M-9G"LFV"=$%+'*$(">V"3'*$()"oRV"_$)65.5'("MJV"]"@$I$("oL"b!QQPc"J"7$*'.0"-7"4,*$("%595:6-%)"

)6%,96,%$..0" %5.$65+" 6-"#%-)-:4'.$" 3-..1"D$%.''0()+2"%6" &B'"P-&(%)-:"I.-0'7G"%6" F.(').'2" %6"

&B'"`)(&'0"F&-&'2"%6"I7'$(.-"QKb<c^KPPEKQ?1"

?!K1" X�W5'.." FJV" >-.5(B-9G"#V"]" @-&'5" J>" b<2!?c" 345" 4')6-%0" -7" 3-..E.'G5" %595:6-%)" E" %5+57'('(/"

'(($65"'**,('601"P-&4$'"$'/('Q2;"X774)%:%+G"!?bNc^CK?ECN21"

?!N1" 3$G5+$" _V" _$')4-" 3V" ]" JG'%$" A" b<22?c" 3-..E.'G5" %595:6-%)1" I))4-:" $'/('Q" %6" (774)%:%+G"

<!^??KE?ON1"

?!O1" _$&$'" 3" ]" JG'%$" A" b<22Qc" 345" %-.5)" -7" 3FM)V" MFM)" $(+" WFM)" '(" :$64-/5(" %59-/('6'-(1"

X)&'$)-&(%)-:"(774)%:%+G"<!bCc^?!OE??O1"

?!P1" A4'" fE" '&" -:;" b<2!!c"J"(-;5." 3-..E.'G5" %595:6-%" 64$6" %59-/('I5)" ;5)'9,.$%" )6-*$6'6')" ;'%,)1"AB'"

S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<PNbNc^CK!OECK<C1"

?!Q1" D)($%+'"DE"'&"-:;"b<22Pc"DMJ_ECE"$(+"H0#PPE+5:5(+5(6":$64&$0)"$%5"5))5(6'$."7-%"645"%5*-;$."

-7"+5;5.-:'(/"$,6-%5$96';5"@"95..)"'("4,*$()1"X774)(&G"<QbKc^OCNEOKO1"

?<21" >,%,%$e$("HV"o$9-B"oV"]"U,.5(+%$("@"b<22Oc"3-..E.'G5"%595:6-%"58:%5))'-("$(+"%5):-()';5(5))"

-7"+')6'(96"*,%'(5"):.5('9"$(+"*,9-)$."@E95.."),B)56)1"D:%F"%)'"<bQc^5PN?1"

?<!1" @5%($)9-('" WFV" X($'" WV" ]" F$(I$;5994'$" J" b<22?c" J" %-.5" 7-%" 3-..E.'G5" %595:6-%)" '(" $9[,'%5+"

'**,('60^",:E%5/,.$6'-("-7"3FMQ"B0"@RM"6%'//5%'(/"'("($';5"@"95..)"$(+"9-()6'6,6';5"58:%5))'-("

'("*5*-%0"@"95..)1"?:%%0"!2!b!!c^CK22ECK2C1"

?<<1" =-5B5"_E"'&"-:;"b<22Kc"R#?N"')"$")5()-%"-7"+'$90./.095%'+5)1"P-&4$'"C??bO2<Kc^K<?EK<O1"

Page 156: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!K""

"

?<?1" >--+%'+/5"=A"]"Y(+5%4'.."#H"b<22Pc"L,(/$."M59-/('6'-("B0"3FM<"$(+"#596'(E!1"H-)09%%1"%6"

']#'$(7')&-:"#B-$7-.%:%+G"b!P?c^POE!2Q1"

?<C1" @$%B$.$6" MV" F$," FV" F-9G).50" MHV" ]" @$%6-(" >H" b<22Qc" 3-..E.'G5" %595:6-%" <" -(" '(7.$**$6-%0"

*-(-9065)" '(+,95)" 60:5" D" '(65%75%-(" '(" %5):-()5" 6-" ;'%$." B,6" (-6" B$965%'$." .'/$(+)1"P-&4$'"

(774)%:%+G"!2b!!c^!<22E!<2O1"

?<K1" JG'%$" AV" Y5*$6)," AV" ]" 3$G5,94'" X" b<22Nc" U$64-/5(" %59-/('6'-(" $(+" '(($65" '**,('601" !'::"

!<CbCc^OP?EP2!1"

?<N1" X/$6$" =E" '&" -:;" b<222c" 345" 6-..E.'G5" %595:6-%" :%-65'(" MU!2K" %5/,.$65)" .':-:-.0)$994$%'+5"

)'/($.'(/"'("@"95..)1"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"!Q<b!c^<?E<Q1"

?<O1" H',%$" tE" '&" -:;" b!QQNc"H-.59,.$%" 9.-('(/" -7" $" 4,*$(" MU!2K" 4-*-.-/,5" $(+" 94%-*-)-*$."

.-9$.'I$6'-("-7"645"*-,)5"$(+"4,*$("MU!2K"/5(5)"bF0NC"$(+"FtNCc1"W')%7(.2"?Pb?c^<QQE?2C1"

?<P1" #';$(-;'9" AE" '&" -:;" b<22Kc" D(4'B'6'-(" -7" 3FMECTH#E<" )'/($.'(/" B0" MU!2KTH#E!1" S%4$)-:" %6"

')0%&%]()"$'2'-$.B"!!bNc^?N?E?NP1"

?<Q1" L5,'..56"ZE" '&"-:;" b<22Nc" D(;-.;5*5(6"-7"3-..E.'G5" %595:6-%"K" '(" 645" %59-/('6'-("-7" 7.$/5..$65+"

B$965%'$1"D$%.''0()+2"%6" &B'"P-&(%)-:"I.-0'7G"%6" F.(').'2"%6" &B'"`)(&'0"F&-&'2"%6"I7'$(.-"

!2?b??c^!<CPOE!<CQ<1"

??21" #5)9$*:)" #E" '&" -:;" b<2!<c" 3-..E.'G5" %595:6-%" K" b3FMKcV" DFE!B56$" )59%56'-(V" $(+" $):$%$/'(5"

5(+-:5:6'+$)5"$%5"9%'6'9$."7$96-%)"7-%"$.;5-.$%"*$9%-:4$/5":4$/-906-)')"$(+"B$965%'$."G'..'(/1"

D$%.''0()+2" %6" &B'" P-&(%)-:" I.-0'7G" %6" F.(').'2" %6" &B'" `)(&'0" F&-&'2" %6" I7'$(.-"

!2QbKc^!N!QE!N<C1"

??!1" Y5*$6),"AE"'&"-:;"b<22Pc"M5/,.$6'-("-7"4,*-%$."$(+"95..,.$%"/,6"'**,('60"B0".$*'($":%-:%'$"

+5(+%'6'9"95..)"58:%5))'(/"3-..E.'G5"%595:6-%"K1"P-&4$'"(774)%:%+G"QbOc^ONQEOON1"

??<1" =$)$(" YE" '&" -:;" b<22Kc" =,*$(" 3FM!2" ')" $" 7,(96'-($." %595:6-%V" 58:%5))5+" B0" @" 95..)" $(+"

:.$)*$906-'+"+5(+%'6'9" 95..)V"&4'94" $96';$65)" /5(5" 6%$()9%':6'-(" 64%-,/4"H0#PP1" S%4$)-:" %6"

(774)%:%+G"!OCbKc^<QC<E<QK21"

???1" >,$("tE" '&"-:;" b<2!2c"=,*$("3FM)"!2"$(+"!" )4$%5" 9-**-("*594$(')*)"-7" '(($65" '**,(5"

)5()'(/"B,6"(-6")'/($.'(/1"S%4$)-:"%6"(774)%:%+G"!PCbQc^K2QCEK!2?1"

??C1" g5..5%"AE"'&"-:;"b<2!<c"D/HpD/#pR#<Op"@"95..)"$%5"*$%G5+.0"%5+,95+"'("DMJ_ECEV"H0#PPEV"$(+"

3DMJUE"B,6"(-6"YWREQ?@E+57'9'5(6":$6'5(6)1"?:%%0"!<2b<Kc^CQQ<EK22!1"

??K1" J.58-:-,.-," FV" =-.6" JRV"H5+I4'6-;" MV" ]" L.$;5.." MJ" b<22!c" M59-/('6'-(" -7" +-,B.5E)6%$(+5+"

MWJ"$(+"$96';$6'-("-7"WLEG$::$@"B0"3-..E.'G5"%595:6-%"?1"P-&4$'"C!?bNPKOc^O?<EO?P1"

??N1" g$(/" 3E" '&" -:;" b<22Cc" 3-..E.'G5" %595:6-%" ?" *5+'$65)" g5)6" W'.5" ;'%,)" 5(6%0" '(6-" 645" B%$'("

9$,)'(/".564$."5(95:4$.'6')1"P-&4$'"7'0(.()'"!2b!<c^!?NNE!?O?1"

??O1" _.5'(*$("HSE"'&"-:;" b<22Pc"A5[,5(95E"$(+" 6$%/56E'(+5:5(+5(6"$(/'-/5(5)')" ),::%5))'-("B0"

)'MWJ";'$"3FM?1"P-&4$'"CK<bO!POc^KQ!EKQO1"

??P1" 3$B56$"_E"'&"-:;"b<22Cc"3-..E.'G5"%595:6-%)"Q"$(+"?"$)"5))5(6'$."9-*:-(5(6)"-7"'(($65"'**,(5"

+575()5" $/$'()6"*-,)5" 906-*5/$.-;'%,)" '(7596'-(1"D$%.''0()+2"%6" &B'"P-&(%)-:"I.-0'7G"%6"

F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2!b!2c^?K!NE?K<!1"

??Q1" f4$(/"AtE"'&"-:;" b<22Oc"3FM?"+57'9'5(90"'(":$6'5(6)"&'64"45%:5)")'*:.58"5(95:4$.'6')1"F.(').'"

?!ObKPCCc^!K<<E!K<O1"

?C21" F5">-77'9"ME"'&"-:;"b<22Nc"#56%'*5(6$."9-(6%'B,6'-("-7"645"3-..E.'G5"%595:6-%"b3FMc?"6-"'(7.,5(I$"

J";'%,)E'(+,95+"$9,65":(5,*-('$1"D8%F"#-&B%+')2"<bNc^5K?1"

?C!1" A94,.I" XE" '&" -:;" b<22Kc" 3-..E.'G5" %595:6-%" ?" :%-*-65)" 9%-))E:%'*'(/" 6-" ;'%,)E'(75965+" 95..)1"

P-&4$'"C??bO2<Pc^PPOEPQ<1"

?C<1" H$6),*-6-" HV" _'GG$&$" AV" _-4$)5" HV" H'0$G5" _V" ]" A50$" 3" b<22<c" S)6$B.')4*5(6" -7" $"

*-(-9.-($." $(6'B-+0" $/$'()6" 4,*$(" 3-..E.'G5" %595:6-%" ?" 64$6" B.-9G)" +-,B.5E)6%$(+5+"MWJE

*5+'$65+")'/($.'(/1"?(%.B'7(.-:"-)0"9(%#BG2(.-:"$'2'-$.B".%774)(.-&(%)2"<Q?bKc^!?NCE!?NQ1"

?C?1" F5'"aE"'&"-:;"b<2!!c"R.5$;$/5"-7"645"$+$:6-%":%-65'("3MDL"B0"5(65%-;'%,)"O!"?R"'(4'B'6)"$(6';'%$."

%5):-()5)"*5+'$65+"B0"3-..E.'G5"%595:6-%"?1"S%4$)-:"%6"/($%:%+G"PKb!Oc^PP!!EPP!P1"

?CC1" z,"FE"'&"-:;"b<2!!c"#')%,:6'-("-7"3FM?")'/($.'(/"+,5"6-"9.5$;$/5"-7"3MDL"B0"645"45:$6'6')"J";'%,)"

:%-65$)5E:-.0*5%$)5":%-95))'(/"'(65%*5+'$65V"?R#1"D8%F"#-&B%+')2"ObQc^5!22<!NQ1"

Page 157: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!N""

"

?CK1" F'"_E"'&"-:;"b<22Kc"D**,(5"5;$)'-("B0"45:$6'6')"R";'%,)"WA?TCJ":%-65$)5E*5+'$65+"9.5$;$/5"-7"

645" 3-..E.'G5" %595:6-%" ?" $+$:6-%" :%-65'(" 3MDL1" D$%.''0()+2" %6" &B'" P-&(%)-:" I.-0'7G" %6"

F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2<bPc^<QQ<E<QQO1"

?CN1" #-((5..0" AE" '&" -:;" b<2!2c" =5.*'(64" 90)65'(5" :%-65$)5)" '(4'B'6" 3MDLE+5:5(+5(6" $96';$6'-(" -7"

*$9%-:4$/5)";'$"+5/%$+$6'-("-7"3FM?1"AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<PKbKc^??P?E??Q<1"

?CO1" S&$.+"ASE"'&"-:;" b<2!!c"W,9.5'9"$9'+"%59-/('6'-("B0"3-..E.'G5"%595:6-%)" ')"9-,:.5+"6-")65:&')5"

:%-95))'(/" B0" 9$645:)'()" $(+" $):$%$/'(5" 5(+-:5:6'+$)51" AB'" S%4$)-:" %6" ']#'$(7')&-:"

7'0(.()'"<2PbCc^NC?ENK!1"

?CP1" @5.." o_E" '&" -:;" b<22Nc" 345"*-.59,.$%" )6%,96,%5" -7" 645" 3FM?" 586%$95..,.$%" +-*$'(1" S%4$)-:" %6"

')0%&%]()"$'2'-$.B"!<bNc^?OKE?OP1"

?CQ1" >$%9'$ER$66$(5-" JE" '&" -:;" b<2!<c" R.5$;$/5" -7" 3-..E.'G5" %595:6-%" ?" B0" 9$645:)'()" @" $(+" =" ')"

5))5(6'$."7-%")'/($.'(/1"D$%.''0()+2"%6"&B'"P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"

%6"I7'$(.-"!2Qb<?c^Q2K?EQ2KP1"

?K21" z'"MV"A'(/4"#V"]"_$-"RR"b<2!<c"U%-65-.06'9":%-95))'(/"%5/,.$65)"3-..E.'G5"%595:6-%"?")6$B'.'60"

$(+"5(+-)-*$.".-9$.'I$6'-(1"AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<POb?Qc^?<N!OE?<N<Q1"

?K!1" 3-)9$(-"LE"'&"-:;"b<2!?c"R.5$;5+T$))-9'$65+"3FM?"%5:%5)5(6)"645":%'*$%0"7-%*"-7"645")'/($.'(/"

%595:6-%1"S%4$)-:"%6"(774)%:%+G"!Q2b<c^ONCEOO?1"

?K<1" >$(+'('" HE" '&" -:;" b<2!?c" #5(/,5" Z'%,)" J96';$65)"H5*B%$(5" 3MJDF" M5.-9$.'I$6'-(" $(+" DLWE

$.:4$"U%-+,96'-("B0"=,*$("U.$)*$906-'+"#5(+%'6'9"R5..)"D("Z'6%-"$(+"D("Z';-1"D8%F")'+:'.&'0"

&$%#(.-:"0(2'-2'2"ObNc^5<<KO1"

?K?1" R-.'))-("ME"'&"-:;" b<2!2c"L%55"=3FZE!"'(+,95)"3FMOE+5:5(+5(6"'(($65"'**,(5"%5):-()5"$(+"

3MJDF"%5.-9$.'I$6'-("'("G'..5%":.$)*$906-'+"+5(+%'6'9"95..)1"?:%%0"!!Kb!!c^<!OOE<!PK1"

?KC1" @5G5%5+e'$(E#'(/"D@E"'&"-:;"b<22Kc"U.$)*$906-'+"+5(+%'6'9"95..)"9-(6%-."3FMO")5()'6';'60"-7"($';5"

@"95..)";'$"60:5"D"DLW1"S%4$)-:"%6"(774)%:%+G"!OCbOc^C2C?EC2K21"

?KK1" >%55(" WHE" '&" -:;" b<22Qc" H,%'(5" @" 95.." %5):-()5" 6-" 3FMO" .'/$(+)" +5:5(+)" -(" $(" DLWEB56$"

755+B$9G".--:1"S%4$)-:"%6"(774)%:%+G"!P?b?c^!KNQE!KON1"

?KN1" a," F>E" '&" -:;" b<2!<c" ZDAJ" ')" %5[,'%5+" 7-%" @" 95.." 58:%5))'-(" -7" 3FMO1" S%4$)-:" %6" (774)%:%+G"

!PPb!c^<CPE<KP1"

?KO1" U')'6G,("UE" '&"-:;" b<22Nc"J,6-%5$96';5"@"95.." %5):-()5)" 6-"MWJE%5.$65+"$(6'/5()"+,5" 6-"3FMO"

/5(5"+,:.'9$6'-(1"F.(').'"?!<bKOP2c^!NNQE!NO<1"

?KP1" g$.)4"SME"'&"-:;" b<2!<c"#,$.")'/($.'(/"B0" '(($65"$(+"$+$:6';5" '**,(5"%595:6-%)" ')"%5[,'%5+"

7-%" 3FMOE'(+,95+" @E95..E*5+'$65+" $,6-'**,('601" D$%.''0()+2" %6" &B'" P-&(%)-:" I.-0'7G" %6"

F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2QbC2c^!N<ONE!N<P!1"

?KQ1" A'(4$"AV">,-"tV"3456"AV"]"t,$("#"b<2!<c"DLW"60:5"D"$(+"60:5"DD"'(+5:5(+5(6"5(4$(95*5(6"-7"@"

95.."3FMO"58:%5))'-("B0"($6,%$."G'..5%"95..)1"S%4$)-:"%6":'41%.G&'"9(%:%+G"Q<bCc^O!?EO<<1"

?N21" =-,"@E"'&"-:;" b<2!!c"A5.596';5",6'.'I$6'-("-7"3-..E.'G5"%595:6-%"$(+"H0#PP")'/($.'(/" '("@"95..)"

7-%"5(4$(95*5(6"-7"645"$(6';'%$."/5%*'($."95(65%"%5):-()51"X774)(&G"?Cb?c^?OKE?PC1"

?N!1" _$)6,%'"AUE"'&"-:;"b<2!!c"U%-/%$**'(/"645"*$/('6,+5"$(+":5%)')65(95"-7"$(6'B-+0"%5):-()5)"

&'64"'(($65"'**,('601"P-&4$'"CO2bO??Kc^KC?EKCO1"

?N<1" @5))$" oV" _-:7" HV" ]" @$94*$((" HL" b<2!2c" R,66'(/" 5+/5^" DFE<!" $(+" 3FM" )'/($.'(/" %5/,.$65"

/5%*'($."95(65%"%5):-()5)" '("$"@"95..E'(6%'()'9"*$((5%1"S%4$)-:"%6" (774)%:%+G"!PCbQc^CN!KE

CN!Q1"

?N?1" _$(5"HE" '&" -:;" b<2!!c" D(($65" '**,(5" )5()'(/"-7" %56%-;'%$." '(7596'-(" ;'$" 3-..E.'G5" %595:6-%"O"

-99,%)",:-(";'%$."5(6%01"X774)(&G"?Kb!c^!?KE!CK1"

?NC1" U--;$))5%0" oA" ]" @')4-:" >J" b<2!<c" 30:5" D" DLW" %595:6-%" $(+" 645" @" 95.." $(6'/5(" %595:6-%"

%5/,.$65" 3FMO" %5):-()5)" ;'$" +')6'(96" *-.59,.$%" *594$(')*)1" S%4$)-:" %6" (774)%:%+G"

!PQbCc^!OKOE!ONC1"

?NK1" F5$+B5665%"SJE"'&"-:;"b<22<c"R4%-*$6'(ED/>"9-*:.585)"$96';$65"@"95..)"B0"+,$."5(/$/5*5(6"-7"

D/H"$(+"3-..E.'G5"%595:6-%)1"P-&4$'"C!NbNPP!c^N2?EN2O1"

?NN1" F$,"RHE"'&"-:;"b<22Kc"MWJE$))-9'$65+"$,6-$(6'/5()"$96';$65"@"95..)"B0"9-*B'(5+"@"95.."$(6'/5("

%595:6-%T3-..E.'G5"%595:6-%"O"5(/$/5*5(61"AB'"S%4$)-:"%6"']#'$(7')&-:"7'0(.()'"<2<bQc^!!O!E

!!OO1"

Page 158: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!O""

"

?NO1" @-5/.'(" SE" '&" -:;" b<2!!c" 3-..E.'G5" %595:6-%" $/-(')6)" )0(5%/'I5" &'64" R#C2F" 6-" '(+,95" 5'645%"

:%-.'75%$6'-("-%":.$)*$"95.."+'775%5(6'$6'-("-7"*-,)5"@"95..)1"D:%F"%)'"Nb!2c^5<KKC<1"

?NP1" Z$(+5(" @,)4" 3o" ]" @')4-:" >J" b<22Pc" 3FMO" $(+" R#C2" 9--:5%$65" '(" DFEN" :%-+,96'-(" ;'$"

5(4$(95+"oW_"$(+"JUE!"$96';$6'-(1"U4$%#'-)"C%4$)-:"%6"(774)%:%+G"?Pb<c^C22EC2Q1"

?NQ1" H$)94$.'+'" AE" '&" -:;" b<2!<c" J):$%$/'(5" 5(+-:5:6'+$)5" 9-(6%-.)" $(6'E'(7.,5(I$" ;'%,)" '**,(5"

%5):-()5)"64%-,/4"3FMO"$96';$6'-(1"D8%F"#-&B%+')2"PbPc^5!22<PC!1"

?O21" _$((-" JE" '&" -:;" b<2!?c" S))5(6'$." %-.5" 7-%" 3-..E.'G5" %595:6-%" O" b3FMOcE,('[,5" 90)65'(5)" '(" $("

'(6%$*-.59,.$%" +'),.7'+5" B-(+V" :%-65-.06'9" 9.5$;$/5" $(+" MWJ" )5()'(/1" X)&'$)-&(%)-:"

(774)%:%+G"<KbOc^C!?EC<<1"

?O!1" =5'."LE"'&"-:;"b<22Cc"A:59'5)E):59'7'9"%59-/('6'-("-7")'(/.5E)6%$(+5+"MWJ";'$"6-..E.'G5"%595:6-%"O"

$(+"P1"F.(').'"?2?bKNN?c^!K<NE!K<Q1"

?O<1" F',"oE"'&"-:;"b<2!2c"J"7';5E$*'(-E$9'+"*-6'7"'("645",(+57'(5+"%5/'-("-7"645"3FMP"596-+-*$'("')"

%5[,'%5+"7-%"):59'5)E):59'7'9".'/$(+"%59-/('6'-(1"*%:'.4:-$"(774)%:%+G"CObKc^!2P?E!2Q21"

?O?1" H$%6'(5I" oV" =,$(/" aV" ]" t$(/" t" b<2!2c" 3-..E.'G5" %595:6-%" PE*5+'$65+" $96';$6'-(" -7" *,%'(5"

:.$)*$906-'+"+5(+%'6'9" 95..)"B0";$99'('$";'%$."#WJ1"D$%.''0()+2"%6" &B'"P-&(%)-:"I.-0'7G"%6"

F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2Ob!Cc^NCC<ENCCO1"

?OC1" H$"tV"=$0(5)"MFV"A'+*$("MFV"]"Z$%6$('$("3"b<22Oc"3FMP^"$("'(($65"'**,(5"%595:6-%"'("B%$'(V"

(5,%-()"$(+"$8-()1"!'::".G.:'"Nb<?c^<PKQE<PNP1"

?OK1" #5*$%'$" XE" '&" -:;" b<2!2c" 3FMP" +57'9'5(90" .5$+)" 6-" $,6-'**,('60" '(" *'951" AB'" S%4$)-:" %6"

.:()(.-:"()/'2&(+-&(%)"!<2b!2c^?NK!E?NN<1"

?ON1" R$*'()94'" DV" H5,65%" AV" ]" =5$64" gM" b<2!?c" #SRE<2K" ')" $" 95.." ),%7$95" %595:6-%" 7-%" R:>"

-.'/-(,9.5-6'+5)1"_).%(774)%:%+G"<b?c^5<?!<P1"

?OO1" F,(+" oV" A$6-" JV" JG'%$" AV" H5+I4'6-;" MV" ]" D&$)$G'" J" b<22?c" 3-..E.'G5" %595:6-%" QE*5+'$65+"

%59-/('6'-(" -7" =5%:5)" )'*:.58" ;'%,)E<" B0" :.$)*$906-'+" +5(+%'6'9" 95..)1" AB'" S%4$)-:" %6"

']#'$(7')&-:"7'0(.()'"!QPb?c^K!?EK<21"

?OP1" _%,/" JE" '&" -:;" b<22Cc" 3FMQE+5:5(+5(6" %59-/('6'-(" -7" HRHZ" B0" DUR" $(+" #R" /5(5%$65)"

9--%+'($65+"906-G'(5"%5):-()5)"64$6"$96';$65"$(6';'%$."W_"95.."7,(96'-(1" X774)(&G"<!b!c^!2OE

!!Q1"

?OQ1" _%,/" JE" '&" -:;" b<22Cc" =5%:5)" )'*:.58" ;'%,)" 60:5" !" $96';$65)" *,%'(5" ($6,%$." '(65%75%-(E

:%-+,9'(/"95..)"64%-,/4"6-..E.'G5"%595:6-%"Q1"?:%%0"!2?bCc^!C??E!C?O1"

?P21" @$7'9$"JE" '&" -:;" b<22Nc"R,66'(/"5+/5^" 3FMQ"$(+"3FM<" )'/($.'(/" 6-/5645%" $99-,(6" 7-%"H0#PPE

+5:5(+5(6" 9-(6%-." -7" :$%$)'65*'$" '(" 3%0:$(-)-*$" 9%,I'" '(7596'-(1" S%4$)-:" %6" (774)%:%+G"

!OObNc^?K!KE?K!Q1"

?P!1" =')$5+$" =E" '&" -:;" b<22Pc" H$.$%'$" :$%$)'65)" %5[,'%5" 3FMQ" )'/($.'(/" 7-%" '**,(5" 5;$)'-(" B0"

$96';$6'(/"%5/,.$6-%0"3"95..)1"S%4$)-:"%6"(774)%:%+G"!P2bCc^<CQNE<K2?1"

?P<1" _5%G*$((" HE" '&" -:;" b<22Kc" A:-(6$(5-,)" 7-%*$6'-(" -7" (,9.5'9" $9'+EB$)5+" ($(-:$%6'9.5)" ')"

%5):-()'B.5"7-%"4'/4"'(65%75%-(E$.:4$"'(+,96'-("B0"R:>EJ"'(":.$)*$906-'+"+5(+%'6'9"95..)1"AB'"

S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<P2bQc^P2PNEP2Q?1"

?P?1" R4'(($64$*B'" AV" R45(" AV" >$(5)$(" AV" ]" =$($/$6$" W" b<2!<c" @'(+'(/" *-+5" -7" R:>"

-.'/-+5-80(,9.5-6'+5)" 6-" ($(-:$%6'9.5)" %5/,.$65)" B'7,%9$65+" 906-G'(5" '(+,96'-(" ;'$" 3-..E.'G5"

%595:6-%"Q1"F.(')&(6(."$'#%$&2"<^K?C1"

?PC1" @.$)',)" JFE" '&" -:;" b<2!2c" A.9!K$CV" JUE?V" $(+" =5%*$()G0EU,+.$G" )0(+%-*5" :%-65'()" $%5"

%5[,'%5+" 7-%" 3-..E.'G5" %595:6-%" )'/($.'(/" '(" :.$)*$906-'+" +5(+%'6'9" 95..)1" D$%.''0()+2" %6" &B'"

P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2ObCNc^!QQO?E!QQOP1"

?PK1" A$)$'" HV" F'(54$(" HHV" ]" D&$)$G'" J" b<2!2c" @'7,%9$6'-(" -7" 3-..E.'G5" %595:6-%" Q" )'/($.'(/" B0"

$+$:6-%":%-65'("?1"F.(').'"?<QbKQQPc^!K?2E!K?C1"

?PN1" D&$6$" AE" '&" -:;" b<2!<c" J*:.'7'9$6'-(" -7" 3-..E.'G5" %595:6-%E*5+'$65+" )'/($.'(/" 64%-,/4" ):.55("

60%-)'(5" G'($)5" '(" 4,*$(" @E95.." $96';$6'-(1" AB'" S%4$)-:" %6" -::'$+G" -)0" .:()(.-:" (774)%:%+G"

!<QbNc^!KQCE!N2!"5!KQ<1"

?PO1" a,"tV"L$("=V"F'"aV"A,("FV"]"=-,"t"b<2!<c"!OB56$ES)6%$+'-."5(4$(95)"%5):-()5"-7"*'95"):.55("@"

95..)"5.'9'65+"B0"3FMQ"$/-(')61"!'::4:-$"(774)%:%+G"<OPb!E<c^!<KE!?K1"

Page 159: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!P""

"

?PP1" S9G.E#-%($" o" ]" @$6')6$" L#" b<22Qc" @RME*5+'$65+" ,:6$G5" -7" $(6'/5(" .'(G5+" 6-" 3FMQ" .'/$(+"

)6'*,.$65)" @E95.." :%-.'75%$6'-(" $(+" $(6'/5(E):59'7'9" :.$)*$" 95.." 7-%*$6'-(1" ?:%%0"

!!?b!Oc^?QNQE?QOO1"

?PQ1" X�W5'.." A_E" '&" -:;" b<22Qc" S(+-906'9" )5[,5)6%$6'-("-7" 645"@" 95.." $(6'/5(" %595:6-%" $(+" 6-..E.'G5"

%595:6-%" Q" '(" $(5%/'9" 95..)1"D$%.''0()+2" %6" &B'"P-&(%)-:"I.-0'7G"%6" F.(').'2" %6" &B'"`)(&'0"

F&-&'2"%6"I7'$(.-"!2Nb!Kc^N<N<EN<NO1"

?Q21" R4$6,%;5+'" JV" #-%&$%+" #V" ]" U'5%95" A_" b<22Pc" 345" @" 95.." %595:6-%" /-;5%()" 645" ),B95..,.$%"

.-9$6'-(" -7" 3-..E.'G5" %595:6-%" Q" .5$+'(/" 6-" 40:5%%5):-()5)" 6-" #WJE9-(6$'('(/" $(6'/5()1"

X774)(&G"<PbNc^OQQEP2Q1"

?Q!1" 3'$(" oE" '&" -:;" b<22Oc" 3-..E.'G5" %595:6-%" QE+5:5(+5(6" $96';$6'-(" B0" #WJE9-(6$'('(/" '**,(5"

9-*:.585)"')"*5+'$65+"B0"=H>@!"$(+"MJ>S1"P-&4$'"(774)%:%+G"PbKc^CPOECQN1"

?Q<1" J;$.-)" JHE" '&" -:;" b<2!2c" MJ>SE'(+5:5(+5(6" $,6-%5$96';5" @" 95.." $96';$6'-(" '(" %5):-()5" 6-"

94%-*$6'("$(+"=H>@!T#WJ"'**,(5"9-*:.585)1"I4&%(774)(&G"C?b!c^!2?E!!21"

?Q?1" @$,*$(("RFE"'&"-:;"b<2!2c"R#!C"')"$"9-%595:6-%"-7"3-..E.'G5"%595:6-%)"O"$(+"Q1"AB'"S%4$)-:"%6"

']#'$(7')&-:"7'0(.()'"<2Ob!<c^<NPQE<O2!1"

?QC1" F$(+5"ME"'&"-:;"b<22Oc"U.$)*$906-'+"+5(+%'6'9"95..)")5()5")5.7E#WJ"9-,:.5+"&'64"$(6'*'9%-B'$."

:5:6'+51"P-&4$'"CCQbO!N<c^KNCEKNQ1"

?QK1" F$6I" SE" '&" -:;" b<22Oc" F'/$(+E'(+,95+" 9-(7-%*$6'-($." 94$(/5)" $..-)65%'9$..0" $96';$65" 3-..E.'G5"

%595:6-%"Q1"P-&4$'"(774)%:%+G"PbOc^OO<EOOQ1"

?QN1" M,6I"HE"'&"-:;"b<22Cc"3-..E.'G5"%595:6-%"Q"B'(+)")'(/.5E)6%$(+5+"R:>E#WJ"'("$")5[,5(95E"$(+"

:=E+5:5(+5(6"*$((5%1"U4$%#'-)"C%4$)-:"%6"(774)%:%+G"?CbQc^<KC!E<KK21"

?QO1" X(e'"HE"'&"-:;" b<2!?c"J("5))5(6'$."%-.5"7-%"645"WE65%*'($." 7%$/*5(6"-7"3-..E.'G5"%595:6-%"Q" '("

#WJ")5()'(/1"P-&4$'".%774)(.-&(%)2"C^!QCQ1"

?QP1" U$%G"@E"'&"-:;" b<22Pc"U%-65-.06'9"9.5$;$/5" '("$("5(+-.0)-)-*$."9-*:$%6*5(6" ')" %5[,'%5+" 7-%"

$96';$6'-("-7"3-..E.'G5"%595:6-%"Q1"P-&4$'"(774)%:%+G"Qb!<c^!C2OE!C!C1"

?QQ1" S&$.+" ASE" '&" -:;" b<22Pc" 345" 596-+-*$'(" -7" 3-..E.'G5" %595:6-%" Q" ')" 9.5$;5+" 6-" /5(5%$65" $"

7,(96'-($."%595:6-%1"P-&4$'"CKNbO<<<c^NKPENN<1"

C221" H$6),*-6-" LE" '&" -:;" b<22Pc" R$645:)'()" $%5" %5[,'%5+" 7-%" 3-..E.'G5" %595:6-%" Q" %5):-()5)1"

?(%.B'7(.-:"-)0"9(%#BG2(.-:"$'2'-$.B".%774)(.-&(%)2"?NOb?c^NQ?ENQQ1"

C2!1" A5:,.;5+$" LSE" '&" -:;" b<22Qc" R%'6'9$." %-.5" 7-%" $):$%$/'(5" 5(+-:5:6'+$)5" '(" 5(+-906'9" 3-..E.'G5"

%595:6-%")'/($.'(/"'("+5(+%'6'9"95..)1"X774)(&G"?!bKc^O?OEOCP1"

C2<1" J)$/'%'" HE" '&" -:;" b<22Pc" R$645:)'(" _E+5:5(+5(6" 6-..E.'G5" %595:6-%" Q" )'/($.'(/" %5;5$.5+" '("

58:5%'*5(6$."$%64%'6')1"F.(').'"?!QbKPN?c^N<CEN<O1"

C2?1" J;$.-)"JHE"'&"-:;"b<2!?c"R5..E):59'7'9"3FMQ"6%$77'9G'(/"'(":%'*$%0"JUR)"-7"6%$()/5('9"3FMQE>LU"

*'951"S%4$)-:"%6"(774)%:%+G"!Q2b<c^NQKEO2<1"

C2C1" JB,EM')4" StV" J*%$('" tV" ]" @%-&('(/" Ho" b<2!?c" 3-..E.'G5" %595:6-%" Q" $96';$6'-(" '(+,95)"

58:%5))'-("-7"*5*B%$(5EB-,(+"@E95.."$96';$6'(/"7$96-%"b@JLLc"-("4,*$("@"95..)"$(+".5$+)"6-"

'(9%5$)5+" :%-.'75%$6'-(" '(" %5):-()5" 6-" B-64" )-.,B.5" $(+" *5*B%$(5EB-,(+" @JLL1"

NB'47-&%:%+G"K<bOc^!!Q2E!<2!1"

C2K1" _$&$'" 3" ]" JG'%$" A" b<2!2c" 345" %-.5" -7" :$665%(E%59-/('6'-(" %595:6-%)" '(" '(($65" '**,('60^"

,:+$65"-("3-..E.'G5"%595:6-%)1"P-&4$'"(774)%:%+G"!!bKc^?O?E?PC1"

C2N1" =,)5B05"=E"'&"-:;" b<22Nc"S(+-906'9":$64&$0)" %5/,.$65"3-..E.'G5" %595:6-%"C")'/($.'(/"$(+" .'(G"

'(($65"$(+"$+$:6';5"'**,('601"AB'"U*?_"C%4$)-:"<KbCc^NP?ENQ<1"

C2O1" _$/$("oRE"'&"-:;" b<22Pc"3MJH"9-,:.5)"5(+-906-)')"-7"3-..E.'G5"%595:6-%"C"6-"645" '(+,96'-("-7"

'(65%75%-(EB56$1"P-&4$'"(774)%:%+G"QbCc^?N!E?NP1"

C2P1" R$%60"HE"'&"-:;" b<22Nc"345"4,*$("$+$:6-%"AJMH"(5/$6';5.0"%5/,.$65)"$+$:6-%":%-65'("3MDLE

+5:5(+5(6"3-..E.'G5"%595:6-%")'/($.'(/1"P-&4$'"(774)%:%+G"Ob!2c^!2OCE!2P!1"

C2Q1" X)65%.-4"oHE"'&"-:;" b<2!<c"+A$%*TA$%*!"')"%5[,'%5+"7-%"$96';$6'-("-7"$(" '(e,%0E'(+,95+"$8-("

+5$64":$64&$01"F.(').'"??ObN2Q?c^CP!ECPC1"

C!21" 3%-,6*$(" 3#E" '&" -:;" b<2!<c" M-.5" 7-%" @E95.." $+$:65%" 7-%" UD?_" b@RJUc" $)" $" )'/($.'(/" $+$:65%"

.'(G'(/" 3-..E.'G5" %595:6-%)" b3FM)c" 6-" )5%'(5T64%5-('(5" G'($)5)" UD?_TJG61" D$%.''0()+2" %6" &B'"

P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"&B'"`)(&'0"F&-&'2"%6"I7'$(.-"!2Qb!c^<O?E<OP1"

Page 160: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!!Q""

"

C!!1" W'" HE" '&" -:;" b<2!<c" @E95.." $+$:6-%" 7-%" UD?_" b@RJUc" (5/$6';5.0" %5/,.$65)" 3-..E.'G5" %595:6-%"

)'/($.'(/"64%-,/4"$96';$6'-("-7"UD?_1"D$%.''0()+2"%6"&B'"P-&(%)-:"I.-0'7G"%6"F.(').'2"%6"&B'"

`)(&'0"F&-&'2"%6"I7'$(.-"!2Qb!c^<NOE<O<1"

C!<1" _'*"AoV" t$(/"=V" _'*"_V" F'*"t3V"]"U0-"=@" b<22Nc" A6,+0"-7" AYEP" 6-"*$G5" $"W'"*$)65%E*-.+^"

J+45)'-(V")'+5&$..":%-7'.5V"$(+"%5*-;$.1"U:'.&$%#B%$'2(2"<Ob!Nc^?<PCE?<QN1"

C!?1" 3$G$4$)4'" _E" '&" -:;" b<22Oc" J" :%-65'(" $))-9'$65+" &'64" 3-..E.'G5" %595:6-%" b3FMc" C" bUMJ3CJc" ')"

%5[,'%5+" 7-%" 3FME+5:5(+5(6" '**,(5" %5):-()5)1" AB'" S%4$)-:" %6" ']#'$(7')&-:" 7'0(.()'"

<2Cb!<c^<QN?E<QON1"

C!C1" 3$B56$"_E" '&"-:;" b<22Nc"345"Y(9Q?B!"*,6$6'-("?+"+')%,:6)"58-/5(-,)" $(6'/5(":%5)5(6$6'-("

$(+")'/($.'(/";'$"3-..E.'G5"%595:6-%)"?V"O"$(+"Q1"P-&4$'"(774)%:%+G"Ob<c^!KNE!NC1"

C!K1" @%'(G*$(("HHE" '&" -:;" b<22Oc" 345" '(65%$96'-(" B56&55(" 645" SM"*5*B%$(5" :%-65'("YWRQ?@"

$(+"3FM?V"OV"$(+"Q"')"9%,9'$."7-%"3FM")'/($.'(/1"AB'"S%4$)-:"%6".'::"9(%:%+G"!OOb<c^<NKE<OK1"

C!N1" R4$6,%;5+'" J" ]" U'5%95" A_" b<22Qc" =-&" .-9$6'-(" /-;5%()" 6-..E.'G5" %595:6-%" )'/($.'(/1" A$-66(."

!2bNc^N<!EN<P1"

C!O1" f$(-('"DE"'&"-:;"b<2!!c"R#!C"9-(6%-.)"645"FUAE'(+,95+"5(+-906-)')"-7"3-..E.'G5"%595:6-%"C1"!'::"

!CObCc^PNPEPP21"

C!P1" =$(" RE" '&" -:;" b<2!2c" D(65/%'(" R#!!B" (5/$6';5.0" %5/,.$65)" 3FME6%'//5%5+" '(7.$**$6-%0"

%5):-()5)"B0"$96';$6'(/"A0G"$(+":%-*-6'(/"+5/%$+$6'-("-7"H0#PP"$(+"3MDL";'$"RB.EB1"P-&4$'"

(774)%:%+G"!!bPc^O?CEOC<1"

C!Q1" a," AE" '&" -:;" b<2!<c" R-()6'6,6';5" H=R" 9.$))" D" *-.59,.5)" (5/$6';5.0" %5/,.$65" 3FME6%'//5%5+"

'(7.$**$6-%0"%5):-()5)";'$"645"L:)EA=UE<":$64&$01"P-&4$'"(774)%:%+G"!?bNc^KK!EKKQ1"

C<21" A65&$%6"RME"'&"-:;" b<2!2c"R#?N" .'/$(+)":%-*-65")65%'.5" '(7.$**$6'-("64%-,/4"$))5*B.0"-7"$"

3-..E.'G5"%595:6-%"C"$(+"N"4565%-+'*5%1"P-&4$'"(774)%:%+G"!!b<c^!KKE!N!1"

C<!1" g$(/"RE"'&"-:;" b<22Qc"345"S?",B'[,'6'(" .'/$)5"W%+:!" �:%575%5(6'$..0�":%-*-65)"3FME*5+'$65+"

:%-+,96'-("-7"60:5"D"'(65%75%-(1"P-&4$'"(774)%:%+G"!2bOc^OCCEOK<1"

C<<1" t$(/" HE" '&" -:;" b<2!!c" S?" ,B'[,'6'(" .'/$)5" R=DU" 7$9'.'6$65)" 3-..E.'G5" %595:6-%" )'/($.'(/" B0"

%59%,'6'(/" $(+" :-.0,B'[,'6'($6'(/" A%9" $(+" $60:'9$." U_R�I56$�1" AB'" S%4$)-:" %6" ']#'$(7')&-:"

7'0(.()'"<2Pb!2c^<2QQE<!!<1"

C<?1" A45*B$+5"WV"H$"JV"]"=$%4$e"Sg" b<2!2c" D(4'B'6'-("-7"WLEG$::$@")'/($.'(/"B0"J<2" 64%-,/4"

+')%,:6'-("-7",B'[,'6'("5(I0*5"9-*:.585)1"F.(').'"?<ObKQNQc^!!?KE!!?Q1"

C<C1" U5%65." 3E" '&" -:;" b<2!!c" 3MDHK" ')" $(" '(($65" '**,(5" )5()-%" 7-%" 645" %56%-;'%,)" 9$:)'+" .$66'951"

P-&4$'"CO<bO?C?c^?N!E?NK1"

C<K1" F',"aE"'&"-:;"b<2!!c"D(6%$95..,.$%"H=R"9.$))"DD"*-.59,.5)":%-*-65"3FME6%'//5%5+"'(($65"'**,(5"

%5):-()5)"B0"*$'(6$'('(/"$96';$6'-("-7"645"G'($)5"@6G1"P-&4$'"(774)%:%+G"!<bKc^C!NEC<C1"

C<N1" U$.))-(EH9#5%*-66"SHE"'&"-:;" b<22Qc"3J>V"$"):.'95";$%'$(6"-7"645"$+$:6-%"3MJHV"(5/$6';5.0"

%5/,.$65)" 645" $+$:6-%" H0#PPE'(+5:5(+5(6" 3FMC" :$64&$01" P-&4$'" (774)%:%+G" !2bNc^KOQE

KPN1"

C<O1" A4'" =aE" '&" -:;" b<2!!c" H'6-94-(+%'$." ,B'[,'6'(" .'/$)5" HJMR=K" :%-*-65)" 3FMO" )'/($.'(/" B0"

$665(,$6'(/"3JW_"$96'-(1"D8%F"#-&B%+')2"ObKc^5!22<2KO1"

C<P1" A$'6-4" 3E" '&" -:;" b<2!!c" J(6';'%$." :%-65'(" Z':5%'(" :%-*-65)" 3-..E.'G5" %595:6-%" OE" $(+" 3-..E.'G5"

%595:6-%"QE*5+'$65+" 60:5" D" '(65%75%-(":%-+,96'-(" '(":.$)*$906-'+"+5(+%'6'9" 95..)1" X774)(&G"

?Cb?c^?K<E?N?1"

C<Q1" >%55(&$.+" DA" ]" =-%;'6I" =M" b!QP2c" ,(9EQ?b5!K22c^" J" B54$;'-%$." *,6$(6" -7" R$5(-%4$B+'6')"

5.5/$()"64$6"+57'(5)"$"/5(5"&'64"$"&'.+E60:5"(,..":45(-60:51"W')'&(.2"QNb!c^!COE!NC1"

C?21" F5;'(" of" ]" =-%;'6I" =M" b!QQ<c" 345" R$5(-%4$B+'6')" 5.5/$()" ,(9EQ?" /5(5" 5(9-+5)" $" :,6$6';5"

6%$()*5*B%$(5" :%-65'(" 64$6" %5/,.$65)" *,)9.5" 9-(6%$96'-(1" AB'" S%4$)-:" %6" .'::" 9(%:%+G"

!!Ob!c^!C?E!KK1"

C?!1" +5".$"R%,I"DUV"F5;'("ofV"R,**'()"RV"J(+5%)-("UV"]"=-%;'6I"=M"b<22?c"),:EQV"),:E!2V"$(+",(9E

Q?"*$0"5(9-+5"9-*:-(5(6)"-7"$"6&-E:-%5"_p"94$((5."64$6"9--%+'($65)"*,)9.5"9-(6%$96'-("'("

R$5(-%4$B+'6')" 5.5/$()1"AB'" S%4$)-:" %6" )'4$%2.(').'" a" &B'" %66(.(-:" C%4$)-:" %6" &B'" F%.('&G" 6%$"

P'4$%2.(').'"<?b<Oc^Q!??EQ!CK1"

Page 161: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!<2""

"

C?<1" D6-4" =E" '&" -:;" b<2!!c" YWRQ?@!" :40)'9$..0" $))-9'$65)"&'64" 4,*$(" 3FMP" $(+" %5/,.$65)" 3FMPE

*5+'$65+")'/($.'(/1"D:%F"%)'"Nb!<c^5<PK221"

C??1" U'75%"MV"@5()-("JV"A6,%/5"RMV"]"t$%-;'()G0"L"b<2!!c"YWRQ?@!"')"5))5(6'$."7-%"3FM!!"$96';$6'-("

$(+" DFE!<E+5:5(+5(6" 4-)6" %5)')6$(95" 6-" 3-8-:.$)*$" /-(+''1" AB'" S%4$)-:" %6" 9(%:%+(.-:"

.B'7(2&$G"<PNbKc^??2OE??!C1"

C?C1" X.+5(B,%/" HE" '&" -:;" b<2!<c" 3FM!?" %59-/('I5)" B$965%'$." <?A" %MWJ" +5;-'+" -7" 5%064%-*09'("

%5)')6$(95E7-%*'(/"*-+'7'9$6'-(1"F.(').'"??ObN2QPc^!!!!E!!!K1"

C?K1" z'" ME" '&" -:;" b<2!2c" A59%56'-(" -7" 645" 4,*$(" 3-..E.'G5" %595:6-%" ?" 596-+-*$'(" ')" $775965+" B0"

)'(/.5" (,9.5-6'+5" :-.0*-%:4')*)" $(+" %5/,.$65+" B0" Y(9Q?B!1" AB'" S%4$)-:" %6" 9(%:%+(.-:"

.B'7(2&$G"<PKbCOc^?NN?KE?NNCC1"

C?N1" U-4$%" oV" U'%45%" WV" @5(9'($" HV" H$(95GE_5B5%" HV" ]" o5%$.$" M" b<2!?c" 345" %-.5" -7" YWRQ?@!"

:%-65'(" '(" ),%7$95" .-9$.'I$6'-("-7"3FM?" %595:6-%"$(+" '("95..":%'*'(/" 6-"(,9.5'9"$9'+"$/-(')6)1"

AB'"S%4$)-:"%6"9(%:%+(.-:".B'7(2&$G"<PPb!c^CC<ECKC1"

C?O1" L,G,'"ME"'&"-:;"b<22Qc"Y(9Q?@!"B'$)5)"3-..E.'G5"%595:6-%"%5):-()5)"6-"(,9.5'9"$9'+"'("+5(+%'6'9"

95..)" 6-&$%+" #WJE" B,6" $/$'()6" MWJE)5()'(/1" AB'" S%4$)-:" %6" ']#'$(7')&-:" 7'0(.()'"

<2NbNc^!??QE!?K21"

C?P1" L,G,'"ME" '&" -:;" b<2!!c"Y(9Q?@!" %5)6%'96)" )0)65*'9" .564$." '(7.$**$6'-("B0"-%945)6%$6'(/"3-..E

.'G5"%595:6-%"O"$(+"Q"6%$77'9G'(/1"X774)(&G"?Kb!c^NQEP!1"

C?Q1" _'*" oE" '&" -:;" b<2!?c" J9'+'9" $*'(-" $9'+" %5)'+,5)" '(" 645" e,86$*5*B%$(5" %5/'-(" -7" 645"

(,9.5-6'+5E)5()'(/" 3FM)" $%5" '*:-%6$(6" 7-%" YWRQ?@!" B'(+'(/" $(+" )'/($.'(/1" S%4$)-:" %6"

(774)%:%+G"!Q2b!2c^K<POEK<QK1"

CC21" F55" @FE" '&" -:;" b<2!?c" YWRQ?@!" *5+'$65)" +'775%5(6'$." 6%$77'9G'(/" -7" 5(+-)-*$." 3FM)1" '8(6'"

<^522<Q!1"

CC!1" H5.-" H@E" '&" -:;" b<2!2c" YWRQ?@!" *5+'$65)" 4-)6" %5)')6$(95" 6-" '(7596'-(" &'64" 3-8-:.$)*$"

/-(+''1"D8%F"#-&B%+')2"NbPc^5!22!2O!1"

CC<1" R$56$(-" @RE" '&" -:;" b<2!!c" M5[,'%5*5(6" -7" YWRQ?@!" %5;5$.)" $" 9%'6'9$." %-.5" 7-%" 3FMO" '(" 4-)6"

%5)')6$(95"6-":%'*$%0"'(7596'-("&'64"3%0:$(-)-*$"9%,I'1"S%4$)-:"%6"(774)%:%+G"!PObCc^!Q2?E

!Q!!1"

CC?1" R$)%-,/5" JE" '&" -:;" b<22Nc" =5%:5)" )'*:.58" ;'%,)" 5(95:4$.'6')" '(" 4,*$(" YWREQ?@" +57'9'5(901"

F.(').'"?!CbKOQOc^?2PE?!<1"

CCC1" W$G$(-"AE"'&"-:;"b<2!2c"Y:E%5/,.$6'-("-7"645"5(+-:.$)*'9"%56'9,.,*"6%$()*5*B%$(5":%-65'("

YWRQ?@" '("645"@"95..)"-7":$6'5(6)"&'64"$96';5")0)65*'9" .,:,)"5%0645*$6-),)1"NB'47-&%:%+G"

CQbKc^PONEPP!1"

CCK1" _-54("oE"'&"-:;"b<22Oc"J))5))'(/"645"7,(96'-("-7"4,*$("YWREQ?@"'("3-..E.'G5"%595:6-%")'/($.'(/"

$(+"*$e-%"4')6-9-*:$6'B'.'60"9-*:.58"DD"%5):-()51"H47-)"(774)%:%+G"NPb!!c^PO!EPOP1"

CCN1" H$%6$"HV"H5'5%"YRV"]"F-B5.."J"b<22Qc"M5/,.$6'-("-7"$,6-'**,(5"5(95:4$.-*05.'6')"B0"6-..E

.'G5"%595:6-%)1"I4&%(774)(&G"$'/('Q2"PbNc^K2NEK2Q1"

CCO1" @%,((5%" RV" J;-6)" JV" _%564" =gV" A5%7.'(/" SV" ]" A94,)65%" Z" b<22<c" @%,6-(�)" 60%-)'(5" G'($)5" ')"

$96';$65+",:-("R#C2")6'*,.$6'-("'("4,*$("@".0*:4-9065)1"X774)%9(%:%+G"<2NbCc^C?<ECC21"

CCP1" 34'B$,.6"#FE"'&"-:;"b<22Pc"DMLQ"$(+"A3J3!"$%5"%5[,'%5+"7-%"D/>"$,6-$(6'B-+0":%-+,96'-("$(+"@"

95.."58:%5))'-("-7"3FMO"'("*'951"AB'"S%4$)-:"%6".:()(.-:"()/'2&(+-&(%)"!!PbCc^!C!OE!C<N1"

CCQ1" R4%')65()5(" AME" '&" -:;" b<22Nc" 3-..E.'G5" %595:6-%" O" $(+" 3FMQ" +'96$65" $,6-$(6'B-+0" ):59'7'9'60"

$(+"4$;5"-::-)'(/"'(7.$**$6-%0"$(+"%5/,.$6-%0"%-.5)"'("$"*,%'(5"*-+5."-7".,:,)1"X774)(&G"

<Kb?c^C!OEC<P1"

CK21" @,694'"W@V"g--+)"3V"#,"HV"H-%/$("3gV"]"U565%)-("_S"b<2!!c"3FMO"$(+"3FMQ"6%'//5%"+')6'(96"

(5,%-'(7.$**$6-%0"%5):-()5)"'("645"RWA1"AB'"I7'$(.-)"C%4$)-:"%6"#-&B%:%+G"!OQb<c^OP?EOQC1"

CK!1" @0%(5" oRE" '&" -:;" b<2!?c" @%,6-(�)" 60%-)'(5" G'($)5" ')" %5[,'%5+" 7-%" $:-:6-6'9" 95.." ,:6$G5" ;'$"

%5/,.$6'(/" 645" :4-):4-%0.$6'-(" $(+" .-9$.'I$6'-(" -7" 9$.%56'9,.'(1" S%4$)-:" %6" (774)%:%+G"

!Q2b!2c^K<2OEK<!K1"

CK<1" Z'e$0$(" ZV" @$,*/$%6EZ-/6" SV" W$'+," AV" z'$(" >V" ]" D**5()94,4" A" b<2!!c" @%,6-(�)" 60%-)'(5"

G'($)5" ')" %5[,'%5+" 7-%" 3FME+5:5(+5(6" 45*5" -80/5($)5E!" /5(5" $96';$6'-(" ;'$" W%7<" '("

*$9%-:4$/5)1"S%4$)-:"%6"(774)%:%+G"!POb<c^P!OEP<O1"

Page 162: Rôle des protéines chaperonnes, UNC93B1 et la chaine invariante

!<!""

"

CK?1" =$)$("HE"'&"-:;"b<22Pc"#57596';5"3-..E.'G5"%595:6-%"QE*5+'$65+"906-G'(5":%-+,96'-("'("@"95..)"

7%-*"@%,6-(�)"60%-)'(5"G'($)5E+57'9'5(6"*'951"X774)%:%+G"!<?b<c^<?QE<CQ1"

CKC1" _5((0"SLE"'&"-:;"b<2!?c"@%,6-(�)"30%-)'(5"_'($)5"H5+'$65)"645"A0(5%/')6'9"A'/($..'(/"B56&55("

3FMQ"$(+"645"@"R5.."M595:6-%"B0"M5/,.$6'(/"R$.9',*"$(+"R$.*-+,.'(1"D:%F"%)'"PbPc^5OC!2?1"

CKK1" >'BB$%+" MoV"H-%.50" UoV"]">$0"Wo" b<22Nc" R-()5%;5+" 75$6,%5)" '(" 645" 586%$95..,.$%" +-*$'(" -7"

4,*$("6-..E.'G5"%595:6-%"P"$%5"5))5(6'$."7-%":=E+5:5(+5(6")'/($.'(/1"AB'"S%4$)-:"%6"9(%:%+(.-:"

.B'7(2&$G"<P!b?Oc^<OK2?E<OK!!1"

CKN1" M,))-"RE"'&"-:;"b<2!!c"A*$.."*-.59,.5"3-..E.'G5"%595:6-%"O"$/-(')6)".-9$.'I5"6-"645"H=R"9.$))"DD"

.-$+'(/"9-*:$%6*5(6"-7"4,*$(":.$)*$906-'+"+5(+%'6'9"95..)1"?:%%0"!!Ob<!c^KNP?EKNQ!1"

CKO1" A6$%.56)" #E" '&" -:;" b<22Nc" R5..E),%7$95" R#OC" '('6'$65)" $" )'/($.'(/" 9$)9$+5" .5$+'(/" 6-" 95.."

:%-.'75%$6'-("$(+"),%;';$.1"?:%%0"!2Ob!<c^CP2OECP!N1"

"

"